[
  {
    "id": "25232d3f2e576e10929618728661c78e057c4ccc0335bbe869d9469789d803e7",
    "title": "Effect of intraoperative ketamine on pain, opioid use, and psychological recovery in orthopedic trauma patients (KOPM trial): protocol for a randomized, single-blind trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 6",
    "outcome_summary": null,
    "doi": "10.1080/17581869.2026.2682470",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42251276/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "75b5ba70f18aabdcb28fb2237d2d5346a6db7cc594af2bcfc94f20e141cb3df5",
    "title": "Ibogaine in the Vet Brain: Changes in Brain Metabolism and Connectivity After Ibogaine Administration in Veterans With Traumatic Brain Injury.",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1016/j.bpsc.2026.04.005",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42250921/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "be3b21858d483c1edc937a7cb04cb7d8106ff2f5cccc8e92f2bcd8511d4abed2",
    "title": "OPTIMIZING EXTRACTION AND CONCENTRATION METHODS FOR LC-MS/MS ANALYSIS OF VETERINARY PHARMACEUTICALS IN EQUINE-ASSOCIATED ENVIRONMENTAL MATRICES.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1016/j.etap.2026.105069",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42250664/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9ac4ce45ccd730d7db06db8b7a823a328eeee54fcb743163909a973aef62cc8e",
    "title": "Esketamine alleviates trigeminal neuralgia and anxiety-like behaviors in mice by inhibiting RIPK1/RIPK3/MLKL-mediated necroptosis.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "anxiety",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1016/j.brainresbull.2026.111987",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42250657/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e04bf6f9eaf8ee77b470a30857427efe705a30db33cc478d102cba9fdca694e5",
    "title": "Psychometric validation of the French version of the five-dimensional altered states of consciousness questionnaire (5D-ASC) and associated 11 OAV subscales.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1016/j.pnpbp.2026.111770",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42250635/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5f53aaee0d20ca8965f1a20d1fde82a3845414284c8ab579b8bd6ccff56a782d",
    "title": "High stakes: how legal cannabis pricing impacts the illicit market.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 6",
    "outcome_summary": null,
    "doi": "10.1186/s42238-026-00455-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42249514/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9784782a9849b5a22e657f3a80d016544bf2eda56d670643a0443e3dff9ebf90",
    "title": "Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1038/s41398-026-04151-x",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42248832/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0515e9601dd70a9f0fb0178a8ef3bb750cea10899f022e8c5db362a94905f3dc",
    "title": "Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1016/j.jad.2026.122063",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42248535/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1ab02d23815dc4ec36c61ca97b8104d6956380f9a63a33bd03cdd1279b88c261",
    "title": "The effect of treatments for postpartum depression on breastfeeding practices: a systematic review and meta-analysis.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.midw.2026.104885",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42248094/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "03b56c6254effe8e586fc0dc7048568dfacbd8f299628513f61bd69c4f17def4",
    "title": "U.S. Poison Center exposure cases involving marijuana and selected comparator substances.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.drugalcdep.2026.113204",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42248033/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0e2b10900ba9829e5413bab8d13137fed0449ce1a639c7898a218f9a4f6ac25f",
    "title": "Response to: Commentary on \"Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study\".",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1016/j.euroneuro.2026.112885",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42247854/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0250ad3ab4ae67f5a2e9b599bf4c7a9a4cb8882e58012183f3660f6c4d5e8863",
    "title": "A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1016/j.drugpo.2026.105348",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42247761/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d1de8563ca6010a77078bf187f03b5a6f6dd4d6d26c474c8d1ecd3df4f00eeff",
    "title": "Genivs Plane Block-A Novel Mix of Regional Blocks for Knee Surgery: Used to Provide Complete Analgesia for Through Knee Amputation With a Continuous Distal Femoral Periosteal Catheter in a Pediatric Patient: A Case Report.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1213/XAA.0000000000002202",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42247319/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "61a9be1005e303cc773068d05f3e9ecbcea7c9f57770c3b9969e90da7732d412",
    "title": "Phylogenomic systematics of Lanmaoa (Boletaceae) reveals cryptic diversity, resolves global evolutionary relationships, and suggests a novel psychoactive lineage.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1080/00275514.2026.2670968",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42247306/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "48bca9f731b6e9aa0dbb8a7034b4f4b92b6ea7b2eaf4df1024fcc2cd28d02e18",
    "title": "Inhaled Mebufotenin (GH001) for Adult Patients With Postpartum Depression: A Phase 2a Open-Label Clinical Trial.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 3",
    "outcome_summary": null,
    "doi": "10.4088/JCP.25m16284",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42247279/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5972d42d2369ed24b0114f6394363ed5252d1d518d3a3cd4923997fd8e100c69",
    "title": "A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis.",
    "compound": "dmt",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1007/s40120-026-00959-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42247185/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2121fcb62f6c5f13c29a882edc62d4ca4d019e899b14f31011267c26616b46fa",
    "title": "Development of a monoclonal antibody-based competitive ELISA for serological detection of lumpy skin disease virus.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fvets.2026.1819650",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42245979/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "29e43aff2af23c83bc2e0c6f1bfdad7df6ff418a9b85340fd23536705b87377e",
    "title": "Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fmed.2026.1828838",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42245962/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1f04f3c70d5c7c65b7ecf3e0bec4fb6a3c3810da8e19bcebff9a81b45c7e8c48",
    "title": "Structural Neurotoxic and Neuroprotective Effects of Ketamine and Esketamine in Preclinical and Human Studies: A Systematic Review.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.21203/rs.3.rs-9827580/v1",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42245795/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d0f1371a512f95648e358e9a252980ab66d3041173bab08bbfbc9dccef4e5483",
    "title": "The role of esketamine in enhancing postoperative recovery and pain management in laparoscopic surgery: a meta-analysis of randomised controlled trials.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1097/EA9.0000000000000103",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42244822/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7393672f64171f0eec63794a8df59c575f8bf42f7c32a2cf23b0bcaa75c52aba",
    "title": "Emergence of synthetic drugs in South America: insights from Brazil, Chile, and Colombia.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1186/s12954-026-01480-4",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42243908/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5e270f712b59ba8c14c58cce3d19b9f8ea70294e35b15ddfa1b936d9df8d8dc8",
    "title": "Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1186/s12888-026-08137-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42243814/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4cfbaa20b8fb087b291157025f6d90d0ebb332f711b6d1f8760c20ca9a136de4",
    "title": "Multimodal opioid-free anesthesia containing esketamine versus opioid-based anesthesia: a systematic review and meta-analysis.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1186/s12871-026-03975-w",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42243697/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5a7917005e0cd1e91fe27e49ae4cf3f3c88aa5ae1eb485075816eead4945de00",
    "title": "Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1007/s40265-026-02339-5",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42243569/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a5e7ac9dead405bb89bcb7d49b890d2f1cebe75561a7c2db38d4d63c2bb5a73",
    "title": "Correction to: Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1007/s11920-026-01685-1",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42243392/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "98a67a4031ff1ad09b9ef5f3535b93381d807babbfa450e3fa7634526d84aa45",
    "title": "Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study.",
    "compound": "mdma",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1038/s41398-026-04148-6",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42243076/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "764c0580733840875ce71bed0c0045d600df482aa0a9d56a46a5a54ad902effb",
    "title": "In situ nasal gel loaded with Lactoferrin-Coated Brexpiprazole nanostructured lipid carriers for Schizophrenia: Cross-Species validation in Ketamine-Induced rat and zebrafish models.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 3",
    "outcome_summary": null,
    "doi": "10.1016/j.ejpb.2026.115131",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42242508/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9eedf87aa43db4e9085d4a663618d178732fbf76e5725b29a26351664c975cba",
    "title": "Relapse-associated versus relapse-independent progression determines disability trajectories in multiple sclerosis beyond EDSS 3.0.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1016/j.msard.2026.107289",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42241787/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5ae4a6086fe57b045111b266a450ced9dc84cf73ae2a336e87a59a927cffd51c",
    "title": "A scalable opto-electrochemical sensor for salivary and urinary detection of ketamine: towards selective assay by naked-eye.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1007/s00604-026-08150-z",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42240866/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "214f57639411ab01aeff65c7ce2336ebc98a868dbe4233f74640c8f6119a27ea",
    "title": "The Comparative Sensitivity to Ketamine-Induced Neuronal Death in Juvenile and Adult Rats.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.1177/10915818261455819",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42240040/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7205f4222dba8d6317041ab611f1d0ff2dabb7425a60e826d61f5ea187b42fce",
    "title": "Child and maternal health outcomes following antenatal exposure to classic psychedelic substances: a systematic review.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.21203/rs.3.rs-9732799/v1",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42239767/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4483eb69be34a19927870518869efbc27f1beecb4e2996db3e5852cbe302a412",
    "title": "Ketaminindusert skade p\u00e5 urinveiene.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.4045/tidsskr.25.0733",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42237795/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c17705e290ea90d73a9e496164e74969ace1ba93ae14321ccb6b2c10b0f07dcc",
    "title": "Evaluations of nurse managers' work environment: a descriptive study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 3",
    "outcome_summary": null,
    "doi": "10.1186/s12912-026-04737-2",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42237148/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8870e1d9daecfa75cb25e7cbb2eea279e1f911dc3e54db340214cf4c85f76baf",
    "title": "Association of Esketamine use with mortality and clinical outcomes in patients with cancer-related depression: A target trial emulation.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1016/j.pnpbp.2026.111764",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42235877/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "df15910136af303261338b2ff675eac8aa87659a921a25a8b32b41aef28e8c2b",
    "title": "A pilot randomized trial of ketamine for suicidal ideation in a pediatric emergency department.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 3",
    "outcome_summary": null,
    "doi": "10.1007/s43678-026-01190-7",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42234079/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2f1796f718d9c11b28d36806ac1cf9501e548de5b50facfee9e579bb493c208a",
    "title": "Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1016/j.vhri.2026.101654",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42233939/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "789fe9c190c476b7c0bc234a109bfd05a69b6f81f20b44adc54c4f84c0e02746",
    "title": "Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fpsyt.2026.1777387",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42233004/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5dae8736b843d36d48f62057d78ff345579d34909a982eac6aee50eb7d9e068b",
    "title": "Deep learning guided propofol ketamine dosing and inflammation trajectories in elderly burns.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fncom.2026.1824898",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42232895/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "171ef6007b6643a5469f44affdd183c473ea23c3f31c75922832c41ffd140104",
    "title": "Locomotor and discriminative stimulus effects of N-cyclohexyl butylone and N-cyclohexyl methylone.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fphar.2026.1823177",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42232187/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8fee636b54019390b5b5debccf9855a451e7c1c7cb876b6613bfede66043feb0",
    "title": "Calcium Signaling Dysregulation as a Convergent Mechanism in Anesthetic-Induced Developmental Neurotoxicity.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.2147/DDDT.S599516",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42232094/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "744a0282a693885a42a4ed5edda293c477c7331ce7968ae578514b4b57577dcd",
    "title": "Dexmedetomidine Dosing Strategies in Sedation and Anesthesia: Pharmacokinetics, Safety, and Clinical Applications - A Narrative Review.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.2147/DDDT.S606156",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42232093/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "eaf8ee15b542266339eeec192d37c8ddbfdd6482315033fd1265eef96c9d2911",
    "title": "Comment on: prophylactic esketamine to reduce postpartum depression in primiparae.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jul 1",
    "outcome_summary": null,
    "doi": "10.1097/EJA.0000000000002409",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42231774/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "42c0a69abac3f4f36f888d30240ba59347ba99d5d1bc58eb843426013d7723b9",
    "title": "Reply to: prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jul 1",
    "outcome_summary": null,
    "doi": "10.1097/EJA.0000000000002423",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42231773/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ac6672c7c40c36b6dc14397172a497753af748ab6192203f1abd9728e2aec306",
    "title": "Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jul 1",
    "outcome_summary": null,
    "doi": "10.1097/EJA.0000000000002399",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42231772/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "42bbb785c68eb2098fb8d1bb55783e4bc91a70f7759a9d419016c611ee58f542",
    "title": "Efficacy and safety of ketamine in total hip arthroplasty: a systematic review.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1186/s13018-026-06972-4",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42231375/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "36864aeea224d8886cacec6a4db7b075fa6eb79f1f8a89bd22ad4791e1944cc9",
    "title": "Increasing dose of esketamine for supplemental analgesia after complex spinal fusion surgery: a randomized and double-blind trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1186/s12871-026-03962-1",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42231178/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3717fc5b0f28d3d063b277f6684f76c4ff8c29e1606cfce87005ba88e0358cdd",
    "title": "Characterizing Antibody-Drug Conjugates with High Molecular Heterogeneity by Native Direct Mass Technology.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1021/acs.analchem.6c00050",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42231128/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1e7400e4071078d88b03a87462ddf80bc7352494a47ebd81e610a88b61253250",
    "title": "Spontaneous and oxytocin-induced contractility of gravid human myometrium with exposure to intravenous anesthetic agents: an ex vivo laboratory study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1007/s12630-026-03124-4",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42231013/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0a89062ec591e071c6a42b1a9934b4a3f9ba443c0c69d86c58c9f93689a1468c",
    "title": "SpiralEdge-IoV: secure and adaptive task offloading in internet of vehicles edge computing using logarithmic spiral defense.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1038/s41598-026-55737-w",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42230946/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e6eaecb4f6b3e2aa2d8c3277404a1dacdb957eeb5012679db74a2d87264926fa",
    "title": "Reply to Z Yu and F Qin.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1016/j.ajcnut.2026.101301",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42230083/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9cb777c55327a4cbb9c3beb686fb4afa7428070c7559769fb1c6c5aa62ee26e9",
    "title": "Unveiling the role of single versus repeated low-dose ketamine in attenuating doxorubicin-induced chemobrain and depression in rats: differential modulation of neuroinflammation, phosphorylated GLT-1, SERT, DAT, and BDNF/TrkB signaling.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.neuropharm.2026.111055",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42229837/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5e8a65ff9f8e7f955e12ce13ff1805ede072efc23e1d37b5efce4c8fce6d223e",
    "title": "MANDIBULAR BONE MICROARCHITECTURE IN PATIENTS WITH MULTIPLE SCLEROSIS: A FRACTAL ANALYSIS STUDY.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.jormas.2026.102862",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42229719/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "edc28cd77c4ff34b93d26cc89a70ad24e7c2f60082f4da61f13b6bbed5acfe78",
    "title": "Allergic reactions to anaesthetics in surgery: current challenges and perspectives.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 3",
    "outcome_summary": null,
    "doi": "10.1515/dmpt-2026-0008",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42229044/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0b294422b2455607dd23b3ddd7bc5f48c0e3a3a8f9399db4cbd05866f5e760b7",
    "title": "Time to embrace the whole: considering the replacement of psilocybin with Psilocybe spp. in psychedelic research and therapy.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1080/14786419.2026.2683121",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42228759/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8641ca1611ad0e57ad3736ab3422901a44fea59d80edc58cd251239b962294ac",
    "title": "Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1097/JCP.0000000000002197",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42228481/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1fe02639d137b79aa8695c2b0ba786cb848b366aff0a1dde04de1f5ffaa349e5",
    "title": "Clinical course after cardiac resynchronization therapy in transthyretin amyloid cardiomyopathy receiving disease-modifying therapy.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1007/s00380-026-02710-2",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42228078/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5512ab9c9ec7200e892c6a38e0976de80e336a942d0a927981b7d414e86c1322",
    "title": "Relative odds of seizure in emergency department cases of analytically confirmed illicit substance exposure.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1080/15563650.2026.2671976",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42227670/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "77d0a6a5f8e13502b00002aa160bd07ad3a234f6f680a2c12f6f4b4df633dc73",
    "title": "The Effect of Vitamin D on the Humoral Immune Response of Calves to the Sheeppox Virus Vaccine.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2025 Sep",
    "outcome_summary": null,
    "doi": "10.32598/ARI.80.5.3611",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42226998/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "86f6cb94ce424dcb386b5dcf35f632e7fd1b94c3883696f112c0d34c69898a1c",
    "title": "Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1111/ejn.70574",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42226515/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "91e090c6d619c66096f84552bc9fd49533895b26a6018d7e6aa924cf9f55e768",
    "title": "Ciprofol-Esketamine Versus Ciprofol-Remifentanil in Hysteroscopic Endometrial Polypectomy: A Randomized Controlled Trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.12659/MSM.952468",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42226428/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "953c14ef9ab042ba0185db9df07b1dbec84ea266a3b3585a2b151ea6c44b7a9e",
    "title": "The antidepressant-like effect of adenosine A(1) receptor over-expression in forebrain neurons does not involve an altered adenosine-mediated control of excitatory synaptic transmission.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.neuropharm.2026.111056",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42225242/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1160f42610023e426ac07a2be78a1804589fa5b84176a0180b3a1eb5cbda5d5f",
    "title": "Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.drugalcdep.2026.113218",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42224931/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "afe47b9a0691fc74ae9389705e2e61d1b0a2cbc9bec1f3645f15cb049e3e56f4",
    "title": "Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1177/13524585261446846",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42224266/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8a2eb70f0cf84e35d560fe7a8fc0f43ce71e3d3ee635c58a0f901b1820cea033",
    "title": "Evaluation of various obturation techniques with AH Plus Jet sealer in simulated C-shaped canals.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1007/s44445-026-00124-4",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42223545/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3bfb85128c73829de1ad1631e81ca81bd6cc5f159f79ccd982b7d519ba14e754",
    "title": "Sedative Effects of Dexmedetomidine and Ketamine or Dexmedetomidine and Midazolam on Tear Production, Ocular Perfusion Pressure and Pupil Diameter in Rabbits.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jul",
    "outcome_summary": null,
    "doi": "10.1002/vms3.71017",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42223161/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "43f8863805afcc797dcb59b6dc06ff4aa45e6a0efa63c05a911e33bd54e19a0a",
    "title": "SMART-MC: Characterizing the Dynamics of Multiple Sclerosis Therapy Transitions Using a Covariate-Based Markov Model.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1080/01621459.2025.2555055",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42221835/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "863a66cc4e527899675c53dcaffb80b50e57418be24aeab12dce377a243d2c10",
    "title": "The prevalence of comorbid migraine in multiple sclerosis: do multiple sclerosis and migraine really coexist?",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.22514/jofph.2026.030",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42220296/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a4030db063389273f4ecee5998785ee5298c118ae66f51e436ef5f3818be219a",
    "title": "EXPRESS: Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: A randomised [(18)F]FDG-PET Study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1177/0271678X261454172",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42220002/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0250203bbba2e4cfd95113f3a09823524441fd81ba763cb73b57e039c7cea2d6",
    "title": "Go With the Flow: MOR(E) to Ketamine Than NMDA Receptor Antagonism.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1176/appi.ajp.20260275",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42219566/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d110ee1c9cba660f358deedb2cd4190ab4ae570cfcca8070125ecdb572c39a8a",
    "title": "An Update on Somatic Treatments for Suicide Risk.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1176/appi.ajp.20260287",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42219565/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "842f0b786424583d3cc6397f0c0bd3ebf789ef1b55380ac8acef21afa21a9bcf",
    "title": "Mu-Opioid Signaling Engagement as a Candidate Maintenance Mechanism for Prolonging Ketamine's Antisuicidal Effects.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1176/appi.ajp.20260266",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42219563/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c67e622a3d3998f4bfdf59e538f9f0f99db1ad90c174980af668436a729589a8",
    "title": "Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data-Linkage Study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1111/ejh.70233",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42219247/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "abb07cb7b044f2432c27143bc18695ecebff326eeaeb0071f9ceb1bdacf8e626",
    "title": "Neuropsychological symptoms and subclinical disease activity in multiple sclerosis patients receiving high-efficacy therapy.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.msard.2026.107279",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42218888/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "dbf7940faf37e4ee5e54f31052693af8ea911915ac49a9245c0fd18e515b56f2",
    "title": "Classic psychedelics and personality: An updated systematic review.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1177/02698811261449386",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42218644/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4291520c25a1742ceef0715c9b09a073f8f8d41b8f3869efa37903354e214f48",
    "title": "Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1177/13524585261448789",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42218618/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0875e143203d24e1ec59434c7d9044b3b1b754d35da452bf2067fd3b16e9f3b5",
    "title": "Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1177/13524585261449988",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42218617/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "61a1fa86c29fc60b516dfeb081c0b02010fafa1852ee6a1eb589858fb64b9e0d",
    "title": "Safety and tolerance of oral ketamine: A systematic review.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1111/pcn.70091",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42218597/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6dee6a96fe31d73eb4554220e47a8ecf268be029e4d3c87ccfeef58f29495f02",
    "title": "Analyzing Global Threat of Lumpy Skin Disease Virus Infection: A Comparative Study of a Time Series Model and Machine Learning Models Across 10 High-Risk Countries.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1007/s00284-026-04982-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42218282/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a38a815a44ef33a393dc47ef9bcef68fe8a20dfafdc51fb6089b925c7a930436",
    "title": "A more optimistic outlook about disease-modifying therapies and depressive symptoms in multiple sclerosis: A cross-sectional analysis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.jad.2026.122056",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42217643/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c66ada999074efef73371932d08d49aafd515e0a22ff289880b0b4b39679ead0",
    "title": "Inhibition of compulsive behavior by dextromethorphan on schedule-induced polydipsia in rats: Role of NMDA, sigma-1, and 5-HT receptors.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.pbb.2026.174218",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42217548/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ba6bbe9ebd2697c50dadfe05f26a26a49e94aa14f35696834fe2b134a8a8b6f4",
    "title": "Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1007/s40120-026-00951-x",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42217095/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4acd4268c2b62f3192762af118afb2ebe31ff7e889981717a20b4e517045374f",
    "title": "Beyond the High: A Narrative Review of the Chronic Complications of Recreational Ketamine Use.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.31083/BJHM53976",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42216615/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b3c1da014c65a66d1254b2751b9af8a4a9a9cd4608c02fbe73efd796355b4b9f",
    "title": "Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41380-026-03657-6",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42215638/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ff877dd4106ad2b669297da497fe661efbefba3442aad65a605aeabc0616a7e9",
    "title": "Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41398-026-04133-z",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42215446/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "682b731720ce070d19be443da17a97f8e97e0559c97fd0c20298059e02c95e6e",
    "title": "A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT\u2082A-TrkB mechanistic paradox.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41421-026-00906-4",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42215437/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c3b105edb3499bc6335f847f47a10ddbd68c7e52f1d2c19d4469af57e0a484b8",
    "title": "Intraoperative low-dose ketamine for postoperative pain outcomes in opioid-na\u00efve patients: a systematic review and meta-analysis.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.accpm.2026.101862",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42214668/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fdb30d35fd1f6994d29eb179a0a0c0b9189c53d7dd91dea06a0210674eb79c08",
    "title": "The Use of Ketamine for Depression in Cancer Patients: A Systematic Review of Efficacy, Safety, and Clinical Applications.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1080/15360288.2026.2679720",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42213692/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b542e3c9a6477dbb4609f0192b70991d28560fc7649a7cc94e012182b822921d",
    "title": "Meta-Analysis: Ketamine Injections Rapidly Reduce Major Depressive Episode Symptoms.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1001/jama.2026.6201",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42213423/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d4981cf59045ffc67398a550068050c6daaa69254d32c894246b9ad7d1e22748",
    "title": "Intramuscular Ketamine Pharmacokinetics in Humans: A Review.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s13318-026-01012-2",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42213372/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bfe71a8477c07d49fbd34bba5e62f6a59ee45e42bbdc6b13d47a9e88606547cf",
    "title": "Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "cluster_headache",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1177/02698811261449380",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42212900/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1da27e245da308b13b99aa9ac043e1fa3ee5fbf43bc374aedcd58642c88784bc",
    "title": "A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1177/02698811261453938",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42212869/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4648c5f1386aa38eee1a8e4ecf4bf9b6d9e8b0684d2c0788b8bafef44ec887f6",
    "title": "Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.15288/jsad.26-00013",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42212774/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05ee723eb1198f61f1db13954eb1d7a7510fa80f0e3c85791f5b9de61a720b88",
    "title": "A conceptual framework based on current and emerging treatments for treatment-resistant depression: mechanistic evolution, clinical evidence, and future directions.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1080/14737175.2026.2675008",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42212413/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2fd9052d7fa7f82f052272605ec49ff624e9c46b0b34cb9fe431aa3b191c9813",
    "title": "Latrepirdine (Dimebon), a potent 5-HT(7) receptor antagonist, modulates stress-mediated behaviors in rodents.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fphar.2026.1771657",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42212270/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ba892ec7407152d0f97717cdbf48da4830eabc4b1e361d6c8a553b32d87eb711",
    "title": "Serum inflammatory cytokines in the progression of depression.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fimmu.2026.1808989",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42212166/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9a32d75842da6a353bf57e93b6e8bd104433dbc514a467570eedf6fd1184cf46",
    "title": "Synthetic cannabinoids in human post-mortem samples - ADB-BUTINACA and metabolites in three fatalities.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/ftox.2026.1826767",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42212046/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "da353085c7507acdfffe7fed605509419c2e6bbee61d28d07e4ad808b730e309",
    "title": "Same pattern, different result: Algorithmic inconsistency in breath alcohol testing-case reports.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1016/j.fsisyn.2026.100689",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42211315/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd0d6b88ed40dd4a188c55cf2fb286fba6bf9c2ef5f892b0a545bc220e33b354",
    "title": "Correction: Catatonia Associated With First-Time Psilocybin Exposure: A Case Report.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.7759/cureus.c439",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42211293/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "54baed3b8076debb3de12e74fdba6d7bb9cc25fcff7580a4fcbef44903026b57",
    "title": "The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1002/cpt.70344",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42209433/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "af6efb3c6a2f93ac0de59b3960cc2c978e1f1e062285beb8c3da2dde6e86c822",
    "title": "Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.euroneuro.2026.112879",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42208423/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "247eecdb3ee653ecefe4e2804f3be6c62cfe5f8a8bacd1ec4a219f449afab9b1",
    "title": "Psilocybin-induced neurocardiogenic syncope: a case report.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s00213-026-07079-8",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42207275/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5d3b5d928e7e3491f9a11337be6ea2872bd267462cd10ecedc8669a6f673c812",
    "title": "Sedative choice alters Klebsiella pneumoniae lung pathogenesis and dissemination.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1128/iai.00069-26",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42206991/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "251c2d969455f92c7e0325cd6f17123b703416404954078fd1da54e8fdc6c5e2",
    "title": "Potentially Surgical Digestive Complications in Patients With Status Epilepticus: Insights From the ICTAL Registry.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1097/CCM.0000000000007176",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42206939/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f3fc5e31faca98347a833842ae71636b285d487620011ee468ed203f5ea2cc54",
    "title": "Applying Distinct CDMS Strategies to Observe Nonclassical Virus Capsid Assembly.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1002/jms.70068",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42206604/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4ffcc58d4dca24a1e87fa8c212229d23b4edc362a99c2aa75a746ce3b21d675f",
    "title": "Conscious Sedation with Ketamine-Dexmedetomidine Versus Midazolam-Pentazocine in Enhancing Minor Oral Surgery Experience: A Parallel Arm Randomized Clinical Trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1007/s12663-025-02630-0",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42206112/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "57a96207628f8d8d5f7a6f37b20217445c85999bdc9369f6b81c91670795a3c8",
    "title": "Case Report: Oral glutamatergic augmentation for trauma-related disorders with fluoxetine-/bupropion-potentiated dextromethorphan \u00b1 piracetam: a four-patient case series.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fpsyt.2026.1752101",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42205993/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0cbe7d730ed4957ed62d56ecfcc542ebab79e1ea9c134f2c45f0921683dd57ba",
    "title": "A Method for Measuring Dissociative Effects of Sub-Anesthetic Doses of Ketamine in Juvenile Female Rats.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jan-D",
    "outcome_summary": null,
    "doi": "10.1177/24705470261451166",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42205353/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aa18d057d954afc407f91f02ae893579654703c7f0769c1cf367fefe26e99e79",
    "title": "Studies on Enzymatic Hydrolysis of Psilocin-O-glucuronide for Screening of Psilocin in Human Urine by Liquid Chromatography-Triple Quadrupole Tandem Mass Spectrometry.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1093/jat/bkag030",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42203689/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1bb9c96e5211f31a4c91a328bb2ad9d2d029490d052b2b70bfd3d33d87f289ff",
    "title": "From feeding cell to fruiting body: Multidrug transport in the life cycle of Dictyostelium discoideum.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1016/bs.ampbs.2026.02.002",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42203389/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "736f94e95b5869629b1811a4d76e9c380add43b846771d7d4dfdeb7c033a208f",
    "title": "Evaluating Antegrade Cerebral Perfusion Flow Rates for Neuroprotection During Hypothermic Circulatory Arrest.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.athoracsur.2026.05.014",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42203134/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4f743476ff9a6b575c3c0e5b1103cfce96cbc9e411ab5fa06caad86e42b4d4b8",
    "title": "Distinguishing psychomimetic from antidepressant-like effects in mice using molecular and electrophysiological biomarkers.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.ejphar.2026.178994",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42203064/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c85af3f03c31ef35ebd885d52b51d58b556b4bda5d9fdc96efcce9f0c80e734a",
    "title": "State-specific inhibition of NMDA receptors by memantine provides insight into NMDAR channel blocker tolerability.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1126/sciadv.aec3154",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42201999/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5139ba98772e11bc8e29989e2ecc3515f3472d1d0666c9ab6f0b4a8c16d4d085",
    "title": "Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1159/000552272",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42201843/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "384252f6665184c157d3dcd9a29465c49c5b04c3a4e1b88efaf2bd1dc23b76eb",
    "title": "Serum Uric Acid Trajectories in Multiple Sclerosis: A 5-Year Longitudinal Comparison of High- and Moderate-Efficacy Therapies.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.3390/medsci14020256",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42201048/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "67b56b590dcfe6307a3ee7e37c33e6a21f65236f886204d808632faed8cf113b",
    "title": "Dopamine, glutamate, and gamma-aminobutyric acid: Key hubs in neurotransmitters, signal transduction, and cognitive dysfunction.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.4103/NRR.NRR-D-25-00849",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42199136/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "df356a2a5daa2f2bc507e07cbb007ea9812bf486cfbade141afcc0e813e05e58",
    "title": "Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1177/00048674261450390",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42198984/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "995911b72f980953f35fb7760599dbf31e480fcb4d9cda5c587e0fd9c803a014",
    "title": "Dosing Strategies for High-Alert Medications in Obese Pediatric Patients: A Systematic Review.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.3390/ph19050766",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42198440/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d0698ba1f038312b2f424e48b23f6a0deca110001fe062a39cc40645aa4ce0e6",
    "title": "The Monoamine-Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Apr 2",
    "outcome_summary": null,
    "doi": "10.3390/ph19050662",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42198336/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a70486b562ddf0b35b1ca98efb44f34c4bbac8948e8cec028a8b42c0b77c777",
    "title": "Undernutrition Risk in Community-Living Older Adults: Post-COVID-19 Results from the 2023 U.S. National Survey of Older Americans Act Participants.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.3390/nu18101619",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42197078/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "daf5de1556944a861b312a2f9ca74229e73f395a274792f4d890bc9536ca3372",
    "title": "Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 9",
    "outcome_summary": null,
    "doi": "10.3390/ijms27104229",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42196212/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a0f92418c6c1b18080f95195ca872e87ccbebc0e2cb3ca82b808e4f3cb03e9d5",
    "title": "Anaesthetic Adverse Events During Propofol-Based Sedation for ERCP: A Real-World Cohort Study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.3390/jcm15103679",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42194640/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2eece513757e6752999511ab34b462b04ddb68c1850d2afa269b18a58d3819e8",
    "title": "Predicting Serious Adverse Events, Medication Abuse, Misuse, and Risk of Dependence for Medications with High Dependence Potential: Role of Patient-Reported Factors and Machine Learning Approach.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 7",
    "outcome_summary": null,
    "doi": "10.3390/healthcare14101265",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42194357/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "23414baa956e20db04557c63ef4285ef8be1d1545d40930da362ce8ca246f620",
    "title": "Multidisciplinary Strategies for Tailored Anesthesia Management in Children Undergoing Radiotherapy.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Apr 2",
    "outcome_summary": null,
    "doi": "10.3390/children13050587",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42194113/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5714f6cc5521bc5a86d8972987a1a75cb29973aaff7fda4d2c885664fc1252c0",
    "title": "Toward Integrating Intranasal Esketamine with Traumatic-Memory Psychotherapy in Treatment-Resistant Depression: A Narrative Review and Feasibility-Oriented Protocol Proposal.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.3390/bs16050771",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42193649/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1d4d90d9368a8b7c34540e1fc226b9ce15fac94ed534632bc5c776c09ab07b90",
    "title": "Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Apr 3",
    "outcome_summary": null,
    "doi": "10.3390/bs16050686",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42193565/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "76fcaf336a49485d1109fc378142703bb6d0dc5a5fc768922e113e9763dcce36",
    "title": "Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Apr 3",
    "outcome_summary": null,
    "doi": "10.3390/brainsci16050496",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42192808/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aa49aeb3144ac30a59cd5ea0b6f8dfd1b472f01b98c4a2d7df51ed4bfa286a8e",
    "title": "Study protocol for the effect of intraoperative subanaesthetic dose esketamine on the incidence of postoperative depressive symptoms in patients with breast cancer: a multicentre, prospective, randomised controlled trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1136/bmjopen-2026-119291",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42192642/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7d78de756a2051881681e5b3994a3fa62794510de12f177c00df50187a73f47d",
    "title": "Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41398-026-03961-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42192100/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "13f4cb22113cd396385d82ae53a6f83a1722cfd02182966f24ea4b6f543ab885",
    "title": "Network dysregulation in depression: A synthesis of HPA Axis, BDNF signaling, and neurotransmitter interactions across multidimensional systems.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.pbb.2026.174215",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42191032/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d88ed051444d88a2712f99690b77b50e227ebc788723e8e4ef4a3b90e16204a7",
    "title": "Neurodevelopmental and behavioral effects of early-life esketamine hydrochloride exposure in zebrafish (Danio rerio).",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.cbpc.2026.110583",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42190857/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "009e25a1ae99391877d5de252ec25cc9710dda4674156420cb910bbf15d910e0",
    "title": "Building an opportunity to improve statusepilepticus treatment through EEG monitoringand the use of ketamine. A case report.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.nrleng.2026.501951",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42190801/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7b1fcc0121f4d2f8fff762ed41aa827d6644c309aec1adfd4c3a1510bebb8124",
    "title": "Effect of dexmedetomidine as an adjuvant in erector spinae plane block on postoperative analgesia in thoracolumbar spine surgery with an opioid free anaesthesia technique: A prospective randomized clinical trial.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.jocn.2026.112109",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42190610/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "58ecb5ad2ac9aa67edbc839522407fd7a4fb242b96ba84a8d3262a1f26974fa8",
    "title": "Opioid Free anesthesia in cardiac surgery: The OFACAR randomized clinical trial.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1097/ALN.0000000000006164",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42190101/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5e1b427fabd832c2eb832af4d23069a510e41a206e157c0b351bd5e8ed09af83",
    "title": "Posterolateral Tibial Plateau Fractures-Does Fixation Choice Matter? A Biomechanical Investigation.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.5435/JAAOSGlobal-D-25-00418",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42190039/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "03f09f245e57dd22ba8a119fd4be0d32fabca8e8d5f73aaa3acf092b9d1a7638",
    "title": "Disease-Modifying Therapies in Spinal Muscular Atrophy: Neurodevelopmental and Behavioral Outcomes in the Treatment Era.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s12325-026-03552-0",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42189425/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d469f0f71ab1617d77909079d2215a7998bbe87a1cf0408ef80ee71ae29ff90e",
    "title": "Sex-Related Differences in Circular RNA Expression in Multiple Sclerosis: A Pilot Study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s12031-026-02548-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42189307/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a4aa87511a52c9f747c507a526933646d9cdb54e98bda980aa72cfaf621f7ebb",
    "title": "Immunogenicity of an Inactivated DIVA Lumpy Skin Disease Virus Vaccine in Guinea Pigs and Lactating Cows, and Its Effects on Cow Lactation.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Apr 2",
    "outcome_summary": null,
    "doi": "10.3390/vaccines14050370",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42188743/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "419572803e94f391851c6bcf467ba5a52627a88eea886532d21ec5312339ba5e",
    "title": "Toxicokinetic Studies of the Two Stimulants M-ALPHA and N-Methyl-cyclazodone Using In Vitro and In Vivo Tools.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Apr 2",
    "outcome_summary": null,
    "doi": "10.3390/metabo16050291",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42188000/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "224a95e9027efd50daa6f2aeff14675a9ee1bcee9c5d6583a8d2f1ac3896db09",
    "title": "Effects of THC, CBD, and Their Combination on EEG Dynamics in Rats.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.33549/physiolres.935771",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42187514/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6a844b7612fd5b8b8aa60d612ceb67f615a6921469aef8ec06fe5294c77a6254",
    "title": "Parkinson's disease drug therapies in the clinical trial pipeline: 2015-2024.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1177/1877718X261454154",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42187233/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9d1882d5783543a3643d2da920c8cde78133571f64c407eeba6254d20fcbceb3",
    "title": "Prophylactic interventions to prevent rebound pain after peripheral nerve block in adults: a systematic review and network meta-analysis of randomised controlled trials.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1111/anae.70236",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42187168/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "79109ba3c6fd73afe85cee1d052ec7d298fbca9c436359141fd2bfe31c15be0f",
    "title": "Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1177/20451253261450747",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42186575/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "df3cd6fd7cd237844d2e36ca1c76e0c89d704f19b042d115b48f15d77f2c1510",
    "title": "Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1097/FBP.0000000000000879",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42186402/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3da3f2550273534e046ce7892c8917522f059e8a5e39fb85d41d98ed1076bf79",
    "title": "Evaluation of illicit drug contaminants in seized cannabis in Arizona and California, 2023-2024.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1111/1556-4029.70365",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42186133/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c3a3a5e434b18156e74261a5b91b61d695000e957eddfe7517229358c1506873",
    "title": "Psilocybin modulates social behaviour in male and female mice in a time-dependent manner.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41386-026-02450-x",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42185639/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bdc45a74629a51a32109fb50c78a467f7410b5c010d32f87781d8c31e44e23db",
    "title": "[Mechanism of SMURF2 regulating silicosis-associated epithelial-mesenchymal transition via the TGF-\u03b2/Smad signaling pathway].",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.3760/cma.j.cn121094-20250501-00175",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42185095/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c32ffe5243a45290bb71787418d8712350e4b29bc2d8564279854df4fbe2139f",
    "title": "[Mechanism of miR-129-5p targeting MAP3K13/p-p38 signaling pathway to inhibit macrophage activation to antagonize silicotic fibrosis in mice].",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.3760/cma.j.cn121094-20241111-00516",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42185093/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7e746208b6678ee30c0cf763fe3cc049ec1e7474898651420229a8237bd06dc0",
    "title": "Pharmacological modulation of anxiety-like behavior by flumazenil, midazolam, and ketamine in rats: Evidence from aversive ultrasonic vocalizations and elevated plus maze.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "anxiety",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.pbb.2026.174216",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42184905/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "53342d1105184467acefd5d0c96dbe447a5081644a69548c23a29f8e4a4d9e5b",
    "title": "Serum and cerebrospinal fluid neuroinflammatory biomarkers and trimethylamine N-oxide: associations with white matter lesion severity.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fimmu.2026.1799968",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42183298/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5e417dd658588c5dcd2d9d88e95c38fd6248456da3f3ad4d5ad7835642efbdea",
    "title": "The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fnbeh.2026.1767175",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42182826/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e5ab3e7164f50ad4c22c3cad6a3228246e592382cc4d0ee9bae9acb683f1e1e1",
    "title": "Efficacy and Safety of Esketamine in Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.7759/cureus.109496",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42182549/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1191fff6b77b695a4e807c1aa41eb5a8c1f69ba5efa756df6c07757c2d55ca05",
    "title": "LSD persistently disrupts affective pain processing.",
    "compound": "lsd",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.64898/2026.05.06.723205",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42182358/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "88ecb34877186c6bfb3c01806499ea697a51007cc68fb6ba258e60b2ed23c8a6",
    "title": "Corrigendum to \"Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study\".",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1177/20451253261452482",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42179909/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ea48ec73f9634a3204f7b5250a764a138cfea46946c69c3a0ca3ddf85a7b4e17",
    "title": "Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1177/20451253261448745",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42179908/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8698820cb3cb87b53d652dd95fbd107c3394df4ced356ef6671d1564b5b36d3f",
    "title": "Assessing the role of Subacute Encephalopathy with Seizures in Alcoholics (SESA) syndrome in the development of status epilepticus: a case report and systematic review with individual patients' analysis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1186/s12883-026-04936-z",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42178529/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0962becb4691a3e2d536e3c1a338705cf31d38da9036512d6a22a00931626247",
    "title": "Comparison of three contrast agents in the diagnosis of cracked teeth using Cone Beam Computed Tomography (CBCT).",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41598-026-54779-4",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42178388/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "efa37cfc7edb407dfb2193f2bd54dabf76be9bfc94cb1885bc216fd717463acc",
    "title": "Evaluation and improvement of two European soybean VCU networks.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s00122-026-05282-x",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42178381/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0138f5d121dcb516a8bf2979ec6f7d29d02ad7dc7983e87c8fabca6914dd88f8",
    "title": "Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.1002/cnr2.70587",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42178235/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "44129447398b3be5060bc51cb0a327599314bb184bb29fd607004687734ea93a",
    "title": "Prevalence of chemical restraint use in hospital care. A consensus and cross-sectional study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1093/intqhc/mzag074",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42178221/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cf8a37afea7f7e2c0192be4f2d215e58b75ec2523305cb19793dc1f707c7f113",
    "title": "Ketamine-based ICU sedation and patient-centered outcomes: A systematic review and meta-analysis of mechanical ventilation duration, ICU length of stay, and delirium.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.jcrc.2026.155617",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42177858/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7846de9fc3e4a1efe4202626bcced86a86d0ebb3c8d282229f42479e700e47c8",
    "title": "From therapeutic promise to evidentiary discipline: Reassessing MDMA-assisted psychotherapy for posttraumatic stress disorder.",
    "compound": "mdma",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1002/jts.70094",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42177668/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1119d6177600a3185cc62c93fe26db81f9ca91906bb76d9c11a1752676f15a80",
    "title": "Lenalidomide ameliorates cognitive impairment via putative AChE inhibition: an in silico and in vivo study in a scopolamine-induced cognitive impairment model.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41598-026-49461-8",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42177211/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9e041c959dedeffc177039d50f529a8b5da0a327afec6c91c577c05ce18d6098",
    "title": "Retraction notice to \"Changes in information integration and brain networks during propofol-, dexmedetomidine-, and ketamine-induced unresponsiveness\" [Br J Anaesth 132 (2024) 528-540].",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1016/j.bja.2026.05.003",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42177057/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c47d3db4d2b65db0097a1899ff354510320202c490fb3e1885f6740f747e5a8f",
    "title": "Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.",
    "compound": "dmt",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1177/02698811261443690",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42175700/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1581d9278c23770c2c67a8e38598b64b056ad5766134cc06199a866f245295e3",
    "title": "Quantification of Specific Urinary Oligosaccharide Biomarkers for Diagnosis and Treatment Monitoring of Alpha-Mannosidosis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.1002/jimd.70208",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42175676/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7ed2c3cee5a33d4c6b8546457eb3735c419fc56838c23f976197db3ae9db5b3d",
    "title": "Morphology of the cervical lamina and spinous processes on CT in northeast China: A retrospective observational study correlating anatomical parameters with cervical spondylosis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1097/MD.0000000000049073",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42175513/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a602bc7439c0e6173983799a2df5e1f7d88b1368441017e0fd76f9e114c1fcac",
    "title": "First molecular and phylogenetic study of the bovine lumpy skin disease virus declared in Algeria in 2024.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s00705-026-06653-x",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42174292/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6cbb5c52511992e0ad37d415e812cdc31fe48409c62d8fe679c6366ee0626baf",
    "title": "Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.brs.2026.103130",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42173313/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9fe83896e5c7582115f1af6652297ccf90ccc22e80ede4a8c55e05bb2ca7a882",
    "title": "Clinical utilization and timing of ketamine in pediatric status Epilepticus: a national cross-sectional survey of physicians in T\u00fcrkiye.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Sep",
    "outcome_summary": null,
    "doi": "10.1016/j.yebeh.2026.111115",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42172703/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e42140450f0294f28fd6b21f6e3e4de1bb51e536be5d249a574ca57a21dceb20",
    "title": "Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience.",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1080/02791072.2026.2673843",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42171381/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "49d8854567f536f3efa5333257ec47b1bb87b50347b9be73c6a30011555a11c8",
    "title": "Major depressive disorder is associated with reduced intrinsic connectivity between the bed nucleus of the stria terminalis and ventral striatum.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jan 1",
    "outcome_summary": null,
    "doi": "10.1139/jpn-2025-0160",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42171126/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f43f090d1e6a4bc960b76eebd3afa8c36162fe14f06effb725faffe53ea094d5",
    "title": "Coarse-grained modeling of hydrodynamic behavior in DNA synthesis monomers.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1063/5.0325256",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42170875/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9428cec2bd2921d6cc8e85a030984fdca17d04aa5bc72c709919a30645b45ee8",
    "title": "Efficacy and Safety of Adjunctive Therapy Using Single High-Dose S-Ketamine Infusion for Fibromyalgia: A Multicenter, Prospective, Randomized, Controlled, Open-Label, Blinded-Endpoint Study Protocol.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.2147/JPR.S598907",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42170615/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "60e2ef277cb18eb6fa86dfbcf2998ffadea8a576d32e9e20e5d1689c144de3f2",
    "title": "Epidemiological Assessment of Lumpy Skin Disease in Cattle: Risk Factors at Farm and Animal Levels in Southern Bangladesh.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1155/tbed/7813523",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42170559/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "964df2105237f7b80373505c11f5de3a8082fff29b82a5fe5e8c9bba4127844e",
    "title": "Inhibitory Effect of Melatonin on the Proliferation of Breast Cancer Cells MDA-MB-468 by Antioxidants Superoxide Dismutase and Glutathione Peroxidase.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.31557/APJCP.2026.27.5.1695",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42169575/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "551ef9b35d454d4b57c9401a71495e8bb1ad2a401df70e2514a208d16c8ecc2d",
    "title": "Understanding and evaluation of the concept of \"palliative psychiatry\" among service users with chronic and treatment-resistant depression: a qualitative study of service user perspectives.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1186/s12888-026-08188-6",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42168971/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2ac64958a29e751eb98db25cec7cac838ef243b1710a4109546bb364adb42d4f",
    "title": "Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats.",
    "compound": "mescaline",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s12264-026-01632-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42168715/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a59c8990fc1e5343a9e6c299461dcf0a4d05982be1fe581285b5eb346841f40c",
    "title": "Shorter to be effective: subanesthetic-dose ketamine infusion reduces the global and regional path length of brain functional connectivity in patients with treatment-resistant depression and suicidal ideation.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s00213-026-07089-6",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42168548/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7edf635f668ff6c2f7e2bdb52619b9f5237d3f76335d464484662d12fd9370d0",
    "title": "PsiConnect: Multimodal Neuroimaging of Context-Dependent Brain and Behaviour Dynamics under Psilocybin.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41597-026-07312-1",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42168232/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9b2f3dc2254657062153ecdc89ebf1e513a87fdc55e57771e21a4ed0ba829c13",
    "title": "Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms.",
    "compound": "mdma",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41398-026-04069-4",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42168162/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8fc10856846db5d31e6b5ad8a2185d9caf5d5c9144e99db43d777501046577b0",
    "title": "Simultaneous LC-MS/MS determination of the emerging ketamine analogue 2F-2-oxo-PCPr and related compounds in human hair and application to forensic casework.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Sep",
    "outcome_summary": null,
    "doi": "10.1016/j.forsciint.2026.113011",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42167022/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3e2d024b587e1efb79cb52eb34d82e648d6f5f2953e96082f30dd8a413c1bcb4",
    "title": "A novel sequential ketamine and D-cycloserine/lurasidone therapy for bipolar depression with acute suicidal ideation.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.1080/13543784.2026.2674645",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42166622/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d2f4b9ef3c70a1f48a54baec70e479f41868444e1bc32f15c955b18e1e7d2dce",
    "title": "Virtual reality interventions in obesity and eating disorders: a systematic review of biomarker, clinical, and behavioral outcomes.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "eating_disorder",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s11154-026-10046-5",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42165996/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0010ab770be2f18c2062bf9b891c11667d443b823c2d1374bad051c0fb966c36",
    "title": "Pilot study on esketamine response in treatment-resistant depression: impact of pharmacogenetic, clinical, and demographic variables.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fphar.2026.1783538",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42164345/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "34299027cddcbc1060d75b932a1c148333c731ff087c148fd8dd6524d7f78875",
    "title": "Electroconvulsive therapy in an older patient with recurrent major depressive disorder and a permanent pacemaker: A case report.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1002/pcn5.70348",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42164249/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a0414c246fbd67383afb23af11a5c2c443d67d170b18683d38a63082cd5da043",
    "title": "Management of Treatment-Resistant Depression: An Updated Narrative Review of Current and Emerging Treatments.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Apr",
    "outcome_summary": null,
    "doi": "10.7759/cureus.107343",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42164210/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "14e1647cea2b7659be63a5540be855439e6281b77bacbf74a68bbcac00596525",
    "title": "Association between VA providers' reported use of care strategies and emergence delirium: a national retrospective cross-sectional survey.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1186/s13741-026-00700-6",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42163320/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e7115fe16620ef6eafd380b06a7658000a37f73192c975c508cbe36e450c7d78",
    "title": "Farmers' knowledge, attitudes, and practices regarding lumpy skin disease in Northern Bangladesh.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1186/s12917-026-05555-z",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42163305/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a0b52e99f591595f319d644e956e04b655d8873720a5266d7908d23830282f2",
    "title": "New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.1002/bdr2.70048",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42163018/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "78097aa362bb5a15ac317a396095a7d3c05bc7b7587e942a479e6ed42b5105ff",
    "title": "Trajectories of processing speed in multiple sclerosis across disease-modifying therapies.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s00415-026-13860-8",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42162514/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "73196da414d5968aa1f1129d5103bfe4d984ae374afd0c3d7c2d02ad294f44ad",
    "title": "Effect of ketamine intervention on hemodynamic responses in patients with treatment-resistant depression.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41598-026-51314-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42162047/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "326f7db31bf91dfec636c88e279f3717cdc3d412c48fecf08ce3db1fbe0a8c1c",
    "title": "Xanomeline-trospium reverses phencyclidine-induced cognitive deficits through modulation of the gut microbiota-brain axis in mice.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1038/s41398-026-04097-0",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42161933/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "87b4d781894ef38b420cee81283220cfa972fe69308a8035852bb7697b842013",
    "title": "Neurometabolic depletion with ketamine during sevoflurane anaesthesia.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.bja.2026.03.072",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42161719/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0a8aac578be3e8e052812f083e205824eafdc6dcda37ee919fa049d9c842c64e",
    "title": "Intranasal sufentanil versus ketamine for acute severe traumatic pain in children: protocol for a phase II randomised controlled trial (SUF-KET-PED).",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1136/bmjopen-2025-112617",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42161544/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "95578e20809907ed2b344bcbbe5f2c7f0603aa531aa20e55101ba89299e588b8",
    "title": "Zebrafish startle habituation: How readout choice influences the interpretation of chemical effects in neurotoxicity screening.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jul 1",
    "outcome_summary": null,
    "doi": "10.1016/j.ecoenv.2026.120289",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42161110/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9e108fef13e186222d1da9765aabade1b56bc26b71e93c92ba554e059edf6468",
    "title": "Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1007/s43440-026-00867-1",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42159864/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5418ea534bd4958d73a1509b82a4d32cd8a1543fab0cb2e711e7ffcc3ee14bed",
    "title": "When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1176/appi.ps.20260203",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42159594/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "08c79c5d6347e3185087d184287dc9bb1e7db7d8d66a09ec2478f192a4dcd5c9",
    "title": "Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "eating_disorder",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.1186/s12916-026-04929-2",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42157199/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5c77310b5ada9e606ac1d75e6a64962f6ac7b82795efb115ab85d6935c64d8f9",
    "title": "Condition-Embedded Visible-Infrared image dataset for typical ground features.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.1038/s41597-026-06847-7",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42156747/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a3a2a043e2d3365926174a0e77da3deae2f8f38ad89937032715dc1a97d095d6",
    "title": "Safety and efficacy of esketamine versus remifentanil as adjuncts to propofol sedation in children undergoing haematologic-oncologic procedures in China: a single-centre, randomised, controlled, crossover trial protocol.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.1136/bmjopen-2025-109040",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42156146/",
    "source": "PubMed",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ecd7fa4359ce2de55f62df59431f6733b0e00075de02ff1669764c27e88f5af3",
    "title": "From monotherapy to sequential models: An updated scoping review on ibogaine\u2019s role in treatment for psychiatric disorders",
    "compound": "dmt",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1177/02698811261443674",
    "url": "https://www.semanticscholar.org/paper/a8b5f01927c960ad525ac4d75a309ca0100325ee",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "760ba230c8531b6e379618e618a27cc03ce0dfc605bd5bdf141df94561520dfc",
    "title": "Clinical Trial Design and Regulatory Requirements for Artificial Intelligence as a Medical Device: A PRISMA-ScR\u2013Guided Scoping Review of Global Guidance and Evidence (2017\u20132025)",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.3390/jcm15051937",
    "url": "https://www.semanticscholar.org/paper/9b172c8cb0d6981f4d80fdd7c20091c9d6153ab1",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1336a3b80cac2c67c449d3c2c9522e9695a906b20d634dcb09216089d96110f9",
    "title": "A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.2215/CJN.0000000969",
    "url": "https://www.semanticscholar.org/paper/4c236d5b7eb7159bcc76f93a65fa2d92ca6ca381",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0ad516b2b7e33cc67079071e2a63a6feb46c1257c3027747058a73b33c5359bb",
    "title": "An updated review of the SMA clinical trial landscape in the United States: Findings from analysis of recruitment targets on ClinicalTrials.gov and a survey of SMA clinical trial sites on factors affecting site capacity and readiness",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1016/j.conctc.2026.101601",
    "url": "https://www.semanticscholar.org/paper/e605757545e8dc3df18b6f02b7a1285f33c47239",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1d3746ded4c13911f8b62d927f84e21e69fbf948cba6af10e6ae0083ff174591",
    "title": "Ultraprocessed foods consumption and risk of preeclampsia: a secondary analysis of the improving mothers for a better prenatal care trial Barcelona (IMPACT BCN) randomized clinical trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1016/j.ajcnut.2026.101255",
    "url": "https://www.semanticscholar.org/paper/1268ec67e588aa84ba3ec175b562682b19c2e22f",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6d1a6b69174cf19f67439765146cc654bfb91245d0bffcd8aad328f44ffb5d37",
    "title": "One\u2010Year Analysis of Clinical and Radiological Outcomes of Two\u2010Piece Zirconia Compared to Titanium Implants: A Multicenter Prospective Randomized Clinical Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1111/clr.70094",
    "url": "https://www.semanticscholar.org/paper/4deb3be132d0fe43324ea35035f0e0ee7e37db5b",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f944072d2e5280d413cff5cdad58001e686e24375691dc8ce6261d1f4ec5ebd2",
    "title": "Changes in Insulin Resistance with Different Weight Loss Methods in Patients with Type Two Diabetes Mellitus and Hypertension: A Comparative Clinical Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.3390/jcm15020546",
    "url": "https://www.semanticscholar.org/paper/bd70c5510a89dd2281aa879856ed4a3537ff1cc4",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6e232e097f01d3b50ccb4a2ea8542cb89a1422b7b79b39c81cb8e32cfb2ea837",
    "title": "Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1200/CCI-25-00262",
    "url": "https://www.semanticscholar.org/paper/0263a2d58e8fc2a379a5671c4edcd2897d5e55cc",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6f32bf3bf0032e215ff9f759b6c5dc2a18395ff46633fbf92358ce751c01cbd6",
    "title": "Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1111/all.70263",
    "url": "https://www.semanticscholar.org/paper/6b9aa66e76a4536f9c0de103ebb7c24ce17d5f67",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f92e081670472280fb0690bdb1f3e897ec7555145034be4772188b778c540b9a",
    "title": "The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s10585-026-10392-3",
    "url": "https://www.semanticscholar.org/paper/565cecb618c1f2ccc4566fe09e260e02c79460af",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "44180ca22fafb0b1c4355e6929d5fcc4e2b9a6dbadefeb083df13036a8298373",
    "title": "Vertical skeletal dimension and dentoalveolar changes in extraction versus non-extraction orthodontic treatment in class I malocclusion: a non-randomized clinical trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s00784-026-06768-0",
    "url": "https://www.semanticscholar.org/paper/48d238d90262b0bac46a2467c2b925b3f0be6ed8",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c0ce4863b6a332237879bfcb19f1a1e1d25120ca5c45ab3ccddb01e095ef9e3d",
    "title": "Diagnostic performance, safety, and biodistribution of [\n 68\n Ga]Ga-OncoACP3 for PET imaging in prostate cancer: A phase I clinical trial.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1200/jco.2026.44.16_suppl.3074",
    "url": "https://www.semanticscholar.org/paper/97ccba1594749d3ed631bc31c046d0e96983b222",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a82bdb22c998e1094ef8e79cdfa0e798dcc0193a5fbf4fe078ba3d9cb4ee7006",
    "title": "Zirconia versus Titanium Implants: 1\u2010year Prosthetic Outcome of Screw\u2010Retained Single Crowns in a Randomized Clinical Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1111/cid.70160",
    "url": "https://www.semanticscholar.org/paper/0b617519602e60e122074933648fa4a066429012",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f42355d4ba8136b4a2f0d4fdc10465467798e9f728317e0e09780059a67618fd",
    "title": "290 Clinical response to clozapine in Black patients: A secondary analysis of an open-label clinical trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1017/cts.2026.10484",
    "url": "https://www.semanticscholar.org/paper/df1279bdd138679f17d9f29a1ba9b11a907a172a",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "985d14de23e67de3bc7f363bd9d1017181f1cc28488f738c21bf8d1b5f1b6435",
    "title": "PhotoBio-HIV: Effects of Vascular Photobiomodulation on Inflammatory and Immunological Biomarkers in People Living with HIV \u2013 Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Clinical Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s42399-026-02468-8",
    "url": "https://www.semanticscholar.org/paper/49c6dac28add52ce6a319481ad96f719850373ee",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "81bd7c6fba25c8fa80a1b4fb3559149b46e006d0d8e1a3f5a3acdb059382ba60",
    "title": "Next-Generation Artificial Intelligence in Clinical Trial Design, Conduct, and Analysis: A Paradigm Shift in Clinical Research",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.31579/2690-4861/1120",
    "url": "https://www.semanticscholar.org/paper/7d464d04671f133cdb6f9b653ee0d99b3ceee96f",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "01db6f2939a4ce6c8ef821f419c9692f032f0152180b3a4a852def5ca92c04f7",
    "title": "225 The OSANOVA Clinical Trial: Can a mandibular advancement device spare surgery in severe to moderate OSA?",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1017/cts.2026.10429",
    "url": "https://www.semanticscholar.org/paper/e3444c44becb13798c34e4098c0c304066a7e779",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b630b795ed2bc9006c3a18cb3ddac8cc7a83707774cf2adea673f45b90063cea",
    "title": "Prophylactic Intravenous Phenylephrine to Prevent Propofol-induced Hypotension during Induction of General Anaesthesia: A Randomised Clinical Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.7860/jcdr/2026/87752.23394",
    "url": "https://www.semanticscholar.org/paper/e95c6453728dc6ef76018f2df1305748b59dad13",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "68ec11bcb7546069b6e5b28b358fc8c270e117d50f6d23502d03b00b6ed6714a",
    "title": "Trueness of Dental Implant Placement Using Dynamic Navigation or Non-Guided Approach by Novice Surgeons: A Randomized, Controlled Clinical Trial.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1111/clr.70119",
    "url": "https://www.semanticscholar.org/paper/25bd979aed445c375e2c9ccdd897ab26c392b798",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "860331846141050cfca0149bfba2f0d666b260852a75a86bf0d54a9556ed8e51",
    "title": "Analgesic Efficacy of Hyperbaric Ropivacaine versus Hyperbaric Bupivacaine with Fentanyl in Infraumbilical Surgeries under Spinal Anaesthesia: A Double-blinded Randomised Clinical Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.7860/jcdr/2026/84065.22772",
    "url": "https://www.semanticscholar.org/paper/42a5c32666ffdeb01c16b29f304416472763b984",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ab71338c26a9e771c24dd1c653b50192cfd3848ea48bfce292343c0c6c297ad0",
    "title": "316 Frontiers Trial Finder: Implementing a mobile platform integrated with a Clinical Trial Management System to enhance accessibility and engagement",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1017/cts.2026.10506",
    "url": "https://www.semanticscholar.org/paper/3005676093c9eb866c562a455d363cba856f39af",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "856d1641d88136d83996aecb27195ad16daadcc1a1419159d090412ebddc5308",
    "title": "A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2004 monotherapy in patients with advanced tumors.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1200/jco.2026.44.16_suppl.tps2686",
    "url": "https://www.semanticscholar.org/paper/f138855e5b92186c9e28001798d52fc35363f1f4",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5a17eee73a8d77e81642f187db60a8d5dbabf6cd6929d2c399ece4181c59940d",
    "title": "Clinical performance of alkasite and glass-hybrid restorations compared with resin composite in class II cavities: a randomized clinical trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s00784-026-06869-w",
    "url": "https://www.semanticscholar.org/paper/0147f8287c34b7bce1dc7400e9e71ad654d929c9",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2dd605d1a0d00804bcf5517d66525c4a1451bdae88e84d1ab2c9e229602d007d",
    "title": "Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1093/cid/ciag337",
    "url": "https://www.semanticscholar.org/paper/9351d9b109e3482cc0273f39ac6ac3498a392430",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b213022feacd15bfc18cb4cb4646fb83e70e41f656822e2f3ad78b8521f6cdf4",
    "title": "Partially demineralized allogeneic cancellous bone plug versus deproteinized bovine bone mineral for guided bone regeneration: a pilot randomized controlled clinical trial",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s00784-026-06914-8",
    "url": "https://www.semanticscholar.org/paper/4a7c994a391880f4a009d3e6e39d2ab88949dfab",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d8c1e3b62a749873a441bbf536613f7cb7a88ed070fd8051796f8393214a3711",
    "title": "Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1177/20420986261436104",
    "url": "https://www.semanticscholar.org/paper/6a65e2ae46089dcd4f4eaac82e4e9009bdd39491",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7633821709ee83fac8de2cb5b4b67532899a0706a4d7bb15c93a8cf18cd4c65f",
    "title": "Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1080/14656566.2026.2654682",
    "url": "https://www.semanticscholar.org/paper/f8759f01e3abee04695f3724c1698e4d990c233f",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0602a4b7b77376f21de587ade4d083e86d4ae0dc1cb74773e88951f45c0d3285",
    "title": "Blinding Integrity in Psychedelic Randomized Clinical Trials",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": "10.1001/jamapsychiatry.2026.0255",
    "url": "https://www.semanticscholar.org/paper/0343664f4cc89dc6ef272499661fdd678bb95fa8",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f4d9cd3de2243c758a597d7e5d0a41ae99f6a4046a8fc0f8aeafcf756ab2afbd",
    "title": "Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University of Calgary",
    "condition": "PTSD",
    "sample_size": 76,
    "status": "recruiting",
    "date": "2026-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06885996",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6b9f8811c1b4a8935d44346e0924e16cc4fd040af78259d69304321f5e048701",
    "title": "Psilocybin as a Novel Therapy for Residual Anhedonia",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 90,
    "status": "recruiting",
    "date": "2026-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07607938",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "68572240fa247ae426f12f9fcdb120bb6b87ecc833e7a40f75911ce29632f696",
    "title": "The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2026-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07610369",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f220d2d0774dec451111b4192a155c6b993190d4a691992506615cc55f7a1c0b",
    "title": "The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Gabriella Gobbi",
    "condition": "other",
    "sample_size": 50,
    "status": "recruiting",
    "date": "2026-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07433452",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d6d622dd0edcfd556a1c7864c4f052b9af0cf8878e4c7a5694427079a84a92c3",
    "title": "Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University of Washington",
    "condition": "depression",
    "sample_size": 72,
    "status": "recruiting",
    "date": "2026-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07565909",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "86a2ac15f2880435a0566ba3c93810f42cbce410cd67cfa3ba50cf67616dddbb",
    "title": "Psilocybin for Prolonged Grief Disorder",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "University of Virginia",
    "condition": "other",
    "sample_size": 12,
    "status": "recruiting",
    "date": "2026-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06724289",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "409ac7b610a7f5f9af15441f6a2620df69d075e61e3604924c4bc41b26e0cb32",
    "title": "Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Indiana University",
    "condition": "depression",
    "sample_size": 50,
    "status": "recruiting",
    "date": "2026-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07499583",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ac3111169aa40594e6320d891fccf408db5f6b79f75e9b284f868d0b84e14771",
    "title": "RCT of Psilocybin-assisted CBT for Depression",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of California, Los Angeles",
    "condition": "depression",
    "sample_size": 50,
    "status": "recruiting",
    "date": "2026-01-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07281352",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e324a69809ddc24437b135eecc9326d950a0c5f826bc80e60cef857ade5f1d0b",
    "title": "Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Alan Davis",
    "condition": "depression",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2026-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07216404",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "dbcef732dcda00d9fa26a59098f5ddcaf82aa0f1af03c299ff392b230694725b",
    "title": "Safety and Tolerability Trial of Psilocybin in Healthy Older Adults",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Colorado, Denver",
    "condition": "other",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2026-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07516405",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1f8567d2feafdfce8d1ae343c02861371c53b634dbd1e9801be2bd4fe8a4d91c",
    "title": "Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of New Mexico",
    "condition": "PTSD",
    "sample_size": 36,
    "status": "recruiting",
    "date": "2026-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07506395",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "dfb54389650d87afce9429b918a67efd6601b77c1e0c55589b83c83f1a24ca27",
    "title": "MDMA-assisted Therapy for Fibromyalgia",
    "compound": "mdma",
    "type": "observational",
    "institution": "Spaulding Rehabilitation Hospital",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2026-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06066853",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "67e19208eb909f59652827ab14f17e506993993b8fc07dfa3bb1c9a333cc3adf",
    "title": "MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "VA Office of Research and Development",
    "condition": "PTSD",
    "sample_size": 80,
    "status": "recruiting",
    "date": "2026-05-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07118839",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c22e60d643f5b5902d6f605cd946b4cfba1ed5756a90164f465ef53ffbf92dcc",
    "title": "A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "eating_disorder",
    "sample_size": 0,
    "status": "completed",
    "date": "2026-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04454684",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "706d79236af3dd0d28d8b30fea94603a01da8e30b20b22f665da95313cee91f5",
    "title": "Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": "Unity Health Toronto",
    "condition": "other",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2026-01-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07301632",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bcda341f6c80b2c1eedf4ffd27e8983860587890b42d16d8995a1720cc1b5dd7",
    "title": "Study of Midomafetamine in Healthy Adults",
    "compound": "other",
    "type": "phase_1",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 32,
    "status": "recruiting",
    "date": "2026-04-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07584720",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d6ee4db511e10893b9dd4e0e6be50e1233801c6c39233ad2f45a77e989801f06",
    "title": "MDMA-Assisted Therapy for Mental Healthcare Providers",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Rachel Yehuda",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2026-02-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07102576",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "dcb0ab622c69c1edc2b440f1e5493156f382f53b33b530a322981e8b10e51243",
    "title": "Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)",
    "compound": "lsd",
    "type": "observational",
    "institution": "Northern Jiangsu People's Hospital",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2026-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07585786",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e4293325660fccdb024c480583af2ca7b98d3a254b7bd0c96803cf49476c9a3a",
    "title": "LSD Treatment for Persons With Alcohol Use Disorder",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Felix Mueller",
    "condition": "other",
    "sample_size": 128,
    "status": "recruiting",
    "date": "2026-01-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05474989",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2b3d80a9a7a28cd0fbf31f37d5552640336c7965cf9afb50cf1611adf4c05583",
    "title": "Salivary Oxytocin as a Biomarker of Psychedelic Treatment",
    "compound": "other",
    "type": "observational",
    "institution": "University of Geneva, Switzerland",
    "condition": "other",
    "sample_size": 80,
    "status": "recruiting",
    "date": "2026-01-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07345858",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8d6b32c8136a3ae829aae8fc96f78ccfe385a69478cd18ec610eecbebcc5ae76",
    "title": "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 165,
    "status": "recruiting",
    "date": "2026-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07592689",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "71d90a90606717abf9bed3b0e00f781ecf4afa039982c85b22435cb706225f80",
    "title": "Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism",
    "compound": "lsd",
    "type": "observational",
    "institution": "Northern Jiangsu People's Hospital",
    "condition": "other",
    "sample_size": 140,
    "status": "recruiting",
    "date": "2026-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07490405",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e544b1e3a296ff9954f7a232dc7a0569589b44f30e9c77cd2795bb0d53981c3d",
    "title": "Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder",
    "compound": "other",
    "type": "observational",
    "institution": "Shanghai Mental Health Center",
    "condition": "other",
    "sample_size": 130,
    "status": "recruiting",
    "date": "2026-05-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07602153",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "07283a548dd523b49928a275ff9627cbcfd536404ba2eb283a5efa37cd4d14a9",
    "title": "Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Aga Khan University",
    "condition": "other",
    "sample_size": 120,
    "status": "recruiting",
    "date": "2026-03-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07197684",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "59e6879d566e95213cd4b5e007ccee85391aeceae4462494b938b2bc6d7ba06e",
    "title": "An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK)",
    "compound": "other",
    "type": "observational",
    "institution": "University of Oxford",
    "condition": "other",
    "sample_size": 90,
    "status": "recruiting",
    "date": "2026-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07543003",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "20d537a7e6d0e1269239045aa96c37b526a60e2d99aeea9f03c03d602cd8d699",
    "title": "Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study",
    "compound": "ketamine",
    "type": "preprint",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026-04-01",
    "outcome_summary": null,
    "doi": "10.64898/2026.03.31.26349757",
    "url": "https://doi.org/10.64898/2026.03.31.26349757",
    "source": "bioRxiv/medRxiv",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ccdbb08bb27015cb6e66fc2af99589872b176f507d072618bb262187ecad6f51",
    "title": "MAPS Celebrates 40 Years at a Defining Moment for Psychedelics",
    "compound": "other",
    "type": "news",
    "institution": "Multidisciplinary Association for Psychedelic Studies (MAPS)",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "Thu, 23 Ap",
    "outcome_summary": "MAPS marks its 40th anniversary, having raised more than $150 million, supported 45 studies, trained 500+ therapists, and contributed to the first NDA submission for a psychedelic-assisted therapy. The organization also notes a new federal Executive Order directing agencies to expand psychedelic research and accelerate regulatory approval.",
    "doi": null,
    "url": "https://maps.org/2026/04/23/maps-celebrates-40-years-at-a-defining-moment-for-psychedelics/",
    "source": "MAPS.org",
    "first_seen": "2026-06-07"
  },
  {
    "id": "31eafba9442cd8caa701faf00f1e33bae186d7ccb67c71da56ade3d87a3dc8ed",
    "title": "MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy",
    "compound": "other",
    "type": "news",
    "institution": "Multidisciplinary Association for Psychedelic Studies (MAPS)",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "Sat, 18 Ap",
    "outcome_summary": "On April 18, 2026, MAPS issued a statement welcoming an Executive Order directing $50 million in federal funds to accelerate research into psychedelic compounds including ibogaine, psilocybin, LSD, and MDMA for serious mental illness, while emphasizing the need for rigorous science, ethical frameworks, and Indigenous community collaboration.",
    "doi": null,
    "url": "https://maps.org/2026/04/18/maps-welcomes-federal-action-to-advance-science-driven-psychedelic-research-and-policy/",
    "source": "MAPS.org",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cafb92f2f8218313be976a39f2efc1b945873fe775d2d6e44afe6ebafc24eb2f",
    "title": "Not Many Patents Threaten Traditional Knowledge About Ayahuasca",
    "compound": "ayahuasca",
    "type": "other",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "Wed, 20 Ma",
    "outcome_summary": "A detailed survey indicates that active patent requests implying undue appropriation of ayahuasca-based traditional knowledge are rare; the article argues that inaccurate or exaggerated information about patent threats spreads alarmism without factual basis and hinders negotiation between Indigenous communities and researchers.",
    "doi": null,
    "url": "https://chacruna.net/not-many-patents-threaten-traditional-knowledge-about-ayahuasca/",
    "source": "Chacruna Institute",
    "first_seen": "2026-06-07"
  },
  {
    "id": "79dcfa6bda85b0172ce405a8038ad7e23af072a7a4fdd9095eba497811269011",
    "title": "An Uneasy Partnership?",
    "compound": "ibogaine",
    "type": "news",
    "institution": null,
    "condition": "addiction",
    "sample_size": null,
    "status": "other",
    "date": "Thu, 09 Ap",
    "outcome_summary": "Ibogaine is increasingly paired with 5-MeO-DMT in retreat settings, which complicates research data; ibogaine has shown improvements in executive function and reductions in PTSD, depression, and anxiety symptoms in study participants. Funding for ibogaine research has increased, including $50 million allocated in Texas.",
    "doi": null,
    "url": "https://chacruna.net/ibogaine-and-5-meo-dmt-an-uneasy-partnership/",
    "source": "Chacruna Institute",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2cb2ced6016f90f2fd9ed6ca40a046985efa0155a97786487338a2ed363efe24",
    "title": "Psychedelic Renaissance Progresses to Psychedelic Enlightenment",
    "compound": "dmt",
    "type": "other",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "Fri, 27 Ma",
    "outcome_summary": null,
    "doi": null,
    "url": "https://chacruna.net/extended-state-dimethyltryptamine-dmt-psychedelic-renaissance-progresses-to-psychedelic-enlightenment/",
    "source": "Chacruna Institute",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4551ce592f46b6cc2b7d9e643ba78ac7b18da0e0e964163e7e9509e60b33220e",
    "title": "Football Player Jordan Poyer Leads the Breath of Life Tour",
    "compound": "ayahuasca",
    "type": "news",
    "institution": "Luminate",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "Wed, 13 Ma",
    "outcome_summary": "NFL player Jordan Poyer founded Luminate in 2024 and launched the \"Breath of Life\" tour, a modern ceremonial concert blending breathwork, sound healing, movement, and live music, with MAPS as a founding sponsor. The tour aims to scale access to psychedelic-informed healing modalities.",
    "doi": null,
    "url": "https://www.lucid.news/football-player-jordan-poyer-leads-the-breath-of-life-tour/",
    "source": "Lucid News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "39ad8516f66f706dfab11ab09db562a16b932ee5fbae45ccbd682c246ff8a77d",
    "title": "Trump Signs Executive Order To Fast-Track Psychedelic Research",
    "compound": "ibogaine",
    "type": "regulatory",
    "institution": "White House / U.S. Department of Health and Human Services / Department of Veterans Affairs",
    "condition": "PTSD",
    "sample_size": null,
    "status": "other",
    "date": "Tue, 21 Ap",
    "outcome_summary": "President Trump signed an executive order on April 18, 2026, directing federal agencies to reduce regulatory barriers and streamline FDA approval for psychedelic therapies, with a specific $50 million federal initiative to study ibogaine for veteran mental health and substance use disorders.",
    "doi": null,
    "url": "https://www.lucid.news/trump-signs-executive-order-designed-to-fast-track-psychedelic-research/",
    "source": "Lucid News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c8b0a8c580a45b06ad4b8daaab8d5d51860e42abebcb1804d4c9e2bb160f74cb",
    "title": "Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai's PCN-101 Phase 2a Readout",
    "compound": "ketamine",
    "type": "news",
    "institution": "atai / Perception Neuroscience",
    "condition": "depression",
    "sample_size": null,
    "status": "active",
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://psychedelicalpha.com/news/racing-beyond-racemic-a-look-at-ketamine-drug-development-ahead-of-atais-pcn-101-phase-2a-readout",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0cfb77b50b77e4a491710966c3716facb80a3b5580fb3bcbf104859aec6c0f25",
    "title": "What Approval Won\u2019t Solve: Brian Barnett on Ketamine\u2019s Lessons, RVUs, and Scaling Psychedelic Care",
    "compound": "ketamine",
    "type": "news",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://psychedelicalpha.com/news/what-approval-wont-solve-brian-barnett-on-ketamines-lessons-rvus-and-scaling-psychedelic-care",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3c929d2556ccd5fe64198cce444ab5f09dc29cff4f68fcdafc53c715d98ca224",
    "title": "Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase 3 Alcoholism Trial Launches",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University of Exeter",
    "condition": "addiction",
    "sample_size": null,
    "status": "active",
    "date": "2026-06-07",
    "outcome_summary": "Phase III trial for ketamine-assisted therapy in alcohol addiction has launched. Professor Celia Morgan of University of Exeter, who has led the world's largest studies of KAT, discusses the therapeutic potential alongside rising concerns about recreational ketamine addiction in the UK.",
    "doi": null,
    "url": "https://psychedelicalpha.com/news/therapy-or-threat-uk-expert-warns-of-rising-ketamine-addiction-as-phase-iii-alcoholism-trial-launches",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "19d32e21ab77350b8845fe5b9a7b0957f0eafd42ba6d05185b8dd51cc9bb11eb",
    "title": "Protocol for intravenous ketamine treatment for patients with therapy-resistant depression",
    "compound": "ketamine",
    "type": "observational",
    "institution": "\u00d8stfold Hospital (The Ketamine Unit at DPS Nordre, \u00d8stfold Hospital)",
    "condition": "depression",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "Protocol describing intravenous ketamine treatment program for therapy-resistant depression at \u00d8stfold Hospital, including indication criteria (MADRS \u226520, failed \u22652 antidepressants), treatment procedures, dosage, psychotherapeutic integration, and safety monitoring framework. Version 1 dated November 2024.",
    "doi": null,
    "url": "https://psychedelicalpha.com/wp-content/uploads/2025/07/protokoll-ketaminbehandling-for-terapiresistent-depresjon-v1-nov.2024-1.pdf",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "88471b6d0206aa9ba942cef376fcf0598e95b629f2e6b0b087a3c73f864e34b9",
    "title": "UCSF Psilocybin Clinical Trials \u2014 San Francisco Bay Area",
    "compound": "psilocybin",
    "type": "other",
    "institution": "UCSF",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.ucsf.edu/psilocybin",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "86f8b42f16400b7b1a2a2274282c99b7fcfb536397ad424e54d79ca97271dc28",
    "title": "MDMA Trials for PTSD in Soldiers, What to Know Now",
    "compound": "mdma",
    "type": "news",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "active",
    "date": "2026-06-07",
    "outcome_summary": "The FDA has reviewed Phase 3 trial data; as of 2026, MDMA has not been approved for general clinical use. The VA does not currently offer MDMA-assisted therapy as a standard treatment, though clinical trials continue through approved research sites.",
    "doi": null,
    "url": "https://valoannetwork.com/mdma-trials-ptsd-soldiers",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3aa1d5a6d57677f40cf45d7ec23fcc5beb210a2d55c3233b67df6f2acc2bd1c0",
    "title": "RFK, Jr., puts psychedelics on fast track to FDA review and approval",
    "compound": "other",
    "type": "regulatory",
    "institution": "U.S. Food and Drug Administration",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "The FDA announced it is fast-tracking review and approval for three companies studying psilocybin and methylone for depression and PTSD, and approved a phase 1 clinical trial of noribogaine for alcohol use disorder.",
    "doi": null,
    "url": "https://www.scientificamerican.com/article/rfk-jr-puts-psychedelics-on-fast-track-to-fda-review-and-approval",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1bf78091adedbf35cf2a1431f68d62a70fc136be37ce1f0d2da15168c781a087",
    "title": "Why Trump reversed course to fast-track psychedelic drugs for mental healthcare",
    "compound": "other",
    "type": "news",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "In April 2026, President Donald Trump signed an executive order to accelerate research into psychedelic drugs for mental illness and issued priority review vouchers to three companies developing psychedelic or MDMA-like therapies (Compass Pathways, Usona Institute, and Transcend Therapeutics) to speed FDA review processes.",
    "doi": null,
    "url": "https://www.cnbc.com/2026/05/31/why-trump-is-encouraging-psychedelics-for-mental-health.html",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "df64e4c8db95c04ca2a22acdbc5d62a6d6a935dee95cd19c98cc8b82b6412374",
    "title": "VA clinical trial on psychedelic-assisted therapy gives Missouri lawmakers hope",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "U.S. Department of Veterans Affairs",
    "condition": "PTSD",
    "sample_size": 80,
    "status": "recruiting",
    "date": "2026-06-07",
    "outcome_summary": "The VA launched a new randomized controlled trial of MDMA-assisted therapy for PTSD and alcohol use disorder in U.S. veterans; it will enroll approximately 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and a control group.",
    "doi": null,
    "url": "https://missouriindependent.com/2026/06/03/va-clinical-trial-on-psychedelic-assisted-therapy-gives-missouri-lawmakers-hope",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0485f8e8029666beffe0d6159160f20de2f3e31a29ad06767011442d5b75e444",
    "title": "VA launches MDMA-assisted mental health therapy trial",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "U.S. Department of Veterans Affairs",
    "condition": "PTSD",
    "sample_size": 80,
    "status": "recruiting",
    "date": "2026-06-07",
    "outcome_summary": "The trial was announced to evaluate safety and efficacy of MDMA-assisted therapy for PTSD and alcohol use disorder in U.S. Veterans. It will enroll approximately 80 Veterans and compare outcomes between MDMA-assisted therapy and identical psychotherapy with an active placebo.",
    "doi": null,
    "url": "https://news.va.gov/press-room/va-launches-mdma-assisted-mental-health-therapy-trial",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5afab74003719ec8791fe3d495fa116e0bce5b57350b20f2377b2c8de1a0563a",
    "title": "Brain scans reveal how ketamine quickly lifts severe depression",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Yokohama City University Graduate School of Medicine",
    "condition": "depression",
    "sample_size": 83,
    "status": "published",
    "date": "2026-06-07",
    "outcome_summary": "PET imaging with [11C]K-2 tracer showed that ketamine's antidepressant effects in treatment-resistant depression are mediated by dynamic, region-specific changes in AMPA receptor density in the living human brain, with some cortical areas showing increased receptor density and reward-processing regions like the habenula showing reductions.",
    "doi": null,
    "url": "https://www.sciencedaily.com/releases/2026/03/260307213234.htm",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8ed7b4a28b26f510a318aac78b052414ca43440bf2c87770e2383e205a22e453",
    "title": "Drug combo is the first to prolong ketamine\u2019s antisuicide effects",
    "compound": "ketamine",
    "type": "other",
    "institution": "Stanford Medicine",
    "condition": "depression",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "A drug combination was found to be the first to prolong ketamine's antisuicide effects, though further research is needed to understand longer term effects and applicability to other types of depression such as bipolar disorder.",
    "doi": null,
    "url": "https://med.stanford.edu/news/all-news/2026/05/drug-ketamine-antisuicide-effects.html",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2ddba848bc4ffae031bd00f0db8cdb1dc4aaeb098f67413e451d07f53cbe145b",
    "title": "Is Ketamine Still a Party Drug in 2026?",
    "compound": "ketamine",
    "type": "news",
    "institution": "Neuroscience Research Institute",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "Article discusses ketamine's dual identity in 2026 as both a continuing recreational/party drug and an established medical treatment for mental health conditions. No specific study results or clinical trial outcomes reported.",
    "doi": null,
    "url": "https://www.neuroscienceresearchinstitute.com/is-ketamine-still-a-party-drug-in-2026",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "298114b5f313676b3ac1a181a4b5848686c99311ed742fee29027bf19f8ef86b",
    "title": "Studies currently recruiting | Johns Hopkins Medicine",
    "compound": null,
    "type": null,
    "institution": null,
    "condition": null,
    "sample_size": null,
    "status": null,
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://www.hopkinsmedicine.org/psychiatry/specialty-areas/moods/research/open-studies",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fe43d2ddd806aee3365a9e9a2c4ec4075fdec474a174653bd7c05eec39605a69",
    "title": "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care ...",
    "compound": null,
    "type": null,
    "institution": null,
    "condition": null,
    "sample_size": null,
    "status": null,
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2840552",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "51b2d35ec6c3f94435a8574ee56e2d338670ae474f609a5e1be633e45ae684c8",
    "title": "MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy",
    "compound": "other",
    "type": "news",
    "institution": "Multidisciplinary Association for Psychedelic Studies (MAPS)",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "MAPS issued a statement welcoming a federal Executive Order directing $50 million in funding to accelerate research on psychedelic compounds including ibogaine, psilocybin, LSD, and MDMA for serious mental illness, while emphasizing the need for rigorous science, ethical frameworks, and collaboration with Indigenous communities.",
    "doi": null,
    "url": "https://maps.org/2026/04/18/maps-welcomes-federal-action-to-advance-science-driven-psychedelic-research-and-policy",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6c933f6b19f84246f598b13bd262fc2f69d5309ebb4283c27dd8fafe6d693167",
    "title": "Psychedelics & Healing Initiative Trends for 2026",
    "compound": "other",
    "type": "news",
    "institution": "Global Wellness Institute",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "The article provides an industry overview of psychedelic medicine trends, noting that eight psychedelic candidates have received FDA 'breakthrough therapy' designations and seven have reached FDA Phase 3 trials. It highlights increasing bipartisan political support and FDA receptiveness to novel psychedelic compounds for integration into the healthcare system.",
    "doi": null,
    "url": "https://globalwellnessinstitute.org/global-wellness-institute-blog/2026/04/02/psychedelics-healing-initiative-trends-for-2026",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "956ad3011b31154dd85f0b26b565ed22cfa00fd57f3e28f7dbd01d59ffae7ace",
    "title": "Psilocybin Patent Tracker",
    "compound": "psilocybin",
    "type": "other",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://psychedelicalpha.com/resources/psilocybin-patent-tracker",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "82fc457089f7f4fb3290841d5c4e13c7a3bde1fe388da39a9204dd3d4b58776a",
    "title": "BREAKING: Second Positive Phase 3 for Compass' Psilocybin, Though Modest Magnitude Raises Questions",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "COMPASS Pathways",
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026-06-07",
    "outcome_summary": "COMPASS Pathways reported a second positive Phase 3 trial for its synthetic psilocybin (COMP360) in treatment-resistant depression, though the modest magnitude of effect and adverse event profile raised questions among analysts and investors.",
    "doi": null,
    "url": "https://psychedelicalpha.com/news/breaking-second-positive-phase-3-for-compass-psilocybin-though-modest-magnitude-raises-questions",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "65ada58afa622beeeaa9bd0520fa967ca7aa2c56b8d9eea9f85d2234c62fb4f1",
    "title": "Australia\u2019s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program",
    "compound": "mdma",
    "type": "news",
    "institution": "Medibank",
    "condition": "PTSD",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "Medibank committed AUD $10 million to fund MDMA-assisted therapy for PTSD and a long-term outcomes and health economics study led by Australian National University researchers, partnering with Emyria to pilot the program.",
    "doi": null,
    "url": "https://psychedelicalpha.com/news/australias-largest-private-health-insurer-commits-10m-to-fund-mdma-therapy-for-ptsd-in-first-of-its-kind-program",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9f350f4438a0029b1ba862d36510f14f5f73dfaae654e2dc429e44c0e02f448e",
    "title": "Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is \u201cSuccessful\u201d, Says MAPS",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "MAPS",
    "condition": "PTSD",
    "sample_size": 104,
    "status": "completed",
    "date": "2026-06-07",
    "outcome_summary": "Results confirmed prior positive findings from MAPP1; no serious adverse events were observed. More than half of participants identified as people of color.",
    "doi": null,
    "url": "https://psychedelicalpha.com/news/confirmatory-phase-3-trial-of-mdma-therapy-for-ptsd-is-successful-says-maps",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ce1aac0f4ae784f60749f47eba79ac5bf3fef8af196b733f2ad53ea72c303843",
    "title": "Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week",
    "compound": "mdma",
    "type": "news",
    "institution": "Lykos Therapeutics",
    "condition": "PTSD",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "Pending FDA decision on New Drug Application (NDA) for MDMA-assisted therapy for PTSD with target PDUFA date of August 11, 2024; three possible outcomes discussed: approval, Complete Response Letter, or delay.",
    "doi": null,
    "url": "https://psychedelicalpha.com/news/vibe-check-fda-set-to-decide-future-of-mdma-assisted-therapy-this-week",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "70a9b634327ac24ab6442b0d7fc81986d16a002077fd242763be043745e33722",
    "title": "Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next",
    "compound": "ketamine",
    "type": "news",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": null,
    "status": "recruiting",
    "date": "2026-06-07",
    "outcome_summary": "Samuel Wilkinson of Yale is leading a large multi-site, open-label, randomized non-inferiority study comparing IV ketamine to intranasal esketamine (Spravato) for treatment-resistant depression. No comparative outcomes are yet reported; existing observational data suggesting IV ketamine may perform better are limited by non-randomized design and socioeconomic confounding.",
    "doi": null,
    "url": "https://psychedelicalpha.com/news/evidence-and-experience-samuel-wilkinson-on-the-state-of-esketamine-therapy-and-what-comes-next",
    "source": "Psychedelic Alpha",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ddfce6f6930cc002e824e7098540b6ea6f97d85b1c289ac8bab9c888590a72f5",
    "title": "Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights",
    "compound": "psilocybin",
    "type": "news",
    "institution": "Compass Pathways plc",
    "condition": "depression",
    "sample_size": null,
    "status": "active",
    "date": "2026-06-07",
    "outcome_summary": "Compass Pathways reported positive primary endpoint results from its first COMP360 Phase 3 trial (COMP005) in treatment-resistant depression, showing a highly statistically significant and clinically meaningful reduction in depression at 6 weeks with no unexpected safety findings. The second Phase 3 trial (COMP006) continues to enroll, with 26-week data expected in late 2026.",
    "doi": null,
    "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Second-Quarter-2025-Financial-Results-and-Business-Highlights/default.aspx",
    "source": "Compass Pathways",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9ba0a2641c7bd0a758ecb0333c14b79c77f648a05e186326853a04d21bb0afd6",
    "title": "Breaking Trauma: Mechanisms of MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://www.psychiatrictimes.com/view/breaking-trauma-mechanisms-of-mdma-assisted-psychotherapy-for-ptsd",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "977f5452539c7a41e14250f99c93ae0aa5a1c43f309ea9c985e0554d45118cb7",
    "title": "UCSF Ketamine Clinical Trials \u2014 San Francisco Bay Area",
    "compound": "ketamine",
    "type": "other",
    "institution": "UCSF",
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": "This is a landing page listing multiple UCSF clinical trials involving ketamine across various conditions including Parkinson's disease, depression, status epilepticus, eating disorders, and methamphetamine use disorder.",
    "doi": null,
    "url": "https://clinicaltrials.ucsf.edu/ketamine",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "28dca7e56efb37695c2a215a4ce215219dcd3e906505d560a4ea7975386591e5",
    "title": "Just a moment...",
    "compound": "other",
    "type": "other",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2840552",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "34faf1204e1f390f9a5f0ae33463dbc3657d28afda2f370321460bd9730394bb",
    "title": "Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": 168,
    "status": "published",
    "date": "2026-06-07",
    "outcome_summary": "The primary endpoint was met; the 180 mg extended-release ketamine tablet group showed a least square mean difference in MADRS score of -6.1 (95% CI 1.0 to 11.16, P = 0.019) compared to placebo at 13 weeks. Relapse rates showed a dose response from 70.6% for placebo to 42.9% for 180 mg. The treatment was well tolerated with no blood pressure changes, minimal sedation and dissociation.",
    "doi": "10.1038/s41591-024-03063-x",
    "url": "https://www.nature.com/articles/s41591-024-03063-x",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "eae07f6892caa26fbc0a75487ea5af671d51a6ad00175e54ac4375bd7ec52cbb",
    "title": "Johns Hopkins Center for Psychedelic and Consciousness Research",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Johns Hopkins Center for Psychedelic and Consciousness Research",
    "condition": "other",
    "sample_size": null,
    "status": "active",
    "date": "2026-06-07",
    "outcome_summary": "The center focuses on exploring psilocybin for various psychiatric and behavioral disorders, with demonstrated safety in regulated settings and potential benefits for anxiety in cancer patients and smoking cessation.",
    "doi": null,
    "url": "https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "87602c9461f80b04ecc876275197921fb2d60753b3672b173a4df23e22506992",
    "title": "Psychedelic Drug Development Tracker",
    "compound": "other",
    "type": "other",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "other",
    "date": "2026-06-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://psychedelicalpha.com/resources/psychedelic-drug-development-tracker",
    "source": "General News",
    "first_seen": "2026-06-07"
  },
  {
    "id": "773c4008c74bf3e563f49eb29bdfe405d55dfef7ec461876f8c712bc0d7490c9",
    "title": "Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Queen's University",
    "condition": "anxiety",
    "sample_size": 50,
    "status": "recruiting",
    "date": "2025-05-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06969170",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8dad6775994bc7a74fd1e9a03d67b4b99281a463ec2fa2fb59482856ed55a256",
    "title": "PRoMiSS: Psilocybin and the Role of Music in Set and Setting",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07180108",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a63c61f0a96d1be4f014a300b8f4ad61be2aa1cff38900a6df7d06a42ec7542",
    "title": "PET Synaptogenesis After Psilocybin In DEpression Recovery",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Washington University School of Medicine",
    "condition": "depression",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05601648",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a8a499557342c109e5b6f140e90b6030a40935ae683df7430b86cd16aaf62892",
    "title": "Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "depression",
    "sample_size": 92,
    "status": "recruiting",
    "date": "2024-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06341426",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9f1704ebc6acb144c25a5154b9e77a9e9590e811e6e4caca25ea124b625b4c16",
    "title": "PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm",
    "compound": "other",
    "type": "observational",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06798636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2ce36b6f6856ac3c74fa3e7cb4777aaf04b4b46c3f7360805b1455d089764b2d",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "MycoMedica Life Sciences PBC",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-11-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06643637",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7f6d72d5a41991625da15ec6011b4185ce13c9d6cd5f2acde9aa991e72909176",
    "title": "UW Psilocybin Pharmacokinetics Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Wisconsin, Madison",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02163707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9b6648605628e1c68dfbf123cbbadb6265df1e06878cfecbc66e7d49323f7ba1",
    "title": "Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "McMaster University",
    "condition": "other",
    "sample_size": 16,
    "status": "recruiting",
    "date": "2025-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06225232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "79655b118a6fdb6d80fdd8f65b9ef29339bdb45474926a0f6dedddeb3cdefe42",
    "title": "Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05399498",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0d81dd8883f6b189389c302858719797d96b7a28759b72c3b67bb72c446a4085",
    "title": "Psilocybin Therapy in Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2023-05-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05398484",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a9a098702a42f1877c1c3525081b6c34bfaab79f1ccf9696972d2556258cc773",
    "title": "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Portland VA Research Foundation, Inc",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2022-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04982796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "501d36d641160bd70b9c36ddd29f57361c136abe88fdb363e7866516dd44bc91",
    "title": "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "other",
    "sample_size": 102,
    "status": "active",
    "date": "2023-01-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05733546",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ab6b24459fc594076009bd9736542b5a107ff7f11384c5a3bec20d741c7d3e7c",
    "title": "ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression",
    "compound": "other",
    "type": "phase_1",
    "institution": "Eleusis Therapeutics",
    "condition": "depression",
    "sample_size": 84,
    "status": "active",
    "date": "2022-10-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05434156",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c885eea8fadce12dbbb2b26868ee67ddfccd910386ec2c4e0599694e15f411c0",
    "title": "Psilocybin for Hospitalized Patients with Treatment-resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Hospital, Ghent",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2024-05-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06378229",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd020033e301ce9c49618456d740745c35292aa14a8a86be2d0a99dbc39b44df",
    "title": "Does Psilocybin Require Psychedelic Effects to Treat Depression?",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05710237",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aa0084ed2547126bc61cfa7beebb79295085417c0f08947d78153b8807c49e7d",
    "title": "Psilocybin-Assisted Therapy in Treatment-Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of North Carolina, Chapel Hill",
    "condition": "depression",
    "sample_size": 20,
    "status": "active",
    "date": "2024-04-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06303739",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a935d742c8538d8b7778bc5b38fd54b8b050acfdaf7bd03c41a78c1be012de07",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2025-07-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07048743",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "15b482b627c5295ce82c32202f4a69f070511ad410e25ee7466449f2d58f9477",
    "title": "Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Apex Labs Ltd.",
    "condition": "depression",
    "sample_size": 160,
    "status": "active",
    "date": "2023-12-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06141876",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c32847784e91dcca5f8b5ad2ceb4bb02b57128fbb484b799288d52424b82d812",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "active",
    "date": "2024-06-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06416085",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a13a1c0367eedae5de056b691c36361126a2d8852dd453e037683fb0831d644",
    "title": "Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 468,
    "status": "recruiting",
    "date": "2025-07-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06605105",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9c723750421adbaa49f789a72115861997933a72d12a69c81fee82784421afcc",
    "title": "Psilocybin-Assisted Therapy for Intergenerational Trauma",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Rachel Yehuda",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06899165",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f0af2e5f936c5f0b079eb172ac322719913f5cc47e75317197b2fcd9e59fa742",
    "title": "Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "OCD",
    "sample_size": 31,
    "status": "completed",
    "date": "2018-11-13",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03356483",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e66af192ed4aa13d0da108aefb2df42f574268f95308e08bf9071b5dbf90372d",
    "title": "\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 220,
    "status": "recruiting",
    "date": "2024-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06564818",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "69a3c0ef8c8a34a0fdffe1b0107624552d8bee00ce55779ce4f9df0e89981e5b",
    "title": "Naturalistic Study of Microdosing With Psilocybin",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "National Council of Scientific and Technical Research, Argentina",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2021-01-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05160220",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "88e91e04f7e4d8d5f2d4e03ab92f2980eec6b9332ebc95a97b77e8bdba911866",
    "title": "Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Healing Advocacy Fund",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2025-03-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189988",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "50f84cd692a434b02ffde1bfd9d98b2ea441338f67be902c950f3ebb4e076e69",
    "title": "Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre Hospitalier St Anne",
    "condition": "depression",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-10-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07210112",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ff164c3432cbce8674fe172b8bbd8921591a4adf442ed77cd23a6d9302019398",
    "title": "Effects of Hallucinogens and Other Drugs on Mood and Performance",
    "compound": "other",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02033707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "688df0737b0712bccd77e166fcc456dfd6b8c5cea50e4ac69cc212d4239114cd",
    "title": "Mood and Cognitive Effects of Psilocybin in Healthy Participants",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Optimi Health Corporation",
    "condition": "anxiety",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05252598",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b903e9c22aa9e1119b94dc8f757a58d77835cbc91992fb2d5b8a684abb23143e",
    "title": "Psilocybin in Cancer Pain Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Yvan Beaussant, MD, MSci",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-09-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06001749",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f50e83ff3f4d5c86e1b28ccf65df88075c026c11101d2e98b64440ccd3bf3266",
    "title": "Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2014-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02145091",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "57c7d8a996201b93e7631dc296f2b63fab613a37837abd985478bcc236f64be7",
    "title": "Northwest Therapies Trauma Psilocybin Study Compassionate Use Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "NWTraumatherapies",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-09-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042466",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ddb6be81b770dba5efdcee855e2aa31a205f51a7dfbe642b07932df68f9539a7",
    "title": "Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "OCD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2024-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06299319",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6d8c9a8120412bdd6ac3cc92fbf2dcd35611f20ed1478bbe9c43607de95a09a8",
    "title": "Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Clairvoyant Therapeutics",
    "condition": "other",
    "sample_size": 128,
    "status": "active",
    "date": "2022-05-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05646303",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fcdc999453f954abf2c2e3649ab675159804f8cdcf40d027a544eee5c48bf0fe",
    "title": "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "depression",
    "sample_size": 19,
    "status": "completed",
    "date": "2020-08-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04739865",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2b04a4025586812fd1c370065cf969a891d8e944564b691f51180a23011a5b9d",
    "title": "Frontline Clinician Psilocybin Study",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-03-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163496",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "15c9eb10cc3ce510974a92be9f4d145f9f94e6ecf9c2bea1fb965ade000bac24",
    "title": "PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Filament Health Corp.",
    "condition": "other",
    "sample_size": 86,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06666010",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "62f4b94c940dfd7c444dc8f6659ef806f1a406bd3d333a216837b62ad29ecfe8",
    "title": "Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "Bruy\u00e8re Health Research Institute.",
    "condition": "other",
    "sample_size": 120,
    "status": "recruiting",
    "date": "2026-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07063862",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "58802597efd9bc70689ed87c3713c732b9b7497438d8e796df21777372a6be09",
    "title": "Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2018-01-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02950467",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "161816474f2666ef27355a7dd80e00efcd5daeff9a29167cd05821c0627618e4",
    "title": "Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2021-02-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04656301",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "da400b627f5d647d623a6b134840f4fa13e01f4399866a0e749adc46266583bc",
    "title": "Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)",
    "compound": "other",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2009-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00886886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "84c6c6db07c7da18eb80bbc858fcc403bd74325eb841e435db0bbe8ed58b1823",
    "title": "Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2021-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04648137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6cd463fce294f6fb78e3988df35d7396d07cc87fdfd75f00e9c20350eb9b67c",
    "title": "Effects of MDMA on Social and Emotional Processing",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "addiction",
    "sample_size": 65,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01849419",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2131bcc12dee58da30e51ca09a469bee2b4d894cb77a03b9ccfcd55a372217e6",
    "title": "MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2004-03-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00090064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "962eaeb0ac8be671a0ee817fd434455e4a5383ef8b96883ea174d52e5b38a536",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 121,
    "status": "completed",
    "date": "2020-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04077437",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d9b6cafa6ca3aa45f907bf6c7bf65c6d60a119e7c43cb249308b95312c654771",
    "title": "Abuse Liability and Human Pharmacology of Mephedrone",
    "compound": "other",
    "type": "phase_1",
    "institution": "Parc de Salut Mar",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02232789",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "148beb6f25f7343c25b1aca0981ddf3be3d42bfb977bad74c3679f95c4f1f820",
    "title": "MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2016-07-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02876172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "63dfa756bfda228e595260d5b3b3ee7a3f0e84068625b8adef8e7bb0ff4af4a5",
    "title": "Effects of MDMA and Methylphenidate on Social Cognition",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2012-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01616407",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6d1ff8fdcd8c7ec6baee2a8abcbe5bb365869aa3c5c8e2db4ab8ebef9768278",
    "title": "A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Remedy",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2021-10-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05067244",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "285021d3b8bee0a8c83df15fccc2697e59e6b1553f217d8b2d87db9555cdffe7",
    "title": "MDMA-assisted Massed Prolonged Exposure for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Healing Breakthrough",
    "condition": "PTSD",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2024-10-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06117306",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e595df7697dc765abf3d2181993010c0bbb2ddd7b7658498e0ec779251b32bcf",
    "title": "Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01136278",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3f074b084e31a218b33a127e5bc64bd2f9bcbf8195810856fb46f78f7aa536e6",
    "title": "Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2023-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05523401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "507d5f90106428c717ac2461928dd78092f096facfc664fe319b48ba307e1167",
    "title": "Characterization of the Prosocial and Prosexual Effects of GHB",
    "compound": "other",
    "type": "observational",
    "institution": "University of Zurich",
    "condition": "other",
    "sample_size": 19,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02342366",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "444cabca36f00025435ed16aa524e3a45dff5de39d11570b28109e6feecda35a",
    "title": "Tolerability of MDMA in Schizophrenia",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Anya Bershad, MD, PhD",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05770375",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a234d42728450159efa4b40420d985790e18ba1800ffa3bbf57c634801aff38",
    "title": "Acute Effects of R- and S-MDMA in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05277636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd76dd410ecc095a679e72801a8a3e0e3032d7b7bd4576013b4e65b2675d431c",
    "title": "MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Sunstone Medical",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2022-10-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05584826",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4d55f0dc6f49e2edc8cd21827226e1e8d4ae516c1b7704b3026c25f1a63ca5dc",
    "title": "MDMA for AUD/PTSD Comorbidity",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Carolina L Haass-Koffler",
    "condition": "PTSD",
    "sample_size": 18,
    "status": "recruiting",
    "date": "2024-02-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05943665",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ff33fafc6e20053d8a5abb6e2f23f0f09796191753274a022599ccba0ec2729c",
    "title": "Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2014-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02102802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f12fd8e76e4eb3cf6ee767fb0cff75821dc8190b4611a0e913313ee55565971f",
    "title": "Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2013-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01951508",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4e22c59825b9ade032f697c4d82dbc5c13c4020259e0730015ddf8a36131b4b1",
    "title": "Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05173831",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "df0bd82dc5d1bd2af03adb28633fdb1305ffca60387ae948b2be92d8177a25b7",
    "title": "Dose Optimization of MDMA-Assisted Therapy for PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Bronx VA Medical Center",
    "condition": "PTSD",
    "sample_size": 60,
    "status": "recruiting",
    "date": "2025-06-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06418178",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5c198bc3ad4fb592acc6833c137fb67ba5b97bef14bb58b8f9f82f20e1a58d74",
    "title": "MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Brigham and Women's Hospital",
    "condition": "anxiety",
    "sample_size": 2,
    "status": "completed",
    "date": "2007-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00252174",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6d73123254183ff7b4c49ca550414a980b2a2881107e538773311ad1b77bd7c5",
    "title": "Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2025-09-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06989957",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cfba5ccc5e2e0a2a862581139f096c4c88e0aaf38d9e7b80441e0459cc5e804a",
    "title": "MDMA-Assisted Therapy for Pathological Narcissism",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 12,
    "status": "active",
    "date": "2024-08-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06565494",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a17a3aee00b4a10000150319948cb364ea5b69cc4d68366323ea48ba2b961f02",
    "title": "Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Albany Research Institute, Inc.",
    "condition": "PTSD",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-08-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05895318",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4e5a6d3d014e2349cacc6541ba0cd4c3964020d3ef89ea13c961ae8e6fb2966c",
    "title": "Bristol Imperial MDMA in Alcoholism Study",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2018-04-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04158778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8eef2ba5573db5dfa73e93515f6ca17d5593d743b7473949817240bfab472cae",
    "title": "MDMA for Co-occurring PTSD and OUD After Childbirth",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of New Mexico",
    "condition": "PTSD",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05219175",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "99f929ad935a61ec4b997912097805d213ddbad568a379cf14102985caa42788",
    "title": "A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 87,
    "status": "completed",
    "date": "2021-03-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04714359",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "44b96caae213fc6dafefcb6fd7a4301c10cf970326ba098b8ed84947ee18ef18",
    "title": "Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01386177",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e2daf8a4cd16d31950e31fc1257394c2a5daf3fe085369fcd8f27bdef435bdca",
    "title": "Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-04-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02008396",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b1bd43aec0b0b6fc9f3a9481dfb54120e7290a35d5707503b21499de1f8cbf84",
    "title": "MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of California, Los Angeles",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06353282",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6c2eadcc0d0a7df52696bc1b247e561a6aba6e2354f5548a7377fd34784dc4c2",
    "title": "Prosocial Effects of MDMA",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 33,
    "status": "completed",
    "date": "2023-07-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948683",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "54d59639e7c54caddbc0524ef0aa7c22b300d1b915b7630563bd6dd8482cfc3e",
    "title": "Epigenetics and MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "University of Southern California",
    "condition": "PTSD",
    "sample_size": 45,
    "status": "completed",
    "date": "2018-11-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06189027",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a4943b4dbc18ffcc90fa185756fd5e2b79127ca24085630b342c971449566c55",
    "title": "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01053403",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d685e6acf4bd8dd58048357f22c71678f514c6e2e677c43b17ef54db2b84984e",
    "title": "Role of Serotonin in Acute and Subacute MDMA Effects",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2009-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00838305",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a0f58758dbcdb84334875a717c37be38c944dd1ce47faf972514540c5014bed",
    "title": "Personality and Drug Use",
    "compound": "other",
    "type": "observational",
    "institution": "Psychedelic Data Society",
    "condition": "addiction",
    "sample_size": 1000,
    "status": "active",
    "date": "2022-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05516823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0f0496c1e23168440c4feee9c6aa51836aa175e43e2547cb346ec874b2aed779",
    "title": "Addiction in Intensive Cardiac Care Units",
    "compound": "other",
    "type": "observational",
    "institution": "Assistance Publique - H\u00f4pitaux de Paris",
    "condition": "addiction",
    "sample_size": 1500,
    "status": "active",
    "date": "2021-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05063097",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0edd5645e3be7aefe0da8fe089f0a5ba403e4960bb4ff5c86b3335515180e57a",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 100,
    "status": "completed",
    "date": "2018-11-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03537014",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bba46491bcce414efd8898ca051aedbc53f2d246e850353bf623262f8facc010",
    "title": "Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "MAPS Europe B.V.",
    "condition": "PTSD",
    "sample_size": 21,
    "status": "completed",
    "date": "2020-06-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04030169",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0a62c84f8d0c4b4c26830a8d4df08b8b4c4f3b3d9a964e45d31a76be1e88648f",
    "title": "Effects of MDMA-like Substances in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2021-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04847206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5f0930ad35cc18b10cc75ad3f33e23ad725e5007927edb8a4650b9795e732b66",
    "title": "Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04968938",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1515e96069ff1b97e044939493f4735f4044d10159af0998abbcf94251491adc",
    "title": "MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "VA Loma Linda Health Care System",
    "condition": "PTSD",
    "sample_size": 5,
    "status": "completed",
    "date": "2021-07-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04264026",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f61706e9f76828f1c40e0ae461f850479a937481325a10c2f4d0880c145c84bb",
    "title": "The NeXT Study; The Netherlands XTC Toxicity Study",
    "compound": "other",
    "type": "observational",
    "institution": "UMC Utrecht",
    "condition": "other",
    "sample_size": 225,
    "status": "completed",
    "date": "2002-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00235768",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "73bed01512b7023d428c09dc8e174e63d286758f14b0f711c3eaf844bdfbd07b",
    "title": "A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 198,
    "status": "completed",
    "date": "2022-08-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05407064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "166fb404e3c53c8cb3c8a162592f1d9d1cf6100405e4f8d2d425a837c9de55da",
    "title": "Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Royan Institute",
    "condition": "other",
    "sample_size": 10,
    "status": "completed",
    "date": "2007-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00736307",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "593a3c6d6d1cc7a13835dae41878b4895ef78a36eb3729289d22d8afa1cadfd8",
    "title": "Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2013-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01878942",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "016eba5535847db659689e61ee49762f398ceb5d8a024f65f510e3a15b877fea",
    "title": "The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers",
    "compound": "other",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2015-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02451072",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "29c8b897183f9c655d38fa5b1db57baca9cfd71c379712675c69d42cab21518f",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 245,
    "status": "active",
    "date": "2025-01-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06809595",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c9bd8e96c404cdf654fce29623289610fdcd274418c0b61e5435908a11874236",
    "title": "The \"Motoric Cognitive Risk\" Syndrome in the Quebec Population",
    "compound": "other",
    "type": "observational",
    "institution": "Jewish General Hospital",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2016-12-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03633253",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "97566582e2e946eb41791cba88bf1e7cdf131715d588e3970fe1c4f430418893",
    "title": "Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05175430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f60f9089871a0e960e6941bb17bf737b59936713cb3cce68a09cc80d71c956fa",
    "title": "Stem Cell Gene Therapy for Cystinosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of California, San Diego",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-07-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03897361",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "04b567b73cc555cafd6bf8721d9c81ecebddd45d1cadf9711e2179d19dd0c887",
    "title": "Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Multidisciplinary Association for Psychedelic Studies",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2008-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00920387",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05a0c0e68ed27017ccd526a4fd18964d82f81f6c8858b90af8f3e39091e83ee8",
    "title": "Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts",
    "compound": "other",
    "type": "observational",
    "institution": "Chaoran Han",
    "condition": "other",
    "sample_size": 18,
    "status": "completed",
    "date": "2024-03-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07415395",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c54802f7bf8a1c20c3beecd067388e0774271a9ef258e8cfd3b423e86a456c18",
    "title": "MCR Syndrome in Quebec : Results From NuAge Study",
    "compound": "other",
    "type": "observational",
    "institution": "Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'\u00cele-de-Montr\u00e9al",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2020-11-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05046275",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd0c381174ece3afbd801dc104b49f80f4ec7242d1d9ac639e222d1b1292fbbf",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 214,
    "status": "active",
    "date": "2024-12-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06741228",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "03067ca4712abd836642748279b8da776132bd6f60cc6cbb8887232d0a05123e",
    "title": "Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy",
    "compound": "other",
    "type": "observational",
    "institution": "Tatiana Aboulafia Brakha",
    "condition": "depression",
    "sample_size": 10,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06557239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7c0a06ecf54c59a7c70e23261c156f5c9616b087b83da25a6cb17db838b707de",
    "title": "Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA",
    "compound": "other",
    "type": "phase_1",
    "institution": "Neutrolis",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2025-09-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07237659",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0b0e849d62de9354d6c2cd33dcb80576d556c4d4c0fa527feb773a99a3a9c660",
    "title": "Sodium Lactate and Brain Relaxation (LSD)",
    "compound": "lsd",
    "type": "phase_3",
    "institution": "Centre Hospitalier Universitaire de Besancon",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2020-09-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04488874",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "808949308380ca60c12d04a5092e821d8b25f9cbef618a04a0503960cefde90b",
    "title": "Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2011-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01515956",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9870a2b3b95ba3299a08e65422b734f8fc9197f6efe2049b2d76b23d537ea651",
    "title": "Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma",
    "compound": "other",
    "type": "phase_2",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2010-01-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01045460",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aff091d3e0020b20f67d75b2c5af37a601c7e8b783f770fc3caa9f3ecaa0cd8d",
    "title": "Investigating Lysosomal Storage Diseases in Minority Groups",
    "compound": "other",
    "type": "observational",
    "institution": "O & O Alpan LLC",
    "condition": "other",
    "sample_size": 20000,
    "status": "active",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02120235",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8a1a0cf7c075b35694cd4b34aa6ca2a27a1aaf8325327fb08e69b8871186e29f",
    "title": "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma",
    "compound": "other",
    "type": "phase_1",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2007-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00566098",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "47a6c822f43008882c9d5d64be719bb39c588abc2aca9972e5fc26e7b495f90b",
    "title": "A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C",
    "compound": "other",
    "type": "observational",
    "institution": "ZevraDenmark",
    "condition": "other",
    "sample_size": 35,
    "status": "completed",
    "date": "2015-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02435030",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05a53dc5e0a01131a0a1316204fd1da2018e69def1159a85d22d3af0b2db79ca",
    "title": "Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "cluster_headache",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2019-01-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03781128",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "458ca894e769fa8da1bb01d5d41d6b549e25daf68e07a75557a3471dd9969355",
    "title": "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01609062",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6623f3e9de2ded35c8720d0f13dccac9343e9a7596203df5e62e4a8e3351e8cd",
    "title": "A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)",
    "compound": "other",
    "type": "observational",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 353,
    "status": "completed",
    "date": "2008-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00787995",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "157681ca00c33bf07de001b086af64b18b6ddb0664d1f3cd6c52e1b91557d43c",
    "title": "Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis",
    "compound": "other",
    "type": "observational",
    "institution": "Universidade do Porto",
    "condition": "other",
    "sample_size": 150,
    "status": "active",
    "date": "2022-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04386538",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "751b28b94f47f6b99e30dfb7f181bede6487f71008537bbee0ed7aa62409ab21",
    "title": "Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders",
    "compound": "other",
    "type": "observational",
    "institution": "Lysosomal and Rare Disorders Research and Treatment Center, Inc.",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2018-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03812055",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a259533ddcc34d2753d1c5199d6bafd5dbf99a3e7178b9392ffec6a7f89d4da3",
    "title": "Comparative Acute Effects of LSD, Psilocybin and Mescaline",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 32,
    "status": "completed",
    "date": "2020-05-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04227756",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "94bb831e6adf7eb9a026a30b4c440806f9c00ca5f56a0a987b60aca4c2f8d35a",
    "title": "A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 149,
    "status": "active",
    "date": "2025-04-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06941844",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b4066a28eab03e35b8e6cba1c8a3f378dc758494a82b48e92de641d4ff1ed74d",
    "title": "LSD Therapy for Persons Suffering From Major Depression",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "depression",
    "sample_size": 60,
    "status": "completed",
    "date": "2019-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03866252",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e7b51d7e04a455af1a23fb01681267fa58ae30c36025327ad80ca5a56f230a9c",
    "title": "Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_3",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 173,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01415427",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1737542c21cfc81d45bc09d379e5d872fa32e4e095cb03a96304931c4daa7039",
    "title": "Mood Effects of Serotonin Agonists",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 80,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03790358",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b02e3987a5f89afca8abd6fb9b8b198331ae559a1004f5431e31508d146c720a",
    "title": "Personality and Drug Use (PDU)",
    "compound": "other",
    "type": "observational",
    "institution": "Quantified Citizen Technologies Inc.",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05180149",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1004b9a4d9de9b98e86e84197a0b2c9d92562135c3e035d7e4c59828da438f8f",
    "title": "Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01155778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4fd4eb350ecfe57a1b7018526f7c6b1c4007098857902da0234d032ba4697fae",
    "title": "The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Maastricht University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05670184",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "10cf7c75d22e14dd1e9be237042a7c14ef41fab02c00a45cac341315bfbc7542",
    "title": "Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2017-11-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03321136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "30392dbba9ef4eb3ecb081e9c621711c74e80d1c81be82aee28129c3f07161cc",
    "title": "Drug Effects on Mood and Behavior - Expectancy",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 48,
    "status": "recruiting",
    "date": "2025-06-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07061886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b3fe699f8a0ee6195dac8ce4d01a88db754ab76ea6a197a9a5dff879525d7d95",
    "title": "A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "Amicus Therapeutics",
    "condition": "other",
    "sample_size": 31,
    "status": "completed",
    "date": "2014-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02082327",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c546446c61ffc0705c106d184174e5c4cd0e345005ef0ab2daff7e8cf6f266fb",
    "title": "Mood Effects of Serotonin Agonists Extended",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 56,
    "status": "completed",
    "date": "2019-04-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03934710",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3c6a37de3c53e9ff64a4e34f688ddfeff385e237c4f0ad4682f8e2a00e5e8944",
    "title": "A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_1",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2010-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01242111",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6b62a57198dd92ceef43efb784d4e21b636374a52e3c231271e138d414bfa4d6",
    "title": "LSD to Improve Cluster Headache Impact Trial",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Radboud University Medical Center",
    "condition": "cluster_headache",
    "sample_size": 65,
    "status": "recruiting",
    "date": "2025-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05477459",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f243c57462c606d6c952be54b24cbc848bb8296d020797cf4a81d7a26701dfa4",
    "title": "Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 53,
    "status": "completed",
    "date": "2021-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05200936",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd8d62c0476bb8042aa7d027738e3c83888dcc4b959f325fd5549c72aed26ab9",
    "title": "Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.",
    "compound": "other",
    "type": "observational",
    "institution": "St. Olavs Hospital",
    "condition": "other",
    "sample_size": 21,
    "status": "completed",
    "date": "2016-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02741622",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3d902aee3ee476719d6e8bce5db47d2b3fb7feb976b4a760d660082b9c32cb49",
    "title": "Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "PTSD",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2024-12-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06624137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a7ba1a51ad0108630cce533946ad4e91d23696caf905c96e6a6856f9f172b69f",
    "title": "Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2011-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01299727",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "80b243a1f339d38e2cb0891f7570803a6c799bd074d225a1a1a3c21b2d7007d5",
    "title": "Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Inonu University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2014-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02267980",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "190f27c0326b4468706f2373998d7eb5eb69c06f4fde9bef3e7fb04eaf49e017",
    "title": "A Study of Human Multi-Sensory Integration",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Pennsylvania",
    "condition": "other",
    "sample_size": 40,
    "status": "active",
    "date": "2018-07-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03498391",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "272f4d58f4a2c906f0e1868d86687c155ac2657792a41aeef3f506841cd6cbb0",
    "title": "Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Dennis Charney",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2009-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00749203",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c779b909ffdd98ac939a95dddcb2f6be0aa887ad2619954ce9e36d0389920a18",
    "title": "Ketamine Augmentation of ECT in Treatment-Resistant Depression",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Universit\u00e0 Vita-Salute San Raffaele",
    "condition": "depression",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-07-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07088380",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5df2690a285d691c7b1af757398ec93a5fd11975a6e79a1374fd90545c3ce807",
    "title": "Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tianjin Nankai Hospital",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2021-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04873479",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "35907f92e5f6b7db2cc3a80ed521f84482628ed40d38cc318f609b9feb15a52f",
    "title": "RIVER At Home Ketamine Protocols",
    "compound": "ketamine",
    "type": "observational",
    "institution": "RIVER Foundation",
    "condition": "anxiety",
    "sample_size": 50000,
    "status": "recruiting",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06070766",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bb5858a2fd2869034395f2e40ae74d0987c25f95c260dd19d853188d0ce55f81",
    "title": "Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2020-11-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04666623",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "764be54047f8d1a55dc5a0ce26d608d6b93984baf70f32dc2a3c731ea4e34b01",
    "title": "(GluEsk) Glutamate and Esketamine",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Oxford",
    "condition": "depression",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-06-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06432322",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6dffb4f84d386c55424843fa6884e3890c9abeb5b4c95def821580838292920d",
    "title": "Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University Tunis El Manar",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2016-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02653651",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a22e5b778593c959e8fef417ce9fda9cd813db3433effde8af96b56ad1bfb5cb",
    "title": "Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric",
    "compound": "other",
    "type": "observational",
    "institution": "Universitas Diponegoro",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02463929",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "06b938a52c289a43c189a3080f6689b5eec6acccf06d9706ca0a86f65a7b2bd6",
    "title": "Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 71,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02568176",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "567b2c15be781d2c22d845d39fc084826d9fcba87e08779829dbd5279ebb1934",
    "title": "Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Alberta",
    "condition": "other",
    "sample_size": 48,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02579642",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "56f81ad05c75ca552f9c95e41680787b199863d15d3ef01c1089eac1dd27dded",
    "title": "Ketamine for Refractory Chronic Migraine: a Pilot Study",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Thomas Jefferson University",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-03-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03896256",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd95d567074ca34e4aab3247d1677d0f074f037a4ba456bfe1da1b56b1a5077d",
    "title": "Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients",
    "compound": "other",
    "type": "observational",
    "institution": "Ayfer Kaya G\u00f6k",
    "condition": "other",
    "sample_size": 100,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07433231",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d65a8e74970d4048d812d23b7fc123bef014151193828159317bf00aae6f22ce",
    "title": "Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second Affiliated Hospital of Nanchang University",
    "condition": "other",
    "sample_size": 80,
    "status": "active",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07556172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "12d22bf68d564ec8a42e0ded07afe58a746af4ad2ad47d07405792cec132f7bb",
    "title": "Neurocognitive Features of Patients With Treatment-Resistant Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Massachusetts General Hospital",
    "condition": "depression",
    "sample_size": 13,
    "status": "completed",
    "date": "2016-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03134066",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d781b84aeb1303c90a3a50aa4ed898261ae9f7717a218e14b2f2325f284df17d",
    "title": "Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Peking University First Hospital",
    "condition": "other",
    "sample_size": 340,
    "status": "completed",
    "date": "2024-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06566469",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e441e1d29d6e74442a4cba1d6789df9874c195c897dd5b09b1d1316f8821f87f",
    "title": "Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2010-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01207206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3f89825fc6ad91a306ac37da00e548ec3bae8cea00cd0c6901d6be29c3331f57",
    "title": "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2016-03-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02682225",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "be58ac26d37943ccab148ec2b0774f8733726e03ab9c9b1aa5ab5953c7c9677c",
    "title": "Heart Rate Variability in Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Emory University",
    "condition": "depression",
    "sample_size": 8,
    "status": "completed",
    "date": "2015-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02525978",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1a07efa77ffb1aa4eed983787046c94a3d6713392c923ce18f6c2185f6117d1e",
    "title": "The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Cedars-Sinai Medical Center",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2013-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02252432",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "767c41a40941939b643bad9429173326eb19a7fc293c5291b8c8b35af97688d7",
    "title": "Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 32,
    "status": "active",
    "date": "2014-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02303847",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8a81776c037a829c11fcddaf63c74258801a7dac6336dbe172644f2a6c25d677",
    "title": "Esketamine and Butorphanol for Post-Lobectomy Pain",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second People's Hospital of Hefei City",
    "condition": "other",
    "sample_size": 223,
    "status": "completed",
    "date": "2022-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06398834",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "292fa963cedfbf88161a1217bc0fee76701a3796c4567737a24f6a7f7706c73d",
    "title": "The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Jinling Hospital, China",
    "condition": "depression",
    "sample_size": 120,
    "status": "completed",
    "date": "2020-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05506787",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9fb9806e1811086c28820346f250d0e7818e7641c5fe734ca579f089077c17de",
    "title": "Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Zhejiang Cancer Hospital",
    "condition": "anxiety",
    "sample_size": 185,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06530706",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd5812308b4351d76436fca1b1ffa9fb56d3e4cea52c46bad8b35caaa33a4e64",
    "title": "To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Adriana Feder",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2014-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02398136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1afda1bf01c35e08e8e40f849aecf1929438c19d0ebc0427aeea5e67b43fe762",
    "title": "Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 56,
    "status": "recruiting",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05306899",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7d267b1053132d8cec363f1995c8741d4ee2cf33042c3422299d700ee7745fac",
    "title": "Ketamine-assisted Therapy for Advanced GI Cancer",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Brian Anderson, MD",
    "condition": "other",
    "sample_size": 1,
    "status": "completed",
    "date": "2024-05-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06077487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "10d637ce957585e62611472f1fd3f5601d4fe905122d686914751b90239fe6e2",
    "title": "The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery",
    "compound": "other",
    "type": "observational",
    "institution": "Yonsei University",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2019-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03462836",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bf1fbef06deaffa37bf5e13329359e0c9534058bb62bb304c9b03665bc1cc743",
    "title": "Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Julia Finkel",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2010-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01325493",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c774e39cb5d8cffd580e9db0a04cf92b5deb271b9490e6f6cdffc23752bfdc04",
    "title": "IM Ketamine vs Midazolam for Suicidal ER Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "New York State Psychiatric Institute",
    "condition": "depression",
    "sample_size": 90,
    "status": "active",
    "date": "2021-02-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04640636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a1859b1894ff20089b7853d1bcf5018ae5debb9fa6eed4439484461ee489c50",
    "title": "Acupuncture ACL (Anterior Cruciate Ligament)",
    "compound": "other",
    "type": "observational",
    "institution": "Hospital for Special Surgery, New York",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2018-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03711734",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a0e6b8b525e3f948c2f1da90787fec07948b261b6ecf8b827eed43f6302924a",
    "title": "Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy Gastrointestinal Endoscopy",
    "compound": "other",
    "type": "observational",
    "institution": "Assiut University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2017-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03235609",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1c31bd995ad004847543039cbf3d94bca4bcd6f95bc2be64486a46cd532e0cde",
    "title": "Ketamine and Postoperative Depressive Symptom-PASSION",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Beijing Tiantan Hospital",
    "condition": "other",
    "sample_size": 84,
    "status": "completed",
    "date": "2017-07-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03086148",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0dcad76a610b9998983490be3a1a0480a405ff9b3923dbe5b52a809172c0fc90",
    "title": "Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy.",
    "compound": "other",
    "type": "observational",
    "institution": "Cairo University",
    "condition": "other",
    "sample_size": 8,
    "status": "active",
    "date": "2025-11-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07246447",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fb84ed3e97314396ad1283b8e282e17fb93e67c19049e483b0216149b79fc1ae",
    "title": "EEG Studies of Sevoflurane-Induced General Anesthesia",
    "compound": "other",
    "type": "phase_2",
    "institution": "Massachusetts General Hospital",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03503578",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd38c69b01576fceb9bdf159efbeefc164bac1412beda0cc5ae114e5420340b2",
    "title": "The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "First Affiliated Hospital of Chongqing Medical University",
    "condition": "depression",
    "sample_size": 396,
    "status": "active",
    "date": "2021-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04777110",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d90ee842fa5cb0dbe2e84e405a8a3292043d35c20a69e759ab45a94e1f735b3a",
    "title": "Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 100,
    "status": "active",
    "date": "2019-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04013958",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8daaf60052f9d2baaf90a81031bb6526dda1ff97fb357a65cb19273e93738b7b",
    "title": "Ketamine and Prolonged Exposure in PTSD",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Minneapolis Veterans Affairs Medical Center",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2019-04-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03960658",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1d1374755cc12c03199b8cfee1a8a71435e10188d012486931d98a18a0f335e7",
    "title": "Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Centre Hospitalier Universitaire de Nice",
    "condition": "other",
    "sample_size": 150,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01544725",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c4cd62bbe62af7874ff01d3ba2039e6aa1eeaa617cdd8a9349afa7e35f3446d1",
    "title": "Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Lille",
    "condition": "depression",
    "sample_size": 42,
    "status": "completed",
    "date": "2016-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02783430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "861175493511f8a7c7ad664f9735a341e50e7b68c5bfe61274892e9539bf5543",
    "title": "Ketamine Versus Etomidate for Rapid Sequence Intubation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Hennepin Healthcare Research Institute",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2013-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01823328",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c334337c15972d221fa1bfb0df4b33c5b13a87c23b8e097c81c8344371d60773",
    "title": "The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence",
    "compound": "other",
    "type": "phase_1",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01535937",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "751eec1f2844cbfc87be5b6e20f6f897b78ac492f0110d35318f7a7c1a0ce704",
    "title": "The OBSERVE Protocol",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 450,
    "status": "recruiting",
    "date": "2024-01-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06725277",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "84554ae17c35fb787aa2bf67cf606f92d1c371c0833471bf45b3d223f68007b7",
    "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Sichuan Purity Pharmaceutical Technology Co., Ltd.",
    "condition": "depression",
    "sample_size": 98,
    "status": "recruiting",
    "date": "2025-05-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07193901",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7555c8ae47415f1ade9fb24b6975944e362c48fd53c92cfe65dbbb2824085bce",
    "title": "Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02228239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a1d0b10d4c336b54c4a999cfa8932bf9254a4e05a454b2f4e984e00fb825a85",
    "title": "Oral Dexmedetomidine for Parental Separation in Pediatrics Undergoing Adenotonsillectomy",
    "compound": "other",
    "type": "observational",
    "institution": "Suez Canal University",
    "condition": "other",
    "sample_size": 74,
    "status": "completed",
    "date": "2016-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03551067",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d8b37ad969513bc321b70eb2258e76a663acf9be128eb7857c7ce3f32750aa50",
    "title": "The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults.",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Kasr El Aini Hospital",
    "condition": "other",
    "sample_size": 120,
    "status": "completed",
    "date": "2023-05-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948267",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8ffbdc4733b96fd7160e84ae8e78b0f9765cbc26e9335601dfb4667cb76059e0",
    "title": "Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS",
    "compound": "dmt",
    "type": "phase_3",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 185,
    "status": "completed",
    "date": "2021-07-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04788615",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e59209a306f49948327e44e8e850beb4d7b401ab677017ae3d97091769c3be4c",
    "title": "A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Cybin IRL Limited",
    "condition": "anxiety",
    "sample_size": 36,
    "status": "active",
    "date": "2024-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06051721",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a2cfec0a69f7f387ba35d2f4fa63a72771e4b0a3d1685c139e17d5e892b3b772",
    "title": "Trifecta Research Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06810765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9673287c7aaeb4389b64aed0fdd445efc8c00478a07884882dbc897a86e24f25",
    "title": "Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2020-11-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06459232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c6c524ddddfcf268b330be837a1bc030e51c186dbce5ac480cd6f373377012d5",
    "title": "Molecular Imaging Study of Harmine/DMT: a Basic Research Approach",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Insel Gruppe AG, University Hospital Bern",
    "condition": "other",
    "sample_size": 17,
    "status": "completed",
    "date": "2024-01-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06252506",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8397953237f78c4a48d86e46b7c0a9cb43b62dc74eedc4a7c9abc55195e52b44",
    "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 263,
    "status": "completed",
    "date": "2017-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03222973",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8b374ad7efc17f97b9dac0cea8645cf5bba28348e589efa1a120965572287b6c",
    "title": "MIH and Hypersensitivity in Children",
    "compound": "other",
    "type": "observational",
    "institution": "Universit\u00e0 degli Studi di Brescia",
    "condition": "other",
    "sample_size": 39,
    "status": "active",
    "date": "2022-01-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05705037",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d4a252dbf349d794d5fd4c4cc234b83d07e47567c7f45964ba23122d547ffab4",
    "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Usona Institute",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2022-12-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05698095",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a7c6bbbb4a7b2db9e4ee2ffb9f36fb403dc33e38657b30cd99a3bf7b81756ead",
    "title": "Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults",
    "compound": "other",
    "type": "phase_1",
    "institution": "Advanced Integrative Medical Science Institute",
    "condition": "depression",
    "sample_size": 12,
    "status": "active",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05894902",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e827018424c727540059966c617761b0901274c13092c55195dec3066259f21d",
    "title": "COVID-19 and Multiple Sclerosis Disease Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Nottingham University Hospitals NHS Trust",
    "condition": "other",
    "sample_size": 14240,
    "status": "active",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04863586",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ebc6d2cb9e4d84a9db1d1049457aca954e38b603d02475665e40a7f24847aad0",
    "title": "Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Strasbourg, France",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06663189",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fe5659f3e050530a37ac51589c0e7c36e75b1c92a9e97a692a2d28f0b0be2805",
    "title": "Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study",
    "compound": "other",
    "type": "observational",
    "institution": "University of British Columbia",
    "condition": "other",
    "sample_size": 4000,
    "status": "completed",
    "date": "2003-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06705608",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5dcb0f502daf7d1a368b6fc4a56118310c0722bd49cf26e3bac1a4996b74c580",
    "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY\u00ae) in Participants Who Took it During Pregnancy And About the Health of Their Babies",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 1178,
    "status": "active",
    "date": "2021-09-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05688436",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "08f52372bc035bac75657108aad5347626c4237e547b6de456a38c15897851ba",
    "title": "Clinical Study of DMT in Healthy Adults",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Biomind Labs Inc.",
    "condition": "other",
    "sample_size": 27,
    "status": "completed",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05573568",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4f753dd3cdbeff3327a4e200b388086dfa8f0c5143b958761133b187c2f54e95",
    "title": "The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative",
    "compound": "other",
    "type": "observational",
    "institution": "Dartmouth-Hitchcock Medical Center",
    "condition": "other",
    "sample_size": 694,
    "status": "completed",
    "date": "2017-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03480854",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fe1140593d82994c1d7ee2968001b7de105de60dc80c6f3c308c58b692e545cf",
    "title": "Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients",
    "compound": "dmt",
    "type": "observational",
    "institution": "Merck KGaA, Darmstadt, Germany",
    "condition": "other",
    "sample_size": 545,
    "status": "completed",
    "date": "2012-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01601119",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "23d314ab1fd3526bdd73e297d3680208643c0e5ef76081ee568dddc5e452c867",
    "title": "Mindfulness and Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Milan Scheidegger",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2023-02-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05780216",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bb2d1f423ba849acce9be30e14930878b487118e15fec78a56e9939c060fa283",
    "title": "SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 66,
    "status": "completed",
    "date": "2021-02-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04673383",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4cc22f54000bd643635786ea4ad4042348b8d140ea53ce4c087b412e7fc272de",
    "title": "A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Montpellier",
    "condition": "other",
    "sample_size": 250,
    "status": "recruiting",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189325",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c1f193d7302ca715a6b68c408a65c10157d27841b0859d3a7819c30e67eba86d",
    "title": "Neuroprotection and Repair in Optic Neuritis",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Calgary",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2010-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01073813",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0c3f81decabbb41f4b7adb295683a33edae8d838ea688ab2b128a98d3c26239b",
    "title": "Effects Of Dance Movement Therapy On Compassionate Flow In Nursing Students",
    "compound": "other",
    "type": "observational",
    "institution": "Mackay Medical College",
    "condition": "other",
    "sample_size": 59,
    "status": "completed",
    "date": "2023-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06220708",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "458f65dce66e0d941276a1cd6738bf5e341be29869b9be92f52dbebf06909136",
    "title": "Antidepressant Response of DMT Masked With Propofol",
    "compound": "dmt",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06927076",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "604aa74e281e83bdb5edccdc5372851dfb8317b70d9f15497754648a09d11092",
    "title": "Ayahuasca Assisted Psychotherapy for Grief",
    "compound": "ayahuasca",
    "type": "phase_2",
    "institution": "Beckley Med Foundation",
    "condition": "other",
    "sample_size": 84,
    "status": "active",
    "date": "2021-10-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06150859",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "affa2207639a5fa63ef6454d808520c1509c1f63e3bfceb48cd4de639ba3f54b",
    "title": "Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "Ying Gao",
    "condition": "other",
    "sample_size": 328,
    "status": "recruiting",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07037823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fbaa96a562ba52784bd35f4c3b4ee6765c09a2f77868292ac7cfe0a2c7845f3a",
    "title": "Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders",
    "compound": "dmt",
    "type": "observational",
    "institution": "Shalvata Mental Health Center",
    "condition": "anxiety",
    "sample_size": 24,
    "status": "active",
    "date": "2015-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02304796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0c7c6806440daee2f4f23c4ef1aa7aa5c272804d36168bb83dfa2c75e593136d",
    "title": "Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers",
    "compound": "other",
    "type": "observational",
    "institution": "MoCA Clinic and Institute",
    "condition": "other",
    "sample_size": 500,
    "status": "recruiting",
    "date": "2025-03-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07041450",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "30f478aedf8f0a98e9f0346688c1eb55fa63129a46cf16caf6c1c709fa514a1d",
    "title": "A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 213,
    "status": "completed",
    "date": "2011-11-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07474311",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d6907de2f9644625c86a8e83da9ce3d8f4514ca0e0dccaefbcb7cd55c5c08e81",
    "title": "Relationship Between Oral DMT Burden and Adherence in MS",
    "compound": "dmt",
    "type": "observational",
    "institution": "Monash University",
    "condition": "other",
    "sample_size": 323,
    "status": "recruiting",
    "date": "2020-09-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04676204",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2404ad4c4cb21bf593a3791b987bbd7b37538bd8cdbf57070342230055b99d82",
    "title": "Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Abu Dhabi Stem Cells Center",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2022-03-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05168384",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "12872c0a3fa470883d41f898f804ac4077fba2f2e639e490a4d1e84b6a3c295f",
    "title": "Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Reconnect Labs",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2023-05-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05829603",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3918890d4d12918083bf574e55c7d4620e692c273b1ec4743a51601e59e462b5",
    "title": "Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2024-06-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05695495",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6f45d2ad04991aca5de6a3f241c8ec4bebadceeff50fef93c89371bdbb6a488f",
    "title": "Dance/Movement Therapy for Bone Mineral Density in Schizophrenia",
    "compound": "other",
    "type": "observational",
    "institution": "Hebei Province Veterans Hospital",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2020-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05716802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cdc6ab6399d4f7a940f6c01d1e7cc96eb59f3c9c1f1d68d393a1058628def4cc",
    "title": "Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2013-11-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04832399",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "63cd052997eba418ae5c3f7a4e835cdc2dcc9d8ecfaa5c191037d23fdc55d686",
    "title": "Phase 2 Clinical Trial of GH001 in Bipolar II Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2023-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05839509",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5e27ba601ebeb3ecbe50813b4d0205a969296ac3c8a60111d5a9cbd60d513729",
    "title": "A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 42,
    "status": "completed",
    "date": "2012-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01578330",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "39fec6f9415d7849e6a3306a23f1917e72a1fe8cd8ff12ecfd103182a3003a3b",
    "title": "Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2020-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04716335",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "93d979744d0bc58dbf333559d90baccd529c5f9e35e9990d8218b3d8a7400dbf",
    "title": "Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-10-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06094907",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "43b62069ae202526008cbfce6c0efb0b2f61371f4ed0060618f6cc149263694e",
    "title": "Tecfidera and the Gut Microbiota",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2015-11-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02471560",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0b0809be1f4e55273778eba9dc2b66f56387c1a64ea5c83b2349fff8a8023c89",
    "title": "IM and IV SPL026 Drug Product in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05644093",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f5cacad300ad47f1970b268a4028a5f07bfabfc4361d9912b12faba09ceb52a2",
    "title": "A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 4805,
    "status": "completed",
    "date": "2025-06-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07403214",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a6ac7d4a968a59de2a52175988a9472bac177922c5d37b0db907a227d0403498",
    "title": "Pharmacokinetics of GH001 in Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 46,
    "status": "completed",
    "date": "2021-06-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163691",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fc508483b010ea25719a39974dd3d5803626c93f6930ddb9acccab2a9d1cdc45",
    "title": "Psilocybin Therapy for Chronic Low Back Pain",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley, MD, PhD",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05351541",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "862609b3ba3e0daafbd9b813255bd08128072ab801f7fdfdcfd9b7310c81119f",
    "title": "Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 30,
    "status": "active",
    "date": "2021-03-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04711915",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "253525c15a23404be35cdd553c55f82d20d5703708b2d2c1cc515671f10e9ef6",
    "title": "A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants",
    "compound": "other",
    "type": "observational",
    "institution": "Bristol-Myers Squibb",
    "condition": "other",
    "sample_size": 2961,
    "status": "active",
    "date": "2021-03-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06133049",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a1fd87c11858d4808367848125ec95fbac19835d9c43b832a17a16ba84209c37",
    "title": "Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Jeffrey Gelfand",
    "condition": "other",
    "sample_size": 5,
    "status": "completed",
    "date": "2018-11-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03594487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "56f8fa8654951753b6ad57602591a8aea57674a30bb336dedc1cb8aa7de281ce",
    "title": "Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "International Center for Ethnobotanical Education, Research, and Service",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2020-10-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04003948",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a8472dbee4ff38751b1498e7cf4f624eefe2e30e0e17b06ac9da2ffcac4cdad",
    "title": "Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "Stanford University",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2021-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04313712",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "42034b58b03ea36a85a62c85a5fcc6711e2710b0f8b0a648b0a9995b19825dc3",
    "title": "Mapping Ibogaine Neural Dynamics in Opioid Use Disorder",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "University of California, Irvine",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07226570",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6ec247e6bd2fe4c3ae2a7ecc80bf0ce09660e4c3edea0bb358efd09bb937941",
    "title": "A Study of Oral Ibogaine in Opioid Withdrawal",
    "compound": "ibogaine",
    "type": "phase_1",
    "institution": "atai Therapeutics, Inc.",
    "condition": "other",
    "sample_size": 116,
    "status": "completed",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05029401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2205af0565e2d1cfac1f1b872f433ac71ed08b35afac93a581f06c507de54ef9",
    "title": "Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03380728",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e9f88d2b3bb5a904eb63d34f94db1d354a1424b112d621c1d4ae607c2d917a96",
    "title": "Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression",
    "compound": "ayahuasca",
    "type": "phase_1",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 35,
    "status": "completed",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02914769",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "724a3f04d998d445fa1228ab0a475276cf9cca32c969629b4c047203bc6f84d6",
    "title": "Ayahuasca, Esketamine and Body Image Perception",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317219",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "915bfce0f72d51bd26a570d2dbf3e81fdffb1ccee6ef28a821905621b2012261",
    "title": "Ayahuasca, Esketamine and Premenstrual Symptoms",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f297c77cbff46505d11bb69d2bfdd0726b17dcf3625c1dcb0488fcbd3d25794b",
    "title": "Ayahuasca, Esketamine and PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ae5bf47b8c21f70c8347be94a0f17598df8f9d8b63309e5be3898573802d861c",
    "title": "Entheogen Resurgence",
    "compound": "other",
    "type": "observational",
    "institution": "Vireo Health",
    "condition": "other",
    "sample_size": 102,
    "status": "completed",
    "date": "2021-09-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "dd8cb146beda67e6d2a65cdc96868d21662ae45ff0fd9a1e3d9edcdec6a8363c",
    "title": "Ayahuasca and Esketamine for Major Depression",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "depression",
    "sample_size": 22,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07212946",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05431a8189731bff6895510ce8559f8effba74196570c6c81b0196aa4c9d34f8",
    "title": "Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness",
    "compound": "mescaline",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2021-08-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04849013",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cdcc6f1de14e082e13f542622a5a2158e041829aca33360d610de8aa27d3aae1",
    "title": "Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis",
    "compound": "mescaline",
    "type": "observational",
    "institution": "Xiangya Hospital of Central South University",
    "condition": "other",
    "sample_size": 205,
    "status": "active",
    "date": "2023-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05933213",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "773c4008c74bf3e563f49eb29bdfe405d55dfef7ec461876f8c712bc0d7490c9",
    "title": "Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Queen's University",
    "condition": "anxiety",
    "sample_size": 50,
    "status": "recruiting",
    "date": "2025-05-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06969170",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8dad6775994bc7a74fd1e9a03d67b4b99281a463ec2fa2fb59482856ed55a256",
    "title": "PRoMiSS: Psilocybin and the Role of Music in Set and Setting",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07180108",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a63c61f0a96d1be4f014a300b8f4ad61be2aa1cff38900a6df7d06a42ec7542",
    "title": "PET Synaptogenesis After Psilocybin In DEpression Recovery",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Washington University School of Medicine",
    "condition": "depression",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05601648",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a8a499557342c109e5b6f140e90b6030a40935ae683df7430b86cd16aaf62892",
    "title": "Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "depression",
    "sample_size": 92,
    "status": "recruiting",
    "date": "2024-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06341426",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9f1704ebc6acb144c25a5154b9e77a9e9590e811e6e4caca25ea124b625b4c16",
    "title": "PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm",
    "compound": "other",
    "type": "observational",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06798636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2ce36b6f6856ac3c74fa3e7cb4777aaf04b4b46c3f7360805b1455d089764b2d",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "MycoMedica Life Sciences PBC",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-11-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06643637",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7f6d72d5a41991625da15ec6011b4185ce13c9d6cd5f2acde9aa991e72909176",
    "title": "UW Psilocybin Pharmacokinetics Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Wisconsin, Madison",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02163707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9b6648605628e1c68dfbf123cbbadb6265df1e06878cfecbc66e7d49323f7ba1",
    "title": "Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "McMaster University",
    "condition": "other",
    "sample_size": 16,
    "status": "recruiting",
    "date": "2025-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06225232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "79655b118a6fdb6d80fdd8f65b9ef29339bdb45474926a0f6dedddeb3cdefe42",
    "title": "Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05399498",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0d81dd8883f6b189389c302858719797d96b7a28759b72c3b67bb72c446a4085",
    "title": "Psilocybin Therapy in Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2023-05-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05398484",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a9a098702a42f1877c1c3525081b6c34bfaab79f1ccf9696972d2556258cc773",
    "title": "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Portland VA Research Foundation, Inc",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2022-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04982796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "501d36d641160bd70b9c36ddd29f57361c136abe88fdb363e7866516dd44bc91",
    "title": "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "other",
    "sample_size": 102,
    "status": "active",
    "date": "2023-01-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05733546",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ab6b24459fc594076009bd9736542b5a107ff7f11384c5a3bec20d741c7d3e7c",
    "title": "ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression",
    "compound": "other",
    "type": "phase_1",
    "institution": "Eleusis Therapeutics",
    "condition": "depression",
    "sample_size": 84,
    "status": "active",
    "date": "2022-10-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05434156",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c885eea8fadce12dbbb2b26868ee67ddfccd910386ec2c4e0599694e15f411c0",
    "title": "Psilocybin for Hospitalized Patients with Treatment-resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Hospital, Ghent",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2024-05-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06378229",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd020033e301ce9c49618456d740745c35292aa14a8a86be2d0a99dbc39b44df",
    "title": "Does Psilocybin Require Psychedelic Effects to Treat Depression?",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05710237",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aa0084ed2547126bc61cfa7beebb79295085417c0f08947d78153b8807c49e7d",
    "title": "Psilocybin-Assisted Therapy in Treatment-Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of North Carolina, Chapel Hill",
    "condition": "depression",
    "sample_size": 20,
    "status": "active",
    "date": "2024-04-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06303739",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a935d742c8538d8b7778bc5b38fd54b8b050acfdaf7bd03c41a78c1be012de07",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2025-07-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07048743",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "15b482b627c5295ce82c32202f4a69f070511ad410e25ee7466449f2d58f9477",
    "title": "Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Apex Labs Ltd.",
    "condition": "depression",
    "sample_size": 160,
    "status": "active",
    "date": "2023-12-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06141876",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c32847784e91dcca5f8b5ad2ceb4bb02b57128fbb484b799288d52424b82d812",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "active",
    "date": "2024-06-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06416085",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a13a1c0367eedae5de056b691c36361126a2d8852dd453e037683fb0831d644",
    "title": "Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 468,
    "status": "recruiting",
    "date": "2025-07-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06605105",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9c723750421adbaa49f789a72115861997933a72d12a69c81fee82784421afcc",
    "title": "Psilocybin-Assisted Therapy for Intergenerational Trauma",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Rachel Yehuda",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06899165",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f0af2e5f936c5f0b079eb172ac322719913f5cc47e75317197b2fcd9e59fa742",
    "title": "Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "OCD",
    "sample_size": 31,
    "status": "completed",
    "date": "2018-11-13",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03356483",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e66af192ed4aa13d0da108aefb2df42f574268f95308e08bf9071b5dbf90372d",
    "title": "\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 220,
    "status": "recruiting",
    "date": "2024-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06564818",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "69a3c0ef8c8a34a0fdffe1b0107624552d8bee00ce55779ce4f9df0e89981e5b",
    "title": "Naturalistic Study of Microdosing With Psilocybin",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "National Council of Scientific and Technical Research, Argentina",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2021-01-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05160220",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "88e91e04f7e4d8d5f2d4e03ab92f2980eec6b9332ebc95a97b77e8bdba911866",
    "title": "Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Healing Advocacy Fund",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2025-03-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189988",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "50f84cd692a434b02ffde1bfd9d98b2ea441338f67be902c950f3ebb4e076e69",
    "title": "Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre Hospitalier St Anne",
    "condition": "depression",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-10-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07210112",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ff164c3432cbce8674fe172b8bbd8921591a4adf442ed77cd23a6d9302019398",
    "title": "Effects of Hallucinogens and Other Drugs on Mood and Performance",
    "compound": "other",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02033707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "688df0737b0712bccd77e166fcc456dfd6b8c5cea50e4ac69cc212d4239114cd",
    "title": "Mood and Cognitive Effects of Psilocybin in Healthy Participants",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Optimi Health Corporation",
    "condition": "anxiety",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05252598",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b903e9c22aa9e1119b94dc8f757a58d77835cbc91992fb2d5b8a684abb23143e",
    "title": "Psilocybin in Cancer Pain Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Yvan Beaussant, MD, MSci",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-09-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06001749",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f50e83ff3f4d5c86e1b28ccf65df88075c026c11101d2e98b64440ccd3bf3266",
    "title": "Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2014-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02145091",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "57c7d8a996201b93e7631dc296f2b63fab613a37837abd985478bcc236f64be7",
    "title": "Northwest Therapies Trauma Psilocybin Study Compassionate Use Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "NWTraumatherapies",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-09-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042466",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ddb6be81b770dba5efdcee855e2aa31a205f51a7dfbe642b07932df68f9539a7",
    "title": "Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "OCD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2024-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06299319",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6d8c9a8120412bdd6ac3cc92fbf2dcd35611f20ed1478bbe9c43607de95a09a8",
    "title": "Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Clairvoyant Therapeutics",
    "condition": "other",
    "sample_size": 128,
    "status": "active",
    "date": "2022-05-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05646303",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fcdc999453f954abf2c2e3649ab675159804f8cdcf40d027a544eee5c48bf0fe",
    "title": "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "depression",
    "sample_size": 19,
    "status": "completed",
    "date": "2020-08-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04739865",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2b04a4025586812fd1c370065cf969a891d8e944564b691f51180a23011a5b9d",
    "title": "Frontline Clinician Psilocybin Study",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-03-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163496",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "15c9eb10cc3ce510974a92be9f4d145f9f94e6ecf9c2bea1fb965ade000bac24",
    "title": "PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Filament Health Corp.",
    "condition": "other",
    "sample_size": 86,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06666010",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "62f4b94c940dfd7c444dc8f6659ef806f1a406bd3d333a216837b62ad29ecfe8",
    "title": "Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "Bruy\u00e8re Health Research Institute.",
    "condition": "other",
    "sample_size": 120,
    "status": "recruiting",
    "date": "2026-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07063862",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "58802597efd9bc70689ed87c3713c732b9b7497438d8e796df21777372a6be09",
    "title": "Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2018-01-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02950467",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "161816474f2666ef27355a7dd80e00efcd5daeff9a29167cd05821c0627618e4",
    "title": "Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2021-02-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04656301",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "da400b627f5d647d623a6b134840f4fa13e01f4399866a0e749adc46266583bc",
    "title": "Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)",
    "compound": "other",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2009-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00886886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "84c6c6db07c7da18eb80bbc858fcc403bd74325eb841e435db0bbe8ed58b1823",
    "title": "Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2021-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04648137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6cd463fce294f6fb78e3988df35d7396d07cc87fdfd75f00e9c20350eb9b67c",
    "title": "Effects of MDMA on Social and Emotional Processing",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "addiction",
    "sample_size": 65,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01849419",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2131bcc12dee58da30e51ca09a469bee2b4d894cb77a03b9ccfcd55a372217e6",
    "title": "MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2004-03-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00090064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "962eaeb0ac8be671a0ee817fd434455e4a5383ef8b96883ea174d52e5b38a536",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 121,
    "status": "completed",
    "date": "2020-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04077437",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d9b6cafa6ca3aa45f907bf6c7bf65c6d60a119e7c43cb249308b95312c654771",
    "title": "Abuse Liability and Human Pharmacology of Mephedrone",
    "compound": "other",
    "type": "phase_1",
    "institution": "Parc de Salut Mar",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02232789",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "148beb6f25f7343c25b1aca0981ddf3be3d42bfb977bad74c3679f95c4f1f820",
    "title": "MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2016-07-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02876172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "63dfa756bfda228e595260d5b3b3ee7a3f0e84068625b8adef8e7bb0ff4af4a5",
    "title": "Effects of MDMA and Methylphenidate on Social Cognition",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2012-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01616407",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6d1ff8fdcd8c7ec6baee2a8abcbe5bb365869aa3c5c8e2db4ab8ebef9768278",
    "title": "A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Remedy",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2021-10-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05067244",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "285021d3b8bee0a8c83df15fccc2697e59e6b1553f217d8b2d87db9555cdffe7",
    "title": "MDMA-assisted Massed Prolonged Exposure for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Healing Breakthrough",
    "condition": "PTSD",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2024-10-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06117306",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e595df7697dc765abf3d2181993010c0bbb2ddd7b7658498e0ec779251b32bcf",
    "title": "Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01136278",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3f074b084e31a218b33a127e5bc64bd2f9bcbf8195810856fb46f78f7aa536e6",
    "title": "Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2023-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05523401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "507d5f90106428c717ac2461928dd78092f096facfc664fe319b48ba307e1167",
    "title": "Characterization of the Prosocial and Prosexual Effects of GHB",
    "compound": "other",
    "type": "observational",
    "institution": "University of Zurich",
    "condition": "other",
    "sample_size": 19,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02342366",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "444cabca36f00025435ed16aa524e3a45dff5de39d11570b28109e6feecda35a",
    "title": "Tolerability of MDMA in Schizophrenia",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Anya Bershad, MD, PhD",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05770375",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a234d42728450159efa4b40420d985790e18ba1800ffa3bbf57c634801aff38",
    "title": "Acute Effects of R- and S-MDMA in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05277636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd76dd410ecc095a679e72801a8a3e0e3032d7b7bd4576013b4e65b2675d431c",
    "title": "MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Sunstone Medical",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2022-10-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05584826",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4d55f0dc6f49e2edc8cd21827226e1e8d4ae516c1b7704b3026c25f1a63ca5dc",
    "title": "MDMA for AUD/PTSD Comorbidity",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Carolina L Haass-Koffler",
    "condition": "PTSD",
    "sample_size": 18,
    "status": "recruiting",
    "date": "2024-02-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05943665",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ff33fafc6e20053d8a5abb6e2f23f0f09796191753274a022599ccba0ec2729c",
    "title": "Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2014-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02102802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f12fd8e76e4eb3cf6ee767fb0cff75821dc8190b4611a0e913313ee55565971f",
    "title": "Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2013-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01951508",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4e22c59825b9ade032f697c4d82dbc5c13c4020259e0730015ddf8a36131b4b1",
    "title": "Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05173831",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "df0bd82dc5d1bd2af03adb28633fdb1305ffca60387ae948b2be92d8177a25b7",
    "title": "Dose Optimization of MDMA-Assisted Therapy for PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Bronx VA Medical Center",
    "condition": "PTSD",
    "sample_size": 60,
    "status": "recruiting",
    "date": "2025-06-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06418178",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5c198bc3ad4fb592acc6833c137fb67ba5b97bef14bb58b8f9f82f20e1a58d74",
    "title": "MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Brigham and Women's Hospital",
    "condition": "anxiety",
    "sample_size": 2,
    "status": "completed",
    "date": "2007-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00252174",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6d73123254183ff7b4c49ca550414a980b2a2881107e538773311ad1b77bd7c5",
    "title": "Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2025-09-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06989957",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cfba5ccc5e2e0a2a862581139f096c4c88e0aaf38d9e7b80441e0459cc5e804a",
    "title": "MDMA-Assisted Therapy for Pathological Narcissism",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 12,
    "status": "active",
    "date": "2024-08-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06565494",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a17a3aee00b4a10000150319948cb364ea5b69cc4d68366323ea48ba2b961f02",
    "title": "Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Albany Research Institute, Inc.",
    "condition": "PTSD",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-08-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05895318",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4e5a6d3d014e2349cacc6541ba0cd4c3964020d3ef89ea13c961ae8e6fb2966c",
    "title": "Bristol Imperial MDMA in Alcoholism Study",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2018-04-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04158778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8eef2ba5573db5dfa73e93515f6ca17d5593d743b7473949817240bfab472cae",
    "title": "MDMA for Co-occurring PTSD and OUD After Childbirth",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of New Mexico",
    "condition": "PTSD",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05219175",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "99f929ad935a61ec4b997912097805d213ddbad568a379cf14102985caa42788",
    "title": "A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 87,
    "status": "completed",
    "date": "2021-03-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04714359",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "44b96caae213fc6dafefcb6fd7a4301c10cf970326ba098b8ed84947ee18ef18",
    "title": "Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01386177",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e2daf8a4cd16d31950e31fc1257394c2a5daf3fe085369fcd8f27bdef435bdca",
    "title": "Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-04-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02008396",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b1bd43aec0b0b6fc9f3a9481dfb54120e7290a35d5707503b21499de1f8cbf84",
    "title": "MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of California, Los Angeles",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06353282",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6c2eadcc0d0a7df52696bc1b247e561a6aba6e2354f5548a7377fd34784dc4c2",
    "title": "Prosocial Effects of MDMA",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 33,
    "status": "completed",
    "date": "2023-07-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948683",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "54d59639e7c54caddbc0524ef0aa7c22b300d1b915b7630563bd6dd8482cfc3e",
    "title": "Epigenetics and MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "University of Southern California",
    "condition": "PTSD",
    "sample_size": 45,
    "status": "completed",
    "date": "2018-11-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06189027",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a4943b4dbc18ffcc90fa185756fd5e2b79127ca24085630b342c971449566c55",
    "title": "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01053403",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d685e6acf4bd8dd58048357f22c71678f514c6e2e677c43b17ef54db2b84984e",
    "title": "Role of Serotonin in Acute and Subacute MDMA Effects",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2009-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00838305",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a0f58758dbcdb84334875a717c37be38c944dd1ce47faf972514540c5014bed",
    "title": "Personality and Drug Use",
    "compound": "other",
    "type": "observational",
    "institution": "Psychedelic Data Society",
    "condition": "addiction",
    "sample_size": 1000,
    "status": "active",
    "date": "2022-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05516823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0f0496c1e23168440c4feee9c6aa51836aa175e43e2547cb346ec874b2aed779",
    "title": "Addiction in Intensive Cardiac Care Units",
    "compound": "other",
    "type": "observational",
    "institution": "Assistance Publique - H\u00f4pitaux de Paris",
    "condition": "addiction",
    "sample_size": 1500,
    "status": "active",
    "date": "2021-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05063097",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0edd5645e3be7aefe0da8fe089f0a5ba403e4960bb4ff5c86b3335515180e57a",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 100,
    "status": "completed",
    "date": "2018-11-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03537014",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bba46491bcce414efd8898ca051aedbc53f2d246e850353bf623262f8facc010",
    "title": "Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "MAPS Europe B.V.",
    "condition": "PTSD",
    "sample_size": 21,
    "status": "completed",
    "date": "2020-06-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04030169",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0a62c84f8d0c4b4c26830a8d4df08b8b4c4f3b3d9a964e45d31a76be1e88648f",
    "title": "Effects of MDMA-like Substances in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2021-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04847206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5f0930ad35cc18b10cc75ad3f33e23ad725e5007927edb8a4650b9795e732b66",
    "title": "Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04968938",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1515e96069ff1b97e044939493f4735f4044d10159af0998abbcf94251491adc",
    "title": "MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "VA Loma Linda Health Care System",
    "condition": "PTSD",
    "sample_size": 5,
    "status": "completed",
    "date": "2021-07-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04264026",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f61706e9f76828f1c40e0ae461f850479a937481325a10c2f4d0880c145c84bb",
    "title": "The NeXT Study; The Netherlands XTC Toxicity Study",
    "compound": "other",
    "type": "observational",
    "institution": "UMC Utrecht",
    "condition": "other",
    "sample_size": 225,
    "status": "completed",
    "date": "2002-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00235768",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "73bed01512b7023d428c09dc8e174e63d286758f14b0f711c3eaf844bdfbd07b",
    "title": "A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 198,
    "status": "completed",
    "date": "2022-08-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05407064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "166fb404e3c53c8cb3c8a162592f1d9d1cf6100405e4f8d2d425a837c9de55da",
    "title": "Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Royan Institute",
    "condition": "other",
    "sample_size": 10,
    "status": "completed",
    "date": "2007-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00736307",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "593a3c6d6d1cc7a13835dae41878b4895ef78a36eb3729289d22d8afa1cadfd8",
    "title": "Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2013-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01878942",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "016eba5535847db659689e61ee49762f398ceb5d8a024f65f510e3a15b877fea",
    "title": "The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers",
    "compound": "other",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2015-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02451072",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "29c8b897183f9c655d38fa5b1db57baca9cfd71c379712675c69d42cab21518f",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 245,
    "status": "active",
    "date": "2025-01-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06809595",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c9bd8e96c404cdf654fce29623289610fdcd274418c0b61e5435908a11874236",
    "title": "The \"Motoric Cognitive Risk\" Syndrome in the Quebec Population",
    "compound": "other",
    "type": "observational",
    "institution": "Jewish General Hospital",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2016-12-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03633253",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "97566582e2e946eb41791cba88bf1e7cdf131715d588e3970fe1c4f430418893",
    "title": "Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05175430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f60f9089871a0e960e6941bb17bf737b59936713cb3cce68a09cc80d71c956fa",
    "title": "Stem Cell Gene Therapy for Cystinosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of California, San Diego",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-07-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03897361",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "04b567b73cc555cafd6bf8721d9c81ecebddd45d1cadf9711e2179d19dd0c887",
    "title": "Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Multidisciplinary Association for Psychedelic Studies",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2008-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00920387",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05a0c0e68ed27017ccd526a4fd18964d82f81f6c8858b90af8f3e39091e83ee8",
    "title": "Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts",
    "compound": "other",
    "type": "observational",
    "institution": "Chaoran Han",
    "condition": "other",
    "sample_size": 18,
    "status": "completed",
    "date": "2024-03-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07415395",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c54802f7bf8a1c20c3beecd067388e0774271a9ef258e8cfd3b423e86a456c18",
    "title": "MCR Syndrome in Quebec : Results From NuAge Study",
    "compound": "other",
    "type": "observational",
    "institution": "Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'\u00cele-de-Montr\u00e9al",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2020-11-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05046275",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd0c381174ece3afbd801dc104b49f80f4ec7242d1d9ac639e222d1b1292fbbf",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 214,
    "status": "active",
    "date": "2024-12-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06741228",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "03067ca4712abd836642748279b8da776132bd6f60cc6cbb8887232d0a05123e",
    "title": "Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy",
    "compound": "other",
    "type": "observational",
    "institution": "Tatiana Aboulafia Brakha",
    "condition": "depression",
    "sample_size": 10,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06557239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7c0a06ecf54c59a7c70e23261c156f5c9616b087b83da25a6cb17db838b707de",
    "title": "Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA",
    "compound": "other",
    "type": "phase_1",
    "institution": "Neutrolis",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2025-09-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07237659",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0b0e849d62de9354d6c2cd33dcb80576d556c4d4c0fa527feb773a99a3a9c660",
    "title": "Sodium Lactate and Brain Relaxation (LSD)",
    "compound": "lsd",
    "type": "phase_3",
    "institution": "Centre Hospitalier Universitaire de Besancon",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2020-09-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04488874",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "808949308380ca60c12d04a5092e821d8b25f9cbef618a04a0503960cefde90b",
    "title": "Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2011-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01515956",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9870a2b3b95ba3299a08e65422b734f8fc9197f6efe2049b2d76b23d537ea651",
    "title": "Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma",
    "compound": "other",
    "type": "phase_2",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2010-01-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01045460",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aff091d3e0020b20f67d75b2c5af37a601c7e8b783f770fc3caa9f3ecaa0cd8d",
    "title": "Investigating Lysosomal Storage Diseases in Minority Groups",
    "compound": "other",
    "type": "observational",
    "institution": "O & O Alpan LLC",
    "condition": "other",
    "sample_size": 20000,
    "status": "active",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02120235",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8a1a0cf7c075b35694cd4b34aa6ca2a27a1aaf8325327fb08e69b8871186e29f",
    "title": "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma",
    "compound": "other",
    "type": "phase_1",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2007-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00566098",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "47a6c822f43008882c9d5d64be719bb39c588abc2aca9972e5fc26e7b495f90b",
    "title": "A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C",
    "compound": "other",
    "type": "observational",
    "institution": "ZevraDenmark",
    "condition": "other",
    "sample_size": 35,
    "status": "completed",
    "date": "2015-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02435030",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05a53dc5e0a01131a0a1316204fd1da2018e69def1159a85d22d3af0b2db79ca",
    "title": "Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "cluster_headache",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2019-01-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03781128",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "458ca894e769fa8da1bb01d5d41d6b549e25daf68e07a75557a3471dd9969355",
    "title": "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01609062",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6623f3e9de2ded35c8720d0f13dccac9343e9a7596203df5e62e4a8e3351e8cd",
    "title": "A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)",
    "compound": "other",
    "type": "observational",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 353,
    "status": "completed",
    "date": "2008-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00787995",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "157681ca00c33bf07de001b086af64b18b6ddb0664d1f3cd6c52e1b91557d43c",
    "title": "Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis",
    "compound": "other",
    "type": "observational",
    "institution": "Universidade do Porto",
    "condition": "other",
    "sample_size": 150,
    "status": "active",
    "date": "2022-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04386538",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "751b28b94f47f6b99e30dfb7f181bede6487f71008537bbee0ed7aa62409ab21",
    "title": "Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders",
    "compound": "other",
    "type": "observational",
    "institution": "Lysosomal and Rare Disorders Research and Treatment Center, Inc.",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2018-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03812055",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a259533ddcc34d2753d1c5199d6bafd5dbf99a3e7178b9392ffec6a7f89d4da3",
    "title": "Comparative Acute Effects of LSD, Psilocybin and Mescaline",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 32,
    "status": "completed",
    "date": "2020-05-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04227756",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "94bb831e6adf7eb9a026a30b4c440806f9c00ca5f56a0a987b60aca4c2f8d35a",
    "title": "A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 149,
    "status": "active",
    "date": "2025-04-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06941844",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b4066a28eab03e35b8e6cba1c8a3f378dc758494a82b48e92de641d4ff1ed74d",
    "title": "LSD Therapy for Persons Suffering From Major Depression",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "depression",
    "sample_size": 60,
    "status": "completed",
    "date": "2019-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03866252",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e7b51d7e04a455af1a23fb01681267fa58ae30c36025327ad80ca5a56f230a9c",
    "title": "Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_3",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 173,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01415427",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1737542c21cfc81d45bc09d379e5d872fa32e4e095cb03a96304931c4daa7039",
    "title": "Mood Effects of Serotonin Agonists",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 80,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03790358",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b02e3987a5f89afca8abd6fb9b8b198331ae559a1004f5431e31508d146c720a",
    "title": "Personality and Drug Use (PDU)",
    "compound": "other",
    "type": "observational",
    "institution": "Quantified Citizen Technologies Inc.",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05180149",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1004b9a4d9de9b98e86e84197a0b2c9d92562135c3e035d7e4c59828da438f8f",
    "title": "Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01155778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4fd4eb350ecfe57a1b7018526f7c6b1c4007098857902da0234d032ba4697fae",
    "title": "The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Maastricht University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05670184",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "10cf7c75d22e14dd1e9be237042a7c14ef41fab02c00a45cac341315bfbc7542",
    "title": "Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2017-11-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03321136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "30392dbba9ef4eb3ecb081e9c621711c74e80d1c81be82aee28129c3f07161cc",
    "title": "Drug Effects on Mood and Behavior - Expectancy",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 48,
    "status": "recruiting",
    "date": "2025-06-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07061886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b3fe699f8a0ee6195dac8ce4d01a88db754ab76ea6a197a9a5dff879525d7d95",
    "title": "A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "Amicus Therapeutics",
    "condition": "other",
    "sample_size": 31,
    "status": "completed",
    "date": "2014-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02082327",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c546446c61ffc0705c106d184174e5c4cd0e345005ef0ab2daff7e8cf6f266fb",
    "title": "Mood Effects of Serotonin Agonists Extended",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 56,
    "status": "completed",
    "date": "2019-04-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03934710",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3c6a37de3c53e9ff64a4e34f688ddfeff385e237c4f0ad4682f8e2a00e5e8944",
    "title": "A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_1",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2010-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01242111",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6b62a57198dd92ceef43efb784d4e21b636374a52e3c231271e138d414bfa4d6",
    "title": "LSD to Improve Cluster Headache Impact Trial",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Radboud University Medical Center",
    "condition": "cluster_headache",
    "sample_size": 65,
    "status": "recruiting",
    "date": "2025-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05477459",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f243c57462c606d6c952be54b24cbc848bb8296d020797cf4a81d7a26701dfa4",
    "title": "Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 53,
    "status": "completed",
    "date": "2021-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05200936",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd8d62c0476bb8042aa7d027738e3c83888dcc4b959f325fd5549c72aed26ab9",
    "title": "Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.",
    "compound": "other",
    "type": "observational",
    "institution": "St. Olavs Hospital",
    "condition": "other",
    "sample_size": 21,
    "status": "completed",
    "date": "2016-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02741622",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3d902aee3ee476719d6e8bce5db47d2b3fb7feb976b4a760d660082b9c32cb49",
    "title": "Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "PTSD",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2024-12-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06624137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a7ba1a51ad0108630cce533946ad4e91d23696caf905c96e6a6856f9f172b69f",
    "title": "Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2011-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01299727",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "80b243a1f339d38e2cb0891f7570803a6c799bd074d225a1a1a3c21b2d7007d5",
    "title": "Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Inonu University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2014-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02267980",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "190f27c0326b4468706f2373998d7eb5eb69c06f4fde9bef3e7fb04eaf49e017",
    "title": "A Study of Human Multi-Sensory Integration",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Pennsylvania",
    "condition": "other",
    "sample_size": 40,
    "status": "active",
    "date": "2018-07-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03498391",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "272f4d58f4a2c906f0e1868d86687c155ac2657792a41aeef3f506841cd6cbb0",
    "title": "Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Dennis Charney",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2009-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00749203",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c779b909ffdd98ac939a95dddcb2f6be0aa887ad2619954ce9e36d0389920a18",
    "title": "Ketamine Augmentation of ECT in Treatment-Resistant Depression",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Universit\u00e0 Vita-Salute San Raffaele",
    "condition": "depression",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-07-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07088380",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5df2690a285d691c7b1af757398ec93a5fd11975a6e79a1374fd90545c3ce807",
    "title": "Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tianjin Nankai Hospital",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2021-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04873479",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "35907f92e5f6b7db2cc3a80ed521f84482628ed40d38cc318f609b9feb15a52f",
    "title": "RIVER At Home Ketamine Protocols",
    "compound": "ketamine",
    "type": "observational",
    "institution": "RIVER Foundation",
    "condition": "anxiety",
    "sample_size": 50000,
    "status": "recruiting",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06070766",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bb5858a2fd2869034395f2e40ae74d0987c25f95c260dd19d853188d0ce55f81",
    "title": "Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2020-11-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04666623",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "764be54047f8d1a55dc5a0ce26d608d6b93984baf70f32dc2a3c731ea4e34b01",
    "title": "(GluEsk) Glutamate and Esketamine",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Oxford",
    "condition": "depression",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-06-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06432322",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6dffb4f84d386c55424843fa6884e3890c9abeb5b4c95def821580838292920d",
    "title": "Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University Tunis El Manar",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2016-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02653651",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a22e5b778593c959e8fef417ce9fda9cd813db3433effde8af96b56ad1bfb5cb",
    "title": "Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric",
    "compound": "other",
    "type": "observational",
    "institution": "Universitas Diponegoro",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02463929",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "06b938a52c289a43c189a3080f6689b5eec6acccf06d9706ca0a86f65a7b2bd6",
    "title": "Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 71,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02568176",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "567b2c15be781d2c22d845d39fc084826d9fcba87e08779829dbd5279ebb1934",
    "title": "Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Alberta",
    "condition": "other",
    "sample_size": 48,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02579642",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "56f81ad05c75ca552f9c95e41680787b199863d15d3ef01c1089eac1dd27dded",
    "title": "Ketamine for Refractory Chronic Migraine: a Pilot Study",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Thomas Jefferson University",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-03-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03896256",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd95d567074ca34e4aab3247d1677d0f074f037a4ba456bfe1da1b56b1a5077d",
    "title": "Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients",
    "compound": "other",
    "type": "observational",
    "institution": "Ayfer Kaya G\u00f6k",
    "condition": "other",
    "sample_size": 100,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07433231",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d65a8e74970d4048d812d23b7fc123bef014151193828159317bf00aae6f22ce",
    "title": "Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second Affiliated Hospital of Nanchang University",
    "condition": "other",
    "sample_size": 80,
    "status": "active",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07556172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "12d22bf68d564ec8a42e0ded07afe58a746af4ad2ad47d07405792cec132f7bb",
    "title": "Neurocognitive Features of Patients With Treatment-Resistant Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Massachusetts General Hospital",
    "condition": "depression",
    "sample_size": 13,
    "status": "completed",
    "date": "2016-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03134066",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d781b84aeb1303c90a3a50aa4ed898261ae9f7717a218e14b2f2325f284df17d",
    "title": "Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Peking University First Hospital",
    "condition": "other",
    "sample_size": 340,
    "status": "completed",
    "date": "2024-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06566469",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e441e1d29d6e74442a4cba1d6789df9874c195c897dd5b09b1d1316f8821f87f",
    "title": "Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2010-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01207206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3f89825fc6ad91a306ac37da00e548ec3bae8cea00cd0c6901d6be29c3331f57",
    "title": "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2016-03-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02682225",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "be58ac26d37943ccab148ec2b0774f8733726e03ab9c9b1aa5ab5953c7c9677c",
    "title": "Heart Rate Variability in Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Emory University",
    "condition": "depression",
    "sample_size": 8,
    "status": "completed",
    "date": "2015-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02525978",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1a07efa77ffb1aa4eed983787046c94a3d6713392c923ce18f6c2185f6117d1e",
    "title": "The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Cedars-Sinai Medical Center",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2013-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02252432",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "767c41a40941939b643bad9429173326eb19a7fc293c5291b8c8b35af97688d7",
    "title": "Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 32,
    "status": "active",
    "date": "2014-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02303847",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8a81776c037a829c11fcddaf63c74258801a7dac6336dbe172644f2a6c25d677",
    "title": "Esketamine and Butorphanol for Post-Lobectomy Pain",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second People's Hospital of Hefei City",
    "condition": "other",
    "sample_size": 223,
    "status": "completed",
    "date": "2022-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06398834",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "292fa963cedfbf88161a1217bc0fee76701a3796c4567737a24f6a7f7706c73d",
    "title": "The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Jinling Hospital, China",
    "condition": "depression",
    "sample_size": 120,
    "status": "completed",
    "date": "2020-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05506787",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9fb9806e1811086c28820346f250d0e7818e7641c5fe734ca579f089077c17de",
    "title": "Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Zhejiang Cancer Hospital",
    "condition": "anxiety",
    "sample_size": 185,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06530706",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd5812308b4351d76436fca1b1ffa9fb56d3e4cea52c46bad8b35caaa33a4e64",
    "title": "To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Adriana Feder",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2014-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02398136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1afda1bf01c35e08e8e40f849aecf1929438c19d0ebc0427aeea5e67b43fe762",
    "title": "Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 56,
    "status": "recruiting",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05306899",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7d267b1053132d8cec363f1995c8741d4ee2cf33042c3422299d700ee7745fac",
    "title": "Ketamine-assisted Therapy for Advanced GI Cancer",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Brian Anderson, MD",
    "condition": "other",
    "sample_size": 1,
    "status": "completed",
    "date": "2024-05-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06077487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "10d637ce957585e62611472f1fd3f5601d4fe905122d686914751b90239fe6e2",
    "title": "The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery",
    "compound": "other",
    "type": "observational",
    "institution": "Yonsei University",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2019-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03462836",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bf1fbef06deaffa37bf5e13329359e0c9534058bb62bb304c9b03665bc1cc743",
    "title": "Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Julia Finkel",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2010-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01325493",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c774e39cb5d8cffd580e9db0a04cf92b5deb271b9490e6f6cdffc23752bfdc04",
    "title": "IM Ketamine vs Midazolam for Suicidal ER Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "New York State Psychiatric Institute",
    "condition": "depression",
    "sample_size": 90,
    "status": "active",
    "date": "2021-02-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04640636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a1859b1894ff20089b7853d1bcf5018ae5debb9fa6eed4439484461ee489c50",
    "title": "Acupuncture ACL (Anterior Cruciate Ligament)",
    "compound": "other",
    "type": "observational",
    "institution": "Hospital for Special Surgery, New York",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2018-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03711734",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a0e6b8b525e3f948c2f1da90787fec07948b261b6ecf8b827eed43f6302924a",
    "title": "Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy Gastrointestinal Endoscopy",
    "compound": "other",
    "type": "observational",
    "institution": "Assiut University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2017-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03235609",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1c31bd995ad004847543039cbf3d94bca4bcd6f95bc2be64486a46cd532e0cde",
    "title": "Ketamine and Postoperative Depressive Symptom-PASSION",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Beijing Tiantan Hospital",
    "condition": "other",
    "sample_size": 84,
    "status": "completed",
    "date": "2017-07-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03086148",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0dcad76a610b9998983490be3a1a0480a405ff9b3923dbe5b52a809172c0fc90",
    "title": "Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy.",
    "compound": "other",
    "type": "observational",
    "institution": "Cairo University",
    "condition": "other",
    "sample_size": 8,
    "status": "active",
    "date": "2025-11-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07246447",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fb84ed3e97314396ad1283b8e282e17fb93e67c19049e483b0216149b79fc1ae",
    "title": "EEG Studies of Sevoflurane-Induced General Anesthesia",
    "compound": "other",
    "type": "phase_2",
    "institution": "Massachusetts General Hospital",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03503578",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd38c69b01576fceb9bdf159efbeefc164bac1412beda0cc5ae114e5420340b2",
    "title": "The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "First Affiliated Hospital of Chongqing Medical University",
    "condition": "depression",
    "sample_size": 396,
    "status": "active",
    "date": "2021-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04777110",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d90ee842fa5cb0dbe2e84e405a8a3292043d35c20a69e759ab45a94e1f735b3a",
    "title": "Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 100,
    "status": "active",
    "date": "2019-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04013958",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8daaf60052f9d2baaf90a81031bb6526dda1ff97fb357a65cb19273e93738b7b",
    "title": "Ketamine and Prolonged Exposure in PTSD",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Minneapolis Veterans Affairs Medical Center",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2019-04-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03960658",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1d1374755cc12c03199b8cfee1a8a71435e10188d012486931d98a18a0f335e7",
    "title": "Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Centre Hospitalier Universitaire de Nice",
    "condition": "other",
    "sample_size": 150,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01544725",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c4cd62bbe62af7874ff01d3ba2039e6aa1eeaa617cdd8a9349afa7e35f3446d1",
    "title": "Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Lille",
    "condition": "depression",
    "sample_size": 42,
    "status": "completed",
    "date": "2016-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02783430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "861175493511f8a7c7ad664f9735a341e50e7b68c5bfe61274892e9539bf5543",
    "title": "Ketamine Versus Etomidate for Rapid Sequence Intubation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Hennepin Healthcare Research Institute",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2013-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01823328",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c334337c15972d221fa1bfb0df4b33c5b13a87c23b8e097c81c8344371d60773",
    "title": "The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence",
    "compound": "other",
    "type": "phase_1",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01535937",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "751eec1f2844cbfc87be5b6e20f6f897b78ac492f0110d35318f7a7c1a0ce704",
    "title": "The OBSERVE Protocol",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 450,
    "status": "recruiting",
    "date": "2024-01-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06725277",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "84554ae17c35fb787aa2bf67cf606f92d1c371c0833471bf45b3d223f68007b7",
    "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Sichuan Purity Pharmaceutical Technology Co., Ltd.",
    "condition": "depression",
    "sample_size": 98,
    "status": "recruiting",
    "date": "2025-05-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07193901",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7555c8ae47415f1ade9fb24b6975944e362c48fd53c92cfe65dbbb2824085bce",
    "title": "Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02228239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a1d0b10d4c336b54c4a999cfa8932bf9254a4e05a454b2f4e984e00fb825a85",
    "title": "Oral Dexmedetomidine for Parental Separation in Pediatrics Undergoing Adenotonsillectomy",
    "compound": "other",
    "type": "observational",
    "institution": "Suez Canal University",
    "condition": "other",
    "sample_size": 74,
    "status": "completed",
    "date": "2016-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03551067",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d8b37ad969513bc321b70eb2258e76a663acf9be128eb7857c7ce3f32750aa50",
    "title": "The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults.",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Kasr El Aini Hospital",
    "condition": "other",
    "sample_size": 120,
    "status": "completed",
    "date": "2023-05-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948267",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8ffbdc4733b96fd7160e84ae8e78b0f9765cbc26e9335601dfb4667cb76059e0",
    "title": "Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS",
    "compound": "dmt",
    "type": "phase_3",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 185,
    "status": "completed",
    "date": "2021-07-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04788615",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e59209a306f49948327e44e8e850beb4d7b401ab677017ae3d97091769c3be4c",
    "title": "A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Cybin IRL Limited",
    "condition": "anxiety",
    "sample_size": 36,
    "status": "active",
    "date": "2024-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06051721",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a2cfec0a69f7f387ba35d2f4fa63a72771e4b0a3d1685c139e17d5e892b3b772",
    "title": "Trifecta Research Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06810765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9673287c7aaeb4389b64aed0fdd445efc8c00478a07884882dbc897a86e24f25",
    "title": "Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2020-11-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06459232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c6c524ddddfcf268b330be837a1bc030e51c186dbce5ac480cd6f373377012d5",
    "title": "Molecular Imaging Study of Harmine/DMT: a Basic Research Approach",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Insel Gruppe AG, University Hospital Bern",
    "condition": "other",
    "sample_size": 17,
    "status": "completed",
    "date": "2024-01-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06252506",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8397953237f78c4a48d86e46b7c0a9cb43b62dc74eedc4a7c9abc55195e52b44",
    "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 263,
    "status": "completed",
    "date": "2017-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03222973",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8b374ad7efc17f97b9dac0cea8645cf5bba28348e589efa1a120965572287b6c",
    "title": "MIH and Hypersensitivity in Children",
    "compound": "other",
    "type": "observational",
    "institution": "Universit\u00e0 degli Studi di Brescia",
    "condition": "other",
    "sample_size": 39,
    "status": "active",
    "date": "2022-01-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05705037",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d4a252dbf349d794d5fd4c4cc234b83d07e47567c7f45964ba23122d547ffab4",
    "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Usona Institute",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2022-12-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05698095",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a7c6bbbb4a7b2db9e4ee2ffb9f36fb403dc33e38657b30cd99a3bf7b81756ead",
    "title": "Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults",
    "compound": "other",
    "type": "phase_1",
    "institution": "Advanced Integrative Medical Science Institute",
    "condition": "depression",
    "sample_size": 12,
    "status": "active",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05894902",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e827018424c727540059966c617761b0901274c13092c55195dec3066259f21d",
    "title": "COVID-19 and Multiple Sclerosis Disease Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Nottingham University Hospitals NHS Trust",
    "condition": "other",
    "sample_size": 14240,
    "status": "active",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04863586",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ebc6d2cb9e4d84a9db1d1049457aca954e38b603d02475665e40a7f24847aad0",
    "title": "Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Strasbourg, France",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06663189",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fe5659f3e050530a37ac51589c0e7c36e75b1c92a9e97a692a2d28f0b0be2805",
    "title": "Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study",
    "compound": "other",
    "type": "observational",
    "institution": "University of British Columbia",
    "condition": "other",
    "sample_size": 4000,
    "status": "completed",
    "date": "2003-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06705608",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5dcb0f502daf7d1a368b6fc4a56118310c0722bd49cf26e3bac1a4996b74c580",
    "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY\u00ae) in Participants Who Took it During Pregnancy And About the Health of Their Babies",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 1178,
    "status": "active",
    "date": "2021-09-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05688436",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "08f52372bc035bac75657108aad5347626c4237e547b6de456a38c15897851ba",
    "title": "Clinical Study of DMT in Healthy Adults",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Biomind Labs Inc.",
    "condition": "other",
    "sample_size": 27,
    "status": "completed",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05573568",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4f753dd3cdbeff3327a4e200b388086dfa8f0c5143b958761133b187c2f54e95",
    "title": "The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative",
    "compound": "other",
    "type": "observational",
    "institution": "Dartmouth-Hitchcock Medical Center",
    "condition": "other",
    "sample_size": 694,
    "status": "completed",
    "date": "2017-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03480854",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fe1140593d82994c1d7ee2968001b7de105de60dc80c6f3c308c58b692e545cf",
    "title": "Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients",
    "compound": "dmt",
    "type": "observational",
    "institution": "Merck KGaA, Darmstadt, Germany",
    "condition": "other",
    "sample_size": 545,
    "status": "completed",
    "date": "2012-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01601119",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "23d314ab1fd3526bdd73e297d3680208643c0e5ef76081ee568dddc5e452c867",
    "title": "Mindfulness and Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Milan Scheidegger",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2023-02-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05780216",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bb2d1f423ba849acce9be30e14930878b487118e15fec78a56e9939c060fa283",
    "title": "SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 66,
    "status": "completed",
    "date": "2021-02-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04673383",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4cc22f54000bd643635786ea4ad4042348b8d140ea53ce4c087b412e7fc272de",
    "title": "A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Montpellier",
    "condition": "other",
    "sample_size": 250,
    "status": "recruiting",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189325",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c1f193d7302ca715a6b68c408a65c10157d27841b0859d3a7819c30e67eba86d",
    "title": "Neuroprotection and Repair in Optic Neuritis",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Calgary",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2010-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01073813",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0c3f81decabbb41f4b7adb295683a33edae8d838ea688ab2b128a98d3c26239b",
    "title": "Effects Of Dance Movement Therapy On Compassionate Flow In Nursing Students",
    "compound": "other",
    "type": "observational",
    "institution": "Mackay Medical College",
    "condition": "other",
    "sample_size": 59,
    "status": "completed",
    "date": "2023-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06220708",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "458f65dce66e0d941276a1cd6738bf5e341be29869b9be92f52dbebf06909136",
    "title": "Antidepressant Response of DMT Masked With Propofol",
    "compound": "dmt",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06927076",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "604aa74e281e83bdb5edccdc5372851dfb8317b70d9f15497754648a09d11092",
    "title": "Ayahuasca Assisted Psychotherapy for Grief",
    "compound": "ayahuasca",
    "type": "phase_2",
    "institution": "Beckley Med Foundation",
    "condition": "other",
    "sample_size": 84,
    "status": "active",
    "date": "2021-10-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06150859",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "affa2207639a5fa63ef6454d808520c1509c1f63e3bfceb48cd4de639ba3f54b",
    "title": "Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "Ying Gao",
    "condition": "other",
    "sample_size": 328,
    "status": "recruiting",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07037823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fbaa96a562ba52784bd35f4c3b4ee6765c09a2f77868292ac7cfe0a2c7845f3a",
    "title": "Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders",
    "compound": "dmt",
    "type": "observational",
    "institution": "Shalvata Mental Health Center",
    "condition": "anxiety",
    "sample_size": 24,
    "status": "active",
    "date": "2015-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02304796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0c7c6806440daee2f4f23c4ef1aa7aa5c272804d36168bb83dfa2c75e593136d",
    "title": "Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers",
    "compound": "other",
    "type": "observational",
    "institution": "MoCA Clinic and Institute",
    "condition": "other",
    "sample_size": 500,
    "status": "recruiting",
    "date": "2025-03-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07041450",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "30f478aedf8f0a98e9f0346688c1eb55fa63129a46cf16caf6c1c709fa514a1d",
    "title": "A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 213,
    "status": "completed",
    "date": "2011-11-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07474311",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d6907de2f9644625c86a8e83da9ce3d8f4514ca0e0dccaefbcb7cd55c5c08e81",
    "title": "Relationship Between Oral DMT Burden and Adherence in MS",
    "compound": "dmt",
    "type": "observational",
    "institution": "Monash University",
    "condition": "other",
    "sample_size": 323,
    "status": "recruiting",
    "date": "2020-09-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04676204",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2404ad4c4cb21bf593a3791b987bbd7b37538bd8cdbf57070342230055b99d82",
    "title": "Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Abu Dhabi Stem Cells Center",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2022-03-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05168384",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "12872c0a3fa470883d41f898f804ac4077fba2f2e639e490a4d1e84b6a3c295f",
    "title": "Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Reconnect Labs",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2023-05-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05829603",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3918890d4d12918083bf574e55c7d4620e692c273b1ec4743a51601e59e462b5",
    "title": "Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2024-06-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05695495",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6f45d2ad04991aca5de6a3f241c8ec4bebadceeff50fef93c89371bdbb6a488f",
    "title": "Dance/Movement Therapy for Bone Mineral Density in Schizophrenia",
    "compound": "other",
    "type": "observational",
    "institution": "Hebei Province Veterans Hospital",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2020-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05716802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cdc6ab6399d4f7a940f6c01d1e7cc96eb59f3c9c1f1d68d393a1058628def4cc",
    "title": "Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2013-11-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04832399",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "63cd052997eba418ae5c3f7a4e835cdc2dcc9d8ecfaa5c191037d23fdc55d686",
    "title": "Phase 2 Clinical Trial of GH001 in Bipolar II Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2023-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05839509",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5e27ba601ebeb3ecbe50813b4d0205a969296ac3c8a60111d5a9cbd60d513729",
    "title": "A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 42,
    "status": "completed",
    "date": "2012-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01578330",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "39fec6f9415d7849e6a3306a23f1917e72a1fe8cd8ff12ecfd103182a3003a3b",
    "title": "Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2020-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04716335",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "93d979744d0bc58dbf333559d90baccd529c5f9e35e9990d8218b3d8a7400dbf",
    "title": "Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-10-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06094907",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "43b62069ae202526008cbfce6c0efb0b2f61371f4ed0060618f6cc149263694e",
    "title": "Tecfidera and the Gut Microbiota",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2015-11-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02471560",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0b0809be1f4e55273778eba9dc2b66f56387c1a64ea5c83b2349fff8a8023c89",
    "title": "IM and IV SPL026 Drug Product in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05644093",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f5cacad300ad47f1970b268a4028a5f07bfabfc4361d9912b12faba09ceb52a2",
    "title": "A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 4805,
    "status": "completed",
    "date": "2025-06-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07403214",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a6ac7d4a968a59de2a52175988a9472bac177922c5d37b0db907a227d0403498",
    "title": "Pharmacokinetics of GH001 in Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 46,
    "status": "completed",
    "date": "2021-06-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163691",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fc508483b010ea25719a39974dd3d5803626c93f6930ddb9acccab2a9d1cdc45",
    "title": "Psilocybin Therapy for Chronic Low Back Pain",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley, MD, PhD",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05351541",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "862609b3ba3e0daafbd9b813255bd08128072ab801f7fdfdcfd9b7310c81119f",
    "title": "Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 30,
    "status": "active",
    "date": "2021-03-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04711915",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "253525c15a23404be35cdd553c55f82d20d5703708b2d2c1cc515671f10e9ef6",
    "title": "A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants",
    "compound": "other",
    "type": "observational",
    "institution": "Bristol-Myers Squibb",
    "condition": "other",
    "sample_size": 2961,
    "status": "active",
    "date": "2021-03-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06133049",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a1fd87c11858d4808367848125ec95fbac19835d9c43b832a17a16ba84209c37",
    "title": "Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Jeffrey Gelfand",
    "condition": "other",
    "sample_size": 5,
    "status": "completed",
    "date": "2018-11-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03594487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "56f8fa8654951753b6ad57602591a8aea57674a30bb336dedc1cb8aa7de281ce",
    "title": "Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "International Center for Ethnobotanical Education, Research, and Service",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2020-10-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04003948",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a8472dbee4ff38751b1498e7cf4f624eefe2e30e0e17b06ac9da2ffcac4cdad",
    "title": "Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "Stanford University",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2021-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04313712",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "42034b58b03ea36a85a62c85a5fcc6711e2710b0f8b0a648b0a9995b19825dc3",
    "title": "Mapping Ibogaine Neural Dynamics in Opioid Use Disorder",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "University of California, Irvine",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07226570",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6ec247e6bd2fe4c3ae2a7ecc80bf0ce09660e4c3edea0bb358efd09bb937941",
    "title": "A Study of Oral Ibogaine in Opioid Withdrawal",
    "compound": "ibogaine",
    "type": "phase_1",
    "institution": "atai Therapeutics, Inc.",
    "condition": "other",
    "sample_size": 116,
    "status": "completed",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05029401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2205af0565e2d1cfac1f1b872f433ac71ed08b35afac93a581f06c507de54ef9",
    "title": "Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03380728",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e9f88d2b3bb5a904eb63d34f94db1d354a1424b112d621c1d4ae607c2d917a96",
    "title": "Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression",
    "compound": "ayahuasca",
    "type": "phase_1",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 35,
    "status": "completed",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02914769",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "724a3f04d998d445fa1228ab0a475276cf9cca32c969629b4c047203bc6f84d6",
    "title": "Ayahuasca, Esketamine and Body Image Perception",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317219",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "915bfce0f72d51bd26a570d2dbf3e81fdffb1ccee6ef28a821905621b2012261",
    "title": "Ayahuasca, Esketamine and Premenstrual Symptoms",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f297c77cbff46505d11bb69d2bfdd0726b17dcf3625c1dcb0488fcbd3d25794b",
    "title": "Ayahuasca, Esketamine and PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ae5bf47b8c21f70c8347be94a0f17598df8f9d8b63309e5be3898573802d861c",
    "title": "Entheogen Resurgence",
    "compound": "other",
    "type": "observational",
    "institution": "Vireo Health",
    "condition": "other",
    "sample_size": 102,
    "status": "completed",
    "date": "2021-09-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "dd8cb146beda67e6d2a65cdc96868d21662ae45ff0fd9a1e3d9edcdec6a8363c",
    "title": "Ayahuasca and Esketamine for Major Depression",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "depression",
    "sample_size": 22,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07212946",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05431a8189731bff6895510ce8559f8effba74196570c6c81b0196aa4c9d34f8",
    "title": "Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness",
    "compound": "mescaline",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2021-08-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04849013",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cdcc6f1de14e082e13f542622a5a2158e041829aca33360d610de8aa27d3aae1",
    "title": "Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis",
    "compound": "mescaline",
    "type": "observational",
    "institution": "Xiangya Hospital of Central South University",
    "condition": "other",
    "sample_size": 205,
    "status": "active",
    "date": "2023-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05933213",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "773c4008c74bf3e563f49eb29bdfe405d55dfef7ec461876f8c712bc0d7490c9",
    "title": "Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Queen's University",
    "condition": "anxiety",
    "sample_size": 50,
    "status": "recruiting",
    "date": "2025-05-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06969170",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8dad6775994bc7a74fd1e9a03d67b4b99281a463ec2fa2fb59482856ed55a256",
    "title": "PRoMiSS: Psilocybin and the Role of Music in Set and Setting",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07180108",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a63c61f0a96d1be4f014a300b8f4ad61be2aa1cff38900a6df7d06a42ec7542",
    "title": "PET Synaptogenesis After Psilocybin In DEpression Recovery",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Washington University School of Medicine",
    "condition": "depression",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05601648",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a8a499557342c109e5b6f140e90b6030a40935ae683df7430b86cd16aaf62892",
    "title": "Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "depression",
    "sample_size": 92,
    "status": "recruiting",
    "date": "2024-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06341426",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9f1704ebc6acb144c25a5154b9e77a9e9590e811e6e4caca25ea124b625b4c16",
    "title": "PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm",
    "compound": "other",
    "type": "observational",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06798636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2ce36b6f6856ac3c74fa3e7cb4777aaf04b4b46c3f7360805b1455d089764b2d",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "MycoMedica Life Sciences PBC",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-11-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06643637",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7f6d72d5a41991625da15ec6011b4185ce13c9d6cd5f2acde9aa991e72909176",
    "title": "UW Psilocybin Pharmacokinetics Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Wisconsin, Madison",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02163707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9b6648605628e1c68dfbf123cbbadb6265df1e06878cfecbc66e7d49323f7ba1",
    "title": "Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "McMaster University",
    "condition": "other",
    "sample_size": 16,
    "status": "recruiting",
    "date": "2025-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06225232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "79655b118a6fdb6d80fdd8f65b9ef29339bdb45474926a0f6dedddeb3cdefe42",
    "title": "Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05399498",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0d81dd8883f6b189389c302858719797d96b7a28759b72c3b67bb72c446a4085",
    "title": "Psilocybin Therapy in Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2023-05-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05398484",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a9a098702a42f1877c1c3525081b6c34bfaab79f1ccf9696972d2556258cc773",
    "title": "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Portland VA Research Foundation, Inc",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2022-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04982796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "501d36d641160bd70b9c36ddd29f57361c136abe88fdb363e7866516dd44bc91",
    "title": "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "other",
    "sample_size": 102,
    "status": "active",
    "date": "2023-01-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05733546",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ab6b24459fc594076009bd9736542b5a107ff7f11384c5a3bec20d741c7d3e7c",
    "title": "ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression",
    "compound": "other",
    "type": "phase_1",
    "institution": "Eleusis Therapeutics",
    "condition": "depression",
    "sample_size": 84,
    "status": "active",
    "date": "2022-10-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05434156",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c885eea8fadce12dbbb2b26868ee67ddfccd910386ec2c4e0599694e15f411c0",
    "title": "Psilocybin for Hospitalized Patients with Treatment-resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Hospital, Ghent",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2024-05-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06378229",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd020033e301ce9c49618456d740745c35292aa14a8a86be2d0a99dbc39b44df",
    "title": "Does Psilocybin Require Psychedelic Effects to Treat Depression?",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05710237",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aa0084ed2547126bc61cfa7beebb79295085417c0f08947d78153b8807c49e7d",
    "title": "Psilocybin-Assisted Therapy in Treatment-Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of North Carolina, Chapel Hill",
    "condition": "depression",
    "sample_size": 20,
    "status": "active",
    "date": "2024-04-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06303739",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a935d742c8538d8b7778bc5b38fd54b8b050acfdaf7bd03c41a78c1be012de07",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2025-07-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07048743",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "15b482b627c5295ce82c32202f4a69f070511ad410e25ee7466449f2d58f9477",
    "title": "Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Apex Labs Ltd.",
    "condition": "depression",
    "sample_size": 160,
    "status": "active",
    "date": "2023-12-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06141876",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c32847784e91dcca5f8b5ad2ceb4bb02b57128fbb484b799288d52424b82d812",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "active",
    "date": "2024-06-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06416085",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a13a1c0367eedae5de056b691c36361126a2d8852dd453e037683fb0831d644",
    "title": "Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 468,
    "status": "recruiting",
    "date": "2025-07-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06605105",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9c723750421adbaa49f789a72115861997933a72d12a69c81fee82784421afcc",
    "title": "Psilocybin-Assisted Therapy for Intergenerational Trauma",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Rachel Yehuda",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06899165",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f0af2e5f936c5f0b079eb172ac322719913f5cc47e75317197b2fcd9e59fa742",
    "title": "Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "OCD",
    "sample_size": 31,
    "status": "completed",
    "date": "2018-11-13",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03356483",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e66af192ed4aa13d0da108aefb2df42f574268f95308e08bf9071b5dbf90372d",
    "title": "\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 220,
    "status": "recruiting",
    "date": "2024-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06564818",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "69a3c0ef8c8a34a0fdffe1b0107624552d8bee00ce55779ce4f9df0e89981e5b",
    "title": "Naturalistic Study of Microdosing With Psilocybin",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "National Council of Scientific and Technical Research, Argentina",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2021-01-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05160220",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "88e91e04f7e4d8d5f2d4e03ab92f2980eec6b9332ebc95a97b77e8bdba911866",
    "title": "Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Healing Advocacy Fund",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2025-03-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189988",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "50f84cd692a434b02ffde1bfd9d98b2ea441338f67be902c950f3ebb4e076e69",
    "title": "Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre Hospitalier St Anne",
    "condition": "depression",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-10-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07210112",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ff164c3432cbce8674fe172b8bbd8921591a4adf442ed77cd23a6d9302019398",
    "title": "Effects of Hallucinogens and Other Drugs on Mood and Performance",
    "compound": "other",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02033707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "688df0737b0712bccd77e166fcc456dfd6b8c5cea50e4ac69cc212d4239114cd",
    "title": "Mood and Cognitive Effects of Psilocybin in Healthy Participants",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Optimi Health Corporation",
    "condition": "anxiety",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05252598",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b903e9c22aa9e1119b94dc8f757a58d77835cbc91992fb2d5b8a684abb23143e",
    "title": "Psilocybin in Cancer Pain Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Yvan Beaussant, MD, MSci",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-09-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06001749",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f50e83ff3f4d5c86e1b28ccf65df88075c026c11101d2e98b64440ccd3bf3266",
    "title": "Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2014-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02145091",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "57c7d8a996201b93e7631dc296f2b63fab613a37837abd985478bcc236f64be7",
    "title": "Northwest Therapies Trauma Psilocybin Study Compassionate Use Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "NWTraumatherapies",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-09-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042466",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ddb6be81b770dba5efdcee855e2aa31a205f51a7dfbe642b07932df68f9539a7",
    "title": "Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "OCD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2024-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06299319",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6d8c9a8120412bdd6ac3cc92fbf2dcd35611f20ed1478bbe9c43607de95a09a8",
    "title": "Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Clairvoyant Therapeutics",
    "condition": "other",
    "sample_size": 128,
    "status": "active",
    "date": "2022-05-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05646303",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fcdc999453f954abf2c2e3649ab675159804f8cdcf40d027a544eee5c48bf0fe",
    "title": "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "depression",
    "sample_size": 19,
    "status": "completed",
    "date": "2020-08-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04739865",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2b04a4025586812fd1c370065cf969a891d8e944564b691f51180a23011a5b9d",
    "title": "Frontline Clinician Psilocybin Study",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-03-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163496",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "15c9eb10cc3ce510974a92be9f4d145f9f94e6ecf9c2bea1fb965ade000bac24",
    "title": "PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Filament Health Corp.",
    "condition": "other",
    "sample_size": 86,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06666010",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "62f4b94c940dfd7c444dc8f6659ef806f1a406bd3d333a216837b62ad29ecfe8",
    "title": "Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "Bruy\u00e8re Health Research Institute.",
    "condition": "other",
    "sample_size": 120,
    "status": "recruiting",
    "date": "2026-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07063862",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "58802597efd9bc70689ed87c3713c732b9b7497438d8e796df21777372a6be09",
    "title": "Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2018-01-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02950467",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "161816474f2666ef27355a7dd80e00efcd5daeff9a29167cd05821c0627618e4",
    "title": "Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2021-02-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04656301",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "da400b627f5d647d623a6b134840f4fa13e01f4399866a0e749adc46266583bc",
    "title": "Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)",
    "compound": "other",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2009-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00886886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "84c6c6db07c7da18eb80bbc858fcc403bd74325eb841e435db0bbe8ed58b1823",
    "title": "Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2021-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04648137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6cd463fce294f6fb78e3988df35d7396d07cc87fdfd75f00e9c20350eb9b67c",
    "title": "Effects of MDMA on Social and Emotional Processing",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "addiction",
    "sample_size": 65,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01849419",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2131bcc12dee58da30e51ca09a469bee2b4d894cb77a03b9ccfcd55a372217e6",
    "title": "MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2004-03-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00090064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "962eaeb0ac8be671a0ee817fd434455e4a5383ef8b96883ea174d52e5b38a536",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 121,
    "status": "completed",
    "date": "2020-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04077437",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d9b6cafa6ca3aa45f907bf6c7bf65c6d60a119e7c43cb249308b95312c654771",
    "title": "Abuse Liability and Human Pharmacology of Mephedrone",
    "compound": "other",
    "type": "phase_1",
    "institution": "Parc de Salut Mar",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02232789",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "148beb6f25f7343c25b1aca0981ddf3be3d42bfb977bad74c3679f95c4f1f820",
    "title": "MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2016-07-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02876172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "63dfa756bfda228e595260d5b3b3ee7a3f0e84068625b8adef8e7bb0ff4af4a5",
    "title": "Effects of MDMA and Methylphenidate on Social Cognition",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2012-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01616407",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6d1ff8fdcd8c7ec6baee2a8abcbe5bb365869aa3c5c8e2db4ab8ebef9768278",
    "title": "A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Remedy",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2021-10-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05067244",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "285021d3b8bee0a8c83df15fccc2697e59e6b1553f217d8b2d87db9555cdffe7",
    "title": "MDMA-assisted Massed Prolonged Exposure for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Healing Breakthrough",
    "condition": "PTSD",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2024-10-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06117306",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e595df7697dc765abf3d2181993010c0bbb2ddd7b7658498e0ec779251b32bcf",
    "title": "Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01136278",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3f074b084e31a218b33a127e5bc64bd2f9bcbf8195810856fb46f78f7aa536e6",
    "title": "Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2023-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05523401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "507d5f90106428c717ac2461928dd78092f096facfc664fe319b48ba307e1167",
    "title": "Characterization of the Prosocial and Prosexual Effects of GHB",
    "compound": "other",
    "type": "observational",
    "institution": "University of Zurich",
    "condition": "other",
    "sample_size": 19,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02342366",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "444cabca36f00025435ed16aa524e3a45dff5de39d11570b28109e6feecda35a",
    "title": "Tolerability of MDMA in Schizophrenia",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Anya Bershad, MD, PhD",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05770375",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4a234d42728450159efa4b40420d985790e18ba1800ffa3bbf57c634801aff38",
    "title": "Acute Effects of R- and S-MDMA in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05277636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd76dd410ecc095a679e72801a8a3e0e3032d7b7bd4576013b4e65b2675d431c",
    "title": "MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Sunstone Medical",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2022-10-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05584826",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4d55f0dc6f49e2edc8cd21827226e1e8d4ae516c1b7704b3026c25f1a63ca5dc",
    "title": "MDMA for AUD/PTSD Comorbidity",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Carolina L Haass-Koffler",
    "condition": "PTSD",
    "sample_size": 18,
    "status": "recruiting",
    "date": "2024-02-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05943665",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ff33fafc6e20053d8a5abb6e2f23f0f09796191753274a022599ccba0ec2729c",
    "title": "Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2014-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02102802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f12fd8e76e4eb3cf6ee767fb0cff75821dc8190b4611a0e913313ee55565971f",
    "title": "Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2013-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01951508",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4e22c59825b9ade032f697c4d82dbc5c13c4020259e0730015ddf8a36131b4b1",
    "title": "Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05173831",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "df0bd82dc5d1bd2af03adb28633fdb1305ffca60387ae948b2be92d8177a25b7",
    "title": "Dose Optimization of MDMA-Assisted Therapy for PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Bronx VA Medical Center",
    "condition": "PTSD",
    "sample_size": 60,
    "status": "recruiting",
    "date": "2025-06-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06418178",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5c198bc3ad4fb592acc6833c137fb67ba5b97bef14bb58b8f9f82f20e1a58d74",
    "title": "MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Brigham and Women's Hospital",
    "condition": "anxiety",
    "sample_size": 2,
    "status": "completed",
    "date": "2007-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00252174",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6d73123254183ff7b4c49ca550414a980b2a2881107e538773311ad1b77bd7c5",
    "title": "Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2025-09-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06989957",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cfba5ccc5e2e0a2a862581139f096c4c88e0aaf38d9e7b80441e0459cc5e804a",
    "title": "MDMA-Assisted Therapy for Pathological Narcissism",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 12,
    "status": "active",
    "date": "2024-08-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06565494",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a17a3aee00b4a10000150319948cb364ea5b69cc4d68366323ea48ba2b961f02",
    "title": "Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Albany Research Institute, Inc.",
    "condition": "PTSD",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-08-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05895318",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4e5a6d3d014e2349cacc6541ba0cd4c3964020d3ef89ea13c961ae8e6fb2966c",
    "title": "Bristol Imperial MDMA in Alcoholism Study",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2018-04-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04158778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8eef2ba5573db5dfa73e93515f6ca17d5593d743b7473949817240bfab472cae",
    "title": "MDMA for Co-occurring PTSD and OUD After Childbirth",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of New Mexico",
    "condition": "PTSD",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05219175",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "99f929ad935a61ec4b997912097805d213ddbad568a379cf14102985caa42788",
    "title": "A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 87,
    "status": "completed",
    "date": "2021-03-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04714359",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "44b96caae213fc6dafefcb6fd7a4301c10cf970326ba098b8ed84947ee18ef18",
    "title": "Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01386177",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e2daf8a4cd16d31950e31fc1257394c2a5daf3fe085369fcd8f27bdef435bdca",
    "title": "Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-04-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02008396",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b1bd43aec0b0b6fc9f3a9481dfb54120e7290a35d5707503b21499de1f8cbf84",
    "title": "MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of California, Los Angeles",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06353282",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6c2eadcc0d0a7df52696bc1b247e561a6aba6e2354f5548a7377fd34784dc4c2",
    "title": "Prosocial Effects of MDMA",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 33,
    "status": "completed",
    "date": "2023-07-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948683",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "54d59639e7c54caddbc0524ef0aa7c22b300d1b915b7630563bd6dd8482cfc3e",
    "title": "Epigenetics and MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "University of Southern California",
    "condition": "PTSD",
    "sample_size": 45,
    "status": "completed",
    "date": "2018-11-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06189027",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a4943b4dbc18ffcc90fa185756fd5e2b79127ca24085630b342c971449566c55",
    "title": "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01053403",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d685e6acf4bd8dd58048357f22c71678f514c6e2e677c43b17ef54db2b84984e",
    "title": "Role of Serotonin in Acute and Subacute MDMA Effects",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2009-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00838305",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a0f58758dbcdb84334875a717c37be38c944dd1ce47faf972514540c5014bed",
    "title": "Personality and Drug Use",
    "compound": "other",
    "type": "observational",
    "institution": "Psychedelic Data Society",
    "condition": "addiction",
    "sample_size": 1000,
    "status": "active",
    "date": "2022-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05516823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0f0496c1e23168440c4feee9c6aa51836aa175e43e2547cb346ec874b2aed779",
    "title": "Addiction in Intensive Cardiac Care Units",
    "compound": "other",
    "type": "observational",
    "institution": "Assistance Publique - H\u00f4pitaux de Paris",
    "condition": "addiction",
    "sample_size": 1500,
    "status": "active",
    "date": "2021-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05063097",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0edd5645e3be7aefe0da8fe089f0a5ba403e4960bb4ff5c86b3335515180e57a",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 100,
    "status": "completed",
    "date": "2018-11-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03537014",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bba46491bcce414efd8898ca051aedbc53f2d246e850353bf623262f8facc010",
    "title": "Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "MAPS Europe B.V.",
    "condition": "PTSD",
    "sample_size": 21,
    "status": "completed",
    "date": "2020-06-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04030169",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0a62c84f8d0c4b4c26830a8d4df08b8b4c4f3b3d9a964e45d31a76be1e88648f",
    "title": "Effects of MDMA-like Substances in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2021-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04847206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5f0930ad35cc18b10cc75ad3f33e23ad725e5007927edb8a4650b9795e732b66",
    "title": "Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04968938",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1515e96069ff1b97e044939493f4735f4044d10159af0998abbcf94251491adc",
    "title": "MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "VA Loma Linda Health Care System",
    "condition": "PTSD",
    "sample_size": 5,
    "status": "completed",
    "date": "2021-07-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04264026",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f61706e9f76828f1c40e0ae461f850479a937481325a10c2f4d0880c145c84bb",
    "title": "The NeXT Study; The Netherlands XTC Toxicity Study",
    "compound": "other",
    "type": "observational",
    "institution": "UMC Utrecht",
    "condition": "other",
    "sample_size": 225,
    "status": "completed",
    "date": "2002-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00235768",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "73bed01512b7023d428c09dc8e174e63d286758f14b0f711c3eaf844bdfbd07b",
    "title": "A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 198,
    "status": "completed",
    "date": "2022-08-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05407064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "166fb404e3c53c8cb3c8a162592f1d9d1cf6100405e4f8d2d425a837c9de55da",
    "title": "Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Royan Institute",
    "condition": "other",
    "sample_size": 10,
    "status": "completed",
    "date": "2007-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00736307",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "593a3c6d6d1cc7a13835dae41878b4895ef78a36eb3729289d22d8afa1cadfd8",
    "title": "Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2013-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01878942",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "016eba5535847db659689e61ee49762f398ceb5d8a024f65f510e3a15b877fea",
    "title": "The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers",
    "compound": "other",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2015-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02451072",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "29c8b897183f9c655d38fa5b1db57baca9cfd71c379712675c69d42cab21518f",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 245,
    "status": "active",
    "date": "2025-01-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06809595",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c9bd8e96c404cdf654fce29623289610fdcd274418c0b61e5435908a11874236",
    "title": "The \"Motoric Cognitive Risk\" Syndrome in the Quebec Population",
    "compound": "other",
    "type": "observational",
    "institution": "Jewish General Hospital",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2016-12-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03633253",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "97566582e2e946eb41791cba88bf1e7cdf131715d588e3970fe1c4f430418893",
    "title": "Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05175430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f60f9089871a0e960e6941bb17bf737b59936713cb3cce68a09cc80d71c956fa",
    "title": "Stem Cell Gene Therapy for Cystinosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of California, San Diego",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-07-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03897361",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "04b567b73cc555cafd6bf8721d9c81ecebddd45d1cadf9711e2179d19dd0c887",
    "title": "Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Multidisciplinary Association for Psychedelic Studies",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2008-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00920387",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05a0c0e68ed27017ccd526a4fd18964d82f81f6c8858b90af8f3e39091e83ee8",
    "title": "Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts",
    "compound": "other",
    "type": "observational",
    "institution": "Chaoran Han",
    "condition": "other",
    "sample_size": 18,
    "status": "completed",
    "date": "2024-03-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07415395",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c54802f7bf8a1c20c3beecd067388e0774271a9ef258e8cfd3b423e86a456c18",
    "title": "MCR Syndrome in Quebec : Results From NuAge Study",
    "compound": "other",
    "type": "observational",
    "institution": "Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'\u00cele-de-Montr\u00e9al",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2020-11-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05046275",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd0c381174ece3afbd801dc104b49f80f4ec7242d1d9ac639e222d1b1292fbbf",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 214,
    "status": "active",
    "date": "2024-12-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06741228",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "03067ca4712abd836642748279b8da776132bd6f60cc6cbb8887232d0a05123e",
    "title": "Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy",
    "compound": "other",
    "type": "observational",
    "institution": "Tatiana Aboulafia Brakha",
    "condition": "depression",
    "sample_size": 10,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06557239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7c0a06ecf54c59a7c70e23261c156f5c9616b087b83da25a6cb17db838b707de",
    "title": "Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA",
    "compound": "other",
    "type": "phase_1",
    "institution": "Neutrolis",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2025-09-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07237659",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0b0e849d62de9354d6c2cd33dcb80576d556c4d4c0fa527feb773a99a3a9c660",
    "title": "Sodium Lactate and Brain Relaxation (LSD)",
    "compound": "lsd",
    "type": "phase_3",
    "institution": "Centre Hospitalier Universitaire de Besancon",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2020-09-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04488874",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "808949308380ca60c12d04a5092e821d8b25f9cbef618a04a0503960cefde90b",
    "title": "Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2011-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01515956",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9870a2b3b95ba3299a08e65422b734f8fc9197f6efe2049b2d76b23d537ea651",
    "title": "Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma",
    "compound": "other",
    "type": "phase_2",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2010-01-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01045460",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "aff091d3e0020b20f67d75b2c5af37a601c7e8b783f770fc3caa9f3ecaa0cd8d",
    "title": "Investigating Lysosomal Storage Diseases in Minority Groups",
    "compound": "other",
    "type": "observational",
    "institution": "O & O Alpan LLC",
    "condition": "other",
    "sample_size": 20000,
    "status": "active",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02120235",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8a1a0cf7c075b35694cd4b34aa6ca2a27a1aaf8325327fb08e69b8871186e29f",
    "title": "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma",
    "compound": "other",
    "type": "phase_1",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2007-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00566098",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "47a6c822f43008882c9d5d64be719bb39c588abc2aca9972e5fc26e7b495f90b",
    "title": "A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C",
    "compound": "other",
    "type": "observational",
    "institution": "ZevraDenmark",
    "condition": "other",
    "sample_size": 35,
    "status": "completed",
    "date": "2015-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02435030",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05a53dc5e0a01131a0a1316204fd1da2018e69def1159a85d22d3af0b2db79ca",
    "title": "Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "cluster_headache",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2019-01-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03781128",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "458ca894e769fa8da1bb01d5d41d6b549e25daf68e07a75557a3471dd9969355",
    "title": "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01609062",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6623f3e9de2ded35c8720d0f13dccac9343e9a7596203df5e62e4a8e3351e8cd",
    "title": "A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)",
    "compound": "other",
    "type": "observational",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 353,
    "status": "completed",
    "date": "2008-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00787995",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "157681ca00c33bf07de001b086af64b18b6ddb0664d1f3cd6c52e1b91557d43c",
    "title": "Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis",
    "compound": "other",
    "type": "observational",
    "institution": "Universidade do Porto",
    "condition": "other",
    "sample_size": 150,
    "status": "active",
    "date": "2022-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04386538",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "751b28b94f47f6b99e30dfb7f181bede6487f71008537bbee0ed7aa62409ab21",
    "title": "Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders",
    "compound": "other",
    "type": "observational",
    "institution": "Lysosomal and Rare Disorders Research and Treatment Center, Inc.",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2018-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03812055",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a259533ddcc34d2753d1c5199d6bafd5dbf99a3e7178b9392ffec6a7f89d4da3",
    "title": "Comparative Acute Effects of LSD, Psilocybin and Mescaline",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 32,
    "status": "completed",
    "date": "2020-05-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04227756",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "94bb831e6adf7eb9a026a30b4c440806f9c00ca5f56a0a987b60aca4c2f8d35a",
    "title": "A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 149,
    "status": "active",
    "date": "2025-04-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06941844",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b4066a28eab03e35b8e6cba1c8a3f378dc758494a82b48e92de641d4ff1ed74d",
    "title": "LSD Therapy for Persons Suffering From Major Depression",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "depression",
    "sample_size": 60,
    "status": "completed",
    "date": "2019-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03866252",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e7b51d7e04a455af1a23fb01681267fa58ae30c36025327ad80ca5a56f230a9c",
    "title": "Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_3",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 173,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01415427",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1737542c21cfc81d45bc09d379e5d872fa32e4e095cb03a96304931c4daa7039",
    "title": "Mood Effects of Serotonin Agonists",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 80,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03790358",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b02e3987a5f89afca8abd6fb9b8b198331ae559a1004f5431e31508d146c720a",
    "title": "Personality and Drug Use (PDU)",
    "compound": "other",
    "type": "observational",
    "institution": "Quantified Citizen Technologies Inc.",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05180149",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1004b9a4d9de9b98e86e84197a0b2c9d92562135c3e035d7e4c59828da438f8f",
    "title": "Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01155778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4fd4eb350ecfe57a1b7018526f7c6b1c4007098857902da0234d032ba4697fae",
    "title": "The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Maastricht University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05670184",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "10cf7c75d22e14dd1e9be237042a7c14ef41fab02c00a45cac341315bfbc7542",
    "title": "Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2017-11-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03321136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "30392dbba9ef4eb3ecb081e9c621711c74e80d1c81be82aee28129c3f07161cc",
    "title": "Drug Effects on Mood and Behavior - Expectancy",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 48,
    "status": "recruiting",
    "date": "2025-06-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07061886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b3fe699f8a0ee6195dac8ce4d01a88db754ab76ea6a197a9a5dff879525d7d95",
    "title": "A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "Amicus Therapeutics",
    "condition": "other",
    "sample_size": 31,
    "status": "completed",
    "date": "2014-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02082327",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c546446c61ffc0705c106d184174e5c4cd0e345005ef0ab2daff7e8cf6f266fb",
    "title": "Mood Effects of Serotonin Agonists Extended",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 56,
    "status": "completed",
    "date": "2019-04-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03934710",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3c6a37de3c53e9ff64a4e34f688ddfeff385e237c4f0ad4682f8e2a00e5e8944",
    "title": "A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_1",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2010-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01242111",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6b62a57198dd92ceef43efb784d4e21b636374a52e3c231271e138d414bfa4d6",
    "title": "LSD to Improve Cluster Headache Impact Trial",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Radboud University Medical Center",
    "condition": "cluster_headache",
    "sample_size": 65,
    "status": "recruiting",
    "date": "2025-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05477459",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f243c57462c606d6c952be54b24cbc848bb8296d020797cf4a81d7a26701dfa4",
    "title": "Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 53,
    "status": "completed",
    "date": "2021-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05200936",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd8d62c0476bb8042aa7d027738e3c83888dcc4b959f325fd5549c72aed26ab9",
    "title": "Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.",
    "compound": "other",
    "type": "observational",
    "institution": "St. Olavs Hospital",
    "condition": "other",
    "sample_size": 21,
    "status": "completed",
    "date": "2016-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02741622",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3d902aee3ee476719d6e8bce5db47d2b3fb7feb976b4a760d660082b9c32cb49",
    "title": "Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "PTSD",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2024-12-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06624137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a7ba1a51ad0108630cce533946ad4e91d23696caf905c96e6a6856f9f172b69f",
    "title": "Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2011-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01299727",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "80b243a1f339d38e2cb0891f7570803a6c799bd074d225a1a1a3c21b2d7007d5",
    "title": "Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Inonu University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2014-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02267980",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "190f27c0326b4468706f2373998d7eb5eb69c06f4fde9bef3e7fb04eaf49e017",
    "title": "A Study of Human Multi-Sensory Integration",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Pennsylvania",
    "condition": "other",
    "sample_size": 40,
    "status": "active",
    "date": "2018-07-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03498391",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "272f4d58f4a2c906f0e1868d86687c155ac2657792a41aeef3f506841cd6cbb0",
    "title": "Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Dennis Charney",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2009-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00749203",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c779b909ffdd98ac939a95dddcb2f6be0aa887ad2619954ce9e36d0389920a18",
    "title": "Ketamine Augmentation of ECT in Treatment-Resistant Depression",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Universit\u00e0 Vita-Salute San Raffaele",
    "condition": "depression",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-07-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07088380",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5df2690a285d691c7b1af757398ec93a5fd11975a6e79a1374fd90545c3ce807",
    "title": "Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tianjin Nankai Hospital",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2021-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04873479",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "35907f92e5f6b7db2cc3a80ed521f84482628ed40d38cc318f609b9feb15a52f",
    "title": "RIVER At Home Ketamine Protocols",
    "compound": "ketamine",
    "type": "observational",
    "institution": "RIVER Foundation",
    "condition": "anxiety",
    "sample_size": 50000,
    "status": "recruiting",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06070766",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bb5858a2fd2869034395f2e40ae74d0987c25f95c260dd19d853188d0ce55f81",
    "title": "Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2020-11-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04666623",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "764be54047f8d1a55dc5a0ce26d608d6b93984baf70f32dc2a3c731ea4e34b01",
    "title": "(GluEsk) Glutamate and Esketamine",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Oxford",
    "condition": "depression",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-06-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06432322",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6dffb4f84d386c55424843fa6884e3890c9abeb5b4c95def821580838292920d",
    "title": "Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University Tunis El Manar",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2016-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02653651",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a22e5b778593c959e8fef417ce9fda9cd813db3433effde8af96b56ad1bfb5cb",
    "title": "Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric",
    "compound": "other",
    "type": "observational",
    "institution": "Universitas Diponegoro",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02463929",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "06b938a52c289a43c189a3080f6689b5eec6acccf06d9706ca0a86f65a7b2bd6",
    "title": "Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 71,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02568176",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "567b2c15be781d2c22d845d39fc084826d9fcba87e08779829dbd5279ebb1934",
    "title": "Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Alberta",
    "condition": "other",
    "sample_size": 48,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02579642",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "56f81ad05c75ca552f9c95e41680787b199863d15d3ef01c1089eac1dd27dded",
    "title": "Ketamine for Refractory Chronic Migraine: a Pilot Study",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Thomas Jefferson University",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-03-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03896256",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd95d567074ca34e4aab3247d1677d0f074f037a4ba456bfe1da1b56b1a5077d",
    "title": "Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients",
    "compound": "other",
    "type": "observational",
    "institution": "Ayfer Kaya G\u00f6k",
    "condition": "other",
    "sample_size": 100,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07433231",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d65a8e74970d4048d812d23b7fc123bef014151193828159317bf00aae6f22ce",
    "title": "Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second Affiliated Hospital of Nanchang University",
    "condition": "other",
    "sample_size": 80,
    "status": "active",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07556172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "12d22bf68d564ec8a42e0ded07afe58a746af4ad2ad47d07405792cec132f7bb",
    "title": "Neurocognitive Features of Patients With Treatment-Resistant Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Massachusetts General Hospital",
    "condition": "depression",
    "sample_size": 13,
    "status": "completed",
    "date": "2016-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03134066",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d781b84aeb1303c90a3a50aa4ed898261ae9f7717a218e14b2f2325f284df17d",
    "title": "Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Peking University First Hospital",
    "condition": "other",
    "sample_size": 340,
    "status": "completed",
    "date": "2024-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06566469",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e441e1d29d6e74442a4cba1d6789df9874c195c897dd5b09b1d1316f8821f87f",
    "title": "Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2010-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01207206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3f89825fc6ad91a306ac37da00e548ec3bae8cea00cd0c6901d6be29c3331f57",
    "title": "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2016-03-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02682225",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "be58ac26d37943ccab148ec2b0774f8733726e03ab9c9b1aa5ab5953c7c9677c",
    "title": "Heart Rate Variability in Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Emory University",
    "condition": "depression",
    "sample_size": 8,
    "status": "completed",
    "date": "2015-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02525978",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1a07efa77ffb1aa4eed983787046c94a3d6713392c923ce18f6c2185f6117d1e",
    "title": "The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Cedars-Sinai Medical Center",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2013-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02252432",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "767c41a40941939b643bad9429173326eb19a7fc293c5291b8c8b35af97688d7",
    "title": "Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 32,
    "status": "active",
    "date": "2014-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02303847",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8a81776c037a829c11fcddaf63c74258801a7dac6336dbe172644f2a6c25d677",
    "title": "Esketamine and Butorphanol for Post-Lobectomy Pain",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second People's Hospital of Hefei City",
    "condition": "other",
    "sample_size": 223,
    "status": "completed",
    "date": "2022-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06398834",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "292fa963cedfbf88161a1217bc0fee76701a3796c4567737a24f6a7f7706c73d",
    "title": "The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Jinling Hospital, China",
    "condition": "depression",
    "sample_size": 120,
    "status": "completed",
    "date": "2020-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05506787",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9fb9806e1811086c28820346f250d0e7818e7641c5fe734ca579f089077c17de",
    "title": "Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Zhejiang Cancer Hospital",
    "condition": "anxiety",
    "sample_size": 185,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06530706",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cd5812308b4351d76436fca1b1ffa9fb56d3e4cea52c46bad8b35caaa33a4e64",
    "title": "To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Adriana Feder",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2014-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02398136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1afda1bf01c35e08e8e40f849aecf1929438c19d0ebc0427aeea5e67b43fe762",
    "title": "Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 56,
    "status": "recruiting",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05306899",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7d267b1053132d8cec363f1995c8741d4ee2cf33042c3422299d700ee7745fac",
    "title": "Ketamine-assisted Therapy for Advanced GI Cancer",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Brian Anderson, MD",
    "condition": "other",
    "sample_size": 1,
    "status": "completed",
    "date": "2024-05-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06077487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "10d637ce957585e62611472f1fd3f5601d4fe905122d686914751b90239fe6e2",
    "title": "The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery",
    "compound": "other",
    "type": "observational",
    "institution": "Yonsei University",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2019-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03462836",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bf1fbef06deaffa37bf5e13329359e0c9534058bb62bb304c9b03665bc1cc743",
    "title": "Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Julia Finkel",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2010-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01325493",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c774e39cb5d8cffd580e9db0a04cf92b5deb271b9490e6f6cdffc23752bfdc04",
    "title": "IM Ketamine vs Midazolam for Suicidal ER Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "New York State Psychiatric Institute",
    "condition": "depression",
    "sample_size": 90,
    "status": "active",
    "date": "2021-02-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04640636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a1859b1894ff20089b7853d1bcf5018ae5debb9fa6eed4439484461ee489c50",
    "title": "Acupuncture ACL (Anterior Cruciate Ligament)",
    "compound": "other",
    "type": "observational",
    "institution": "Hospital for Special Surgery, New York",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2018-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03711734",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a0e6b8b525e3f948c2f1da90787fec07948b261b6ecf8b827eed43f6302924a",
    "title": "Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy Gastrointestinal Endoscopy",
    "compound": "other",
    "type": "observational",
    "institution": "Assiut University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2017-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03235609",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1c31bd995ad004847543039cbf3d94bca4bcd6f95bc2be64486a46cd532e0cde",
    "title": "Ketamine and Postoperative Depressive Symptom-PASSION",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Beijing Tiantan Hospital",
    "condition": "other",
    "sample_size": 84,
    "status": "completed",
    "date": "2017-07-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03086148",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0dcad76a610b9998983490be3a1a0480a405ff9b3923dbe5b52a809172c0fc90",
    "title": "Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy.",
    "compound": "other",
    "type": "observational",
    "institution": "Cairo University",
    "condition": "other",
    "sample_size": 8,
    "status": "active",
    "date": "2025-11-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07246447",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fb84ed3e97314396ad1283b8e282e17fb93e67c19049e483b0216149b79fc1ae",
    "title": "EEG Studies of Sevoflurane-Induced General Anesthesia",
    "compound": "other",
    "type": "phase_2",
    "institution": "Massachusetts General Hospital",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03503578",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bd38c69b01576fceb9bdf159efbeefc164bac1412beda0cc5ae114e5420340b2",
    "title": "The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "First Affiliated Hospital of Chongqing Medical University",
    "condition": "depression",
    "sample_size": 396,
    "status": "active",
    "date": "2021-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04777110",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d90ee842fa5cb0dbe2e84e405a8a3292043d35c20a69e759ab45a94e1f735b3a",
    "title": "Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 100,
    "status": "active",
    "date": "2019-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04013958",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8daaf60052f9d2baaf90a81031bb6526dda1ff97fb357a65cb19273e93738b7b",
    "title": "Ketamine and Prolonged Exposure in PTSD",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Minneapolis Veterans Affairs Medical Center",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2019-04-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03960658",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "1d1374755cc12c03199b8cfee1a8a71435e10188d012486931d98a18a0f335e7",
    "title": "Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Centre Hospitalier Universitaire de Nice",
    "condition": "other",
    "sample_size": 150,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01544725",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c4cd62bbe62af7874ff01d3ba2039e6aa1eeaa617cdd8a9349afa7e35f3446d1",
    "title": "Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Lille",
    "condition": "depression",
    "sample_size": 42,
    "status": "completed",
    "date": "2016-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02783430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "861175493511f8a7c7ad664f9735a341e50e7b68c5bfe61274892e9539bf5543",
    "title": "Ketamine Versus Etomidate for Rapid Sequence Intubation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Hennepin Healthcare Research Institute",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2013-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01823328",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c334337c15972d221fa1bfb0df4b33c5b13a87c23b8e097c81c8344371d60773",
    "title": "The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence",
    "compound": "other",
    "type": "phase_1",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01535937",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "751eec1f2844cbfc87be5b6e20f6f897b78ac492f0110d35318f7a7c1a0ce704",
    "title": "The OBSERVE Protocol",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 450,
    "status": "recruiting",
    "date": "2024-01-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06725277",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "84554ae17c35fb787aa2bf67cf606f92d1c371c0833471bf45b3d223f68007b7",
    "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Sichuan Purity Pharmaceutical Technology Co., Ltd.",
    "condition": "depression",
    "sample_size": 98,
    "status": "recruiting",
    "date": "2025-05-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07193901",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "7555c8ae47415f1ade9fb24b6975944e362c48fd53c92cfe65dbbb2824085bce",
    "title": "Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02228239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3a1d0b10d4c336b54c4a999cfa8932bf9254a4e05a454b2f4e984e00fb825a85",
    "title": "Oral Dexmedetomidine for Parental Separation in Pediatrics Undergoing Adenotonsillectomy",
    "compound": "other",
    "type": "observational",
    "institution": "Suez Canal University",
    "condition": "other",
    "sample_size": 74,
    "status": "completed",
    "date": "2016-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03551067",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d8b37ad969513bc321b70eb2258e76a663acf9be128eb7857c7ce3f32750aa50",
    "title": "The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults.",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Kasr El Aini Hospital",
    "condition": "other",
    "sample_size": 120,
    "status": "completed",
    "date": "2023-05-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948267",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8ffbdc4733b96fd7160e84ae8e78b0f9765cbc26e9335601dfb4667cb76059e0",
    "title": "Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS",
    "compound": "dmt",
    "type": "phase_3",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 185,
    "status": "completed",
    "date": "2021-07-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04788615",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e59209a306f49948327e44e8e850beb4d7b401ab677017ae3d97091769c3be4c",
    "title": "A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Cybin IRL Limited",
    "condition": "anxiety",
    "sample_size": 36,
    "status": "active",
    "date": "2024-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06051721",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a2cfec0a69f7f387ba35d2f4fa63a72771e4b0a3d1685c139e17d5e892b3b772",
    "title": "Trifecta Research Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06810765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "9673287c7aaeb4389b64aed0fdd445efc8c00478a07884882dbc897a86e24f25",
    "title": "Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2020-11-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06459232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c6c524ddddfcf268b330be837a1bc030e51c186dbce5ac480cd6f373377012d5",
    "title": "Molecular Imaging Study of Harmine/DMT: a Basic Research Approach",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Insel Gruppe AG, University Hospital Bern",
    "condition": "other",
    "sample_size": 17,
    "status": "completed",
    "date": "2024-01-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06252506",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8397953237f78c4a48d86e46b7c0a9cb43b62dc74eedc4a7c9abc55195e52b44",
    "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 263,
    "status": "completed",
    "date": "2017-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03222973",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "8b374ad7efc17f97b9dac0cea8645cf5bba28348e589efa1a120965572287b6c",
    "title": "MIH and Hypersensitivity in Children",
    "compound": "other",
    "type": "observational",
    "institution": "Universit\u00e0 degli Studi di Brescia",
    "condition": "other",
    "sample_size": 39,
    "status": "active",
    "date": "2022-01-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05705037",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d4a252dbf349d794d5fd4c4cc234b83d07e47567c7f45964ba23122d547ffab4",
    "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Usona Institute",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2022-12-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05698095",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a7c6bbbb4a7b2db9e4ee2ffb9f36fb403dc33e38657b30cd99a3bf7b81756ead",
    "title": "Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults",
    "compound": "other",
    "type": "phase_1",
    "institution": "Advanced Integrative Medical Science Institute",
    "condition": "depression",
    "sample_size": 12,
    "status": "active",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05894902",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e827018424c727540059966c617761b0901274c13092c55195dec3066259f21d",
    "title": "COVID-19 and Multiple Sclerosis Disease Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Nottingham University Hospitals NHS Trust",
    "condition": "other",
    "sample_size": 14240,
    "status": "active",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04863586",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ebc6d2cb9e4d84a9db1d1049457aca954e38b603d02475665e40a7f24847aad0",
    "title": "Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Strasbourg, France",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06663189",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fe5659f3e050530a37ac51589c0e7c36e75b1c92a9e97a692a2d28f0b0be2805",
    "title": "Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study",
    "compound": "other",
    "type": "observational",
    "institution": "University of British Columbia",
    "condition": "other",
    "sample_size": 4000,
    "status": "completed",
    "date": "2003-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06705608",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5dcb0f502daf7d1a368b6fc4a56118310c0722bd49cf26e3bac1a4996b74c580",
    "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY\u00ae) in Participants Who Took it During Pregnancy And About the Health of Their Babies",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 1178,
    "status": "active",
    "date": "2021-09-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05688436",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "08f52372bc035bac75657108aad5347626c4237e547b6de456a38c15897851ba",
    "title": "Clinical Study of DMT in Healthy Adults",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Biomind Labs Inc.",
    "condition": "other",
    "sample_size": 27,
    "status": "completed",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05573568",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4f753dd3cdbeff3327a4e200b388086dfa8f0c5143b958761133b187c2f54e95",
    "title": "The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative",
    "compound": "other",
    "type": "observational",
    "institution": "Dartmouth-Hitchcock Medical Center",
    "condition": "other",
    "sample_size": 694,
    "status": "completed",
    "date": "2017-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03480854",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fe1140593d82994c1d7ee2968001b7de105de60dc80c6f3c308c58b692e545cf",
    "title": "Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients",
    "compound": "dmt",
    "type": "observational",
    "institution": "Merck KGaA, Darmstadt, Germany",
    "condition": "other",
    "sample_size": 545,
    "status": "completed",
    "date": "2012-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01601119",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "23d314ab1fd3526bdd73e297d3680208643c0e5ef76081ee568dddc5e452c867",
    "title": "Mindfulness and Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Milan Scheidegger",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2023-02-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05780216",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "bb2d1f423ba849acce9be30e14930878b487118e15fec78a56e9939c060fa283",
    "title": "SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 66,
    "status": "completed",
    "date": "2021-02-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04673383",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "4cc22f54000bd643635786ea4ad4042348b8d140ea53ce4c087b412e7fc272de",
    "title": "A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Montpellier",
    "condition": "other",
    "sample_size": 250,
    "status": "recruiting",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189325",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "c1f193d7302ca715a6b68c408a65c10157d27841b0859d3a7819c30e67eba86d",
    "title": "Neuroprotection and Repair in Optic Neuritis",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Calgary",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2010-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01073813",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0c3f81decabbb41f4b7adb295683a33edae8d838ea688ab2b128a98d3c26239b",
    "title": "Effects Of Dance Movement Therapy On Compassionate Flow In Nursing Students",
    "compound": "other",
    "type": "observational",
    "institution": "Mackay Medical College",
    "condition": "other",
    "sample_size": 59,
    "status": "completed",
    "date": "2023-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06220708",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "458f65dce66e0d941276a1cd6738bf5e341be29869b9be92f52dbebf06909136",
    "title": "Antidepressant Response of DMT Masked With Propofol",
    "compound": "dmt",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06927076",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "604aa74e281e83bdb5edccdc5372851dfb8317b70d9f15497754648a09d11092",
    "title": "Ayahuasca Assisted Psychotherapy for Grief",
    "compound": "ayahuasca",
    "type": "phase_2",
    "institution": "Beckley Med Foundation",
    "condition": "other",
    "sample_size": 84,
    "status": "active",
    "date": "2021-10-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06150859",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "affa2207639a5fa63ef6454d808520c1509c1f63e3bfceb48cd4de639ba3f54b",
    "title": "Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "Ying Gao",
    "condition": "other",
    "sample_size": 328,
    "status": "recruiting",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07037823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fbaa96a562ba52784bd35f4c3b4ee6765c09a2f77868292ac7cfe0a2c7845f3a",
    "title": "Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders",
    "compound": "dmt",
    "type": "observational",
    "institution": "Shalvata Mental Health Center",
    "condition": "anxiety",
    "sample_size": 24,
    "status": "active",
    "date": "2015-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02304796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0c7c6806440daee2f4f23c4ef1aa7aa5c272804d36168bb83dfa2c75e593136d",
    "title": "Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers",
    "compound": "other",
    "type": "observational",
    "institution": "MoCA Clinic and Institute",
    "condition": "other",
    "sample_size": 500,
    "status": "recruiting",
    "date": "2025-03-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07041450",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "30f478aedf8f0a98e9f0346688c1eb55fa63129a46cf16caf6c1c709fa514a1d",
    "title": "A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 213,
    "status": "completed",
    "date": "2011-11-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07474311",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "d6907de2f9644625c86a8e83da9ce3d8f4514ca0e0dccaefbcb7cd55c5c08e81",
    "title": "Relationship Between Oral DMT Burden and Adherence in MS",
    "compound": "dmt",
    "type": "observational",
    "institution": "Monash University",
    "condition": "other",
    "sample_size": 323,
    "status": "recruiting",
    "date": "2020-09-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04676204",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2404ad4c4cb21bf593a3791b987bbd7b37538bd8cdbf57070342230055b99d82",
    "title": "Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Abu Dhabi Stem Cells Center",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2022-03-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05168384",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "12872c0a3fa470883d41f898f804ac4077fba2f2e639e490a4d1e84b6a3c295f",
    "title": "Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Reconnect Labs",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2023-05-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05829603",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "3918890d4d12918083bf574e55c7d4620e692c273b1ec4743a51601e59e462b5",
    "title": "Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2024-06-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05695495",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "6f45d2ad04991aca5de6a3f241c8ec4bebadceeff50fef93c89371bdbb6a488f",
    "title": "Dance/Movement Therapy for Bone Mineral Density in Schizophrenia",
    "compound": "other",
    "type": "observational",
    "institution": "Hebei Province Veterans Hospital",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2020-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05716802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cdc6ab6399d4f7a940f6c01d1e7cc96eb59f3c9c1f1d68d393a1058628def4cc",
    "title": "Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2013-11-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04832399",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "63cd052997eba418ae5c3f7a4e835cdc2dcc9d8ecfaa5c191037d23fdc55d686",
    "title": "Phase 2 Clinical Trial of GH001 in Bipolar II Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2023-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05839509",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "5e27ba601ebeb3ecbe50813b4d0205a969296ac3c8a60111d5a9cbd60d513729",
    "title": "A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 42,
    "status": "completed",
    "date": "2012-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01578330",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "39fec6f9415d7849e6a3306a23f1917e72a1fe8cd8ff12ecfd103182a3003a3b",
    "title": "Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2020-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04716335",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "93d979744d0bc58dbf333559d90baccd529c5f9e35e9990d8218b3d8a7400dbf",
    "title": "Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-10-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06094907",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "43b62069ae202526008cbfce6c0efb0b2f61371f4ed0060618f6cc149263694e",
    "title": "Tecfidera and the Gut Microbiota",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2015-11-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02471560",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "0b0809be1f4e55273778eba9dc2b66f56387c1a64ea5c83b2349fff8a8023c89",
    "title": "IM and IV SPL026 Drug Product in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05644093",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f5cacad300ad47f1970b268a4028a5f07bfabfc4361d9912b12faba09ceb52a2",
    "title": "A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 4805,
    "status": "completed",
    "date": "2025-06-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07403214",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a6ac7d4a968a59de2a52175988a9472bac177922c5d37b0db907a227d0403498",
    "title": "Pharmacokinetics of GH001 in Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 46,
    "status": "completed",
    "date": "2021-06-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163691",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "fc508483b010ea25719a39974dd3d5803626c93f6930ddb9acccab2a9d1cdc45",
    "title": "Psilocybin Therapy for Chronic Low Back Pain",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley, MD, PhD",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05351541",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "862609b3ba3e0daafbd9b813255bd08128072ab801f7fdfdcfd9b7310c81119f",
    "title": "Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 30,
    "status": "active",
    "date": "2021-03-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04711915",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "253525c15a23404be35cdd553c55f82d20d5703708b2d2c1cc515671f10e9ef6",
    "title": "A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants",
    "compound": "other",
    "type": "observational",
    "institution": "Bristol-Myers Squibb",
    "condition": "other",
    "sample_size": 2961,
    "status": "active",
    "date": "2021-03-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06133049",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "a1fd87c11858d4808367848125ec95fbac19835d9c43b832a17a16ba84209c37",
    "title": "Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Jeffrey Gelfand",
    "condition": "other",
    "sample_size": 5,
    "status": "completed",
    "date": "2018-11-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03594487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "56f8fa8654951753b6ad57602591a8aea57674a30bb336dedc1cb8aa7de281ce",
    "title": "Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "International Center for Ethnobotanical Education, Research, and Service",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2020-10-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04003948",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2a8472dbee4ff38751b1498e7cf4f624eefe2e30e0e17b06ac9da2ffcac4cdad",
    "title": "Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "Stanford University",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2021-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04313712",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "42034b58b03ea36a85a62c85a5fcc6711e2710b0f8b0a648b0a9995b19825dc3",
    "title": "Mapping Ibogaine Neural Dynamics in Opioid Use Disorder",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "University of California, Irvine",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07226570",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "b6ec247e6bd2fe4c3ae2a7ecc80bf0ce09660e4c3edea0bb358efd09bb937941",
    "title": "A Study of Oral Ibogaine in Opioid Withdrawal",
    "compound": "ibogaine",
    "type": "phase_1",
    "institution": "atai Therapeutics, Inc.",
    "condition": "other",
    "sample_size": 116,
    "status": "completed",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05029401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "2205af0565e2d1cfac1f1b872f433ac71ed08b35afac93a581f06c507de54ef9",
    "title": "Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03380728",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "e9f88d2b3bb5a904eb63d34f94db1d354a1424b112d621c1d4ae607c2d917a96",
    "title": "Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression",
    "compound": "ayahuasca",
    "type": "phase_1",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 35,
    "status": "completed",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02914769",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "724a3f04d998d445fa1228ab0a475276cf9cca32c969629b4c047203bc6f84d6",
    "title": "Ayahuasca, Esketamine and Body Image Perception",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317219",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "915bfce0f72d51bd26a570d2dbf3e81fdffb1ccee6ef28a821905621b2012261",
    "title": "Ayahuasca, Esketamine and Premenstrual Symptoms",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "f297c77cbff46505d11bb69d2bfdd0726b17dcf3625c1dcb0488fcbd3d25794b",
    "title": "Ayahuasca, Esketamine and PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "ae5bf47b8c21f70c8347be94a0f17598df8f9d8b63309e5be3898573802d861c",
    "title": "Entheogen Resurgence",
    "compound": "other",
    "type": "observational",
    "institution": "Vireo Health",
    "condition": "other",
    "sample_size": 102,
    "status": "completed",
    "date": "2021-09-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "dd8cb146beda67e6d2a65cdc96868d21662ae45ff0fd9a1e3d9edcdec6a8363c",
    "title": "Ayahuasca and Esketamine for Major Depression",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "depression",
    "sample_size": 22,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07212946",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "05431a8189731bff6895510ce8559f8effba74196570c6c81b0196aa4c9d34f8",
    "title": "Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness",
    "compound": "mescaline",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2021-08-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04849013",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "cdcc6f1de14e082e13f542622a5a2158e041829aca33360d610de8aa27d3aae1",
    "title": "Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis",
    "compound": "mescaline",
    "type": "observational",
    "institution": "Xiangya Hospital of Central South University",
    "condition": "other",
    "sample_size": 205,
    "status": "active",
    "date": "2023-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05933213",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-07"
  },
  {
    "id": "773c4008c74bf3e563f49eb29bdfe405d55dfef7ec461876f8c712bc0d7490c9",
    "title": "Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Queen's University",
    "condition": "anxiety",
    "sample_size": 50,
    "status": "recruiting",
    "date": "2025-05-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06969170",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8dad6775994bc7a74fd1e9a03d67b4b99281a463ec2fa2fb59482856ed55a256",
    "title": "PRoMiSS: Psilocybin and the Role of Music in Set and Setting",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07180108",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4a63c61f0a96d1be4f014a300b8f4ad61be2aa1cff38900a6df7d06a42ec7542",
    "title": "PET Synaptogenesis After Psilocybin In DEpression Recovery",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Washington University School of Medicine",
    "condition": "depression",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05601648",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a8a499557342c109e5b6f140e90b6030a40935ae683df7430b86cd16aaf62892",
    "title": "Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "depression",
    "sample_size": 92,
    "status": "recruiting",
    "date": "2024-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06341426",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "9f1704ebc6acb144c25a5154b9e77a9e9590e811e6e4caca25ea124b625b4c16",
    "title": "PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm",
    "compound": "other",
    "type": "observational",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06798636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2ce36b6f6856ac3c74fa3e7cb4777aaf04b4b46c3f7360805b1455d089764b2d",
    "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "MycoMedica Life Sciences PBC",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-11-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06643637",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "7f6d72d5a41991625da15ec6011b4185ce13c9d6cd5f2acde9aa991e72909176",
    "title": "UW Psilocybin Pharmacokinetics Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Wisconsin, Madison",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02163707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "9b6648605628e1c68dfbf123cbbadb6265df1e06878cfecbc66e7d49323f7ba1",
    "title": "Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "McMaster University",
    "condition": "other",
    "sample_size": 16,
    "status": "recruiting",
    "date": "2025-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06225232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "79655b118a6fdb6d80fdd8f65b9ef29339bdb45474926a0f6dedddeb3cdefe42",
    "title": "Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05399498",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0d81dd8883f6b189389c302858719797d96b7a28759b72c3b67bb72c446a4085",
    "title": "Psilocybin Therapy in Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2023-05-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05398484",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a9a098702a42f1877c1c3525081b6c34bfaab79f1ccf9696972d2556258cc773",
    "title": "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Portland VA Research Foundation, Inc",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2022-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04982796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "501d36d641160bd70b9c36ddd29f57361c136abe88fdb363e7866516dd44bc91",
    "title": "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "other",
    "sample_size": 102,
    "status": "active",
    "date": "2023-01-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05733546",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ab6b24459fc594076009bd9736542b5a107ff7f11384c5a3bec20d741c7d3e7c",
    "title": "ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression",
    "compound": "other",
    "type": "phase_1",
    "institution": "Eleusis Therapeutics",
    "condition": "depression",
    "sample_size": 84,
    "status": "active",
    "date": "2022-10-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05434156",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c885eea8fadce12dbbb2b26868ee67ddfccd910386ec2c4e0599694e15f411c0",
    "title": "Psilocybin for Hospitalized Patients with Treatment-resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Hospital, Ghent",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2024-05-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06378229",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "bd020033e301ce9c49618456d740745c35292aa14a8a86be2d0a99dbc39b44df",
    "title": "Does Psilocybin Require Psychedelic Effects to Treat Depression?",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05710237",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "aa0084ed2547126bc61cfa7beebb79295085417c0f08947d78153b8807c49e7d",
    "title": "Psilocybin-Assisted Therapy in Treatment-Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of North Carolina, Chapel Hill",
    "condition": "depression",
    "sample_size": 20,
    "status": "active",
    "date": "2024-04-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06303739",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a935d742c8538d8b7778bc5b38fd54b8b050acfdaf7bd03c41a78c1be012de07",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2025-07-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07048743",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "15b482b627c5295ce82c32202f4a69f070511ad410e25ee7466449f2d58f9477",
    "title": "Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Apex Labs Ltd.",
    "condition": "depression",
    "sample_size": 160,
    "status": "active",
    "date": "2023-12-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06141876",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c32847784e91dcca5f8b5ad2ceb4bb02b57128fbb484b799288d52424b82d812",
    "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 15,
    "status": "active",
    "date": "2024-06-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06416085",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2a13a1c0367eedae5de056b691c36361126a2d8852dd453e037683fb0831d644",
    "title": "Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 468,
    "status": "recruiting",
    "date": "2025-07-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06605105",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "9c723750421adbaa49f789a72115861997933a72d12a69c81fee82784421afcc",
    "title": "Psilocybin-Assisted Therapy for Intergenerational Trauma",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Rachel Yehuda",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-08-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06899165",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f0af2e5f936c5f0b079eb172ac322719913f5cc47e75317197b2fcd9e59fa742",
    "title": "Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "OCD",
    "sample_size": 31,
    "status": "completed",
    "date": "2018-11-13",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03356483",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e66af192ed4aa13d0da108aefb2df42f574268f95308e08bf9071b5dbf90372d",
    "title": "\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 220,
    "status": "recruiting",
    "date": "2024-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06564818",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "69a3c0ef8c8a34a0fdffe1b0107624552d8bee00ce55779ce4f9df0e89981e5b",
    "title": "Naturalistic Study of Microdosing With Psilocybin",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "National Council of Scientific and Technical Research, Argentina",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2021-01-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05160220",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "88e91e04f7e4d8d5f2d4e03ab92f2980eec6b9332ebc95a97b77e8bdba911866",
    "title": "Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Healing Advocacy Fund",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2025-03-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189988",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "50f84cd692a434b02ffde1bfd9d98b2ea441338f67be902c950f3ebb4e076e69",
    "title": "Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre Hospitalier St Anne",
    "condition": "depression",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-10-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07210112",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ff164c3432cbce8674fe172b8bbd8921591a4adf442ed77cd23a6d9302019398",
    "title": "Effects of Hallucinogens and Other Drugs on Mood and Performance",
    "compound": "other",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02033707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "688df0737b0712bccd77e166fcc456dfd6b8c5cea50e4ac69cc212d4239114cd",
    "title": "Mood and Cognitive Effects of Psilocybin in Healthy Participants",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Optimi Health Corporation",
    "condition": "anxiety",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05252598",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b903e9c22aa9e1119b94dc8f757a58d77835cbc91992fb2d5b8a684abb23143e",
    "title": "Psilocybin in Cancer Pain Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Yvan Beaussant, MD, MSci",
    "condition": "other",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-09-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06001749",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f50e83ff3f4d5c86e1b28ccf65df88075c026c11101d2e98b64440ccd3bf3266",
    "title": "Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2014-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02145091",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "57c7d8a996201b93e7631dc296f2b63fab613a37837abd985478bcc236f64be7",
    "title": "Northwest Therapies Trauma Psilocybin Study Compassionate Use Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "NWTraumatherapies",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-09-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042466",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ddb6be81b770dba5efdcee855e2aa31a205f51a7dfbe642b07932df68f9539a7",
    "title": "Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "OCD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2024-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06299319",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6d8c9a8120412bdd6ac3cc92fbf2dcd35611f20ed1478bbe9c43607de95a09a8",
    "title": "Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Clairvoyant Therapeutics",
    "condition": "other",
    "sample_size": 128,
    "status": "active",
    "date": "2022-05-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05646303",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "fcdc999453f954abf2c2e3649ab675159804f8cdcf40d027a544eee5c48bf0fe",
    "title": "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "depression",
    "sample_size": 19,
    "status": "completed",
    "date": "2020-08-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04739865",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2b04a4025586812fd1c370065cf969a891d8e944564b691f51180a23011a5b9d",
    "title": "Frontline Clinician Psilocybin Study",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-03-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163496",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "15c9eb10cc3ce510974a92be9f4d145f9f94e6ecf9c2bea1fb965ade000bac24",
    "title": "PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Filament Health Corp.",
    "condition": "other",
    "sample_size": 86,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06666010",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "62f4b94c940dfd7c444dc8f6659ef806f1a406bd3d333a216837b62ad29ecfe8",
    "title": "Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "Bruy\u00e8re Health Research Institute.",
    "condition": "other",
    "sample_size": 120,
    "status": "recruiting",
    "date": "2026-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07063862",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "58802597efd9bc70689ed87c3713c732b9b7497438d8e796df21777372a6be09",
    "title": "Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley",
    "condition": "depression",
    "sample_size": 30,
    "status": "completed",
    "date": "2018-01-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02950467",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "161816474f2666ef27355a7dd80e00efcd5daeff9a29167cd05821c0627618e4",
    "title": "Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2021-02-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04656301",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "da400b627f5d647d623a6b134840f4fa13e01f4399866a0e749adc46266583bc",
    "title": "Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)",
    "compound": "other",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2009-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00886886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "84c6c6db07c7da18eb80bbc858fcc403bd74325eb841e435db0bbe8ed58b1823",
    "title": "Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2021-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04648137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b6cd463fce294f6fb78e3988df35d7396d07cc87fdfd75f00e9c20350eb9b67c",
    "title": "Effects of MDMA on Social and Emotional Processing",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "addiction",
    "sample_size": 65,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01849419",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2131bcc12dee58da30e51ca09a469bee2b4d894cb77a03b9ccfcd55a372217e6",
    "title": "MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2004-03-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00090064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "962eaeb0ac8be671a0ee817fd434455e4a5383ef8b96883ea174d52e5b38a536",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 121,
    "status": "completed",
    "date": "2020-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04077437",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d9b6cafa6ca3aa45f907bf6c7bf65c6d60a119e7c43cb249308b95312c654771",
    "title": "Abuse Liability and Human Pharmacology of Mephedrone",
    "compound": "other",
    "type": "phase_1",
    "institution": "Parc de Salut Mar",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02232789",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "148beb6f25f7343c25b1aca0981ddf3be3d42bfb977bad74c3679f95c4f1f820",
    "title": "MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2016-07-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02876172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "63dfa756bfda228e595260d5b3b3ee7a3f0e84068625b8adef8e7bb0ff4af4a5",
    "title": "Effects of MDMA and Methylphenidate on Social Cognition",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2012-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01616407",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b6d1ff8fdcd8c7ec6baee2a8abcbe5bb365869aa3c5c8e2db4ab8ebef9768278",
    "title": "A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Remedy",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2021-10-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05067244",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "285021d3b8bee0a8c83df15fccc2697e59e6b1553f217d8b2d87db9555cdffe7",
    "title": "MDMA-assisted Massed Prolonged Exposure for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Healing Breakthrough",
    "condition": "PTSD",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2024-10-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06117306",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e595df7697dc765abf3d2181993010c0bbb2ddd7b7658498e0ec779251b32bcf",
    "title": "Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2010-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01136278",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3f074b084e31a218b33a127e5bc64bd2f9bcbf8195810856fb46f78f7aa536e6",
    "title": "Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2023-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05523401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "507d5f90106428c717ac2461928dd78092f096facfc664fe319b48ba307e1167",
    "title": "Characterization of the Prosocial and Prosexual Effects of GHB",
    "compound": "other",
    "type": "observational",
    "institution": "University of Zurich",
    "condition": "other",
    "sample_size": 19,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02342366",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "444cabca36f00025435ed16aa524e3a45dff5de39d11570b28109e6feecda35a",
    "title": "Tolerability of MDMA in Schizophrenia",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Anya Bershad, MD, PhD",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05770375",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4a234d42728450159efa4b40420d985790e18ba1800ffa3bbf57c634801aff38",
    "title": "Acute Effects of R- and S-MDMA in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05277636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "cd76dd410ecc095a679e72801a8a3e0e3032d7b7bd4576013b4e65b2675d431c",
    "title": "MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Sunstone Medical",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2022-10-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05584826",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4d55f0dc6f49e2edc8cd21827226e1e8d4ae516c1b7704b3026c25f1a63ca5dc",
    "title": "MDMA for AUD/PTSD Comorbidity",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Carolina L Haass-Koffler",
    "condition": "PTSD",
    "sample_size": 18,
    "status": "recruiting",
    "date": "2024-02-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05943665",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ff33fafc6e20053d8a5abb6e2f23f0f09796191753274a022599ccba0ec2729c",
    "title": "Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2014-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02102802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f12fd8e76e4eb3cf6ee767fb0cff75821dc8190b4611a0e913313ee55565971f",
    "title": "Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2013-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01951508",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4e22c59825b9ade032f697c4d82dbc5c13c4020259e0730015ddf8a36131b4b1",
    "title": "Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05173831",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "df0bd82dc5d1bd2af03adb28633fdb1305ffca60387ae948b2be92d8177a25b7",
    "title": "Dose Optimization of MDMA-Assisted Therapy for PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Bronx VA Medical Center",
    "condition": "PTSD",
    "sample_size": 60,
    "status": "recruiting",
    "date": "2025-06-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06418178",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "5c198bc3ad4fb592acc6833c137fb67ba5b97bef14bb58b8f9f82f20e1a58d74",
    "title": "MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Brigham and Women's Hospital",
    "condition": "anxiety",
    "sample_size": 2,
    "status": "completed",
    "date": "2007-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00252174",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6d73123254183ff7b4c49ca550414a980b2a2881107e538773311ad1b77bd7c5",
    "title": "Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2025-09-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06989957",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "cfba5ccc5e2e0a2a862581139f096c4c88e0aaf38d9e7b80441e0459cc5e804a",
    "title": "MDMA-Assisted Therapy for Pathological Narcissism",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 12,
    "status": "active",
    "date": "2024-08-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06565494",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a17a3aee00b4a10000150319948cb364ea5b69cc4d68366323ea48ba2b961f02",
    "title": "Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Albany Research Institute, Inc.",
    "condition": "PTSD",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-08-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05895318",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4e5a6d3d014e2349cacc6541ba0cd4c3964020d3ef89ea13c961ae8e6fb2966c",
    "title": "Bristol Imperial MDMA in Alcoholism Study",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2018-04-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04158778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8eef2ba5573db5dfa73e93515f6ca17d5593d743b7473949817240bfab472cae",
    "title": "MDMA for Co-occurring PTSD and OUD After Childbirth",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of New Mexico",
    "condition": "PTSD",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05219175",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "99f929ad935a61ec4b997912097805d213ddbad568a379cf14102985caa42788",
    "title": "A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 87,
    "status": "completed",
    "date": "2021-03-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04714359",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "44b96caae213fc6dafefcb6fd7a4301c10cf970326ba098b8ed84947ee18ef18",
    "title": "Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01386177",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e2daf8a4cd16d31950e31fc1257394c2a5daf3fe085369fcd8f27bdef435bdca",
    "title": "Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-04-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02008396",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b1bd43aec0b0b6fc9f3a9481dfb54120e7290a35d5707503b21499de1f8cbf84",
    "title": "MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of California, Los Angeles",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06353282",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6c2eadcc0d0a7df52696bc1b247e561a6aba6e2354f5548a7377fd34784dc4c2",
    "title": "Prosocial Effects of MDMA",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 33,
    "status": "completed",
    "date": "2023-07-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948683",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "54d59639e7c54caddbc0524ef0aa7c22b300d1b915b7630563bd6dd8482cfc3e",
    "title": "Epigenetics and MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "University of Southern California",
    "condition": "PTSD",
    "sample_size": 45,
    "status": "completed",
    "date": "2018-11-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06189027",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a4943b4dbc18ffcc90fa185756fd5e2b79127ca24085630b342c971449566c55",
    "title": "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01053403",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d685e6acf4bd8dd58048357f22c71678f514c6e2e677c43b17ef54db2b84984e",
    "title": "Role of Serotonin in Acute and Subacute MDMA Effects",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2009-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00838305",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3a0f58758dbcdb84334875a717c37be38c944dd1ce47faf972514540c5014bed",
    "title": "Personality and Drug Use",
    "compound": "other",
    "type": "observational",
    "institution": "Psychedelic Data Society",
    "condition": "addiction",
    "sample_size": 1000,
    "status": "active",
    "date": "2022-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05516823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0f0496c1e23168440c4feee9c6aa51836aa175e43e2547cb346ec874b2aed779",
    "title": "Addiction in Intensive Cardiac Care Units",
    "compound": "other",
    "type": "observational",
    "institution": "Assistance Publique - H\u00f4pitaux de Paris",
    "condition": "addiction",
    "sample_size": 1500,
    "status": "active",
    "date": "2021-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05063097",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0edd5645e3be7aefe0da8fe089f0a5ba403e4960bb4ff5c86b3335515180e57a",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 100,
    "status": "completed",
    "date": "2018-11-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03537014",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "bba46491bcce414efd8898ca051aedbc53f2d246e850353bf623262f8facc010",
    "title": "Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "MAPS Europe B.V.",
    "condition": "PTSD",
    "sample_size": 21,
    "status": "completed",
    "date": "2020-06-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04030169",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0a62c84f8d0c4b4c26830a8d4df08b8b4c4f3b3d9a964e45d31a76be1e88648f",
    "title": "Effects of MDMA-like Substances in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2021-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04847206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "5f0930ad35cc18b10cc75ad3f33e23ad725e5007927edb8a4650b9795e732b66",
    "title": "Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04968938",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1515e96069ff1b97e044939493f4735f4044d10159af0998abbcf94251491adc",
    "title": "MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "VA Loma Linda Health Care System",
    "condition": "PTSD",
    "sample_size": 5,
    "status": "completed",
    "date": "2021-07-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04264026",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f61706e9f76828f1c40e0ae461f850479a937481325a10c2f4d0880c145c84bb",
    "title": "The NeXT Study; The Netherlands XTC Toxicity Study",
    "compound": "other",
    "type": "observational",
    "institution": "UMC Utrecht",
    "condition": "other",
    "sample_size": 225,
    "status": "completed",
    "date": "2002-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00235768",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "73bed01512b7023d428c09dc8e174e63d286758f14b0f711c3eaf844bdfbd07b",
    "title": "A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 198,
    "status": "completed",
    "date": "2022-08-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05407064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "166fb404e3c53c8cb3c8a162592f1d9d1cf6100405e4f8d2d425a837c9de55da",
    "title": "Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Royan Institute",
    "condition": "other",
    "sample_size": 10,
    "status": "completed",
    "date": "2007-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00736307",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "593a3c6d6d1cc7a13835dae41878b4895ef78a36eb3729289d22d8afa1cadfd8",
    "title": "Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2013-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01878942",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "016eba5535847db659689e61ee49762f398ceb5d8a024f65f510e3a15b877fea",
    "title": "The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers",
    "compound": "other",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2015-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02451072",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "29c8b897183f9c655d38fa5b1db57baca9cfd71c379712675c69d42cab21518f",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 245,
    "status": "active",
    "date": "2025-01-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06809595",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c9bd8e96c404cdf654fce29623289610fdcd274418c0b61e5435908a11874236",
    "title": "The \"Motoric Cognitive Risk\" Syndrome in the Quebec Population",
    "compound": "other",
    "type": "observational",
    "institution": "Jewish General Hospital",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2016-12-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03633253",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "97566582e2e946eb41791cba88bf1e7cdf131715d588e3970fe1c4f430418893",
    "title": "Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-10-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05175430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f60f9089871a0e960e6941bb17bf737b59936713cb3cce68a09cc80d71c956fa",
    "title": "Stem Cell Gene Therapy for Cystinosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of California, San Diego",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-07-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03897361",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "04b567b73cc555cafd6bf8721d9c81ecebddd45d1cadf9711e2179d19dd0c887",
    "title": "Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Multidisciplinary Association for Psychedelic Studies",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2008-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00920387",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "05a0c0e68ed27017ccd526a4fd18964d82f81f6c8858b90af8f3e39091e83ee8",
    "title": "Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts",
    "compound": "other",
    "type": "observational",
    "institution": "Chaoran Han",
    "condition": "other",
    "sample_size": 18,
    "status": "completed",
    "date": "2024-03-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07415395",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c54802f7bf8a1c20c3beecd067388e0774271a9ef258e8cfd3b423e86a456c18",
    "title": "MCR Syndrome in Quebec : Results From NuAge Study",
    "compound": "other",
    "type": "observational",
    "institution": "Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'\u00cele-de-Montr\u00e9al",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2020-11-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05046275",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "cd0c381174ece3afbd801dc104b49f80f4ec7242d1d9ac639e222d1b1292fbbf",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 214,
    "status": "active",
    "date": "2024-12-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06741228",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "03067ca4712abd836642748279b8da776132bd6f60cc6cbb8887232d0a05123e",
    "title": "Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy",
    "compound": "other",
    "type": "observational",
    "institution": "Tatiana Aboulafia Brakha",
    "condition": "depression",
    "sample_size": 10,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06557239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "7c0a06ecf54c59a7c70e23261c156f5c9616b087b83da25a6cb17db838b707de",
    "title": "Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA",
    "compound": "other",
    "type": "phase_1",
    "institution": "Neutrolis",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2025-09-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07237659",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0b0e849d62de9354d6c2cd33dcb80576d556c4d4c0fa527feb773a99a3a9c660",
    "title": "Sodium Lactate and Brain Relaxation (LSD)",
    "compound": "lsd",
    "type": "phase_3",
    "institution": "Centre Hospitalier Universitaire de Besancon",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2020-09-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04488874",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "808949308380ca60c12d04a5092e821d8b25f9cbef618a04a0503960cefde90b",
    "title": "Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2011-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01515956",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "9870a2b3b95ba3299a08e65422b734f8fc9197f6efe2049b2d76b23d537ea651",
    "title": "Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma",
    "compound": "other",
    "type": "phase_2",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2010-01-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01045460",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "aff091d3e0020b20f67d75b2c5af37a601c7e8b783f770fc3caa9f3ecaa0cd8d",
    "title": "Investigating Lysosomal Storage Diseases in Minority Groups",
    "compound": "other",
    "type": "observational",
    "institution": "O & O Alpan LLC",
    "condition": "other",
    "sample_size": 20000,
    "status": "active",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02120235",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8a1a0cf7c075b35694cd4b34aa6ca2a27a1aaf8325327fb08e69b8871186e29f",
    "title": "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma",
    "compound": "other",
    "type": "phase_1",
    "institution": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2007-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00566098",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "47a6c822f43008882c9d5d64be719bb39c588abc2aca9972e5fc26e7b495f90b",
    "title": "A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C",
    "compound": "other",
    "type": "observational",
    "institution": "ZevraDenmark",
    "condition": "other",
    "sample_size": 35,
    "status": "completed",
    "date": "2015-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02435030",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "05a53dc5e0a01131a0a1316204fd1da2018e69def1159a85d22d3af0b2db79ca",
    "title": "Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "cluster_headache",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2019-01-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03781128",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "458ca894e769fa8da1bb01d5d41d6b549e25daf68e07a75557a3471dd9969355",
    "title": "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01609062",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6623f3e9de2ded35c8720d0f13dccac9343e9a7596203df5e62e4a8e3351e8cd",
    "title": "A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)",
    "compound": "other",
    "type": "observational",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 353,
    "status": "completed",
    "date": "2008-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00787995",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "157681ca00c33bf07de001b086af64b18b6ddb0664d1f3cd6c52e1b91557d43c",
    "title": "Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis",
    "compound": "other",
    "type": "observational",
    "institution": "Universidade do Porto",
    "condition": "other",
    "sample_size": 150,
    "status": "active",
    "date": "2022-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04386538",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "751b28b94f47f6b99e30dfb7f181bede6487f71008537bbee0ed7aa62409ab21",
    "title": "Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders",
    "compound": "other",
    "type": "observational",
    "institution": "Lysosomal and Rare Disorders Research and Treatment Center, Inc.",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2018-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03812055",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a259533ddcc34d2753d1c5199d6bafd5dbf99a3e7178b9392ffec6a7f89d4da3",
    "title": "Comparative Acute Effects of LSD, Psilocybin and Mescaline",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 32,
    "status": "completed",
    "date": "2020-05-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04227756",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "94bb831e6adf7eb9a026a30b4c440806f9c00ca5f56a0a987b60aca4c2f8d35a",
    "title": "A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 149,
    "status": "active",
    "date": "2025-04-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06941844",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b4066a28eab03e35b8e6cba1c8a3f378dc758494a82b48e92de641d4ff1ed74d",
    "title": "LSD Therapy for Persons Suffering From Major Depression",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "depression",
    "sample_size": 60,
    "status": "completed",
    "date": "2019-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03866252",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e7b51d7e04a455af1a23fb01681267fa58ae30c36025327ad80ca5a56f230a9c",
    "title": "Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_3",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 173,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01415427",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1737542c21cfc81d45bc09d379e5d872fa32e4e095cb03a96304931c4daa7039",
    "title": "Mood Effects of Serotonin Agonists",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 80,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03790358",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b02e3987a5f89afca8abd6fb9b8b198331ae559a1004f5431e31508d146c720a",
    "title": "Personality and Drug Use (PDU)",
    "compound": "other",
    "type": "observational",
    "institution": "Quantified Citizen Technologies Inc.",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05180149",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1004b9a4d9de9b98e86e84197a0b2c9d92562135c3e035d7e4c59828da438f8f",
    "title": "Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01155778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4fd4eb350ecfe57a1b7018526f7c6b1c4007098857902da0234d032ba4697fae",
    "title": "The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Maastricht University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05670184",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "10cf7c75d22e14dd1e9be237042a7c14ef41fab02c00a45cac341315bfbc7542",
    "title": "Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2017-11-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03321136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "30392dbba9ef4eb3ecb081e9c621711c74e80d1c81be82aee28129c3f07161cc",
    "title": "Drug Effects on Mood and Behavior - Expectancy",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 48,
    "status": "recruiting",
    "date": "2025-06-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07061886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b3fe699f8a0ee6195dac8ce4d01a88db754ab76ea6a197a9a5dff879525d7d95",
    "title": "A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "Amicus Therapeutics",
    "condition": "other",
    "sample_size": 31,
    "status": "completed",
    "date": "2014-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02082327",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c546446c61ffc0705c106d184174e5c4cd0e345005ef0ab2daff7e8cf6f266fb",
    "title": "Mood Effects of Serotonin Agonists Extended",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 56,
    "status": "completed",
    "date": "2019-04-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03934710",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3c6a37de3c53e9ff64a4e34f688ddfeff385e237c4f0ad4682f8e2a00e5e8944",
    "title": "A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_1",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2010-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01242111",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6b62a57198dd92ceef43efb784d4e21b636374a52e3c231271e138d414bfa4d6",
    "title": "LSD to Improve Cluster Headache Impact Trial",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Radboud University Medical Center",
    "condition": "cluster_headache",
    "sample_size": 65,
    "status": "recruiting",
    "date": "2025-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05477459",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f243c57462c606d6c952be54b24cbc848bb8296d020797cf4a81d7a26701dfa4",
    "title": "Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 53,
    "status": "completed",
    "date": "2021-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05200936",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "cd8d62c0476bb8042aa7d027738e3c83888dcc4b959f325fd5549c72aed26ab9",
    "title": "Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.",
    "compound": "other",
    "type": "observational",
    "institution": "St. Olavs Hospital",
    "condition": "other",
    "sample_size": 21,
    "status": "completed",
    "date": "2016-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02741622",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3d902aee3ee476719d6e8bce5db47d2b3fb7feb976b4a760d660082b9c32cb49",
    "title": "Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "PTSD",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2024-12-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06624137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a7ba1a51ad0108630cce533946ad4e91d23696caf905c96e6a6856f9f172b69f",
    "title": "Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2011-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01299727",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "80b243a1f339d38e2cb0891f7570803a6c799bd074d225a1a1a3c21b2d7007d5",
    "title": "Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Inonu University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2014-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02267980",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "190f27c0326b4468706f2373998d7eb5eb69c06f4fde9bef3e7fb04eaf49e017",
    "title": "A Study of Human Multi-Sensory Integration",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Pennsylvania",
    "condition": "other",
    "sample_size": 40,
    "status": "active",
    "date": "2018-07-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03498391",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "272f4d58f4a2c906f0e1868d86687c155ac2657792a41aeef3f506841cd6cbb0",
    "title": "Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Dennis Charney",
    "condition": "depression",
    "sample_size": 41,
    "status": "completed",
    "date": "2009-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00749203",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c779b909ffdd98ac939a95dddcb2f6be0aa887ad2619954ce9e36d0389920a18",
    "title": "Ketamine Augmentation of ECT in Treatment-Resistant Depression",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Universit\u00e0 Vita-Salute San Raffaele",
    "condition": "depression",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-07-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07088380",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "5df2690a285d691c7b1af757398ec93a5fd11975a6e79a1374fd90545c3ce807",
    "title": "Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tianjin Nankai Hospital",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2021-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04873479",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "35907f92e5f6b7db2cc3a80ed521f84482628ed40d38cc318f609b9feb15a52f",
    "title": "RIVER At Home Ketamine Protocols",
    "compound": "ketamine",
    "type": "observational",
    "institution": "RIVER Foundation",
    "condition": "anxiety",
    "sample_size": 50000,
    "status": "recruiting",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06070766",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "bb5858a2fd2869034395f2e40ae74d0987c25f95c260dd19d853188d0ce55f81",
    "title": "Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2020-11-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04666623",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "764be54047f8d1a55dc5a0ce26d608d6b93984baf70f32dc2a3c731ea4e34b01",
    "title": "(GluEsk) Glutamate and Esketamine",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Oxford",
    "condition": "depression",
    "sample_size": 16,
    "status": "completed",
    "date": "2024-06-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06432322",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6dffb4f84d386c55424843fa6884e3890c9abeb5b4c95def821580838292920d",
    "title": "Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University Tunis El Manar",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2016-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02653651",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a22e5b778593c959e8fef417ce9fda9cd813db3433effde8af96b56ad1bfb5cb",
    "title": "Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric",
    "compound": "other",
    "type": "observational",
    "institution": "Universitas Diponegoro",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02463929",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "06b938a52c289a43c189a3080f6689b5eec6acccf06d9706ca0a86f65a7b2bd6",
    "title": "Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 71,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02568176",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "567b2c15be781d2c22d845d39fc084826d9fcba87e08779829dbd5279ebb1934",
    "title": "Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Alberta",
    "condition": "other",
    "sample_size": 48,
    "status": "completed",
    "date": "2015-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02579642",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "56f81ad05c75ca552f9c95e41680787b199863d15d3ef01c1089eac1dd27dded",
    "title": "Ketamine for Refractory Chronic Migraine: a Pilot Study",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Thomas Jefferson University",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-03-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03896256",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "bd95d567074ca34e4aab3247d1677d0f074f037a4ba456bfe1da1b56b1a5077d",
    "title": "Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients",
    "compound": "other",
    "type": "observational",
    "institution": "Ayfer Kaya G\u00f6k",
    "condition": "other",
    "sample_size": 100,
    "status": "completed",
    "date": "2023-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07433231",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d65a8e74970d4048d812d23b7fc123bef014151193828159317bf00aae6f22ce",
    "title": "Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second Affiliated Hospital of Nanchang University",
    "condition": "other",
    "sample_size": 80,
    "status": "active",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07556172",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "12d22bf68d564ec8a42e0ded07afe58a746af4ad2ad47d07405792cec132f7bb",
    "title": "Neurocognitive Features of Patients With Treatment-Resistant Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Massachusetts General Hospital",
    "condition": "depression",
    "sample_size": 13,
    "status": "completed",
    "date": "2016-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03134066",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d781b84aeb1303c90a3a50aa4ed898261ae9f7717a218e14b2f2325f284df17d",
    "title": "Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Peking University First Hospital",
    "condition": "other",
    "sample_size": 340,
    "status": "completed",
    "date": "2024-09-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06566469",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e441e1d29d6e74442a4cba1d6789df9874c195c897dd5b09b1d1316f8821f87f",
    "title": "Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2010-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01207206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3f89825fc6ad91a306ac37da00e548ec3bae8cea00cd0c6901d6be29c3331f57",
    "title": "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2016-03-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02682225",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "be58ac26d37943ccab148ec2b0774f8733726e03ab9c9b1aa5ab5953c7c9677c",
    "title": "Heart Rate Variability in Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Emory University",
    "condition": "depression",
    "sample_size": 8,
    "status": "completed",
    "date": "2015-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02525978",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1a07efa77ffb1aa4eed983787046c94a3d6713392c923ce18f6c2185f6117d1e",
    "title": "The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Cedars-Sinai Medical Center",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2013-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02252432",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "767c41a40941939b643bad9429173326eb19a7fc293c5291b8c8b35af97688d7",
    "title": "Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University of Washington",
    "condition": "other",
    "sample_size": 32,
    "status": "active",
    "date": "2014-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02303847",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8a81776c037a829c11fcddaf63c74258801a7dac6336dbe172644f2a6c25d677",
    "title": "Esketamine and Butorphanol for Post-Lobectomy Pain",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Second People's Hospital of Hefei City",
    "condition": "other",
    "sample_size": 223,
    "status": "completed",
    "date": "2022-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06398834",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "292fa963cedfbf88161a1217bc0fee76701a3796c4567737a24f6a7f7706c73d",
    "title": "The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Jinling Hospital, China",
    "condition": "depression",
    "sample_size": 120,
    "status": "completed",
    "date": "2020-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05506787",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "9fb9806e1811086c28820346f250d0e7818e7641c5fe734ca579f089077c17de",
    "title": "Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Zhejiang Cancer Hospital",
    "condition": "anxiety",
    "sample_size": 185,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06530706",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "cd5812308b4351d76436fca1b1ffa9fb56d3e4cea52c46bad8b35caaa33a4e64",
    "title": "To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Adriana Feder",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2014-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02398136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1afda1bf01c35e08e8e40f849aecf1929438c19d0ebc0427aeea5e67b43fe762",
    "title": "Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 56,
    "status": "recruiting",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05306899",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "7d267b1053132d8cec363f1995c8741d4ee2cf33042c3422299d700ee7745fac",
    "title": "Ketamine-assisted Therapy for Advanced GI Cancer",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Brian Anderson, MD",
    "condition": "other",
    "sample_size": 1,
    "status": "completed",
    "date": "2024-05-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06077487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "10d637ce957585e62611472f1fd3f5601d4fe905122d686914751b90239fe6e2",
    "title": "The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery",
    "compound": "other",
    "type": "observational",
    "institution": "Yonsei University",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2019-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03462836",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "bf1fbef06deaffa37bf5e13329359e0c9534058bb62bb304c9b03665bc1cc743",
    "title": "Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Julia Finkel",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2010-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01325493",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c774e39cb5d8cffd580e9db0a04cf92b5deb271b9490e6f6cdffc23752bfdc04",
    "title": "IM Ketamine vs Midazolam for Suicidal ER Patients",
    "compound": "ketamine",
    "type": "observational",
    "institution": "New York State Psychiatric Institute",
    "condition": "depression",
    "sample_size": 90,
    "status": "active",
    "date": "2021-02-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04640636",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2a1859b1894ff20089b7853d1bcf5018ae5debb9fa6eed4439484461ee489c50",
    "title": "Acupuncture ACL (Anterior Cruciate Ligament)",
    "compound": "other",
    "type": "observational",
    "institution": "Hospital for Special Surgery, New York",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2018-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03711734",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3a0e6b8b525e3f948c2f1da90787fec07948b261b6ecf8b827eed43f6302924a",
    "title": "Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy Gastrointestinal Endoscopy",
    "compound": "other",
    "type": "observational",
    "institution": "Assiut University",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2017-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03235609",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1c31bd995ad004847543039cbf3d94bca4bcd6f95bc2be64486a46cd532e0cde",
    "title": "Ketamine and Postoperative Depressive Symptom-PASSION",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Beijing Tiantan Hospital",
    "condition": "other",
    "sample_size": 84,
    "status": "completed",
    "date": "2017-07-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03086148",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0dcad76a610b9998983490be3a1a0480a405ff9b3923dbe5b52a809172c0fc90",
    "title": "Ketodex Versus Opioid Based Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy.",
    "compound": "other",
    "type": "observational",
    "institution": "Cairo University",
    "condition": "other",
    "sample_size": 8,
    "status": "active",
    "date": "2025-11-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07246447",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "fb84ed3e97314396ad1283b8e282e17fb93e67c19049e483b0216149b79fc1ae",
    "title": "EEG Studies of Sevoflurane-Induced General Anesthesia",
    "compound": "other",
    "type": "phase_2",
    "institution": "Massachusetts General Hospital",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03503578",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "bd38c69b01576fceb9bdf159efbeefc164bac1412beda0cc5ae114e5420340b2",
    "title": "The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "First Affiliated Hospital of Chongqing Medical University",
    "condition": "depression",
    "sample_size": 396,
    "status": "active",
    "date": "2021-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04777110",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d90ee842fa5cb0dbe2e84e405a8a3292043d35c20a69e759ab45a94e1f735b3a",
    "title": "Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Tel-Aviv Sourasky Medical Center",
    "condition": "other",
    "sample_size": 100,
    "status": "active",
    "date": "2019-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04013958",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8daaf60052f9d2baaf90a81031bb6526dda1ff97fb357a65cb19273e93738b7b",
    "title": "Ketamine and Prolonged Exposure in PTSD",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Minneapolis Veterans Affairs Medical Center",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2019-04-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03960658",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1d1374755cc12c03199b8cfee1a8a71435e10188d012486931d98a18a0f335e7",
    "title": "Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Centre Hospitalier Universitaire de Nice",
    "condition": "other",
    "sample_size": 150,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01544725",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c4cd62bbe62af7874ff01d3ba2039e6aa1eeaa617cdd8a9349afa7e35f3446d1",
    "title": "Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University Hospital, Lille",
    "condition": "depression",
    "sample_size": 42,
    "status": "completed",
    "date": "2016-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02783430",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "861175493511f8a7c7ad664f9735a341e50e7b68c5bfe61274892e9539bf5543",
    "title": "Ketamine Versus Etomidate for Rapid Sequence Intubation",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Hennepin Healthcare Research Institute",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2013-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01823328",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c334337c15972d221fa1bfb0df4b33c5b13a87c23b8e097c81c8344371d60773",
    "title": "The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence",
    "compound": "other",
    "type": "phase_1",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 55,
    "status": "completed",
    "date": "2012-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01535937",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "751eec1f2844cbfc87be5b6e20f6f897b78ac492f0110d35318f7a7c1a0ce704",
    "title": "The OBSERVE Protocol",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 450,
    "status": "recruiting",
    "date": "2024-01-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06725277",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "84554ae17c35fb787aa2bf67cf606f92d1c371c0833471bf45b3d223f68007b7",
    "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Sichuan Purity Pharmaceutical Technology Co., Ltd.",
    "condition": "depression",
    "sample_size": 98,
    "status": "recruiting",
    "date": "2025-05-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07193901",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "7555c8ae47415f1ade9fb24b6975944e362c48fd53c92cfe65dbbb2824085bce",
    "title": "Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Janssen Research & Development, LLC",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02228239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3a1d0b10d4c336b54c4a999cfa8932bf9254a4e05a454b2f4e984e00fb825a85",
    "title": "Oral Dexmedetomidine for Parental Separation in Pediatrics Undergoing Adenotonsillectomy",
    "compound": "other",
    "type": "observational",
    "institution": "Suez Canal University",
    "condition": "other",
    "sample_size": 74,
    "status": "completed",
    "date": "2016-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03551067",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d8b37ad969513bc321b70eb2258e76a663acf9be128eb7857c7ce3f32750aa50",
    "title": "The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults.",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Kasr El Aini Hospital",
    "condition": "other",
    "sample_size": 120,
    "status": "completed",
    "date": "2023-05-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948267",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8ffbdc4733b96fd7160e84ae8e78b0f9765cbc26e9335601dfb4667cb76059e0",
    "title": "Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS",
    "compound": "dmt",
    "type": "phase_3",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 185,
    "status": "completed",
    "date": "2021-07-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04788615",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e59209a306f49948327e44e8e850beb4d7b401ab677017ae3d97091769c3be4c",
    "title": "A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Cybin IRL Limited",
    "condition": "anxiety",
    "sample_size": 36,
    "status": "active",
    "date": "2024-05-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06051721",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a2cfec0a69f7f387ba35d2f4fa63a72771e4b0a3d1685c139e17d5e892b3b772",
    "title": "Trifecta Research Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06810765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "9673287c7aaeb4389b64aed0fdd445efc8c00478a07884882dbc897a86e24f25",
    "title": "Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2020-11-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06459232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c6c524ddddfcf268b330be837a1bc030e51c186dbce5ac480cd6f373377012d5",
    "title": "Molecular Imaging Study of Harmine/DMT: a Basic Research Approach",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Insel Gruppe AG, University Hospital Bern",
    "condition": "other",
    "sample_size": 17,
    "status": "completed",
    "date": "2024-01-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06252506",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8397953237f78c4a48d86e46b7c0a9cb43b62dc74eedc4a7c9abc55195e52b44",
    "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 263,
    "status": "completed",
    "date": "2017-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03222973",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8b374ad7efc17f97b9dac0cea8645cf5bba28348e589efa1a120965572287b6c",
    "title": "MIH and Hypersensitivity in Children",
    "compound": "other",
    "type": "observational",
    "institution": "Universit\u00e0 degli Studi di Brescia",
    "condition": "other",
    "sample_size": 39,
    "status": "active",
    "date": "2022-01-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05705037",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d4a252dbf349d794d5fd4c4cc234b83d07e47567c7f45964ba23122d547ffab4",
    "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Usona Institute",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2022-12-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05698095",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a7c6bbbb4a7b2db9e4ee2ffb9f36fb403dc33e38657b30cd99a3bf7b81756ead",
    "title": "Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults",
    "compound": "other",
    "type": "phase_1",
    "institution": "Advanced Integrative Medical Science Institute",
    "condition": "depression",
    "sample_size": 12,
    "status": "active",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05894902",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e827018424c727540059966c617761b0901274c13092c55195dec3066259f21d",
    "title": "COVID-19 and Multiple Sclerosis Disease Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Nottingham University Hospitals NHS Trust",
    "condition": "other",
    "sample_size": 14240,
    "status": "active",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04863586",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ebc6d2cb9e4d84a9db1d1049457aca954e38b603d02475665e40a7f24847aad0",
    "title": "Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Strasbourg, France",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2025-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06663189",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "fe5659f3e050530a37ac51589c0e7c36e75b1c92a9e97a692a2d28f0b0be2805",
    "title": "Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study",
    "compound": "other",
    "type": "observational",
    "institution": "University of British Columbia",
    "condition": "other",
    "sample_size": 4000,
    "status": "completed",
    "date": "2003-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06705608",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "5dcb0f502daf7d1a368b6fc4a56118310c0722bd49cf26e3bac1a4996b74c580",
    "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY\u00ae) in Participants Who Took it During Pregnancy And About the Health of Their Babies",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 1178,
    "status": "active",
    "date": "2021-09-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05688436",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "08f52372bc035bac75657108aad5347626c4237e547b6de456a38c15897851ba",
    "title": "Clinical Study of DMT in Healthy Adults",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Biomind Labs Inc.",
    "condition": "other",
    "sample_size": 27,
    "status": "completed",
    "date": "2022-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05573568",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4f753dd3cdbeff3327a4e200b388086dfa8f0c5143b958761133b187c2f54e95",
    "title": "The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative",
    "compound": "other",
    "type": "observational",
    "institution": "Dartmouth-Hitchcock Medical Center",
    "condition": "other",
    "sample_size": 694,
    "status": "completed",
    "date": "2017-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03480854",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "fe1140593d82994c1d7ee2968001b7de105de60dc80c6f3c308c58b692e545cf",
    "title": "Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients",
    "compound": "dmt",
    "type": "observational",
    "institution": "Merck KGaA, Darmstadt, Germany",
    "condition": "other",
    "sample_size": 545,
    "status": "completed",
    "date": "2012-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01601119",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "23d314ab1fd3526bdd73e297d3680208643c0e5ef76081ee568dddc5e452c867",
    "title": "Mindfulness and Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Milan Scheidegger",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2023-02-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05780216",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "bb2d1f423ba849acce9be30e14930878b487118e15fec78a56e9939c060fa283",
    "title": "SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 66,
    "status": "completed",
    "date": "2021-02-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04673383",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "4cc22f54000bd643635786ea4ad4042348b8d140ea53ce4c087b412e7fc272de",
    "title": "A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Montpellier",
    "condition": "other",
    "sample_size": 250,
    "status": "recruiting",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189325",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c1f193d7302ca715a6b68c408a65c10157d27841b0859d3a7819c30e67eba86d",
    "title": "Neuroprotection and Repair in Optic Neuritis",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of Calgary",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2010-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01073813",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0c3f81decabbb41f4b7adb295683a33edae8d838ea688ab2b128a98d3c26239b",
    "title": "Effects Of Dance Movement Therapy On Compassionate Flow In Nursing Students",
    "compound": "other",
    "type": "observational",
    "institution": "Mackay Medical College",
    "condition": "other",
    "sample_size": 59,
    "status": "completed",
    "date": "2023-09-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06220708",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "458f65dce66e0d941276a1cd6738bf5e341be29869b9be92f52dbebf06909136",
    "title": "Antidepressant Response of DMT Masked With Propofol",
    "compound": "dmt",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06927076",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "604aa74e281e83bdb5edccdc5372851dfb8317b70d9f15497754648a09d11092",
    "title": "Ayahuasca Assisted Psychotherapy for Grief",
    "compound": "ayahuasca",
    "type": "phase_2",
    "institution": "Beckley Med Foundation",
    "condition": "other",
    "sample_size": 84,
    "status": "active",
    "date": "2021-10-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06150859",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "affa2207639a5fa63ef6454d808520c1509c1f63e3bfceb48cd4de639ba3f54b",
    "title": "Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "Ying Gao",
    "condition": "other",
    "sample_size": 328,
    "status": "recruiting",
    "date": "2025-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07037823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "fbaa96a562ba52784bd35f4c3b4ee6765c09a2f77868292ac7cfe0a2c7845f3a",
    "title": "Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders",
    "compound": "dmt",
    "type": "observational",
    "institution": "Shalvata Mental Health Center",
    "condition": "anxiety",
    "sample_size": 24,
    "status": "active",
    "date": "2015-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02304796",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0c7c6806440daee2f4f23c4ef1aa7aa5c272804d36168bb83dfa2c75e593136d",
    "title": "Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers",
    "compound": "other",
    "type": "observational",
    "institution": "MoCA Clinic and Institute",
    "condition": "other",
    "sample_size": 500,
    "status": "recruiting",
    "date": "2025-03-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07041450",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "30f478aedf8f0a98e9f0346688c1eb55fa63129a46cf16caf6c1c709fa514a1d",
    "title": "A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 213,
    "status": "completed",
    "date": "2011-11-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07474311",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d6907de2f9644625c86a8e83da9ce3d8f4514ca0e0dccaefbcb7cd55c5c08e81",
    "title": "Relationship Between Oral DMT Burden and Adherence in MS",
    "compound": "dmt",
    "type": "observational",
    "institution": "Monash University",
    "condition": "other",
    "sample_size": 323,
    "status": "recruiting",
    "date": "2020-09-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04676204",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2404ad4c4cb21bf593a3791b987bbd7b37538bd8cdbf57070342230055b99d82",
    "title": "Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Abu Dhabi Stem Cells Center",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2022-03-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05168384",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "12872c0a3fa470883d41f898f804ac4077fba2f2e639e490a4d1e84b6a3c295f",
    "title": "Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Reconnect Labs",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2023-05-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05829603",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3918890d4d12918083bf574e55c7d4620e692c273b1ec4743a51601e59e462b5",
    "title": "Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2024-06-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05695495",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6f45d2ad04991aca5de6a3f241c8ec4bebadceeff50fef93c89371bdbb6a488f",
    "title": "Dance/Movement Therapy for Bone Mineral Density in Schizophrenia",
    "compound": "other",
    "type": "observational",
    "institution": "Hebei Province Veterans Hospital",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2020-07-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05716802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "cdc6ab6399d4f7a940f6c01d1e7cc96eb59f3c9c1f1d68d393a1058628def4cc",
    "title": "Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2013-11-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04832399",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "63cd052997eba418ae5c3f7a4e835cdc2dcc9d8ecfaa5c191037d23fdc55d686",
    "title": "Phase 2 Clinical Trial of GH001 in Bipolar II Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2023-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05839509",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "5e27ba601ebeb3ecbe50813b4d0205a969296ac3c8a60111d5a9cbd60d513729",
    "title": "A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 42,
    "status": "completed",
    "date": "2012-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01578330",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "39fec6f9415d7849e6a3306a23f1917e72a1fe8cd8ff12ecfd103182a3003a3b",
    "title": "Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects",
    "compound": "dmt",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2020-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04716335",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "93d979744d0bc58dbf333559d90baccd529c5f9e35e9990d8218b3d8a7400dbf",
    "title": "Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression",
    "compound": "dmt",
    "type": "phase_2",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-10-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06094907",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "43b62069ae202526008cbfce6c0efb0b2f61371f4ed0060618f6cc149263694e",
    "title": "Tecfidera and the Gut Microbiota",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2015-11-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02471560",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0b0809be1f4e55273778eba9dc2b66f56387c1a64ea5c83b2349fff8a8023c89",
    "title": "IM and IV SPL026 Drug Product in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05644093",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f5cacad300ad47f1970b268a4028a5f07bfabfc4361d9912b12faba09ceb52a2",
    "title": "A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 4805,
    "status": "completed",
    "date": "2025-06-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07403214",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a6ac7d4a968a59de2a52175988a9472bac177922c5d37b0db907a227d0403498",
    "title": "Pharmacokinetics of GH001 in Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 46,
    "status": "completed",
    "date": "2021-06-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163691",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "fc508483b010ea25719a39974dd3d5803626c93f6930ddb9acccab2a9d1cdc45",
    "title": "Psilocybin Therapy for Chronic Low Back Pain",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Joshua Woolley, MD, PhD",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05351541",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "862609b3ba3e0daafbd9b813255bd08128072ab801f7fdfdcfd9b7310c81119f",
    "title": "Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "depression",
    "sample_size": 30,
    "status": "active",
    "date": "2021-03-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04711915",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "253525c15a23404be35cdd553c55f82d20d5703708b2d2c1cc515671f10e9ef6",
    "title": "A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants",
    "compound": "other",
    "type": "observational",
    "institution": "Bristol-Myers Squibb",
    "condition": "other",
    "sample_size": 2961,
    "status": "active",
    "date": "2021-03-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06133049",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a1fd87c11858d4808367848125ec95fbac19835d9c43b832a17a16ba84209c37",
    "title": "Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "Jeffrey Gelfand",
    "condition": "other",
    "sample_size": 5,
    "status": "completed",
    "date": "2018-11-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03594487",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "56f8fa8654951753b6ad57602591a8aea57674a30bb336dedc1cb8aa7de281ce",
    "title": "Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "International Center for Ethnobotanical Education, Research, and Service",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2020-10-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04003948",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2a8472dbee4ff38751b1498e7cf4f624eefe2e30e0e17b06ac9da2ffcac4cdad",
    "title": "Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "Stanford University",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2021-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04313712",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "42034b58b03ea36a85a62c85a5fcc6711e2710b0f8b0a648b0a9995b19825dc3",
    "title": "Mapping Ibogaine Neural Dynamics in Opioid Use Disorder",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "University of California, Irvine",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07226570",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b6ec247e6bd2fe4c3ae2a7ecc80bf0ce09660e4c3edea0bb358efd09bb937941",
    "title": "A Study of Oral Ibogaine in Opioid Withdrawal",
    "compound": "ibogaine",
    "type": "phase_1",
    "institution": "atai Therapeutics, Inc.",
    "condition": "other",
    "sample_size": 116,
    "status": "completed",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05029401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2205af0565e2d1cfac1f1b872f433ac71ed08b35afac93a581f06c507de54ef9",
    "title": "Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03380728",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e9f88d2b3bb5a904eb63d34f94db1d354a1424b112d621c1d4ae607c2d917a96",
    "title": "Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression",
    "compound": "ayahuasca",
    "type": "phase_1",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 35,
    "status": "completed",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02914769",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "724a3f04d998d445fa1228ab0a475276cf9cca32c969629b4c047203bc6f84d6",
    "title": "Ayahuasca, Esketamine and Body Image Perception",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317219",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "915bfce0f72d51bd26a570d2dbf3e81fdffb1ccee6ef28a821905621b2012261",
    "title": "Ayahuasca, Esketamine and Premenstrual Symptoms",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f297c77cbff46505d11bb69d2bfdd0726b17dcf3625c1dcb0488fcbd3d25794b",
    "title": "Ayahuasca, Esketamine and PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ae5bf47b8c21f70c8347be94a0f17598df8f9d8b63309e5be3898573802d861c",
    "title": "Entheogen Resurgence",
    "compound": "other",
    "type": "observational",
    "institution": "Vireo Health",
    "condition": "other",
    "sample_size": 102,
    "status": "completed",
    "date": "2021-09-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "dd8cb146beda67e6d2a65cdc96868d21662ae45ff0fd9a1e3d9edcdec6a8363c",
    "title": "Ayahuasca and Esketamine for Major Depression",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "depression",
    "sample_size": 22,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07212946",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "05431a8189731bff6895510ce8559f8effba74196570c6c81b0196aa4c9d34f8",
    "title": "Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness",
    "compound": "mescaline",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2021-08-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04849013",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "cdcc6f1de14e082e13f542622a5a2158e041829aca33360d610de8aa27d3aae1",
    "title": "Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis",
    "compound": "mescaline",
    "type": "observational",
    "institution": "Xiangya Hospital of Central South University",
    "condition": "other",
    "sample_size": 205,
    "status": "active",
    "date": "2023-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05933213",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e19a8c402d4fb90e6cc578c47f74c3f4284fbedbc1c8c96c28c89e6b54a7e19f",
    "title": "\u201cThe mushroom was more alive and vibrant\u201d: Patient reports of synthetic versus organic forms\u00a0of psilocybin",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1556/2054.2024.00379",
    "url": "https://www.semanticscholar.org/paper/459a20f599257469b04e48f92902abff4d92985e",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "50738e082f35f26021c342deef662b5ef6cc7cff41a14ffbfca3cd94643ce109",
    "title": "Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "anxiety",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1080/02791072.2023.2251133",
    "url": "https://www.semanticscholar.org/paper/76708406177b18e26c0806c69d23ce7133d7f702",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1b113ef2f9267fe1e877afef300c0c2ce8bb109ec527088110f3a1e65b96f9e3",
    "title": "Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1111/add.16762",
    "url": "https://www.semanticscholar.org/paper/8357b19735790ba3578da72bd346769635b7b930",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f12733e418b8c31ebb1792dd8bf0f56ee3c8c81a86d6d2820ff793786bd24639",
    "title": "Psychedelics, entactogens and psychoplastogens for depression and related disorders.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1111/bph.70088",
    "url": "https://www.semanticscholar.org/paper/a01277817531ca86c1d459bfe733eb7f78382489",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d63f9683570df27f5b8d6a155a3491700f0e90cab592b905577daedd2d957a39",
    "title": "A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s40501-025-00373-w",
    "url": "https://www.semanticscholar.org/paper/45394527228d7e63b029fac68baa3be53b468e6f",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a70076f37389f8e6e2127cc89a0d2359193cb3de94aefa062dca17e0ccb9494b",
    "title": "Psychedelics are Bringing a new wind to the Pharmacopoeia",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.31579/2578-8868/360",
    "url": "https://www.semanticscholar.org/paper/2945297f2610194aec04ffb6780b11daef208f95",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "1adff420c9b1622b7b70385fc1e5db6a4c59004598ac215f4993ea3663de0a4e",
    "title": "Psychedelics Drug Legislative Reform ant legalization in the US",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2022-01-01",
    "outcome_summary": null,
    "doi": "10.1001/jamapsychiatry.2022.4101",
    "url": "https://www.semanticscholar.org/paper/14f591fde310dac40aa0d5b0dc93983de1053bb2",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "82a677cab2301971d7f146c57942b2c3ecc7ac72fd429c892584081ea41ab606",
    "title": "Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1080/17512433.2023.2295997",
    "url": "https://www.semanticscholar.org/paper/6c954a4590f34f016fb597b856a0c0c2813e1d87",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ad5c0f130d9b241dfb274c8be09b32b8defeb23bcd132712a3a35f37542e5d7b",
    "title": "Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1080/14740338.2023.2253144",
    "url": "https://www.semanticscholar.org/paper/4251074ca87c4b7c395e7f97d66612687e044e58",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "6751b4e9810b5e55a8a2dd5f94287b99a913760c9a1fbc02390fa77ea15f2be2",
    "title": "Minorities\u2019 diminished psychedelic returns: Depression, suicide, distress, and serious mental illness",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1177/20503245251337357",
    "url": "https://www.semanticscholar.org/paper/6baa97546c2c439e0bb8fc23e88070db5813de3c",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2ba28d36fe832cffc65f37d397ff46b353e60a387bc5e9515ce032249a84898d",
    "title": "Minorities\u2019 Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s40615-024-02023-y",
    "url": "https://www.semanticscholar.org/paper/122fc6f6b09a3b95b5e12bbfbdda17e07568c7b8",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "70a0580b33e7b70f4a3a36c958cd7f08431b17e3c9496c2658567b9a69c2c809",
    "title": "Registered clinical studies investigating psychedelic drugs for psychiatric disorders.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "published",
    "date": "2021-01-01",
    "outcome_summary": null,
    "doi": "10.1016/j.jpsychires.2021.05.019",
    "url": "https://www.semanticscholar.org/paper/1682d648c4cb89ec16347be974bc3a1ca9b45ecb",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "41c26f451feded011456fb6e1a7d9d29dd73e727401cebecc3453cce140e26fd",
    "title": "Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1038/s41380-024-02830-z",
    "url": "https://www.semanticscholar.org/paper/d3b17658a385547a0ed28a83a8254e8319c157a1",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0b6677da56e01cdd6fc1b84e2693ba7fb4e10a4f0e39ed18fe4ea1537ea61635",
    "title": "A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.3390/brainsci14030248",
    "url": "https://www.semanticscholar.org/paper/b34254d4efd07691372d449b85a4f7b99b8f112a",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "191d99c50b735119cbe1f527c72ae05fccc6c3272a3ee47d0d5a40b8f2260025",
    "title": "Psychedelics: From Cave Art to 21st-Century Medicine for Addiction",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "addiction",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1159/000540062",
    "url": "https://www.semanticscholar.org/paper/f1a04016a3de4c282c3949e0497392c1bfd96e40",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2902c0c4409e10cdab7dcf40b4ba2d641a5ceac67614e1104173f1735d9ed537",
    "title": "Minorities\u2019 Diminished Psychedelic Returns: Gender, Perceived Stigma, and Distress",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.3390/psychoactives3020019",
    "url": "https://www.semanticscholar.org/paper/a46ea808789badaef38986bd3df5aa51e790a00e",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "5ca34a22869ca757a3b84e0b031528e590e7bfa0f3510c8e043fbe3f35767dcf",
    "title": "In vivo mapping of pharmacologically induced functional reorganization onto the human brain\u2019s neurotransmitter landscape",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1126/sciadv.adf8332",
    "url": "https://www.semanticscholar.org/paper/5fcb68aaca8161b6c56c8a90467fd8be58c262cf",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "eb498647e98fd08e60e51cf64ff3fc76d16d04b438c996737fe23d9393b1f20e",
    "title": "Associations between psychedelic use and cannabis use disorder in a nationally representative sample.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1016/j.drugalcdep.2024.112502",
    "url": "https://www.semanticscholar.org/paper/ecad6b1ced27e4469aad4ccfa29223e299cbe5e5",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "9c631ad99f18fd81acede29fc547df13b412c5a55ff73c77c23b189f23675b86",
    "title": "Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.3390/ph17111484",
    "url": "https://www.semanticscholar.org/paper/805fa5fb5367af73c1f735986ed2e29e7bbb74bd",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f911bde31a783f5d0dece06923995e2b5634d79cdb4433bb8ce46b3e9bd9071f",
    "title": "Psychedelics for treatment resistant depression: are they game changers?",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1080/14656566.2023.2281582",
    "url": "https://www.semanticscholar.org/paper/dcccd34e0a2fb9d3826b5a8e6f2e4222f17fa49b",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b8b9663bbcfcf636963a90051f62c6bd8219b944020926e650f0d682edde0231",
    "title": "Trips through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1089/derm.2023.0292",
    "url": "https://www.semanticscholar.org/paper/80939c30ae4c0da8b28c2726b5dd2f7319f98269",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "80cfec6da4a9d8e96fb7439d9a584ebf26ab254feeb5b36e53569dc62c9649c5",
    "title": "Exploring the World of Psychedelics: An Introduction",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.64239/pi-vl8201",
    "url": "https://www.semanticscholar.org/paper/2da72ff354bbde0c48073dd771405c56e4ace9c1",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "85ffc0d37e163f8ab2eeb63086922de074d7fa2267528d5f4ac3d8aebaa3509e",
    "title": "From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream Medicine",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.59324/ejahss.2024.1(3).10",
    "url": "https://www.semanticscholar.org/paper/c0d5d52d3aa9d516eba1c247d7ac3fbf85252a09",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3d0373ee190caedf11435ae0ba0758be3b52f13961658e2da31828d472b4552a",
    "title": "IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.63050/jpps.21.02.935",
    "url": "https://www.semanticscholar.org/paper/69cf0978aebec1709c26d9001aea93d3da4ba630",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "be6befb3d26b41eb1d5d0922bc1a898fdf72d802739f5504af379696e5993953",
    "title": "Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1089/psymed.2024.0021",
    "url": "https://www.semanticscholar.org/paper/7cb82fb9d374a781d34384b1241e4905ecf45b55",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c3b13c82ba59bc1549fbf86ef058f5aae7568eb35106a80277e5279739fdc01c",
    "title": "Psilocybin, psychological distress, and suicidality",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2015-01-01",
    "outcome_summary": null,
    "doi": "10.1177/0269881115598338",
    "url": "https://www.semanticscholar.org/paper/3841f621cf71cbd057de5d1a27e19b0d9261ae0c",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a4efdd428877b3e3c3f02b20149caf8b57233b8e8da59d75ba7c5211711d0b01",
    "title": "Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2022-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s40596-022-01662-9",
    "url": "https://www.semanticscholar.org/paper/dc433c9e4b17d31357eb99f1e14e1c8f20468e89",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "93fc8f4c03a91ffd4971642717a0749682c1e60139a18de212221f717bcedbdd",
    "title": "Analysis of recreational psychedelic substance use experiences classified by substance",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2022-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s00213-022-06062-3",
    "url": "https://www.semanticscholar.org/paper/1c05ea5be4f2330805524f63eeece3533a149372",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8df3f8c0adfcdcd4a6ab5fc12da222bb113fee8b405f0f9268d197a4d49fb393",
    "title": "Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1177/02698811221146356",
    "url": "https://www.semanticscholar.org/paper/997d1423066b1b15425a7d70cd4021eb89b81edd",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "daec693db5232f0ca3b76c2f7a0e13d57210d6aae3a1c7f0c648028aee3ac98d",
    "title": "What is needed for the roll-out of psychedelic treatments?",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1097/YCO.0000000000000946",
    "url": "https://www.semanticscholar.org/paper/4bfcced066b5649be1b652beac3556a920ac1757",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0ad453ff41818456aea0934feb6ee4a5c1bf7b99a91e9c3dd91c5d708349d28f",
    "title": "Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2021-01-01",
    "outcome_summary": null,
    "doi": "10.1080/02791072.2022.2133757",
    "url": "https://www.semanticscholar.org/paper/a8340c29ff7252c662b2c260176d6208f664a93c",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b5aab9aa86602e72638d22a5cd5439ea8b0c7cf76a897c0cfe139717d1abbb4d",
    "title": "Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1080/18387357.2023.2235030",
    "url": "https://www.semanticscholar.org/paper/ff4407bbcbe0c83a8ec523d8721411a4067348f3",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ce25fadaa61ea24e9a482ab0c4d292b389ff1accc3b35872ac5331e2e70bf289",
    "title": "Therapeutic potential of psychedelic drugs: navigating high hopes, strong claims, weak evidence, and big money",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1146/annurev-psych-020124-023532",
    "url": "https://www.semanticscholar.org/paper/2413b0d29c68cc93803fb83d5bb26b823ca2f37b",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "611fa6dee72731ad627cf02b721805d59f6ef3cf7de0a8145c028d360ec352d9",
    "title": "Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "anxiety",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1016/j.pnpbp.2025.111534",
    "url": "https://www.semanticscholar.org/paper/064c7664c3e0ebcc05769e22e4023c63fbf52ecc",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c535cc4cd1e2aafac535a9265571ceeaba056fa2bc0994cbf0c7a7584bb67ed2",
    "title": "Mapping Pharmacologically-induced Functional Reorganisation onto the Brain\u2019s Neurotransmitter Landscape",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2022-01-01",
    "outcome_summary": null,
    "doi": "10.1101/2022.07.12.499688",
    "url": "https://www.semanticscholar.org/paper/5548a8835b670fdefbb3a35bb42eaf639af730b4",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "a069aced6b90b4af4063d975377240663872ebd22d77c75c91ea872bd3d9ba9f",
    "title": "Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "anxiety",
    "sample_size": null,
    "status": "published",
    "date": "2021-01-01",
    "outcome_summary": null,
    "doi": "10.51731/cjht.2021.90",
    "url": "https://www.semanticscholar.org/paper/378596df4ada234f174c40993851547d69b00cd9",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "e94d94d1eae48f0ccefee3c131ce054fbaba093066dc54f52cc953eafda06cbd",
    "title": "Psychedelics in the treatment of unipolar and bipolar depression",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2022-01-01",
    "outcome_summary": null,
    "doi": "10.1186/s40345-022-00265-5",
    "url": "https://www.semanticscholar.org/paper/e4e7f18de33f10d06b138ac3c179bf1bd182f632",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "992eb71962fd71f3105f68f2d0f7c5a3f311e2a4c413d818605adf3adc975b3a",
    "title": "Analysis of recreational psychedelic substance use experiences classified by substance",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2022-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s00213-022-06062-3",
    "url": "https://www.semanticscholar.org/paper/75941200bf963236da5deaa7cc4dee773aaecd41",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "816230a792110edc1eed7d2cb0cf85872a8991d9eb266b46d906bb879f563400",
    "title": "The Development and Regulation of Psychedelic Medicines",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2017-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://www.semanticscholar.org/paper/fe34f5f521f26b5896d0b8bf8c18b644ebcc26e5",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "451d89aa8b26959b757e30f7b5cbb9ecf90879775612711372974f2f82438603",
    "title": "Psychedelics and cognitive function: A systematic review",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.33448/rsd-v12i14.44436",
    "url": "https://www.semanticscholar.org/paper/1d19441f00b76e914a5ac1a784b53c733f34d0c5",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "3f5f282ba35b3e7e5a77586cbd177dc085b5cd533031cd35ea758b4bc8687015",
    "title": "The therapeutic potential of psychedelic substances in Hospice and Palliative Care",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2022-01-01",
    "outcome_summary": null,
    "doi": "10.1080/09699260.2022.2001140",
    "url": "https://www.semanticscholar.org/paper/dc0e98d79a6e4ed9fa52d745df6f29bea701ac60",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "487b19412af25e8554d9e06f68140598eec505fa61294913e160fde9cfb358e5",
    "title": "Pharmacists and psychedelic medicine",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.1002/jac5.1876",
    "url": "https://www.semanticscholar.org/paper/28d5ff4b21621b628bc01decd748e12974a2b53a",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "2fc1b8abf0c14e33528263ee9482c8c25c2befc5c1b81427b748c4adf3ed79fe",
    "title": "Shaping the renaissance of psychedelic research.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2012-01-01",
    "outcome_summary": null,
    "doi": "10.1016/S0140-6736(12)60600-X",
    "url": "https://www.semanticscholar.org/paper/e15f7093b0a15a56ccd1da8950afb33e49c21706",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b5dd6ee2e8302ff5ce541e2983b6a7d10ffd14428bd32439099ceb867546d453",
    "title": "Bakunin and the Entheogenic Challenge to Atheism 1",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2016-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://www.semanticscholar.org/paper/142e5553624ffc1402a5c0194fdadfeec59122c1",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "0f68e20c4fbb564a25bdc2bfd8b6bab35a95831c4b8092c34936e326b170b654",
    "title": "Psychedelics: A new era of treatment?",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2021-01-01",
    "outcome_summary": null,
    "doi": "10.1192/j.eurpsy.2021.1290",
    "url": "https://www.semanticscholar.org/paper/37aa3bdd15ed85e0c89d2633e67463f9621b5c20",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "b95c6bd6a604dc018df4365fb9cec2fae61c5e9c44302b2c04b53e5999788557",
    "title": "From Acid Revolution to Entheogenic Evolution: Psychedelic Philosophy in the Sixties and Beyond : Winner of the William M. Jones Best Graduate Student Paper Award at the 2013 American Culture Association Conference",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2013-01-01",
    "outcome_summary": null,
    "doi": "10.1111/JACC.12051",
    "url": "https://www.semanticscholar.org/paper/7be48931967ea377ca9a658f0670a24c57381011",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "150750b503854e7c793e22ee811cfbb074124a6d609acf878284fe6a2ea98e40",
    "title": "A Comparative Review of the Neuro - Psychopharmacology of Hallucinogen - Induced Altered States of Consciousness: The Uniqueness of Some Hallucinogens",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2012-01-01",
    "outcome_summary": null,
    "doi": "10.14704/NQ.2012.10.2.528",
    "url": "https://www.semanticscholar.org/paper/736ef1f69892b4f9fc1c3f90247e3e5d67f31b47",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "d7fbe7a6622dc37ab26ee00c8cbff5da56a6d25398a2d298dfbd98bd1186174c",
    "title": "Altered States of Consciousness . A Comparative Review of the NeuroPsychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2013-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://www.semanticscholar.org/paper/1ff0683b5ef25cb708a3e95db33a0d0893bd5308",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "ae8c97b4f4494dae035bca6735ef1a7d212889f594854734b3186467944b3672",
    "title": "Psychedelics in the Treatment of Substance Use Disorders and Addictive Behaviors: A Scoping Review",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s40429-025-00629-8",
    "url": "https://www.semanticscholar.org/paper/f3f9f4bf7d98cdca04226d29b02de7afd96906e9",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "58b811925993d5c8aade031291c2f1111e43b33cddd2a746a35c4164a1c71aee",
    "title": "Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2025-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s40266-025-01221-5",
    "url": "https://www.semanticscholar.org/paper/68cb4ad0cc929072368835a67becfd32887e2aa2",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "76fe56782edf4a75c763c20847140beb864684eba4a33dcf95ec2b6bacaf1e45",
    "title": "The Psychedelic Future of Post-Traumatic Stress Disorder Treatment",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "PTSD",
    "sample_size": null,
    "status": "published",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": "10.2174/1570159x22666231027111147",
    "url": "https://www.semanticscholar.org/paper/18e099ad605b5b0990bf15598b312aecc4ed4538",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c830074c201086434bd1d958884c05f6473f1de1605e6c8115f568d50617747c",
    "title": "Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2020-01-01",
    "outcome_summary": null,
    "doi": "10.1007/s40263-020-00748-y",
    "url": "https://www.semanticscholar.org/paper/45ab11380ab944dadc86dd5c840029f2d2c9306b",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "8b17717e26424157828b985c8c598a1d2cbaf56619ae8d1a8e8700ef6d9ca044",
    "title": "Psychedelic Therapy: A Primer for Primary Care Clinicians\u2014Historical Perspective and Overview",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": "10.1097/MJT.0000000000001727",
    "url": "https://www.semanticscholar.org/paper/352e59712ee27562debe16621416df51b6c33267",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "f662343aba9c459f4ced809bdb6eb0dcd131c3286a6caec754c8f9a652c690b1",
    "title": "United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.",
    "compound": "psilocybin",
    "type": "meta_analysis",
    "institution": null,
    "condition": "addiction",
    "sample_size": null,
    "status": "published",
    "date": "2021-01-01",
    "outcome_summary": null,
    "doi": "10.1016/j.drugpo.2021.103473",
    "url": "https://www.semanticscholar.org/paper/0e256f8daf8578eb41353e12bc43d4c27b636ad8",
    "source": "Semantic Scholar",
    "first_seen": "2026-06-08"
  },
  {
    "id": "c9df9daef5e8510d75d7f3715d182177676604e43d5438be041fe9608f9df856",
    "title": "Neuronal Population Effects of Ketamine on Human Brain Organoids",
    "compound": "ketamine",
    "type": "preprint",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026-03-10",
    "outcome_summary": null,
    "doi": "10.64898/2026.03.09.710454",
    "url": "https://doi.org/10.64898/2026.03.09.710454",
    "source": "bioRxiv/medRxiv",
    "first_seen": "2026-06-08"
  },
  {
    "id": "01365c6a4b0b296e934ee03db6b5cd27fd27d64d04d9b69ea694c46eefe23e65",
    "title": "Effect of postoperative esketamine on depression after pancreatoduodenectomy: a randomized controlled trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1186/s13741-026-00711-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42286774/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "80a55e67aac853b2c9480713273934c94e17e953ab46022e39e6fe11415f5dde",
    "title": "Comment on \"Effect of Remimazolam or Propofol Combined With Esketamine on Anesthesia and Early Perioperative Neurocognitive Disorders in Patients Undergoing Thoracoscopic Partial Lung Resection: A Randomized Clinical Trial\".",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.clinthera.2026.04.023",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42285826/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "77bc4f7fd497898b275ba39fbdc734555490d48f16d766ad576c943ed3fdff17",
    "title": "Psilocybin restores behavior and 5-HT(2A) signaling while reducing microglial density after chronic traumatic brain injury in rats.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.xcrm.2026.102867",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42285092/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "7a5551be912093ebc0d5f5d84b606566fcb218ab820d1d676fc1c261f466ec3a",
    "title": "AMPA receptor modulation in depression: from molecular mechanisms of plasticity to therapeutic translation.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1007/s43440-026-00871-5",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42284011/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b8582ab81439f71feba945898ab0f7824f3b69cdeb40c589f319a6986149da51",
    "title": "Monte Carlo Wavelet Analysis for Objective Peak Detection in SRM LC-MS/MS Analysis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1021/acs.analchem.5c08007",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42283555/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d09e2edadcd5793dcf978658f42b1c0388696142904014fd8d26a8df6d65b7a5",
    "title": "Reorganization of Human Brain Waves Across Diverse States of Consciousness.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.64898/2026.05.27.728182",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42282806/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "29ff3056e08480c8f526d1381c7c65330da7cb2d31c09de3d1db4d7f4827de71",
    "title": "Losmapimod, an Oral Anti-p38 MAP Kinase, Demonstrates Anti-Neuropathic and Anti-Inflammatory Effects in Rat Acute Pain.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.3390/jcm15114265",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42279126/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "439a7bd6efa26655138a703fd047244a61cf8f0f999492e16eb344b067dcc1cd",
    "title": "Developing Methods for Observing Awe Narration in Psilocybin-Assisted Therapy.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.3390/healthcare14111589",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42278842/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0e3321246f1e72291ae400a95098977b1598f86c69230db45500a26c884521c5",
    "title": "Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 3",
    "outcome_summary": null,
    "doi": "10.3390/healthcare14111559",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42278812/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f1233beae923a8128eba6acccadae94abdf0a3dc47fab9525fe83d2781b86bb4",
    "title": "Psychedelic-Assisted Interventions in Palliative Care: A Narrative Overview and Critical Evaluation.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.3390/healthcare14111550",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42278803/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "6e3416d6dc24bd30b06a6463bc29ef953b8ab08214369b8b28e535b7f1945ea5",
    "title": "Longitudinal and Stability-Aware Analysis Reveals Treatment-Specific MicroRNA Response Signatures Following Immune-Reconstitution and B-Cell-Targeted Therapies in Multiple Sclerosis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.3390/ijms27114935",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42278461/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "037ddb94a7c785d2b732302fb25ac701a15bc075e1824318b7d4ed185ea3464b",
    "title": "Physiological Responses and Safety Evaluation of Combined Fremont\u2122 Snare and Medetomidine-Ketamine-Acepromazine Immobilization in Free-Ranging Apennine Wolves (Canis lupus italicus).",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 4",
    "outcome_summary": null,
    "doi": "10.3390/ani16111735",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42278167/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4c6c77a9e3194c713e50b678885d6ba0bddbda9d58fb284e337481d1f5676d74",
    "title": "Glaucoma in a Siberian Tiger (Panthera tigris altaica) Maintained Under Human Care: A Case Report.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.3390/ani16111647",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42278081/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "88edabfa770a38245fc2cbbbd762f9122594bdfae6df3f7d18d09480d02c2841",
    "title": "Telehealth-supported ketamine for depression and anxiety: A systematic review.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1177/10398562261458880",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42277616/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "036fcb75956f5e76e4be23a79cbbaea9236f08f04778556296626c8d8efcd837",
    "title": "Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression.",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.phrs.2026.108290",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42276399/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "96b16601697c296a6fa62e4d7bfb2a065d67cbc0a3c4fe7e6c0d95c549189f59",
    "title": "A comparison of analgesia between ropivacaine and liposomal bupivacaine for the erector spinae plane block in dogs undergoing hemiaminectomy surgery.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 3",
    "outcome_summary": null,
    "doi": "10.1016/j.vaa.2026.101252",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42275766/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "dbc9414f45272ad81562aa0f60c226b73edf17f292ce60aa9f9caa017f385310",
    "title": "Comparison of the effects of two drug combinations: ropivacaine-dexmedetomidine and ropivacaine-ketamine administered subcutaneously for postoperative pain control in patients with inguinal hernia: a double-blind clinical trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1007/s10029-026-03653-3",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42274783/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "36cebb318464750033439bb678692b0396c31c2f10d16126b90e2a44bb3ea41d",
    "title": "Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jul",
    "outcome_summary": null,
    "doi": "10.1111/fcp.70095",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42274347/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "db601a87ffaf6dc071b666456f63b9906c7cb0ed68096cb9468631951958908a",
    "title": "Anthracaurisin A\u2500Discovery of a Cytotoxic Nor-Sesquiterpene Dimer from Patagonian Anthracophyllum discolor.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1021/acs.jnatprod.6c00531",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42273985/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "69c8b2d2c17a36add53ca43961c4e4aedc7b9aa9e6f80781916505945206c3a2",
    "title": "Ketamine-Assisted Psychotherapy for Depression: A Survey of Current Practices, Rationales, and Future Directions.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1080/02791072.2026.2685515",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42272233/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "af62ccfa7d28ae37d80bd6d70b5377c257ba5128f6f2598cb44a043115245472",
    "title": "LFM-pilot-based localization and monitoring of multiple-spot multipath interference in discrete multitone systems.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.1364/OE.587061",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42271938/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1945cead2ab7790a7be9351061e38dccd9eb4d06e90c18ef9277cd3858887d6c",
    "title": "Dreaming during anaesthesia: a scoping review.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.bja.2026.05.002",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42270528/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9e2040095db9a238e16ba522a3ad999c4afe86f6d0c253e42cb6d9b5e0621b3c",
    "title": "Letter to the Editor: Esketamine in treatment-resistant depression: Beyond symptom reduction toward psychopathological network reorganization.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.1016/j.ajp.2026.105044",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42269353/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f36aa8d30fe3650b1dac6a771d6c18352e65ef2905ae6dad5d32bdaf70632392",
    "title": "Shifting Patterns in Ecstasy Use: Increasing Detection of MDA in Forensic Seizures and Toxicological Cases in Southern Brazil.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1080/02791072.2026.2686365",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42267710/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "535281a02cd870451224a6e7ac429f0f6151f41dfc5ce5403a4a5f8e07246400",
    "title": "Electroconvulsive Therapy and Ketamine Infusion in Patients with Bipolar I or II Depression: A Case Series.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.64719/pb.18534",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42267236/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "858f856f397b5f02d8d27381d05013f2395d6137e7eae74b233d6008324d8fb8",
    "title": "GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 5",
    "outcome_summary": null,
    "doi": "10.64719/pb.18507",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42267234/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5f23540c679a068321738fb4371969c52d90ee34abade021981d1082ca7c0c85",
    "title": "Rural-Urban Disparities in Access to Interventional Psychiatry Treatments among VA Patients.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1037/rmh0000333",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42267190/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "201a1e22229afb683a699d8009a3f551471c64f7b0e79341a8ed978625dfc7b6",
    "title": "Nationwide trends in intravenous sedative and analgesic drug use in Korean dental institutions: a big data analysis using the Narcotics Information Management System from 2020 to 2024.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.17245/jdapm.2026.26.085",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42266418/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "cacef88ee96b9897fabe9cb5e9d25089042e297375ee0e9ba7bda16580b9c4b7",
    "title": "The entropic brain today.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1093/brain/awag206",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42266156/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "20364209620f26811ffd4e23f7b1b2c787ffb738ece19fec01315bacf3d4fd00",
    "title": "Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1192/j.eurpsy.2026.12233",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42266089/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c88e9ee92b4ad327d13c30bca540be8397b9c9c8fb25a49f73ca2a963779b725",
    "title": "The effects of psychedelics on attention deficit and hyperactivity disorder - a systematic review.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1017/neu.2026.10088",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42265057/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5a8f314417cc3181d3e6335dcfafa30e49dca004758f824a04a45def75e9cae6",
    "title": "Atomic insights into the physiological and functional diversity of NMDA receptors.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 9",
    "outcome_summary": null,
    "doi": "10.1016/j.tins.2026.05.004",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42265035/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f90d5ba72b5c93583630b6f2ccc0ce399f20327efe5e53cfa67077e4d4e1b719",
    "title": "Ultrasound guided bilateral superficial cervical plexus block versus intravenous ketamine and dexmedetomidine infusion as opioid sparing analgesia for upper tracheal resection and reconstruction surgeries: a randomized comparative study.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 9",
    "outcome_summary": null,
    "doi": "10.1080/17581869.2026.2685605",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42264928/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "7151dac5864e3a7f421e75259733c06d287d2525979a51e7f39f3a3a0a95208c",
    "title": "Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 8",
    "outcome_summary": null,
    "doi": "10.1016/j.jad.2026.122106",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42264307/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "dcb74848100e63f4bfdac64609288b30c466c3e15199b4a435e28c4efdca8f57",
    "title": "Intranasal ketamine versus intravenous opioids for acute pain in the emergency department: A scoping review.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 2",
    "outcome_summary": null,
    "doi": "10.1016/j.ajem.2026.06.002",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42263334/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "ca6465dfc4e546ab35cc9a671998c84b3d46559980e2f7d211d226b879cdc128",
    "title": "Impact of ideal vs actual body weight on analgesic and sedative requirements in critically ill patients with obesity.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 9",
    "outcome_summary": null,
    "doi": "10.1093/ajhp/zxag159",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42262836/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "ea903a542f0c8139f074bfaf1cae0e4f0d24e3a00c872e36b44c4b8470cba77d",
    "title": "Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 9",
    "outcome_summary": null,
    "doi": "10.1007/s00415-026-13909-8",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42262609/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "45c388e57c7dfb2b05eb54dad73d208cfb549ae76c2b8d75214ee4c7263912ec",
    "title": "Alcohol consumption and substance use among French medical students: A nationwide cross-sectional study: Consommation d'alcool et de substances chez les \u00e9tudiants en m\u00e9decine de France : une \u00e9tude transversale nationale.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 9",
    "outcome_summary": null,
    "doi": "10.1177/07067437261457220",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42262154/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b15e3c5d57449d22919d9dd55ba9571f0dd2d244617fcf41d4404371109fab34",
    "title": "A Study on the ED90 of Esketamine Combined with Ropivacaine for Early Epidural Analgesia During the First Stage of Labor in Nulliparous Women: A Randomized, Sequential Dose-Finding Trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.2147/IJWH.S608041",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42261465/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c1b1451d94a1c5d2e85e21cfddab61fcd39ab4b59e559517237ac58621645cb1",
    "title": "Investigation of Esketamine Administration During Surgical Procedures for the Alleviation of Postoperative Anxiety and Depression in Adolescent Patients: A Randomized Controlled Trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.2147/DDDT.S587626",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42261442/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e20983c43f03ad94d55c8d4bddcff82743cb9f64640149bba9426c27a7cb8bee",
    "title": "Esketamine Accelerates Emergence from Propofol Anesthesia in Patients Undergoing Laparoscopic Gynecological Surgery: A Randomized Controlled Trial.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.2147/DDDT.S608572",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42261441/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "dd895a2979a0b44a843aacfa43f41971967252f6ecaf3c1c40b9f63e86643824",
    "title": "Comparing transcranial magnetic stimulation and esketamine treatment response trajectories in resistant depression.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 7",
    "outcome_summary": null,
    "doi": "10.1016/j.jad.2026.122107",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42259490/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "ed012bb303b0e8976be38b84a70c767ca7affa12f72f68288e9a410fbe35a1d1",
    "title": "Direct and indirect associations linking COVID-19 severity to internalizing disorders and symptoms among participants in New Haven, CT.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 7",
    "outcome_summary": null,
    "doi": "10.1016/j.jad.2026.122082",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42259487/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "7ef88aecabc981a8f87e4ad805b1759f4668c1c372258a17104ead02a530a65f",
    "title": "From psychache to neuroplasticity: A unified rescue-repair model of Ketamine's anti-suicidal action.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 7",
    "outcome_summary": null,
    "doi": "10.1016/j.neubiorev.2026.106804",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42259434/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "7ff21c4b56c7216afbdbf251dc58fcbb09a92931558ab2bfc14326aa41b9951c",
    "title": "The transcription factor LSD-one-like 2 binds to a novel identified cis-element LBE (GCCAAAAC) and regulates molecular response of Populus davidiana\u00d7P. bolleana to salt stress.",
    "compound": "lsd",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 7",
    "outcome_summary": null,
    "doi": "10.1016/j.ijbiomac.2026.152915",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42259417/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "493e4e0936091331ab6868ee11e00f8b65828345572f0d8c211b02b38794e1a7",
    "title": "[Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects].",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 8",
    "outcome_summary": null,
    "doi": "10.1055/a-2846-4275",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42259381/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4af22c9ba0953e708e2d4ccba41730583fecc889954fef3bc919f1da92df37f2",
    "title": "Efficacy and safety of perioperative esketamine in improving postoperative sleep disturbances: A systematic review and meta-analysis.",
    "compound": "ketamine",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 8",
    "outcome_summary": null,
    "doi": "10.1016/j.jclinane.2026.112246",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42259161/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0ce48cff1dd1de7cb6cdc2768e2d863344be91894b4e2d4b5e65718f09a7ffe2",
    "title": "Non-Opioid Pharmaceutical Alternatives for Acute Pain Management in the Emergency Department: A Scoping Review.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 1",
    "outcome_summary": null,
    "doi": "10.5811/westjem.47925",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42258864/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0966156f21f0b405df961d4074e49eaf02294a85dcb7f0038004a12ffc90b4b8",
    "title": "Psychedelics disrupt hierarchical cortical propagations in the default mode network of humans and mice.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1073/pnas.2522000123",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42258710/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f9d21e0312faf1a730cbed9ecf09db3029d58d501dc78257102701aa7df650c7",
    "title": "Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.",
    "compound": "other",
    "type": "meta_analysis",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 8",
    "outcome_summary": null,
    "doi": "10.1021/acschemneuro.6c00202",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42257400/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e159ab75bf754b2c05186bc2e79d5d30e9cc7890e27d22971bc0e09d5f05ce9d",
    "title": "Effect of Niacin Supplementation During In Vitro Maturation on Fertilization Rate and Mitochondrial Competence of Vitrified and Nonvitrified Bovine Oocytes.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1155/vmi/9027270",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42257056/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4ceeae995b8c916127be544b030e8aac68a6f294390d021d8dd70ee05fe1f1a2",
    "title": "Severe Hyponatremic Encephalopathy Induced by Unsupervised \"Therapeutic\" 3,4-Methylenedioxymethamphetamine Use in a 55-Year-Old Woman: A Diagnostic Pitfall.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May",
    "outcome_summary": null,
    "doi": "10.7759/cureus.108360",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42255873/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "52fdb77a4b5d6812fd2bcc65a91b467cca825f424c083fb2a2a466bf983e8e52",
    "title": "Computational spirits: a neuroscientific account of psychedelic entity encounters.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.1093/nc/niaf069",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42255330/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f464b44def5660a1d546d920e9a7407df0f1ae5e05f3040c98b9ccc3d4995f9d",
    "title": "Research on the application of tree drawing projection tests in the condition assessment of depression.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "depression",
    "sample_size": null,
    "status": "published",
    "date": "2026",
    "outcome_summary": null,
    "doi": "10.3389/fpsyt.2026.1794378",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42254734/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "ba4eadb4f27ceb2bf7e773315b754253b07448450a8667056c99d7fcf79d95c0",
    "title": "Anti-inflammatory and antioxidative stress effects of Sclerocarya birrea (Anacardiaceae) trunk bark aqueous extract on acetic acid-induced ulcerative colitis in rats.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1097/MS9.0000000000005042",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42254229/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d099c1e38876c4f90db4c72ccad67d1cd43002ba5a56946bc5f3693a581ec08e",
    "title": "Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy.",
    "compound": "mdma",
    "type": "phase_2",
    "institution": null,
    "condition": "anxiety",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun",
    "outcome_summary": null,
    "doi": "10.1097/MS9.0000000000004936",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42254210/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "02ceda91b8b5fcbf628139cc3d19fa073d852717f917ce3b718c037089084e32",
    "title": "The Interplay of Neighborhood Deprivation, Race, and Multiple Sclerosis.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jan",
    "outcome_summary": null,
    "doi": "10.18865/EthnDis-2025-12",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42253514/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "585ee9c26cc79315fa94bfdf443167dc95261cb80e33becde25d2987e86108dc",
    "title": "Role of accumbens medium spiny neurons subtypes in reinstatement to ketamine cues in male and female Long Evans rats.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 6",
    "outcome_summary": null,
    "doi": "10.1016/j.neuropharm.2026.111067",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42252079/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d8fc9dd0ef8f0d02e738e1f33e01f116837d651bd013237bb0858cf372529b98",
    "title": "Mandibular bone microarchitecture in patients with multiple sclerosis: A fractal analysis study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1016/j.jormas.2026.102862",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42229719/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "34a42e3d1a9ee006e208305f729d27d8c08ec78669caeecd38fe3df1ab11274e",
    "title": "Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [(18)F]FDG-PET study.",
    "compound": "other",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 Jun 1",
    "outcome_summary": null,
    "doi": "10.1177/0271678X261454172",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42220002/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a46652544f82667b0ddea75215022287a1fc9c96ecdb9019e79dc80968bc4dcb",
    "title": "Creating an opportunity in status epilepticus management through EEG monitoring and the use of ketamine. A case report.",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": null,
    "condition": "other",
    "sample_size": null,
    "status": "published",
    "date": "2026 May 2",
    "outcome_summary": null,
    "doi": "10.1016/j.nrleng.2026.501951",
    "url": "https://pubmed.ncbi.nlm.nih.gov/42190801/",
    "source": "PubMed",
    "first_seen": "2026-06-15"
  },
  {
    "id": "83f93b50182c14d4b593810a39ec4fa6671ef461bb80cd88a37cf67b55816f2c",
    "title": "Safety for Home Administration of Microdose Psilocybin Use",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2024-12-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06450210",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e633b408384ee15cd5594f206ff7b631c65d635704b2113da2119d33f94336a7",
    "title": "The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "PTSD",
    "sample_size": 22,
    "status": "completed",
    "date": "2022-06-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05312151",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "16d316e9c73f84a519ccd7b293debbfb1761fd716e3d6d1f1ed2fb616301f118",
    "title": "Psilocybin Therapy for Depression in Parkinson's Disease",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Joshua Woolley, MD, PhD",
    "condition": "depression",
    "sample_size": 60,
    "status": "recruiting",
    "date": "2024-08-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06455293",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e9f783db30be4d63cc2cb85713ad116bcdbf4f4a86d9f1ecb04c83937659a4ee",
    "title": "Mindfulness-based Psilocybin Therapy for PTSD",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Anthony P King",
    "condition": "depression",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2026-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07104916",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "fd41bf9e280ffbe795c48b004312dc3509570c4d9f1df7fcdd734b9c3fc08eb7",
    "title": "Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "recruiting",
    "date": "2025-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06899334",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e65ebf5b798fff3ccc1028838b323e9f3f963fa426d0416f3d3c7ac429606c59",
    "title": "Comparing the Effects of Psilocin and Psilocybin in Healthy Adults",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of California, San Francisco",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2022-05-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05317689",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1684d3787f6780fb1bcfaafa097b28d84cf315d71ed7b5ee1446249eb635e7c6",
    "title": "Psilocybin Administration With 5-HT1a Blockade",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 18,
    "status": "recruiting",
    "date": "2026-06-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07565493",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "945c289db2086f596df349b7f1cf71bbdd305b985731fc31acd5471216a8a709",
    "title": "Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "other",
    "sample_size": 12,
    "status": "recruiting",
    "date": "2025-05-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06160284",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "415b86e713e5f116a0c7d4d429a69e4caabc59ac912820f7c5aa9d97bcade36f",
    "title": "Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2025-08-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06349083",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4cb5bf2decf75858b4139a50d1044d9c162e9a0089f2be60b339508175f89d82",
    "title": "TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "M.D. Anderson Cancer Center",
    "condition": "depression",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-05-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06801041",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "22895dc288cfd3e4a03805c4ee922db7d5ffe05a7d8d2a201c7ff5073d67dd8f",
    "title": "Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder",
    "compound": "psilocybin",
    "type": "phase_3",
    "institution": "Lakshmi N Yatham",
    "condition": "depression",
    "sample_size": 90,
    "status": "recruiting",
    "date": "2026-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06943573",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "33c2003c8bf3588fa79b2cbbb6089f2b0458f433c3220aac76ab3cb1b81910a7",
    "title": "Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Washington",
    "condition": "anxiety",
    "sample_size": 55,
    "status": "completed",
    "date": "2023-06-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05847686",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a07c8432cf49d9ef4b17eb70e2acfe59ad8d79690336df10d072d62dbc0931cd",
    "title": "Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 25,
    "status": "recruiting",
    "date": "2026-01-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07296328",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e5a58bdf9f4bbfb1cb4d87973c44537f09321c1a102352f70dee1498ae670992",
    "title": "Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Yale University",
    "condition": "other",
    "sample_size": 45,
    "status": "recruiting",
    "date": "2026-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07306364",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a8a499557342c109e5b6f140e90b6030a40935ae683df7430b86cd16aaf62892",
    "title": "Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University Health Network, Toronto",
    "condition": "depression",
    "sample_size": 92,
    "status": "recruiting",
    "date": "2024-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06341426",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0fa9221feab81d9094869075c85670a72a6e960c5392faa43df9bd512df6f094",
    "title": "Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2022-08-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05548075",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d01043d390475387ae16a785ee1e300dd260bbd2c2fafdf8984ec23e7b6200d9",
    "title": "Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Joshua Woolley, MD, PhD",
    "condition": "depression",
    "sample_size": 12,
    "status": "completed",
    "date": "2021-08-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04932434",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c5947c5e7469154fc44cc2fca46107282735d12d00a156cfcecf0b696e096d0d",
    "title": "Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 10,
    "status": "completed",
    "date": "2013-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01988311",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "6d73123254183ff7b4c49ca550414a980b2a2881107e538773311ad1b77bd7c5",
    "title": "Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2025-09-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06989957",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4cb627c3c5186a76db48c5b2b1d2862340a1df55325b8a6ceef78924acc5f4af",
    "title": "Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "eating_disorder",
    "sample_size": 32,
    "status": "completed",
    "date": "2022-10-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05481736",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0e47d3c93ff97965d347e488f1fa10689778544f2ab6e109dce23e893505b648",
    "title": "Psilocybin for Treatment of Obsessive Compulsive Disorder",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Arizona",
    "condition": "OCD",
    "sample_size": 15,
    "status": "completed",
    "date": "2019-01-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03300947",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9a5222e924ecca59bcbdbd487338ebf1307e293d9d93d95b92cb8faa1f750ae0",
    "title": "Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "recruiting",
    "date": "2025-04-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06884514",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9ac193a74ddbd082ab416e4fa2c1d738ca0433dc9e1cae7a1ee12a1558790623",
    "title": "Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Khyber Medical University Peshawar",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2024-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06746441",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b28f3a652c5669ea4ae7b1e1c40766f4f45647af8c4e77d47e593b27f6074cf2",
    "title": "Psilocybin Brain Stimulation and Imaging Pilot Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 15,
    "status": "active",
    "date": "2025-04-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06835699",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "57c7d8a996201b93e7631dc296f2b63fab613a37837abd985478bcc236f64be7",
    "title": "Northwest Therapies Trauma Psilocybin Study Compassionate Use Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "NWTraumatherapies",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2023-09-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042466",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4ddbc53fdc194317d9993a19e210faf1a909c2da66faaa5bbb89b39bc00063ed",
    "title": "Psilocybin rTMS for Treatment Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "University of Texas at Austin",
    "condition": "depression",
    "sample_size": 100,
    "status": "recruiting",
    "date": "2025-01-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06132178",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4fc537d1dce536c7fba10f7fb686916cb58f9c9fe8720673c88c101438323791",
    "title": "Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "University of Utah",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2021-10-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04522804",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e6fc17d75eaca878e0177535feb470188435ca67804e7dcfc3be76c281df8add",
    "title": "Psilocybin to Treat Depression in Spinal Cord Injury",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "James J. Peters Veterans Affairs Medical Center",
    "condition": "depression",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2026-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07251491",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "683ceb3e50d828a42b18f8585a600c746df32801574928e1b3eb411cfc5cda91",
    "title": "Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Centre for Addiction and Mental Health",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2026-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07405606",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "6171b9c4507c0e5533a68ec214d9227edc946fb5c87462d98ed1993d05ea4056",
    "title": "Group PACBT for Depression",
    "compound": "other",
    "type": "phase_2",
    "institution": "University of California, Los Angeles",
    "condition": "depression",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2027-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07566104",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2a13a1c0367eedae5de056b691c36361126a2d8852dd453e037683fb0831d644",
    "title": "Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Cybin IRL Limited",
    "condition": "other",
    "sample_size": 468,
    "status": "recruiting",
    "date": "2025-07-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06605105",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "88e91e04f7e4d8d5f2d4e03ab92f2980eec6b9332ebc95a97b77e8bdba911866",
    "title": "Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Healing Advocacy Fund",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2025-03-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189988",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "89d02b155a2a71aa3d071df29946dd71ea914e087b488fff70aafe65ad361cba",
    "title": "Effect of SSRIs on Response to Psilocybin Therapy",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Cybin Therapeutics Inc.",
    "condition": "depression",
    "sample_size": 0,
    "status": "completed",
    "date": "2023-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05594667",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a2d52e79168f498aee4119ecf13b76363514739410be1e5af43cc7ec072652e7",
    "title": "Psilocybin Microdosing on Cognition, Mood and Quality of Life",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Yale University",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2026-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07449351",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c0ddf47e440b6475bf79d104e96436fe4f9e81ea74b5fe4e61dec2e73b096b1c",
    "title": "Psilocybin for Major Depressive Disorder",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Washington University School of Medicine",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05675800",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e9bac97fc602026e893c68a587b619ea94cb799c6465f43f2463d04b65c9522b",
    "title": "Psilocybin and Spiritual Practice",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 75,
    "status": "completed",
    "date": "2009-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00802282",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0979181b3d75e05cf6d5608317071c8b1c350c0b06091fafd8ac53cd64ac05b5",
    "title": "Effects of Psilocybin in Concussion Headache",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Yale University",
    "condition": "PTSD",
    "sample_size": 12,
    "status": "completed",
    "date": "2019-03-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03806985",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5d1572b60df5f484768bca301db90817c9e6d0828bf1bdb8698067c4a1ffc00d",
    "title": "Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of California, Berkeley",
    "condition": "other",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2025-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06367738",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "596b9cc8beb771ea1fbb494a1547e12f6b8022b9301f22f119787a8fcd14e8c0",
    "title": "Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "Region Skane",
    "condition": "eating_disorder",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2026-04-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07169747",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4f3bfb9c5d0e63ff6e5c7c92a4f64e528789a6847ba481e14e15d030a08d9d02",
    "title": "Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Johns Hopkins University",
    "condition": "depression",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2021-03-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04123314",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "8de25b1ffea26c436fbde82ad28fd479c38122eeac588c82bda987f0b5d8f144",
    "title": "Psilocybin for Opioid Use Disorder (OUD)",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "NYU Langone Health",
    "condition": "other",
    "sample_size": 480,
    "status": "recruiting",
    "date": "2025-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06796062",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "892e62fd6c33709e29e5804f74b1933643b5455896733c84ac17b499c4dfc3ef",
    "title": "Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Emory University",
    "condition": "other",
    "sample_size": 11,
    "status": "completed",
    "date": "2022-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05506982",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "8b56539b8fdc569c6c215f9bd8ea7112f98a2e9954f0a67302dc320ef18ec0c4",
    "title": "Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "recruiting",
    "date": "2025-04-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06796361",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "92d09b8b75f129c8ae20427c545109626fa173f44474888df6967be2488096eb",
    "title": "Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self",
    "compound": "other",
    "type": "observational",
    "institution": "University of Zurich",
    "condition": "other",
    "sample_size": 140,
    "status": "completed",
    "date": "2013-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03736980",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1fd4819fe9d4b162d6ede278c1b3eea589d9aa6a527e057c689d5035263e3bca",
    "title": "Low-Income Group Psilocybin Assisted Therapy for Depression",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "Matthew Hicks",
    "condition": "depression",
    "sample_size": 20,
    "status": "completed",
    "date": "2024-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06372197",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "73b35e00ab6f675fc1b13e78eec1733055f6cd2fda7d389bb52461f22dcb901e",
    "title": "Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Zurich",
    "condition": "other",
    "sample_size": 122,
    "status": "completed",
    "date": "2023-10-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06081179",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0185a2514e7c423c9635b37e3898cff24c0d3315a7439c0fd23218219ef26c70",
    "title": "Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)",
    "compound": "other",
    "type": "phase_1",
    "institution": "Beckley Psytech Limited",
    "condition": "other",
    "sample_size": 4,
    "status": "completed",
    "date": "2021-08-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04905121",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "7f6d72d5a41991625da15ec6011b4185ce13c9d6cd5f2acde9aa991e72909176",
    "title": "UW Psilocybin Pharmacokinetics Study",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University of Wisconsin, Madison",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02163707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "fcdc999453f954abf2c2e3649ab675159804f8cdcf40d027a544eee5c48bf0fe",
    "title": "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression",
    "compound": "psilocybin",
    "type": "phase_2",
    "institution": "COMPASS Pathways",
    "condition": "depression",
    "sample_size": 19,
    "status": "completed",
    "date": "2020-08-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04739865",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2131bcc12dee58da30e51ca09a469bee2b4d894cb77a03b9ccfcd55a372217e6",
    "title": "MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 23,
    "status": "completed",
    "date": "2004-03-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00090064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "15e5340737b93d1b415aa6ce611ebbf0f085f3c3b328b92e5e73cc0032a7c26c",
    "title": "Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2011-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01270672",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c01af4135d88798058570f3ca6771076978eb03993a11279a420199a42344787",
    "title": "Food Effects on Bioavailability of MDMA in Healthy Volunteers",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 14,
    "status": "completed",
    "date": "2022-07-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05147402",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0583804efaffeb7efed5adc5491d1e82c53af68b6ead475c2f7df9d35a1e3812",
    "title": "Social Anxiety MDMA-Assisted Therapy Investigation",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Jason B Luoma",
    "condition": "anxiety",
    "sample_size": 90,
    "status": "completed",
    "date": "2022-04-13",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05138068",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4f6d398cfcd545da897667ad6652d569a891fcf92da4bf781f660b02a67f0803",
    "title": "Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 26,
    "status": "completed",
    "date": "2025-07-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06905652",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "da400b627f5d647d623a6b134840f4fa13e01f4399866a0e749adc46266583bc",
    "title": "Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)",
    "compound": "other",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2009-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00886886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5065b23908e2a81ea0fae03cdf18d7802a5fe69f1f51cbc7ce8a2af0f843d924",
    "title": "MDMA Assisted Therapy for BN",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Icahn School of Medicine at Mount Sinai",
    "condition": "eating_disorder",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2026-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07542145",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "74802fb72a060af00dd07822e3c77901e0ab0530a6f3162b236895a7742098a4",
    "title": "Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2019-10-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03527316",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f869dd6b51ccb38289262551d1b4485da022267cd997af803f9b7e7efebdcdae",
    "title": "Correlates of Anxiety Associated With a Life-threatening Illness",
    "compound": "other",
    "type": "observational",
    "institution": "Resilient Pharmaceuticals",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2015-11-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02954562",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "90978d8e5c174ebfeabfc56dc427a9412f97577d9ff9d98e019a5c79741cbeac",
    "title": "Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy",
    "compound": "mdma",
    "type": "observational",
    "institution": "Apollo Neuroscience, Inc.",
    "condition": "PTSD",
    "sample_size": 200,
    "status": "active",
    "date": "2021-12-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05274230",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a9b1a611bff207020d3c16884410438bea1b6d075fc9e834132f58ae58ae0867",
    "title": "A Phase 2A Trial of DT402 for Autism Spectrum Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07303907",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d685e6acf4bd8dd58048357f22c71678f514c6e2e677c43b17ef54db2b84984e",
    "title": "Role of Serotonin in Acute and Subacute MDMA Effects",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 13,
    "status": "completed",
    "date": "2009-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00838305",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "860334cd5527cf395ac3a8301d1d7efef5cd7259b6dfac894769c7563f8c8365",
    "title": "Neurobiology and Pharmacokinets of Acute MDMA Administration",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "National Institute on Drug Abuse (NIDA)",
    "condition": "other",
    "sample_size": 187,
    "status": "completed",
    "date": "2004-02-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01148342",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0edd5645e3be7aefe0da8fe089f0a5ba403e4960bb4ff5c86b3335515180e57a",
    "title": "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 100,
    "status": "completed",
    "date": "2018-11-21",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03537014",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "878d9ef4fb070d6353e40ebb0e092d0fe2e6713cdb13163f4a39932e64ed8e50",
    "title": "Naturalistic Study Into the Hangover Effects of MDMA",
    "compound": "mdma",
    "type": "observational",
    "institution": "Utrecht Institute for Pharmaceutical Sciences",
    "condition": "other",
    "sample_size": 39,
    "status": "completed",
    "date": "2010-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01400204",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5c9279f4bc35d3b7ff3ecdc94f36dc308a2a846981ece3b59b17ab556ed473f3",
    "title": "Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 5,
    "status": "completed",
    "date": "2007-05-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00402298",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5f0930ad35cc18b10cc75ad3f33e23ad725e5007927edb8a4650b9795e732b66",
    "title": "Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04968938",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "99c279d4dc9fda27141810db08738ec649b0b9c59456067972c34e99c73b0371",
    "title": "MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Resilient Pharmaceuticals",
    "condition": "other",
    "sample_size": 16,
    "status": "recruiting",
    "date": "2026-03-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03606538",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "34bc10966fbeed38419f7b9bf134a539a67fb8ce52f5e3381ce07b00a8aa1b25",
    "title": "Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 38,
    "status": "completed",
    "date": "2017-11-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03282123",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c9432d414b8cf0f55b590ea1f21212fad5957b25b7642f2cda9f63c9f470f1f1",
    "title": "Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging",
    "compound": "mdma",
    "type": "observational",
    "institution": "University of Zurich",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2006-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01296802",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "15ac818ec6fe8ed39b04a3da549913d427965c0e71765dd1cac6e39b532791ff",
    "title": "Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "HaEmek Medical Center, Israel",
    "condition": "PTSD",
    "sample_size": 60,
    "status": "active",
    "date": "2023-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05732155",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a73eac86084ab616e6962cb081938284f0b91356d2d895d729285d574f82ca91",
    "title": "Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "Herzog Hospital",
    "condition": "PTSD",
    "sample_size": 60,
    "status": "recruiting",
    "date": "2024-02-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06394284",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d9b6cafa6ca3aa45f907bf6c7bf65c6d60a119e7c43cb249308b95312c654771",
    "title": "Abuse Liability and Human Pharmacology of Mephedrone",
    "compound": "other",
    "type": "phase_1",
    "institution": "Parc de Salut Mar",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02232789",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "3f074b084e31a218b33a127e5bc64bd2f9bcbf8195810856fb46f78f7aa536e6",
    "title": "Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2023-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05523401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "54d59639e7c54caddbc0524ef0aa7c22b300d1b915b7630563bd6dd8482cfc3e",
    "title": "Epigenetics and MDMA-Assisted Psychotherapy for PTSD",
    "compound": "mdma",
    "type": "phase_3",
    "institution": "University of Southern California",
    "condition": "PTSD",
    "sample_size": 45,
    "status": "completed",
    "date": "2018-11-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06189027",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "84c6c6db07c7da18eb80bbc858fcc403bd74325eb841e435db0bbe8ed58b1823",
    "title": "Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2021-02-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04648137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e2daf8a4cd16d31950e31fc1257394c2a5daf3fe085369fcd8f27bdef435bdca",
    "title": "Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2014-04-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02008396",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d6eef33a2b64a54c43fcf6e4ed55d8d58a0508ed61209628b2edb3aa20658621",
    "title": "Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2013-01-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01689740",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1515e96069ff1b97e044939493f4735f4044d10159af0998abbcf94251491adc",
    "title": "MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "VA Loma Linda Health Care System",
    "condition": "PTSD",
    "sample_size": 5,
    "status": "completed",
    "date": "2021-07-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04264026",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e9b82f8ceed1a13765621a81bc6618074e5952e149c165bf88fe4ff9b077cd05",
    "title": "Drug Effects on Interpersonal Interaction",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2021-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05123716",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e4cc66db6f279affc60b931eb585dd422962c97bcd051270e0f474d6c11797bc",
    "title": "A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": null,
    "status": "active",
    "date": "2026-06-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04438512",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "444cabca36f00025435ed16aa524e3a45dff5de39d11570b28109e6feecda35a",
    "title": "Tolerability of MDMA in Schizophrenia",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Anya Bershad, MD, PhD",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05770375",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b6d1ff8fdcd8c7ec6baee2a8abcbe5bb365869aa3c5c8e2db4ab8ebef9768278",
    "title": "A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Remedy",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "completed",
    "date": "2021-10-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05067244",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a4943b4dbc18ffcc90fa185756fd5e2b79127ca24085630b342c971449566c55",
    "title": "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.",
    "compound": "mdma",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01053403",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1ca32816b85bafc888e326e0218cbf371685610a70376aea23fae8cb38a1c596",
    "title": "Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 43,
    "status": "completed",
    "date": "2022-05-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05379959",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "8eef2ba5573db5dfa73e93515f6ca17d5593d743b7473949817240bfab472cae",
    "title": "MDMA for Co-occurring PTSD and OUD After Childbirth",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "University of New Mexico",
    "condition": "PTSD",
    "sample_size": 15,
    "status": "recruiting",
    "date": "2024-04-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05219175",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "dc551d993d78b5db509f9d7f9ed14b656c764da76242949d6ee1aca53947b84c",
    "title": "Stanford Regulating Circuits of the Brain Study - MDMA",
    "compound": "mdma",
    "type": "observational",
    "institution": "Stanford University",
    "condition": "other",
    "sample_size": 22,
    "status": "completed",
    "date": "2021-11-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04060108",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d5d1a5d4e502a7ce4407a43417f73e89b22547985ccd7917e57471f56bbeec97",
    "title": "Abuse Potential and Human Pharmacology of Methylone",
    "compound": "other",
    "type": "phase_1",
    "institution": "Germans Trias i Pujol Hospital",
    "condition": "addiction",
    "sample_size": 17,
    "status": "active",
    "date": "2021-12-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05488171",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4e5a6d3d014e2349cacc6541ba0cd4c3964020d3ef89ea13c961ae8e6fb2966c",
    "title": "Bristol Imperial MDMA in Alcoholism Study",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "Imperial College London",
    "condition": "other",
    "sample_size": 20,
    "status": "active",
    "date": "2018-04-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04158778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "3c1cd0a852105d4a2586c3e77a76c58f52f982ace9a6016e88b77a133012eafd",
    "title": "Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls",
    "compound": "mdma",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "recruiting",
    "date": "2025-01-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06789705",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2fc4d578b33de3ca5a0ce4aaa461f1017ed82e8ad0951abf468e51e73df7aba2",
    "title": "Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Resilient Pharmaceuticals",
    "condition": "PTSD",
    "sample_size": 186,
    "status": "completed",
    "date": "2021-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05066282",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a17a3aee00b4a10000150319948cb364ea5b69cc4d68366323ea48ba2b961f02",
    "title": "Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD",
    "compound": "mdma",
    "type": "observational",
    "institution": "Albany Research Institute, Inc.",
    "condition": "PTSD",
    "sample_size": 30,
    "status": "completed",
    "date": "2022-08-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05895318",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b02e3987a5f89afca8abd6fb9b8b198331ae559a1004f5431e31508d146c720a",
    "title": "Personality and Drug Use (PDU)",
    "compound": "other",
    "type": "observational",
    "institution": "Quantified Citizen Technologies Inc.",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2022-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05180149",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "231a49b1abfa187811e27065e68b927f4676e19e0d0a71abdd2a011565ed2135",
    "title": "MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder",
    "compound": "mdma",
    "type": "phase_2",
    "institution": "Stephen Robert Marder",
    "condition": "other",
    "sample_size": 40,
    "status": "recruiting",
    "date": "2025-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05790239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "3be007c1650b1800e91910ce4760b30cdf929a109655018071a54f200fc5a058",
    "title": "Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]",
    "compound": "other",
    "type": "observational",
    "institution": "California Pacific Medical Center Research Institute",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2009-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00823407",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f0a79d61e82f10e7d0b279d63362b8ba9ebfc59cc1732d05d4b688a3370794b6",
    "title": "A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_3",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 177,
    "status": "completed",
    "date": "2011-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01275066",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "94bb831e6adf7eb9a026a30b4c440806f9c00ca5f56a0a987b60aca4c2f8d35a",
    "title": "A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 149,
    "status": "active",
    "date": "2025-04-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06941844",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "8058d2ca808d26603604e926266111bf81cf18209823fa19bf7cc49e86dfdde9",
    "title": "Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD",
    "compound": "lsd",
    "type": "observational",
    "institution": "Northern Jiangsu People's Hospital",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2026-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07461532",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "cd0c381174ece3afbd801dc104b49f80f4ec7242d1d9ac639e222d1b1292fbbf",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 214,
    "status": "active",
    "date": "2024-12-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06741228",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "47a6c822f43008882c9d5d64be719bb39c588abc2aca9972e5fc26e7b495f90b",
    "title": "A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C",
    "compound": "other",
    "type": "observational",
    "institution": "ZevraDenmark",
    "condition": "other",
    "sample_size": 35,
    "status": "completed",
    "date": "2015-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02435030",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "751b28b94f47f6b99e30dfb7f181bede6487f71008537bbee0ed7aa62409ab21",
    "title": "Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders",
    "compound": "other",
    "type": "observational",
    "institution": "Lysosomal and Rare Disorders Research and Treatment Center, Inc.",
    "condition": "other",
    "sample_size": 50,
    "status": "active",
    "date": "2018-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03812055",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b3fe699f8a0ee6195dac8ce4d01a88db754ab76ea6a197a9a5dff879525d7d95",
    "title": "A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "Amicus Therapeutics",
    "condition": "other",
    "sample_size": 31,
    "status": "completed",
    "date": "2014-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02082327",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "808949308380ca60c12d04a5092e821d8b25f9cbef618a04a0503960cefde90b",
    "title": "Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 15,
    "status": "completed",
    "date": "2011-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01515956",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2e1be2f7c0d7612bd8da838fd810d40aaa28a8313ea9b9fb7eaec762ccfb2f3e",
    "title": "Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2024-02-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05964647",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "016eba5535847db659689e61ee49762f398ceb5d8a024f65f510e3a15b877fea",
    "title": "The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers",
    "compound": "other",
    "type": "observational",
    "institution": "Psychiatric University Hospital, Zurich",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2015-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02451072",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f6a067ce7222f26c145dcea606c190f421c35ba1c5ee2a16f35abc88647c4c3e",
    "title": "A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA",
    "compound": "other",
    "type": "phase_1",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2009-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00884949",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "30392dbba9ef4eb3ecb081e9c621711c74e80d1c81be82aee28129c3f07161cc",
    "title": "Drug Effects on Mood and Behavior - Expectancy",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 48,
    "status": "recruiting",
    "date": "2025-06-26",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07061886",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "654d6b2f68a02d8bc8ef33fa9fcfb41f8dd8c49bc9fe45d5a7606cc1a8e82f01",
    "title": "Lysergic Acid Diethylamide (LSD) in Palliative Care",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "depression",
    "sample_size": 60,
    "status": "recruiting",
    "date": "2024-06-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05883540",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "80e028e9587252efd6f5e42d6856083775ee59842c5f3e1fe50e9c2aee2acfbd",
    "title": "Neuronal Correlates of Altered States of Consciousness",
    "compound": "other",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2014-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02308969",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "cc9dfece9ad9a0b569713c8a838fea1d8b289daa4905b4ba95f58fddfee938ad",
    "title": "A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Eleusis Therapeutics",
    "condition": "other",
    "sample_size": 48,
    "status": "completed",
    "date": "2015-06-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04421105",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "86362e364cf04e47e79c134ab037ce091060328fd086f973a664dfddc70038b6",
    "title": "BMN 110 US Expanded Access Program",
    "compound": "other",
    "type": "observational",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": null,
    "status": "active",
    "date": "2026-06-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01858103",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "10cf7c75d22e14dd1e9be237042a7c14ef41fab02c00a45cac341315bfbc7542",
    "title": "Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2017-11-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03321136",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9a38b7a92d0a75b7d5e7079cf80f37a82e1914f12f446dd12cbfb9a3cf1e65ec",
    "title": "Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2012-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01697319",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "29c8b897183f9c655d38fa5b1db57baca9cfd71c379712675c69d42cab21518f",
    "title": "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 245,
    "status": "active",
    "date": "2025-01-29",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06809595",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1004b9a4d9de9b98e86e84197a0b2c9d92562135c3e035d7e4c59828da438f8f",
    "title": "Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients",
    "compound": "other",
    "type": "phase_1",
    "institution": "Shire",
    "condition": "other",
    "sample_size": 12,
    "status": "completed",
    "date": "2010-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01155778",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "cd8d62c0476bb8042aa7d027738e3c83888dcc4b959f325fd5549c72aed26ab9",
    "title": "Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.",
    "compound": "other",
    "type": "observational",
    "institution": "St. Olavs Hospital",
    "condition": "other",
    "sample_size": 21,
    "status": "completed",
    "date": "2016-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02741622",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "458ca894e769fa8da1bb01d5d41d6b549e25daf68e07a75557a3471dd9969355",
    "title": "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome",
    "compound": "other",
    "type": "phase_2",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 25,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01609062",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "73bed01512b7023d428c09dc8e174e63d286758f14b0f711c3eaf844bdfbd07b",
    "title": "A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "anxiety",
    "sample_size": 198,
    "status": "completed",
    "date": "2022-08-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05407064",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "83c8d2e04842f495bd17374f048eb8dbb8448209c62653e87146224ae0d6e916",
    "title": "Effect of Ketanserin After LSD Administration",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2020-10-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04558294",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "80e773bb26f6578c589aaa5af277e2fb8dac1bdc99530e1ad90613eab959106e",
    "title": "Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin",
    "compound": "psilocybin",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 28,
    "status": "completed",
    "date": "2019-03-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03604744",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "166fb404e3c53c8cb3c8a162592f1d9d1cf6100405e4f8d2d425a837c9de55da",
    "title": "Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "Royan Institute",
    "condition": "other",
    "sample_size": 10,
    "status": "completed",
    "date": "2007-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00736307",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c546446c61ffc0705c106d184174e5c4cd0e345005ef0ab2daff7e8cf6f266fb",
    "title": "Mood Effects of Serotonin Agonists Extended",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 56,
    "status": "completed",
    "date": "2019-04-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03934710",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "606e3b093203f3a1d55ef82358a4cf4f20e5bdb6af1f1f9991716c3360003437",
    "title": "LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects",
    "compound": "lsd",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2022-03-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04865653",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e7b51d7e04a455af1a23fb01681267fa58ae30c36025327ad80ca5a56f230a9c",
    "title": "Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)",
    "compound": "other",
    "type": "phase_3",
    "institution": "BioMarin Pharmaceutical",
    "condition": "other",
    "sample_size": 173,
    "status": "completed",
    "date": "2011-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01415427",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "04b567b73cc555cafd6bf8721d9c81ecebddd45d1cadf9711e2179d19dd0c887",
    "title": "Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "Multidisciplinary Association for Psychedelic Studies",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2008-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00920387",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "76e09cfff4cf81307f63fe9b1d831be15def8d692c663c82d4f18fd6ebd942b8",
    "title": "Mood Effects of Serotonin Agonists: Depression",
    "compound": "other",
    "type": "observational",
    "institution": "University of Chicago",
    "condition": "depression",
    "sample_size": 48,
    "status": "recruiting",
    "date": "2025-06-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07017478",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "7c0a06ecf54c59a7c70e23261c156f5c9616b087b83da25a6cb17db838b707de",
    "title": "Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA",
    "compound": "other",
    "type": "phase_1",
    "institution": "Neutrolis",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2025-09-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07237659",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c54802f7bf8a1c20c3beecd067388e0774271a9ef258e8cfd3b423e86a456c18",
    "title": "MCR Syndrome in Quebec : Results From NuAge Study",
    "compound": "other",
    "type": "observational",
    "institution": "Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'\u00cele-de-Montr\u00e9al",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2020-11-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05046275",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "3af6770e06aa5813a5d01bf87657ac6fb1ba58115e3fd7e11e95cfaeeb70a422",
    "title": "Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects",
    "compound": "mdma",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2021-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04516902",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "05a0c0e68ed27017ccd526a4fd18964d82f81f6c8858b90af8f3e39091e83ee8",
    "title": "Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts",
    "compound": "other",
    "type": "observational",
    "institution": "Chaoran Han",
    "condition": "other",
    "sample_size": 18,
    "status": "completed",
    "date": "2024-03-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07415395",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c9bd8e96c404cdf654fce29623289610fdcd274418c0b61e5435908a11874236",
    "title": "The \"Motoric Cognitive Risk\" Syndrome in the Quebec Population",
    "compound": "other",
    "type": "observational",
    "institution": "Jewish General Hospital",
    "condition": "other",
    "sample_size": 1741,
    "status": "active",
    "date": "2016-12-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03633253",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "3d902aee3ee476719d6e8bce5db47d2b3fb7feb976b4a760d660082b9c32cb49",
    "title": "Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Yale University",
    "condition": "PTSD",
    "sample_size": 200,
    "status": "recruiting",
    "date": "2024-12-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06624137",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "05a53dc5e0a01131a0a1316204fd1da2018e69def1159a85d22d3af0b2db79ca",
    "title": "Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache",
    "compound": "lsd",
    "type": "phase_2",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "cluster_headache",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2019-01-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03781128",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a259533ddcc34d2753d1c5199d6bafd5dbf99a3e7178b9392ffec6a7f89d4da3",
    "title": "Comparative Acute Effects of LSD, Psilocybin and Mescaline",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 32,
    "status": "completed",
    "date": "2020-05-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04227756",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1737542c21cfc81d45bc09d379e5d872fa32e4e095cb03a96304931c4daa7039",
    "title": "Mood Effects of Serotonin Agonists",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of Chicago",
    "condition": "other",
    "sample_size": 80,
    "status": "completed",
    "date": "2018-05-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03790358",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f243c57462c606d6c952be54b24cbc848bb8296d020797cf4a81d7a26701dfa4",
    "title": "Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial",
    "compound": "other",
    "type": "phase_2",
    "institution": "Definium Therapeutics US, Inc.",
    "condition": "other",
    "sample_size": 53,
    "status": "completed",
    "date": "2021-12-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05200936",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a11d5849083243cab1c2fb66a0d338a1c8d9ff2f11e36d7e044e41fdc4776b0f",
    "title": "Microdosing LSD in Women With Premenstrual Disorders",
    "compound": "lsd",
    "type": "observational",
    "institution": "Friederike Holze",
    "condition": "other",
    "sample_size": 150,
    "status": "recruiting",
    "date": "2025-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189299",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "827589bfa42db669f0dcef13809ebe62b3a64636167d5668d805eb049a3903d3",
    "title": "Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "recruiting",
    "date": "2026-03-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07309471",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "03067ca4712abd836642748279b8da776132bd6f60cc6cbb8887232d0a05123e",
    "title": "Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy",
    "compound": "other",
    "type": "observational",
    "institution": "Tatiana Aboulafia Brakha",
    "condition": "depression",
    "sample_size": 10,
    "status": "completed",
    "date": "2024-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06557239",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "593a3c6d6d1cc7a13835dae41878b4895ef78a36eb3729289d22d8afa1cadfd8",
    "title": "Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study",
    "compound": "lsd",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2013-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01878942",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f60f9089871a0e960e6941bb17bf737b59936713cb3cce68a09cc80d71c956fa",
    "title": "Stem Cell Gene Therapy for Cystinosis",
    "compound": "other",
    "type": "phase_1",
    "institution": "University of California, San Diego",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2019-07-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03897361",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e92d9e7b30ae0c0c89c2208be97f3a4ad0be6f1f19826526d54a9f35a1c04a14",
    "title": "Ketamine for Methamphetamine Use Disorder",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Texas Southwestern Medical Center",
    "condition": "addiction",
    "sample_size": 120,
    "status": "recruiting",
    "date": "2024-09-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06496750",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "21c9c691ee7cb7cc16a10d6b322c5f49bf6030e740ccfe45f8c1e3dacec1b1a1",
    "title": "A Study of Ketamine in Patients With Treatment-resistant Depression",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Janssen Research & Development, LLC",
    "condition": "depression",
    "sample_size": 68,
    "status": "completed",
    "date": "2012-08-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01627782",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "22c40209c680f172122f0e6a6c569408629617e09cd79bbb62758bbc50e08142",
    "title": "Ketamine and fMRI for Neuropathic Pain",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University Health Network, Toronto",
    "condition": "other",
    "sample_size": 39,
    "status": "completed",
    "date": "2015-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02373449",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1e147baaffe15446d8001f1ff423525f9a597435430b87ce7afb48f539590fa5",
    "title": "Opioid-Free Combined Anesthesia With Spontaneous Breathing for VATS",
    "compound": "other",
    "type": "observational",
    "institution": "Tongji Hospital",
    "condition": "other",
    "sample_size": 480,
    "status": "recruiting",
    "date": "2024-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06367218",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "34ca8acbd94840f10604d2288c8176b779594d3a036023a7ee7560d8c600cec7",
    "title": "Is it Possible to Replace Fentanyl in Anesthesia for Minor Procedures?",
    "compound": "other",
    "type": "observational",
    "institution": "Ain Shams University",
    "condition": "other",
    "sample_size": 120,
    "status": "completed",
    "date": "2018-01-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03806374",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5d306cf6efe4697cb5fbc322e8ab758816b293ff3d45938413326d8c6deb07ae",
    "title": "Postoperative Pain Protocol Limiting Narcotics for Laparoscopic Hand-assisted Donor Nephrectomy",
    "compound": "other",
    "type": "observational",
    "institution": "Stony Brook University",
    "condition": "other",
    "sample_size": 56,
    "status": "completed",
    "date": "2014-05-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06458842",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "18b18c38c8b1df191000013aa43bb22bc90d573692b238156b4373ecf6912f13",
    "title": "Comparison of the Efficacy of Ketamine in Pediatric Patients With Idiopathic Scoliosis After Surgery",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "Fundaci\u00f3 Sant Joan de D\u00e9u",
    "condition": "other",
    "sample_size": 48,
    "status": "completed",
    "date": "2012-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02571491",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2762d953d0436c0239faeef81e40103490f5a6a2e283a337dc19aeb91976381f",
    "title": "Ketamine Infusion for Treatment-resistant Major Depressive Disorder",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Massachusetts General Hospital",
    "condition": "other",
    "sample_size": 14,
    "status": "completed",
    "date": "2012-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01582945",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "139770b020f767d3c721677c7f8f315a6ecd6a5b5f16208ca650afd8eeb6787c",
    "title": "NMDA Antagonists in Bipolar Depression",
    "compound": "other",
    "type": "observational",
    "institution": "New York State Psychiatric Institute",
    "condition": "depression",
    "sample_size": 8,
    "status": "completed",
    "date": "2013-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01833897",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "947085fa86cf847b8e23f1b22779d665113192f7ed3c86ec55f2a10913ffab26",
    "title": "Efficient Postoperative Pain Management With Multimodal IV",
    "compound": "other",
    "type": "observational",
    "institution": "Benha University",
    "condition": "other",
    "sample_size": 100,
    "status": "completed",
    "date": "2024-07-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06661746",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "3407fb2bcca7b188bebae061c780e8aaf058ecafe1dba47f60229e734d510f86",
    "title": "Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "New Valley University",
    "condition": "other",
    "sample_size": 2,
    "status": "recruiting",
    "date": "2026-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06490731",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c946c81ef2462179d118349cab89c332befb257dff3cfc554dd59625e61fbe58",
    "title": "ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Centre Hospitalier Universitaire de Nice",
    "condition": "other",
    "sample_size": 74,
    "status": "completed",
    "date": "2025-05-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06853041",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c1aa501b25290b6b3e4427fe727c5e1d6c0b45957536247df3336a30aa26e865",
    "title": "Comparison of Intranasal Ketorolac and Intranasal Ketamine in Digital Nerve Block Pain",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Tehran University of Medical Sciences",
    "condition": "other",
    "sample_size": 64,
    "status": "recruiting",
    "date": "2025-12-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07305883",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "473ebe8b361dc07b475f2cb260954489333a6b0ba10ae5af4e70b5edc87e21fb",
    "title": "The Impact Opioid Free Anesthesia on Postoperative Pain Intensity and Stress Response After Open Gynecology Surgery",
    "compound": "other",
    "type": "observational",
    "institution": "Cantonal Hospital Zenica",
    "condition": "other",
    "sample_size": 80,
    "status": "active",
    "date": "2025-07-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07138053",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a22e5b778593c959e8fef417ce9fda9cd813db3433effde8af96b56ad1bfb5cb",
    "title": "Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric",
    "compound": "other",
    "type": "observational",
    "institution": "Universitas Diponegoro",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02463929",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a2d7262b8e23d53e6a51bc3cf3e61dc4058dd077f5616917e4901124222a55dd",
    "title": "Adjunctive Esketamine for Analgesia in Mechanically Ventilated Septic Shock Patients",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Nanfang Hospital, Southern Medical University",
    "condition": "other",
    "sample_size": 124,
    "status": "active",
    "date": "2023-05-31",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05839366",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f5b61ee6efcb9fefd5eb98d0bdf30fac8ecf0120bb0c4c09a0db717b7d6ceebe",
    "title": "The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University Medical Center of Southern Nevada",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2016-03-17",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02657031",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c7117b7e65d07429d7820fb8581a312443a1c448495eaabb43a5f6392f848055",
    "title": "Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Assiut University",
    "condition": "other",
    "sample_size": 90,
    "status": "completed",
    "date": "2015-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02462681",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f3e11bd64a4feff54dc5fcc1466096431482f4719f55ad937908c42b881dad59",
    "title": "Dexmedetomidine Versus Ketamine-midazolam Sedation in Awake Fiberoptic Intubation in Suspected Difficult Airway",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Zagazig University",
    "condition": "other",
    "sample_size": 34,
    "status": "completed",
    "date": "2023-05-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06946212",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "30fb8e214007f99e4738846ad4aae8a665c0e6a7018cb51d5a2365d4962086d3",
    "title": "The Effect of Dexmedetomidine and Esketamine Combined Infusion Quality of Sleep Undergoing Modified Radical Mastectomy",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Anqing Municipal Hospital",
    "condition": "other",
    "sample_size": 105,
    "status": "active",
    "date": "2024-05-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06414941",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "adcd4bdf916d2519e4574a67739bd9686d5c91146775725ffcb3daf74b3c79b8",
    "title": "Effect of Subanesthetic Dose Esketamine on Propofol-refentanil Closed-loop Targeted Controlled Infusion",
    "compound": "ketamine",
    "type": "observational",
    "institution": "bo xu",
    "condition": "other",
    "sample_size": 48,
    "status": "active",
    "date": "2023-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05943028",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c03c3af95a8983567cc04484c51b867d2fe2b201ef5706551f1f71ac8307f244",
    "title": "Ketamine for Pain in the Emergency Department",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Hackensack Meridian Health",
    "condition": "other",
    "sample_size": 11,
    "status": "completed",
    "date": "2019-05-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03896230",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "11d85b63a2dcf0be990389ecb33704b2840fd1717a5bb0945fb20c2f9193ffba",
    "title": "Glutamatergic Mechanisms: Aim2",
    "compound": "other",
    "type": "phase_1",
    "institution": "New York State Psychiatric Institute",
    "condition": "other",
    "sample_size": 120,
    "status": "active",
    "date": "2022-10-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05401227",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "ff2aee69e9f2959ac0d3ce036cca1c75c02d5167e32d54882a270c8e17c3c06a",
    "title": "Oral Morphine Versus Ketamine in Pain Management",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Mbarara University of Science and Technology",
    "condition": "other",
    "sample_size": 44,
    "status": "completed",
    "date": "2021-03-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05163366",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "6eda7c60fc15f1d2fa4b03dbd41283555c06e7efecce6af23cf0379e1d785e79",
    "title": "Tramadol and Tramadol Plus Ketamine for Shivering Prevention After Spinal Anesthesia in Lower Segment Caeserian Section",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Ziauddin University",
    "condition": "other",
    "sample_size": 190,
    "status": "active",
    "date": "2023-08-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06134895",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2028351d57bde5304725af2964bd6a5227c77312b6a16a2ba43193cb1469378d",
    "title": "Dose Low Dose Ketamine in Casesarian",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Inonu University",
    "condition": "depression",
    "sample_size": 150,
    "status": "active",
    "date": "2024-06-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06237569",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b9a2a93496ac681f0b512386bed9e3d7a8ee20f57d09bd7742101dafe669298d",
    "title": "Intravenous Subdissociative-dose Ketamine Versus Morphine for Prehospital Analgesia",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Nantes University Hospital",
    "condition": "other",
    "sample_size": 285,
    "status": "completed",
    "date": "2017-11-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03236805",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "46c3d524431fbfc612cc4cc993849210d7706d942a987ef139e937866b7a962e",
    "title": "Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University Hospital, Montpellier",
    "condition": "depression",
    "sample_size": 456,
    "status": "active",
    "date": "2024-11-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07199179",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "bbc8bd02d51c6e9ee7528b65153566cf617459fa4af1c5c1c1e32db01b3ff6e6",
    "title": "Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy",
    "compound": "other",
    "type": "observational",
    "institution": "Hospices Civils de Lyon",
    "condition": "other",
    "sample_size": 40,
    "status": "active",
    "date": "2004-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00129597",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4348dfae5b130ae8ca9cfcb28745bb7e6148cafb6739a2d31c273e1efc86b36c",
    "title": "Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography",
    "compound": "other",
    "type": "observational",
    "institution": "Post Graduate Institute of Medical Education and Research, Chandigarh",
    "condition": "other",
    "sample_size": 50,
    "status": "completed",
    "date": "2016-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02867930",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "258f2e9684ea51181ae13be1016f4962da5bf601c0e50f6dce64b0197e3747e1",
    "title": "Dexmedetomidine and Ketamine in MRI",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Children's Hospital Medical Center, Cincinnati",
    "condition": "other",
    "sample_size": 22,
    "status": "completed",
    "date": "2016-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02652507",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "31a0a9130f3856845ffdc093d36a173bdf0523c6c381ae41d5baf211d1082c63",
    "title": "MRI Studies of Emotion in Depression",
    "compound": "other",
    "type": "observational",
    "institution": "Icahn School of Medicine at Mount Sinai",
    "condition": "depression",
    "sample_size": 135,
    "status": "completed",
    "date": "2011-07-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02429011",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "69be4e82c9030653c15446ea3d526025daf753bf434da4cbfdd1697f7507344d",
    "title": "Comparison Between Tranversus Abdominis Plane (TAP) Block With Only Bupivacaine and TAP Block With Bupivacaine Plus Ketamine in Reducing Postoperative Pain After Total Abdominal Hystrectomy",
    "compound": "ketamine",
    "type": "phase_1",
    "institution": "Liaquat National Hospital & Medical College",
    "condition": "other",
    "sample_size": 30,
    "status": "recruiting",
    "date": "2025-11-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07482709",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "6be8019c091541c41ad46901d54b464192b8505ec554b0f60f0b62d901e2df15",
    "title": "MAC vs TIVA Ambulatory Breast Augmentation",
    "compound": "other",
    "type": "phase_3",
    "institution": "Ain Shams University",
    "condition": "other",
    "sample_size": 80,
    "status": "completed",
    "date": "2014-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03764267",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "8a94e6c5302ef796fe9be9a7db8a6f06c0849c191b5d131560bde794abddaeec",
    "title": "US-Guided Preemptive Brachial Plexus Blockade May Reduce Post-operative Pain: a Randomized Study",
    "compound": "other",
    "type": "observational",
    "institution": "University of Sao Paulo General Hospital",
    "condition": "other",
    "sample_size": 70,
    "status": "completed",
    "date": "2022-12-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04005534",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "34d2acb260fa2ce0aa9b171263bab72bc5fb221561d37ceb3ec1fc88dbe9c9f9",
    "title": "Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy",
    "compound": "other",
    "type": "observational",
    "institution": "IVO JURISIC",
    "condition": "other",
    "sample_size": 36,
    "status": "recruiting",
    "date": "2025-07-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07084753",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "85080158752d8a965710833fd5d1c4d29406f865a7ba7b3f8d1058bd7584afa7",
    "title": "Intranasal Ketamine for Acute Traumatic Pain",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Tel Aviv Medical Center",
    "condition": "other",
    "sample_size": 90,
    "status": "completed",
    "date": "2012-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02817477",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "da13961beafd0343c24f14636a72b40453bb3241ab32e61bf63891c31abb9677",
    "title": "ECT vs. Esketamine",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Medical University Innsbruck",
    "condition": "depression",
    "sample_size": 0,
    "status": "completed",
    "date": "2021-07-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04924257",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "af58a0ceffb2e16b41dd5840ff58635f8878d7a8315231492a2e41f920f6a2e5",
    "title": "Intranasal Ketamine Versus Intranasal Fentanyl",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Isfahan University of Medical Sciences",
    "condition": "other",
    "sample_size": 125,
    "status": "completed",
    "date": "2017-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04414800",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1de94e9887793aca48f5556f8a8bf5e538c9bf6374252de3d7a8496ab05bb5c7",
    "title": "Application of Different Modes of Esketamine Administration in Pediatric Day Circumcision",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Yangzhou University",
    "condition": "other",
    "sample_size": 70,
    "status": "active",
    "date": "2023-04-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05811221",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c92337cafff74cbe5006dc838950a67a0b7bb298880cd51ababf679d10743468",
    "title": "Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Adriaan Dirk van der Wart",
    "condition": "PTSD",
    "sample_size": 5,
    "status": "recruiting",
    "date": "2026-07-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07614581",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a09a247ebd09046930ef673da1fb28fbeb7fdf34411a85c8fb2ba8f9cc6bed6b",
    "title": "Effects of Adding Dexamethasone Plus Ketamine to Bupivacine in Serrtatus Plane Block",
    "compound": "ketamine",
    "type": "observational",
    "institution": "National Cancer Institute, Egypt",
    "condition": "other",
    "sample_size": 60,
    "status": "active",
    "date": "2022-02-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05775393",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e5dd2c25db69533d1a6ebddbd17418e04c0896dcb49f3cfe2d832465e7672285",
    "title": "Preemptive Low-dose Epidural Ketamine for Preventing Chronic Post-thoracotomy Pain",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Seoul National University Hospital",
    "condition": "other",
    "sample_size": 209,
    "status": "completed",
    "date": "2004-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01017393",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0f42bb9326b80d273cf7fff3d3141f6ca079de4c643489d65c75ce93af749a2a",
    "title": "Intra-nasal Ketamine for Analgesia in the Emergency Department",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Lions Gate Hospital",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2012-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01686009",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "96d5e2deb3d03a16ec5c4156df061e5bb6ac22f436677818d0b40260d1a3e6fc",
    "title": "A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis",
    "compound": "other",
    "type": "phase_3",
    "institution": "Asklepion Pharmaceuticals, LLC",
    "condition": "other",
    "sample_size": 120,
    "status": "recruiting",
    "date": "2025-07-25",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06989567",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2119a49384d99ca4fbeb9915bb4760b67ab806cb921b710f830e8960bbf3b393",
    "title": "Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Mid-Atlantic Epilepsy and Sleep Center, LLC",
    "condition": "other",
    "sample_size": 0,
    "status": "completed",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02726867",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9ae13725491f8ce2c1fb2fd5dc773c7e7623866232e699f79f392a02a53f620f",
    "title": "Ketamine Versus Neostigmine in Ultrasound-Guided Transversus Abdominis Plane Block in Caesarean Section",
    "compound": "ketamine",
    "type": "phase_3",
    "institution": "Alexandria University",
    "condition": "other",
    "sample_size": 80,
    "status": "completed",
    "date": "2024-01-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06871033",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b44b619e5cc7db6441041d344374940c5164001bece0d1e5b31deb75ba4a6341",
    "title": "The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series",
    "compound": "other",
    "type": "phase_2",
    "institution": "Washington University School of Medicine",
    "condition": "depression",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-10-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06048263",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d6ca366385f400f259bdba93b566c39b0bb69ecff1e736d7048163a5fc35b25d",
    "title": "Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia",
    "compound": "ketamine",
    "type": "observational",
    "institution": "Beijing Tiantan Hospital",
    "condition": "other",
    "sample_size": 150,
    "status": "recruiting",
    "date": "2024-05-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06430645",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "4cc22f54000bd643635786ea4ad4042348b8d140ea53ce4c087b412e7fc272de",
    "title": "A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis",
    "compound": "other",
    "type": "phase_3",
    "institution": "University Hospital, Montpellier",
    "condition": "other",
    "sample_size": 250,
    "status": "recruiting",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07189325",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "bb2d1f423ba849acce9be30e14930878b487118e15fec78a56e9939c060fa283",
    "title": "SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 66,
    "status": "completed",
    "date": "2021-02-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04673383",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "db5bf7787c7472e104e5c22f4e2b5657b2dccaee3a3b4e97f00ad6de261adfd9",
    "title": "Impact of Fingolimod Adherence on Outcomes",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 694,
    "status": "completed",
    "date": "2020-05-18",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05141669",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "cdc6ab6399d4f7a940f6c01d1e7cc96eb59f3c9c1f1d68d393a1058628def4cc",
    "title": "Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 60,
    "status": "completed",
    "date": "2013-11-12",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04832399",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5a3093223fea2b62c7179d77d8a01c26f8f8cc0d3f5da350b487ffdf893f03a3",
    "title": "Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis",
    "compound": "dmt",
    "type": "observational",
    "institution": "Novartis",
    "condition": "other",
    "sample_size": 3632,
    "status": "completed",
    "date": "2023-02-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06644638",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "253525c15a23404be35cdd553c55f82d20d5703708b2d2c1cc515671f10e9ef6",
    "title": "A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants",
    "compound": "other",
    "type": "observational",
    "institution": "Bristol-Myers Squibb",
    "condition": "other",
    "sample_size": 2961,
    "status": "active",
    "date": "2021-03-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06133049",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "dc55d9a6ff51ee2b3963c84e9df09f646f8e678aeb2d5188849b58f884310064",
    "title": "Covid-19 Vaccine Immune Response in Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "University Hospitals of North Midlands NHS Trust",
    "condition": "other",
    "sample_size": 240,
    "status": "active",
    "date": "2022-02-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05269888",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "919df1ff64e43c2205aa9fa16d9f310f1e4641f9978af9df1c30acadad15e563",
    "title": "A Innovative Web-based Dance Movement Therapy",
    "compound": "other",
    "type": "observational",
    "institution": "Chin-Tsung Shen",
    "condition": "other",
    "sample_size": 67,
    "status": "completed",
    "date": "2024-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07474246",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0c7c6806440daee2f4f23c4ef1aa7aa5c272804d36168bb83dfa2c75e593136d",
    "title": "Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers",
    "compound": "other",
    "type": "observational",
    "institution": "MoCA Clinic and Institute",
    "condition": "other",
    "sample_size": 500,
    "status": "recruiting",
    "date": "2025-03-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07041450",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2036bd62394f84b4eb612f9d4c3076fc408ce915f096ffb6e03c703dd11a5d21",
    "title": "Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 908,
    "status": "recruiting",
    "date": "2023-10-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05658497",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d4a252dbf349d794d5fd4c4cc234b83d07e47567c7f45964ba23122d547ffab4",
    "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Usona Institute",
    "condition": "other",
    "sample_size": 54,
    "status": "completed",
    "date": "2022-12-27",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05698095",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "fe1140593d82994c1d7ee2968001b7de105de60dc80c6f3c308c58b692e545cf",
    "title": "Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients",
    "compound": "dmt",
    "type": "observational",
    "institution": "Merck KGaA, Darmstadt, Germany",
    "condition": "other",
    "sample_size": 545,
    "status": "completed",
    "date": "2012-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01601119",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9a676948097fa0037731fbba7f95088a42ddb0655e59694f7917d65a9bdd250c",
    "title": "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)",
    "compound": "dmt",
    "type": "phase_3",
    "institution": "Genentech, Inc.",
    "condition": "other",
    "sample_size": 608,
    "status": "completed",
    "date": "2016-02-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02637856",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f9f2edefe25802182a5c8cac79bd1bb784aa0ed9f89fe796a25de38fe2a932e3",
    "title": "The 'Wearing Off' Effect of DMT",
    "compound": "dmt",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 39,
    "status": "completed",
    "date": "2023-01-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05627271",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "28b245c29ab7e29266a79a6adc0632d059fa23ef9ed06c319a7be445ab32a6f4",
    "title": "Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects",
    "compound": "other",
    "type": "phase_1",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 52,
    "status": "recruiting",
    "date": "2024-08-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06511947",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "d48b428b1ee19e040e280b58521aa03738d1147bc3d160a84382ff625aa04fa7",
    "title": "Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control",
    "compound": "other",
    "type": "observational",
    "institution": "John F. Foley, MD",
    "condition": "other",
    "sample_size": 164,
    "status": "completed",
    "date": "2012-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01626248",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "6ee7770d335299f4220676abebb1949359cdd25af72a2b722a2b5a6d1f3a9486",
    "title": "Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "State University of New York at Buffalo",
    "condition": "other",
    "sample_size": 30,
    "status": "completed",
    "date": "2015-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03046251",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a8bb18f37cb9b40d9554d5389dcaa89e5b704fadfe8fd6a85671f5e54cdbd559",
    "title": "Biogen Multiple Sclerosis Pregnancy Exposure Registry",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 408,
    "status": "completed",
    "date": "2013-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01911767",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a2cfec0a69f7f387ba35d2f4fa63a72771e4b0a3d1685c139e17d5e892b3b772",
    "title": "Trifecta Research Study",
    "compound": "other",
    "type": "phase_2",
    "institution": "Johns Hopkins University",
    "condition": "PTSD",
    "sample_size": 0,
    "status": "completed",
    "date": "2025-09",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06810765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "dc67852841fb6d63523389eca2c82419d044f2b6297748fa718a34fbc5e21723",
    "title": "Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study",
    "compound": "dmt",
    "type": "observational",
    "institution": "University of Utah",
    "condition": "other",
    "sample_size": 46,
    "status": "completed",
    "date": "2008-07",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00722943",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b1decb0406b21ca4e726166d589d18fc0a42337b9dfba47ca8f03dfe29d380b8",
    "title": "Safety of GH001 in Healthy Volunteers",
    "compound": "other",
    "type": "phase_1",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 22,
    "status": "completed",
    "date": "2019-03-13",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04640831",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "458f65dce66e0d941276a1cd6738bf5e341be29869b9be92f52dbebf06909136",
    "title": "Antidepressant Response of DMT Masked With Propofol",
    "compound": "dmt",
    "type": "observational",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 112,
    "status": "recruiting",
    "date": "2025-08-05",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06927076",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "8bf3b45b2796e8d7ec666b6a15343b230df13d801da92b5c531411c3dcc43f42",
    "title": "Acute Dose-dependent Effects of DMT in Healthy Subjects",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 24,
    "status": "completed",
    "date": "2022-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05384678",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "43b62069ae202526008cbfce6c0efb0b2f61371f4ed0060618f6cc149263694e",
    "title": "Tecfidera and the Gut Microbiota",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 36,
    "status": "completed",
    "date": "2015-11-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02471560",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "0b0809be1f4e55273778eba9dc2b66f56387c1a64ea5c83b2349fff8a8023c89",
    "title": "IM and IV SPL026 Drug Product in Healthy Participants",
    "compound": "other",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 14,
    "status": "completed",
    "date": "2023-01-03",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05644093",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f5cacad300ad47f1970b268a4028a5f07bfabfc4361d9912b12faba09ceb52a2",
    "title": "A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 4805,
    "status": "completed",
    "date": "2025-06-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07403214",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "87c3e938a77eeb46930770711af07ffbbc285babb1c95f811799fcf4afa2e06e",
    "title": "A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 1053,
    "status": "completed",
    "date": "2010-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01216072",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9673287c7aaeb4389b64aed0fdd445efc8c00478a07884882dbc897a86e24f25",
    "title": "Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis",
    "condition": "other",
    "sample_size": 143,
    "status": "completed",
    "date": "2020-11-19",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06459232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "505786358bb8c68e177d9a7e4d978b40d64bea6b9949946e9d45b130d0dfaeb3",
    "title": "Influence of Therapeutic Failure on the Psychosocial Experience in Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "University Hospital, Caen",
    "condition": "other",
    "sample_size": 150,
    "status": "recruiting",
    "date": "2026-02-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07372599",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "9a1b2f932e5f83c2ccd064bb4aed470e44831fe832e238a8cfecadfdd76a7915",
    "title": "Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study",
    "compound": "other",
    "type": "observational",
    "institution": "Biogen",
    "condition": "other",
    "sample_size": 160,
    "status": "completed",
    "date": "2021-07-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05197699",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b2d41160c1f091c7232cda22a502c41e9f6ce6d2dcf3581e049bce0b38319bb3",
    "title": "Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety",
    "compound": "psilocybin",
    "type": "phase_1",
    "institution": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
    "condition": "anxiety",
    "sample_size": 12,
    "status": "completed",
    "date": "2004-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT00302744",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "8ffbdc4733b96fd7160e84ae8e78b0f9765cbc26e9335601dfb4667cb76059e0",
    "title": "Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS",
    "compound": "dmt",
    "type": "phase_3",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 185,
    "status": "completed",
    "date": "2021-07-23",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04788615",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "c6c524ddddfcf268b330be837a1bc030e51c186dbce5ac480cd6f373377012d5",
    "title": "Molecular Imaging Study of Harmine/DMT: a Basic Research Approach",
    "compound": "dmt",
    "type": "phase_1",
    "institution": "Insel Gruppe AG, University Hospital Bern",
    "condition": "other",
    "sample_size": 17,
    "status": "completed",
    "date": "2024-01-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06252506",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "69eac3791ae4abe88e10566b9f0b8800ade197b98ca1d32a15ecb207ae997e4a",
    "title": "SPL026 With or Without SSRIs in Participants With MDD",
    "compound": "other",
    "type": "phase_1",
    "institution": "Small Pharma Ltd",
    "condition": "other",
    "sample_size": 18,
    "status": "completed",
    "date": "2022-12-13",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05553691",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "1fd1f13d21daf270852e461b3d5476d3def9685489e2db65ca189555328869db",
    "title": "Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)",
    "compound": "other",
    "type": "phase_3",
    "institution": "Rennes University Hospital",
    "condition": "other",
    "sample_size": 250,
    "status": "active",
    "date": "2019-01-24",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03653273",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "94a41916701d36ddab58de1c5275fd4cbdf7c51ab0f5c69df8cd792eef0e58b1",
    "title": "An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD",
    "compound": "other",
    "type": "phase_3",
    "institution": "Biocad",
    "condition": "other",
    "sample_size": 44,
    "status": "completed",
    "date": "2022-03-22",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06987851",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a7c6bbbb4a7b2db9e4ee2ffb9f36fb403dc33e38657b30cd99a3bf7b81756ead",
    "title": "Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults",
    "compound": "other",
    "type": "phase_1",
    "institution": "Advanced Integrative Medical Science Institute",
    "condition": "depression",
    "sample_size": 12,
    "status": "active",
    "date": "2023-10-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05894902",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f5f247d8c33120d740fdcd41efba8273e4ca2919a74eedfe37503de314ccf20c",
    "title": "Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 298,
    "status": "completed",
    "date": "2012-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01534182",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e827018424c727540059966c617761b0901274c13092c55195dec3066259f21d",
    "title": "COVID-19 and Multiple Sclerosis Disease Modifying Therapies",
    "compound": "other",
    "type": "observational",
    "institution": "Nottingham University Hospitals NHS Trust",
    "condition": "other",
    "sample_size": 14240,
    "status": "active",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04863586",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "50c086b48061485c03ecbabf5772f5652a83dea98cd5ea00a4626bcfca7ab022",
    "title": "Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis",
    "condition": "other",
    "sample_size": 1665,
    "status": "completed",
    "date": "2021-10-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06662812",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "59f08dd86fb0a8a5428e750d0d96e969699f254fb7724b546099888080de371b",
    "title": "A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 700,
    "status": "recruiting",
    "date": "2024-10-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06551519",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "5e27ba601ebeb3ecbe50813b4d0205a969296ac3c8a60111d5a9cbd60d513729",
    "title": "A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720",
    "compound": "other",
    "type": "observational",
    "institution": "Novartis Pharmaceuticals",
    "condition": "other",
    "sample_size": 42,
    "status": "completed",
    "date": "2012-10",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT01578330",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "63cd052997eba418ae5c3f7a4e835cdc2dcc9d8ecfaa5c191037d23fdc55d686",
    "title": "Phase 2 Clinical Trial of GH001 in Bipolar II Disorder",
    "compound": "other",
    "type": "phase_2",
    "institution": "GH Research Ireland Limited",
    "condition": "other",
    "sample_size": 6,
    "status": "completed",
    "date": "2023-04-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05839509",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "a0dfa156be97f0ef38f25d99830d691d67a85ef5af3811ef2be75fcb59b44c68",
    "title": "An Intervention Integrating Physical Therapy Exercise and Dance Movement Therapy for Preventing Falls in Older Adults",
    "compound": "other",
    "type": "observational",
    "institution": "University of Haifa",
    "condition": "other",
    "sample_size": 61,
    "status": "completed",
    "date": "2023-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05948735",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b8b44584a576d5077eb805785653f2f82dde0161a5d5f51fd559a3574fece081",
    "title": "Single Ascending Dose Study With BPL-003 in Healthy Subjects",
    "compound": "other",
    "type": "phase_1",
    "institution": "Beckley Psytech Limited",
    "condition": "other",
    "sample_size": 62,
    "status": "completed",
    "date": "2022-02-14",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05347849",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "56f8fa8654951753b6ad57602591a8aea57674a30bb336dedc1cb8aa7de281ce",
    "title": "Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "International Center for Ethnobotanical Education, Research, and Service",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2020-10-28",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04003948",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "42034b58b03ea36a85a62c85a5fcc6711e2710b0f8b0a648b0a9995b19825dc3",
    "title": "Mapping Ibogaine Neural Dynamics in Opioid Use Disorder",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "University of California, Irvine",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-09-08",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07226570",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2205af0565e2d1cfac1f1b872f433ac71ed08b35afac93a581f06c507de54ef9",
    "title": "Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial",
    "compound": "ibogaine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 9,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT03380728",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "b6ec247e6bd2fe4c3ae2a7ecc80bf0ce09660e4c3edea0bb358efd09bb937941",
    "title": "A Study of Oral Ibogaine in Opioid Withdrawal",
    "compound": "ibogaine",
    "type": "phase_1",
    "institution": "atai Therapeutics, Inc.",
    "condition": "other",
    "sample_size": 116,
    "status": "completed",
    "date": "2021-04-01",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05029401",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "2a8472dbee4ff38751b1498e7cf4f624eefe2e30e0e17b06ac9da2ffcac4cdad",
    "title": "Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure",
    "compound": "ibogaine",
    "type": "observational",
    "institution": "Stanford University",
    "condition": "other",
    "sample_size": 30,
    "status": "active",
    "date": "2021-11-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04313712",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "3a0f58758dbcdb84334875a717c37be38c944dd1ce47faf972514540c5014bed",
    "title": "Personality and Drug Use",
    "compound": "other",
    "type": "observational",
    "institution": "Psychedelic Data Society",
    "condition": "addiction",
    "sample_size": 1000,
    "status": "active",
    "date": "2022-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05516823",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "e9f88d2b3bb5a904eb63d34f94db1d354a1424b112d621c1d4ae607c2d917a96",
    "title": "Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression",
    "compound": "ayahuasca",
    "type": "phase_1",
    "institution": "Universidade Federal do Rio Grande do Norte",
    "condition": "depression",
    "sample_size": 35,
    "status": "completed",
    "date": "2014-02",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02914769",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "23d314ab1fd3526bdd73e297d3680208643c0e5ef76081ee568dddc5e452c867",
    "title": "Mindfulness and Psychedelics",
    "compound": "other",
    "type": "observational",
    "institution": "Milan Scheidegger",
    "condition": "other",
    "sample_size": 40,
    "status": "completed",
    "date": "2023-02-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05780216",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "ae5bf47b8c21f70c8347be94a0f17598df8f9d8b63309e5be3898573802d861c",
    "title": "Entheogen Resurgence",
    "compound": "other",
    "type": "observational",
    "institution": "Vireo Health",
    "condition": "other",
    "sample_size": 102,
    "status": "completed",
    "date": "2021-09-16",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05042765",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "724a3f04d998d445fa1228ab0a475276cf9cca32c969629b4c047203bc6f84d6",
    "title": "Ayahuasca, Esketamine and Body Image Perception",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317219",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "604aa74e281e83bdb5edccdc5372851dfb8317b70d9f15497754648a09d11092",
    "title": "Ayahuasca Assisted Psychotherapy for Grief",
    "compound": "ayahuasca",
    "type": "phase_2",
    "institution": "Beckley Med Foundation",
    "condition": "other",
    "sample_size": 84,
    "status": "active",
    "date": "2021-10-15",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT06150859",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "f297c77cbff46505d11bb69d2bfdd0726b17dcf3625c1dcb0488fcbd3d25794b",
    "title": "Ayahuasca, Esketamine and PTSD",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "PTSD",
    "sample_size": 10,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317206",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "915bfce0f72d51bd26a570d2dbf3e81fdffb1ccee6ef28a821905621b2012261",
    "title": "Ayahuasca, Esketamine and Premenstrual Symptoms",
    "compound": "ketamine",
    "type": "observational",
    "institution": "University of Sao Paulo",
    "condition": "other",
    "sample_size": 20,
    "status": "recruiting",
    "date": "2025-12-20",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07317232",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "dd8cb146beda67e6d2a65cdc96868d21662ae45ff0fd9a1e3d9edcdec6a8363c",
    "title": "Ayahuasca and Esketamine for Major Depression",
    "compound": "ketamine",
    "type": "phase_2",
    "institution": "University of Sao Paulo",
    "condition": "depression",
    "sample_size": 22,
    "status": "completed",
    "date": "2022-10-30",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT07212946",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "05431a8189731bff6895510ce8559f8effba74196570c6c81b0196aa4c9d34f8",
    "title": "Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness",
    "compound": "mescaline",
    "type": "phase_1",
    "institution": "University Hospital, Basel, Switzerland",
    "condition": "other",
    "sample_size": 16,
    "status": "completed",
    "date": "2021-08-11",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT04849013",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "cdcc6f1de14e082e13f542622a5a2158e041829aca33360d610de8aa27d3aae1",
    "title": "Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis",
    "compound": "mescaline",
    "type": "observational",
    "institution": "Xiangya Hospital of Central South University",
    "condition": "other",
    "sample_size": 205,
    "status": "active",
    "date": "2023-07-06",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT05933213",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  },
  {
    "id": "ff164c3432cbce8674fe172b8bbd8921591a4adf442ed77cd23a6d9302019398",
    "title": "Effects of Hallucinogens and Other Drugs on Mood and Performance",
    "compound": "other",
    "type": "phase_1",
    "institution": "Johns Hopkins University",
    "condition": "other",
    "sample_size": 20,
    "status": "completed",
    "date": "2014-04",
    "outcome_summary": null,
    "doi": null,
    "url": "https://clinicaltrials.gov/study/NCT02033707",
    "source": "ClinicalTrials.gov",
    "first_seen": "2026-06-15"
  }
]